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SUMMARY 
 
NOVEL FORMULATIONS FOR AMPHOTERICIN B DELIVERY 
INTRODUCTION 
Amphotericin B (AmB), a macrolide antibiotic with broad spectra of action, has been 
widely used in the treatment of systemic fungal infections since more than 40 years. 
Even though several new antifungal drugs have been developed, AmB remains the drug 
of choice in the treatment of severe systemic fungal diseases and in the treatment of 
visceral leishmaniasis when the parasite develops resistance to antimonial compounds.  
The poor AmB solubility is the main drawback for the development of pharmaceutical 
formulations. So far, many attempts have been made to develop AmB formulations with 
enhanced therapeutic profiles, including solid-lipid nanoparticles, polymeric 
nanoparticles, liposomes, micelles and polymer bioconjugates.  
Even though the amphotericin B associated nephrotoxicity is the main drawback for the 
use of this molecule in clinic, the fact that this antibiotic is only available for 
intravenous administration also limits its prescription. The development of AmB oral, 
intravenous and/or topical formulations with decreased toxicity will allow not only for 
the treatment of systemic fungal infections but also for the treatment of topical mixed-
infections resistant to conventional treatments. These formulations will improve patient 
compliance and reduce the sanitary cost of the treatment. 
OBJECTIVE  
Taking into account the rising importance and clinical repercussion of the mold 
infections in humans and animals, the development of new formulations that reinforce 
the current therapeutic arsenal is needed. 
The wide spectra of action of amphotericin B together with its low appearance of 
resistance, makes this drug a suitable candidate for the treatment of different types of 
mycosis. Thus, the main objective of the present thesis will be focused on the 
development of new amphotericin B (AmB) formulations for the treatment of systemic 
and topical mycosis with reduced side effects.  
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Two AmB formulations will be developed. The first part of this project will be focused 
on the development of a new AmB topical formulation; a nail lacquer formulation for 
the treatment of mixed onychomycosis resistant to conventional treatments. 
The second part of the thesis will be performed in collaboration with the University 
Degli Studi di Padova and it will be focused on the development and optimization of an 
AmB pegylated formulation for the treatment of systemic fungal infections by oral and 
intravenous administration. The AmB interactions with cholesterol-type molecules are 
known to favor the drug solubility. Thus, the conjugation of cholesterol-type molecules 
with different PEGs will allow for the encapsulation and solubilization of AmB. To 
achieve this general purpose some specific objectives are proposed which included the 
synthesis of different AmB pegylated complexes; the solubility studies in different 
conditions; the complexes characterization by DLS, HPLC, DSC, RX, FTIR, CD, ITC 
and synchrotron analysis; the ex vivo characterization of these complexes (toxicity by 
hemolysis and antifungal efficacy against Candida albicans) and finally, the in vivo 
pharmacokinetic studies after oral and intravenous administration. The pharmacokinetic 
properties of the new AmB formulation will be determined and compared to the 
commercialized formulations Ambisome® and Fungizone®. 
RESULTS 
With regards to the AmB topical formulation, different water permeable and 
impermeable nail lacquer formulations were prepared. The drying time, viscosity, 
aspect of the film, extensibility, brightness, AmB incorporation and pH were studied. 
From all the formulations developed, three of them were selected for further 
characterization and in vitro studies (F11, F13 and F19). Even though formulations 11, 
13 and 19 overcame the AmB low solubility problems, the short-term stability of these 
formulations (1 month) was still a problem. The strategy used to overcome the short 
AmB stability was focused on obtaining powders for reconstitution. The freeze drying 
(for F11 and F13) and spray drying (for F19) generated stable lyophilized and spray 
dried products easily redispersable. In vitro nail penetration studies on female human 
nails, demonstrated the higher nail penetration reached with F19 (EF=1.95) compared to 
F11, F13 and to the control. The in vitro efficacy studies against Candida albicans 
showed that the most active formulation was F19 (103%). The AmB nail lacquer was 
active against the dermatophyte and non-dermatophyte infections located on keratinized 
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structures. Treatment (30 days) with F19, administered in alternate days, once daily, 
cleared up the infections caused by T. mentagrophytes, T. rubrum, A. niger, 
F.oxysporum and F.solani. After 30 days of treatment no microorganisms were found 
nor in the culture media neither in the direct examination. 
As far as the AmB pegylated formulation is concerned, the solubility studies showed 
that PEG5kDa-cholane can increase more than 10
5 times the AmB solubility according to 
a linear [dissolved drug]/ [polymer concentration] correlation. The different capability 
of PEG5kDa-cholane to solubilize AmB observed was explained by the effect of the 
dissolution conditions in the formation of monomeric and multimeric soluble species. 
The high affinity of AmB for PEG5kDa-cholane was observed by isothermal calorimetry 
(ITC). This technique highlighted the complexity of the PEG5kDa-cholane interaction 
with AmB, which takes place with different AmB soluble species, namely monomers, 
dimers, tetramers, and other multimeric nanoaggregates, of which abundance depends 
on the pH. The three different binding sites calculated by ITC analyses reasonably result 
from the PEG5kDa-cholane interaction with different AmB species through hydrophobic 
interactions between the cholane moiety and the heptaene side of the drug molecule to 
form different supramolecular structures. The lyophilization process produced a fluffy 
powder with low moisture content and without cake formation which was stable 
throughout the time. The CD studies showed that, similarly to Fungizone® and heated 
Fungizone®, AmB/PEG5kDa-cholane micelles did not induce structural alterations of 
human serum albumin (HSA). The hemolysis studies confirmed that the AmB/PEG5kDa-
cholane micelles were less hemolytic than Fungizone®. Even at concentrations in which 
the Fungizone® caused 100% hemolysis, the new formulation produced not more than 
30% hemolysis. The biological in vitro studies showed that the AmB formulated with 
PEG5kDa-cholane maintains high antimicrobial activity, which is very close to AmB in 
solution. The oral administration of 5 mg/kg AmB demonstrated that the new 
formulation developed had the highest half-life of all assayed formulations.  
Finally, The IV administration of 1 mg/kg AmB in Ambisome®, Fungizone® and 
AmB/PEG5kDa-cholane showed that the new formulation developed had a significantly 
(P<0.01) lower apparent elimination constant and consequently, a higher half-life 
compared to the marketed formulations Ambisome® and Fungizone®. 
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CONCLUSIONS 
This thesis includes the development of two different types of amphotericin B 
formulations: one topical formulation for the treatment of nail infections (conclusions 1-
3) and one intravenous/oral formulation for the treatment systemic fungal infections. 
(Conclusions 4-12). 
Conclusions: 
1.- A new water-impermeable stable nail lacquer formulation containing amphotericin B 
has been designed for the treatment of onychomycosis. The polymer (Eudragit L100®) 
and the amphotericin B solvent used (N-methyl-2-pyrrolidone) showed no compatibility 
problems. Once applied over a surface, the nail lacquer formed a continuous, 
homogenous and smooth film resistant to water.   
2.- In vitro nail penetration studies showed that the lacquer was able to penetrate the nail 
(enhancement factor almost twice than the control). In vitro activity studies 
demonstrated the efficacy of the nail lacquer against dermatophyte and non-
dermatophyte molds as well as yeasts (gender Candida). 
3.- In vivo efficacy studies on keratinized structures of animal origin supported the 
efficacy of amphotericin B. After 30 days treatment on alternate days, the nail lacquer 
was able to clear up the infections caused by Trichophyton mentagrophytes, 
Trichophyton rubrum, Aspergillus niger, Fusarium. oxysporum and Fusarium solani. 
4.- A novel formulation for amphotericin B delivery has been developed by using a 
micelle forming 5 kDa monomethoxy-polyethylene glycol end functionalized with 
cholanic acid (PEG5kDa-cholane). This polymer was found to increase 10
5 times the 
amphotericin B solubility with a 12:1 AmB/PEG5kDa-cholane molar ratio (2:1 w/w 
ratio).  
5.- The system AmB/PEG5kDa-cholane forms 30 nm micelles with the hydrophobic 
cholane moieties localized inside the micelles. Zeta potential analysis showed that at 
neutral pHs (5.5-7.2) the overall micelle surface is nearly neutral. The PEG5kDa-cholane 
interacts with amphotericin B according to three binding sites depending on the pH, 
suggesting that the polymer interaction depends on the amphotericin B ionization and 
aggregation.  
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6.- Once lyophilized, the freeze-dried product could be promptly redispersed to form an 
homogeneous colloidal dispersion. The dispersion was physicochemically stable. 
Fourier Transform infrared spectrometry, differential scanning calorimetry and X-ray 
diffractometry showed that in the lyophilized product, amphotericin B and PEG5kDa-
cholane interacts intimately.  
7.- The amphotericin B release from the PEG5kDa-cholane micelles showed a biphasic 
profile. The best fittings were obtained with the Higuchi and Korsmeyer-Peppas 
models.  
8.- The toxicity of the new formulation was tested as hemolysis. The new 
AmB/PEG5kDa-cholane nanoformulation was always less hemolytic than the reference 
marketed formulation Fungizone®. 
9.- The amphotericin B antifungal activity assayed against Candida albicans showed 
that AmB/PEG5kDa-cholane was 15% more active than the free amphotericin B in 
buffer. 
10.- The IV pharmacokinetics profiles of the different formulations studied 
(Ambisome®, Fungizone® and AmB/PEG5kDa-cholane) were significantly different. 
The apparent elimination constant (Ke) of the new formulation is significantly (P<0.01) 
lower than both Ambisome® and Fungizone®. Accordingly, the half-life value of this 
new formulation was found to be higher. The IV administration of 1 mg/kg 
AmB/PEG5kDa-cholane caused less pain effect in the mice than the administration of the 
same dose of Fungizone® or Ambisome®.  
11.- Oral pharmacokinetic studies confirmed that this new formulation has a higher 
half-life than Ambisome® and Fungizone® marketed formulations. The AUC0-24 values 
were similar for all tested formulations. 
12.- It can be concluded that the new AmB/PEG5kDa-cholane formulation is a promising 
soluble controlled delivery system for amphotericin B with lower toxicity than the 
reference marketed formulation Fungizone®. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
15 
RESUMEN 
NUEVAS FORMULACIONES PARA LA LIBERACIÓN DE ANFOTERICINA B 
INTRODUCCIÓN  
La anfotericina B (AmB), un antibiótico macrólico con una amplio espectro de acción, 
se utiliza desde hace más de 40 años para el tratamiento de infecciones micóticas 
sistémicas. A pesar de que se han desarrollado nuevos fármacos antifúngicos, la AmB 
sigue siendo el fármaco de elección tanto en el tratamiento de infecciones fúngicas 
sistémicas graves como en el tratamiento de la leishmaniasis visceral, cuando el parásito 
desarrolla resistencia a los derivados antimoniales. 
La baja solubilidad de la AmB es el principal inconveniente para el desarrollo de nuevas 
formulaciones. Hasta el momento se han llevado a cabo diversos intentos para 
desarrollar formulaciones de AmB con mejoras en el perfil terapéutico; se han 
desarrollado nanopartículas con lípidos sólidos, nanopartículas poliméricas, liposomas, 
micelas y bioconjugados poliméricos. 
Un  inconveniente importante para el uso de esta molécula en clínica es su elevada 
nefrotoxicidad, así como el hecho de que se formule y comercialice solo para 
administración intravenosa. El desarrollo de nuevas formulaciones orales, intravenosas 
y/o tópicas de AmB con toxicidad reducida, permitirá no sólo el tratamiento de 
infecciones fúngicas sistémicas sino también el tratamiento de infecciones tópicas 
mixtas resistentes a tratamientos convencionales. 
 El amplio espectro de acción de la anfotericina B junto con su baja apariencia de 
resistencias hacen de este fármaco un candidato adecuado para el tratamiento de 
diferentes tipos de micosis. 
OBJETIVO  
El objetivo principal de la presente tesis es el desarrollo de nuevas formulaciones de 
anfotericina B (AmB)  para el tratamiento de micosis sistémicas y tópicas. 
En esta tesis doctoral se desarrollarán dos tipos de formulaciones de AmB. La primera 
parte de la tesis se centrará en el desarrollo de una nueva formulación tópica, una laca 
de uñas para el tratamiento de la onicomicosis resistente a tratamientos convencionales.  
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La segunda parte de la tesis se realizará en colaboración con la Universidad Degli Studi 
di Padova y se centrará en el desarrollo y la optimización de una formulación pegilada 
de AmB para el tratamiento de infecciones fúngicas sistémicas por vía oral e 
intravenosa. Dado que las interacciones de la AmB con moléculas de tipo colesterol 
favorecen la solubilidad del fármaco, la conjugación de moléculas de este tipo con 
diferentes PEGs permitirá la encapsulación y solubilización de la AmB. Para lograr ésto 
se proponen algunos objetivos específicos que incluyen la síntesis de diferentes 
complejos pegilados de AmB, los estudios de solubilidad en diferentes condiciones, la 
caracterización de los complejos por DLS, HPLC, DSC, RX, FTIR, CD, ITC y 
sincrotrón,  la caracterización ex vivo de estos complejos (toxicidad  por hemólisis y 
eficacia antifúngica contra Candida albicans) y finalmente, los estudios 
farmacocinéticos in vivo después de la administración oral e intravenosa. Finalmente se 
compararán las propiedades farmacocinéticas de la nueva formulación con las de dos 
formulaciones comercializadas: AmBisome® y Fungizone®. 
RESULTADOS 
Con respecto a la formulación tópica de AmB, se prepararon diferentes formulaciones 
de lacas de uñas permeables e impermeables al agua. Se estudió el tiempo de secado, la 
viscosidad, el aspecto de la película, la extensibilidad, el brillo, la incorporación de 
AmB y el pH. De todas las formulaciones desarrolladas, tres de ellas fueron 
seleccionadas para su posterior caracterización y estudio in vitro (F11, F13 y F19). 
Aunque las formulaciones 11, 13 y 19 solventaron los problemas de baja solubilidad de 
la AmB, la estabilidad a corto plazo de estas formulaciones (1 mes) seguía siendo un 
problema. La estrategia utilizada para mejorar la corta estabilidad de los preparados de 
AmB se centró en la obtención de polvos para reconstitución. La liofilización (para F11 
y F13) y el secado por pulverización (para F19) generaron productos estables fácilmente 
redispersables. Los estudios de penetración in vitro en uñas de voluntarios sanos 
demostraron que la penetración obtenida con F19 (EF=1.95) fue mayor en comparación 
con F11, F13 y con el control. Los estudios de eficacia in vitro contra Candida albicans 
mostraron que la formulación más activa fue F19 (103%). La laca de uñas de AmB fue 
activa contra las infecciones provocadas por dermatofitos y no dermatofitos localizadas 
en las estructuras queratinizadas. El tratamiento (30 días) con F19, administrado en días 
alternos y una vez al día, eliminó las infecciones causadas por T. mentagrophytes, T 
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rubrum, A. niger, F. oxysporum y F. solani. Tras 30 días de tratamiento no se 
encontraron microorganismos ni en el medio de cultivo ni en el examen directo.  
Respecto a la formulación pegilada de AmB, los estudios de solubilidad mostraron que 
el PEG5kDa-colánico puede aumentar más de 10
5 veces la solubilidad de la AmB. La 
diferente capacidad de PEG5kDa-colánico para solubilizar la AmB observada se explica 
por el efecto que las condiciones de disolución tienen en la formación de especies 
solubles monoméricas y multiméricas. La alta afinidad de la AmB por el PEG5kDa-
colánico se observó mediante calorimetría isotérmica (ITC). Esta técnica resaltó la 
complejidad de la interacción entre el PEG5kDa-colánico y la AmB que tiene lugar a 
través de diferentes especies solubles de AmB, principalmente monómeros, dímeros, 
tetrámeros y otros nanoagregados multiméricos cuya abundancia depende del pH. Los 
tres sitios de unión diferentes calculados mediante análisis por ITC resultan de la 
interacción del PEG5kDa-colánico con diferentes especies de AmB mediante las 
interacciones hidrofóbicas entre el resto colánico y el lado del heptaeno de la molécula 
de AmB para formar diferentes estructuras supramoleculares. El proceso de liofilización 
produjo un polvo esponjoso con bajo contenido en humedad y sin formación de torta 
que se mostró estable a lo largo del tiempo. Los estudios de CD mostraron que de 
formar similar a la Fungizona® y a la Fungizona® calentada, las micelas de 
AmB/PEG5kDa-colánico no indujeron alteraciones estructurales de la albúmina sérica 
humana (HSA). Los estudios de hemólisis confirmaron que las micelas de 
AmB/PEG5kDa-colánico eran menos hemolíticas que Fungizona®. Incluso a 
concentraciones en las que la Fungizona® causó 100% de hemólisis, la nueva 
formulación produjo no más del 30%. Los estudios biológicos in vitro demostraron que 
la AmB formulada con PEG5kDa-colánico mantiene una alta actividad microbiana que 
está muy cerca de la AmB en solución. La administración oral de 5 mg/kg de AmB 
demostró que la nueva formulación desarrollada tenía la semivida más alta de todas las 
formulaciones ensayadas. Por último, la administración intravenosa de 1 mg/kg de AmB 
en AmBisome®, Fungizone® y AmB/PEG5kDa-colánico mostró que la nueva 
formulación desarrollada tenía una constante de eliminación aparente significativamente 
menor (P<0,01) y consecuentemente una semivida más alta en comparación con las 
formulaciones comercializadas Ambisome® and Fungizona®. 
CONCLUSIONES 
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Esta tesis incluye el desarrollo de dos tipos diferentes de formulaciones de anfotericina 
B; una formulación tópica para el tratamiento de las infecciones de las uñas 
(conclusiones 1-3) y una formulación intravenosa/oral para el tratamiento de las 
infecciones fúngicas sistémicas (conclusiones 4-12). 
Conclusiones: 
1.- Se ha diseñado una laca de uñas de AmB estable e impermeable al agua para el 
tratamiento de la onicomicosis. El polímero (Eudragit L100®) y el disolvente usado 
para la anfotericina B (N-metil-2-pirrolidona) no mostraron problemas de 
compatibilidad. Una vez aplicadas sobre la superficie, la laca de uñas forma una 
película continua, homogénea, lisa y resistente al agua. 
2.- Los estudios de penetración in vitro demostraron que la laca era capaz de penetrar la 
uña (factor de penetración casi dos veces el del control). Los estudios de actividad in 
vitro demostraron la eficacia de la laca de uñas contra hongos dermatofitos y no 
dermatofitos así como contra levaduras (género Cándida) 
3.- Los estudios de eficacia in vitro sobre estructuras queratinizadas de origen animal 
apoyaron la eficacia de la anfotericina B. Después de 30 días de tratamiento en días 
alternos, la laca de uñas fue capaz de eliminar las infecciones causadas por 
Trichophyton mentagrophytes, Trichophyton rubrum, Aspergillus niger, Fusarium 
oxysporum y Fusarium solani. 
4.- Se ha desarrollado una nueva formulación para la liberación de AmB empleando un 
polímero capaz de formar micelas (5 kDa monometoxi-polietilenglicol funcionalizado 
con ácido colánico - PEG5kDa-colánico). Se observó que este polímero aumentaba 10
5 
veces la solubilidad de la anfotericina B con una relación molar AmB/PEG5kDa-colánico 
de 12:1 (relación p/p 2:1). 
5.- El sistema AmB/PEG5kDa-colánico forma micelas de 30 nm con las cavidades 
hidrofóbicas del colánico localizadas dentro de las micelas. El análisis del potencial zeta 
mostró que a pH neutro (pH 5.5 -7.2) la superficie global de la micela es casi neutra. El 
PEG5kDa-colánico interactúa con la anfotericina B a través de tres sitios de unión 
dependiendo del pH, lo que sugiere que la interacción polimérica depende del grado de 
ionización y de la agregación de la anfotericina B.  
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6.- Una vez liofilizado, el producto obtenido puede ser rápidamente redispersado para 
formar una dispersión coloidal homogénea. La dispersión es físico-químicamente 
estable. La espectrometría infrarroja por transformada de Fourier, la calorimetría 
diferencial de barrido y la difractometría de rayos X mostraron que en el producto 
liofilizado la anfotericina B y el PEG5kDa-colánico interactúan íntimamente.  
7.- La liberación de la anfotericina B de las micelas de PEG5kDa-colánico mostró un 
perfil bifásico. Los mejores ajustes fueron obtenidos con los modelos de Higuchi y 
Korsmeyer-Peppas. 
8.- La toxicidad de la nueva formulación se ensayó en términos de hemólisis. La nueva 
nanoformulación de AmB/PEG5kDa-colánico fue en todos los casos menos hemolítica 
que la formulación comercializada de referencia Fungizona® 
9.- La actividad antifúngica de la anfotericina B ensayada contra Candida albicans 
mostró que la formulación de AmB/PEG5kDa-colánico era un 15% más activa que la 
anfotericina B libre en tampón.  
10.- Los perfiles farmacocinéticos IV de las diferentes formulaciones estudiadas 
(AmBisome®, Fungizona® y AmB/PEG5kDa-colánico) fueron significativamente 
diferentes. La constante de eliminación aparente (Ke) de la nueva formulación fue 
significativamente menor (P<0.01) que la de AmBisome® y Fungizona®. 
Consecuentemente, el valor de la semivida de esta formulación fue mayor. La 
administración intravenosa de 1 mg/kg de AmB/PEG5kDa-colánico causó menos efecto 
de dolor en las ratones que la administración de la misma dosis de Fungizona® o 
AmBisome®  
11.- Los estudios de farmacocinética oral confirmaron que esta nueva formulación tiene 
una semivida más alta que las formulaciones comercializadas Ambisome® y 
Fungizona®. Los valores de AUC0-24 fueron muy similares para todas las formulaciones 
ensayadas.  
12.- Se puede concluir que la nueva formulación AmB/PEG5kDa-colánico es un sistema 
de liberación controlada soluble muy prometedor y con una menor toxicidad en 
comparación con la Fungizona® 
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SOMMARIO 
 
NUOVE FORMULAZIONI PER LA VEICOLAZIONE DI AMFOTERICINA B 
INTRODUZIONE 
L’amphotericina B (AmB) è un antibiotico macrolide con un ampio spettro d’azione, da 
oltre 40 anni usato nel trattamento di infezioni micotiche sistemiche. 
Sebbene recentemente siano stati sviluppati nuovi farmaci antifungni, AmB rimane il 
farmaco di prima scelta nel trattamento di gravi infezioni fungine e nel trattamento di 
leismaniasi viscerale nel caso in cui i parassiti sviluppino una resistenza ai composti 
antimoniali. 
La bassa solubilità di AmB è il principale problema al suo sviluppo farmaceutico e ad 
oggi si sono fatti numerosi tentativi per sviluppare formulazioni di AmB con migliorate 
caratterisitiche biofarmaceutiche e profilo terapeutico. Tra le principali formulazioni vi 
sono nanoparticlelle lipidiche solide, nanoparticelle polimeriche, micelle e bioconiugati 
polimerici  
La nefrotossicità è uno dei maggiori problemi all’uso clinico di questo farmaco che si 
unisce alla difficoltà della somministrazione  intravenosa. 
 Lo sviluppo di formualzioni per uso orale, intravenoso e topico  con ridotta tossicità 
consente l’impiego di AmB nel trattamento di infezioni fungine sistemiche e topiche nel 
caso di infezioni miste resistenti oltre che nei tratatmenti tradizionali. Pertanto 
formulazioni innovative consentono un uso più razionale, sicuro e ampio di questo 
farmaco con una migliore performance terapeutica e compliance del paziente. 
 OBIETTIVI 
La crescente importanza delle ripercussioni cliniche delle infezioni nell’uomo e 
nell’animale ha portato alla necessità di sviluppare formulazioni che possano essere 
sempre più efficacy nel trattamento di quetse patologie e in grado di coprire in modo 
ampio lo sviluppo di infesioni. 
L’ampio spettro di azione di amfotericina B (AmB) unitamente alla bassa resitenza 
sviluppata, rendono questo farmaco un eccellente candidato per il trattamento di vari 
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tipi di micosi. Pertanto, il principale obiettivo di questo lavoro di tesi è stato lo sviluppo 
di nuove formulazioni di AmB per il tratatmento topico e sistemico di micosi con 
ridotta tossicità. Sono state sviluppate due tipi di formulazioni.  
Nella prima parte del lavoro di tesi lo studio si è focalizzato su formulazioni per uso 
topico. In particolare, si è sviluppato uno smalto per unghie contenente AmB per il 
tratatmento di onicomicosi miste resistenti ai tarttamenti tradizionali.  
Nella seconda parte del lavoro di tesi sono stati condotti studi formulativi di AmB in 
collaborazione con l’Università degli Studi di Padova. In quetso caso si è sviluppata una 
formualzione di AmB fisicamente PEGilata per il trattamento sistemico  di infezioni 
fungine dopo somministarzione orale o intravenosa.  In questo caso si è considerato che 
AmB è nota interagire con molecole di colesterolo e in generale stereoidee che ne 
favorisono la sua solubilità. Pertanto,  si sono prodotti bioconiugati di moelcole  
steroidee con PEG in grado di aumentare la solubilità e stabilità di AmB. Si sono quindi 
preparati bioconiugati PEG-cholane e si sono ottenuti diversi tipi di assemblati 
AmB/PEG-cholane che sono stati caratterizzati attarverso varie tecniche tra cui: DLS, 
HPLC, DSC, RX, FTIR, CD, ITC e analisi con sicrotrone. Negli studi ex vivo di questi 
complessi si è studiata la tossicità mediante test di emolisi e l’efficacia antifungina 
contro Candida albicans. Infine, sono stati condotti alcuni studi in vivo dopo 
somministrazione orale e intarvenosa a topi. Le proprietà farmacocinetiche delle 
formualzioni di AmB sono state esaminate comapartvamente rispetto al farmaco in 
soluzione libera e a prodotti commerciali quali Ambisome® and Fungizone®. 
RESULTATI 
Per quanto riguarda le formulazioni di AmB per uso topico, sono state preparate diverse 
formulazioni di smalto per le unghie sia permeabili che impermabili.  Per queste 
preparazioni sono stati studiati il tempo sdi essiccamento, la visocsità, l’spetto del film, 
la stesura in film, la brillantezza, il pH e la capacià di incorporamento di AmB. Tra i 
vari prototipi formulativi preprati, ne sono stati slezionati tre che sono stati oggetto di 
ulteriori studi in vitro (F11, F13 and F19). Sebbene le formulazioni 11, 13 e  19 
consentissero di superare i problemi di bassa solubilità di AmB, la stabilità nel breve 
periodo (1 mese) ha rappresentato ancora un grande limite al loro impiego. La strategia 
impiegata per superare i problemi d stabilità di AmB  ha portato a considerare in 
particolare lo sviluppo di polveri da ricostituire estemporaneamente. Le tecniche di 
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freeze drying (nel caso di F11 e F13) e spray drying (nel caso di F19) hanno generato 
prodotti essiccati e liofilizzati stabili e facilmente risispersibili. Studi di penettrazione 
unghieale in vitro condotti su unghie femminili umane, hanno dimostrato una maggiore 
penetrazione nel caso di F19 (EF=1.95) rispetto a F11, F13 e al controllo. Gli studi in 
vitro condotti con Candida albicans ha dimostrato che la formualzione più efficace era  
F19 (103%). Lo smalto per unghie contenente AmB è risultato efficace nel tratatmento 
di infzsione dermatofitiche e non-dermatofitiche non localizzate nelle strutture 
cheratinizzate. Il trattamento per 30 giorni con F19, somministarto una volta al giorno a 
giorni alternati, ha portato all’eliminazione dell’infezione di T. mentagrophytes, T. 
rubrum, A. niger, F.oxysporum and F.solani. Dopo 30 giorni di trattamento non si è 
rilevato alcun microorganizmo né per esame diretto né con studi con culture cellulari. 
Per quanto riguarda le formulazioni PEGilate di AmB, gli studi di solubilità hanno 
dimostrato che il PEG5kDa-cholane può aumentare fino a 10
5 volte la solubilità di AmB 
con una correlazione lineare [farmaco sciolto]/[polimero]. La diversa capacità del 
PEG5kDa-cholane di solubilizzare AmB è stata ascritta alle diverse forme fisiche, 
monmeriche, multimeriche e aggregate del farmaco. Mediante calorimetria isotermica 
(ITC) è stata osservata una elevata affinità di AmB per PEG5kDa-cholane. Questa tecnica 
ha evidenziato la complessità delle inetrazioni tra il farmaco e il polimero che 
avvengono con diverse forme di AmB, monomeri e multimeri, inclusi nanoaggergati 
solubili la cui composizione e abbndanza  dipende dal pH. I tre diversi siti di binding 
calcolati mediante ITC risultano ragionevolemente dalle interazioni di varie zone 
idrofobiche eptaeniche di AmB con la frazione dell’acido colanico. Il processo di 
liofilizzazione ha prodotto una polvere soffice con basso contenuto di umidità senza 
formazione di un cake. Questo prodotto è risultato stabile nel lungo periodo. L’analisi 
spettoemtrica CD ha mostrato che come nel caso di  Fungizone® e Fungizone® 
riscaldato, le micelle di AmB/PEG5kDa-cholane non inuucono alterazioni struttirali di 
albumina (HSA). Gli studi di emolisi hanno confermato che le micelle di  
AmB/PEG5kDa-cholane sono meno emolitiche di Fungizone®. Anche nel caso in cui  
Fungizone® induce il 100% di emolisi, la formulazione AmB/PEG-cholane non 
provoca più del 30% di emolisi. Gli studi di attività biologica hanno mostrato che AmB 
formulate con PEG5kDa-cholane mantiene una elevata attività antifungina, che è risultata 
essere molto simile a quella di AmB in soluzione libera. La somministarzione orale di 5 
mg/kg di AmB ha mostrato una maggiore emivita plasmatica del farmaco rispetto ad 
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alter formulazioni. Infine, la somministarzione intravenosa di 1 mg/kg di AmB in 
Ambisome®, Fungizone® e AmB/PEG5kDa-cholane ha mostrato che la nuova 
formulazione ha una significativamente (P<0.01) minore costante di eliminazione 
apparente e una maggiore emivita plasmatica rispetto alle formualzioni commerciali 
Ambisome® and Fungizone®. 
CONCLUSIONI 
In questo lavoro di tesi vengono riportate le preparazioni di due tipi di formulazioni di 
AmB, una per uso topico per il trattamento di infezioni fungine unghieali (conclusione 
1-3) e una formulazione per la somministrazione intarvenosa o orale per il trattamento 
di infesioni sistemiche (conclusione 4-12). 
Conclusioni: 
1.- Un nuovo smalto per unghie impermeabile conetenente AmB è stato prodotto per il 
trattamento di onicomicosi. Il polimero (Eudragit L100®) e AmB non hanno dimostarto 
incompatibilità con il solvente (N-methyl-2-pyrrolidone). Una volta applicato sulla 
superficie lo smalto forma uno strato omogeneo, continuo, liscio e resistente all’acqua.   
2.- Studi in vitro hanno dimostrato che lo smalto può penetrare le unghie con un 
incremento di quasi 2 volte rispetto al controllo. Studi di attività in vitro hanno 
dimostarto l’efficacia dello smalto per unghie nel trattamento di dermatofiti e non 
dermatofiti quali muffe (tipo Candida). 
3.- Gli studi di efficacia in vivo condotti su cheratina di origine animale hanno 
dimostrato l’efficacia di AmB. Dopo un tratatmento di  30 giorni a giorni alternati, lo 
smalto per unghie ha eliminato le infezioni da Trichophyton mentagrophytes, 
Trichophyton rubrum, Aspergillus niger, Fusarium. oxysporum e Fusarium solani. 
4.- E’ stata sviluppata una nuova formualzione di AmB usando micelle costituite da un 
bioconiugato di  5 kDa monometossi polietilene glicole funzioanlizzato ad un terminale 
con acido colanico (PEG5kDa-cholane). Il polimero aumenta la solubilità di AmB di 10
5 
volte con un rapporto molare 12:1 AmB/PEG5kDa-cholane (2:1 rapporto ponderale).  
5.- Il sistema AmB/PEG5kDa-cholane forma micelle di 30 nm con le frazioni 
iderofobiche localizzate nella parte interna delle vescicole. L’anali del potenziale zeta a 
vari pH (5.5-7.2) ha dimostrato che in superficie le micelle sono quasi neutre. Il 
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PEG5kDa-cholane interagisce con AmB attarverso tre siti di binding a seconda del pH 
suggerendo che l’interazione con il polimero dipende dallo stato di ionizzazione e 
aggergazione di AmB.  
6.- Dopo liofilizzaizone, il prodotto può essere estempraneamnete risdisperso per 
formare una dispersione omogenea colloidale. La dispersione è risultata stabile da un 
punto di vista fisicochimico. Studi condotti con FTIR, DSC and XRD hanno dimostrato 
che nel prodotto liofilizzato, AmB e PEG5kDa-cholane interagiscono intimamente.  
7.- Il rilascio di AmB dale micelle di PEG5kDa-cholane è riusltato avvenire con un 
profilo bifasico. Il  best fitting dei profili di rilascio è stato ottenuto con il modello di 
Higuchi e Korsmeyer-Peppas.  
8.- La tossicità della nuova formualzione è stata testata in termini di emolisi. La nuova 
formulazione AmB/PEG5kDa-cholane è sempre risultata meno emolitica rispetto al 
riferimento  Fungizone®. 
9.- L’attività antifungina di AmB testate contro Candida albicans ha mostrato che  
AmB/PEG5kDa-cholane è 15% più attiva del farmaco in tampone. 
10.- I profili farmacocinetici ottenuti per somministarzione intarvenosa condotti con 
Ambisome®, Fungizone® e AmB/PEG5kDa-cholane sono risultati significativamente 
diversi. La costante di eliminazione apparente (Ke) della nuova formulazione è 
signficativamente (P<0.01) più bassa di quella ottenuta con Ambisome® e Fungizone®. 
Pertanto, il valore di emivita della nuova formulazione è risultata maggiore. Nei topi la 
somministarzione intravenosa di 1 mg/kg AmB/PEG5kDa-cholane ha causto una minore 
sofferenza rispetto alla stessa dose di  Fungizone® e Ambisome®.  
11.- Gli studi farmacocinetici condotti per somministarzione orale hanno dimostrato che 
questa formualzione consente di ottenere una maggiore emivita rispetto ad Ambisome® 
e Fungizone®. L’ AUC0-24 era simile in tutte le formualzioni testate. 
12.- Si può quindi concludere che òa nuova formulazione AmB/PEG5kDa-cholane è un 
sistema di veicolazione promettente in quanto stabile, con minore tossicità rispetto a 
AmB libera  e rispetto al prodotto commericale Fungizone®. 
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1. INTRODUCTION 
1.1. Polyene antibiotics 
 
Polyene antibiotics, produced by different species of Streptomyces, are considered as a 
chemical and biological subdivision of the macrolide class. They are characterized by 
the presence of a macrocyclic lactone ring (carbon atoms closed by lactonization) and a 
series of conjugated double bonds in their structure. Being the latter, the responsible for 
the differences observed in between the polyene and erythromicin groups. The main 
differences accounted for these groups (polyene and erythromicin) are related to the 
antimicrobial spectrum of action, the site of action and the mode of action [1]. While the 
erythromicin group is active against gram-positive bacteria, Haemophilus, Brucella and 
Neisseria, the polyene antibiotics are inactive against bacteria. With regards to the site 
of action, the polyene antibiotics act on sterol or ergosterol-containing membranes and 
the erythromycin group on the 70S ribosome. Finally, the mode of action of the polyene 
group is based on the alteration of the cell permeability, while the erythromycin 
antibiotics mechanism of action is based on the peptidyl synthetase inhibition and 
translocation. 
Some of the already described polyene antimycotics, approximately 200 to date, are not 
unique or even pure [1, 2]. These polyenes differ ones to the others in the number of 
conjugated carbon-to-carbon double bonds, the size of the conjugated ring and the 
presence or absence of a hexosamine sugar or aromatic moeity in the molecule [3].  
The antibiotics belonging to the polyene group are classified firstly, by the number of 
conjugated double bonds and secondly, by the presence or lack of a glycosidically 
linked carbohydrate in their structure [1]. The carbohydrate moiety, if present, is in all 
cases except for the perimycin, the hexosamine mycosamine. The perimycin has an 
isomer of the mycosamine (the perosamine) in its structure. Considering the number of 
double bonds, the polyene antibiotics can be classified as trienes, tetraenes, pentaenes, 
hexaenes and heptaenes. Tables 1-8 (adapted from [1] summarize the properties of each 
of the above mentioned groups. 
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Table 1. Properties of the trienes 
Name Producing organism 
Chemical composition and 
molecular weight 
References 
Discovery Chemistry 
MM-8 Streptomyces sp. 4% N, no carbohydrates (Mw 726) [4]  
Mycotrienin Strepromyces sp. C36 H50 N2 O8 (Mw 638)  [5]  
Proticin Bacillus licheniformis 
var. mesentericus 
C31 H45 O7 P (Mw 560) [6] [7] 
Resistaphylin S. antibioticus C24 H34 N2 O7 (Mw 463) [8]  
Trienine Streptomyces sp. C, 54.7; H, 8; N 1.3 to 1 (Mw 1,300) [9]  
 
Table 2. Properties of the mycosamine-containing tetraenes 
Name Producing organism 
Chemical composition 
and molecular weight 
References 
Discovery Chemistry 
Amphotericin A 
Streptomyces nodosus 
C, 60.3; H 8.4; N 1.7 
(Mw 915) 
[10] [11] 
Lucensomycin S. lucensis C36H53NO13 (Mw 708) 
[12] [13-15] 
Nystatin S. albulus 
S. noursei 
C47H75NO17 (Mw 926) 
[16] [17] 
PA 166 Streptomyces sp. C35H53NO14 (Mw 712) 
[18] [19] 
Pimaricin (Tennecetin) S. natalensis 
S. chattanoogensis 
S. gilveosporus 
C33H47NO14 (Mw 666) 
[20] [21] 
Rimocidin S. rimosus C38H63NO13 (Mw 742) 
[22] [23] 
Tetramycin S. noursei var. 
jenensis 
C34H53NO14 (Mw 699) 
 
[24]  
Tetrin A Streptomyces sp. C34H51NO13 (Mw 681) 
[25] [19] 
Tetrin B Streptomyces sp. C34H51NO14 (Mw 697) 
[25] [26] 
Unamycin A 
S. fungicidicus 
C, 52.2; H, 7.8; N, 1.7; 
O, 38.3 
[27]  
 
Table 3. Properties of other tetraenes 
Name Producing organism 
Chemical composition 
and molecular weight 
References 
Discovery Chemistry 
Akitamycin Streptomyces akitaensis C 53.7; H, 7.7; N, 1.65 
[28] [29] 
Antimycoin A S. aureus  
[30]  
Chromin S. chromogenes C, 58.2; H, 7.8;  N, 2.3 
[31] [32] 
Endomycin A S. endus 
S. hygroscopicus var. 
- (Mw ≈845) [33] [34] 
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enhygrus 
Polifungin S. noursei var. 
polifungini 
 
[35] [36] 
Protocidin Streptomyces sp. C29H45NO13 (Mw 615) 
[37, 38] [39] 
7071-RP Streptomyces sp. C, 58.3; H, 8; N, 1.65; 
O, 31.5 (Mw 859) 
[40]  
Sistomycosin S. viridosporus Contains N 
[41]  
 
Table 4. Properties of methylpentaenes and lactone-conjugated pentanes 
Name Producing organism 
Chemical composition 
and molecular weight 
References 
Discovery Chemistry 
Methylpentaenes     
  No carbohydrate:     
    Aurenin Streptomyces 
aureorectus 
C33H54O11 (Mw 626) 
[42]  
    Cabicidin S. gougeroti C35H60O13 (Mw 688) 
[43]  
    Chainin Chainia sp. C33H54O10 (Mw 610) 
[44] [45] 
    Durhamycin S. durhamensis C, 63.8; H, 10.2; O, 
25.5 
[46] [47] 
    Filipin complex (I-IV) S. filipensis C35H58O11 (Mw 655) 
(Filipin III) 
[48]  
    Fungichromin (lagostin) S. cinnamomeus  var. 
cinnamomeus 
S. roseoluteus 
S. cellulosae 
C35H58O12 (Mw 671) 
[49]  
    Neopentaene Streptomyces sp. C, 61.3; H, 8.8 
[50]  
    Pentaene S. sanguineus C, 62.1; H, 9.2; O, 28.9   
    Pentamycin (moldcidin 
    B) 
S. pentaticus C35H60O13 (Mw 688) 
[51] [52, 53]  
    Xantholycin S. xantholyticus C, 70.6; H, 9.8; O, 19.7   
         
  Contains carbohydrate:     
    Moldcidin A Streptomyces sp. C42H81NO19 (Mw 903)   
    Lactone-conjugated  
    pentaenes 
    
    Flavomycoin S. roseoflavus var. 
jenensis 
C41H68O10 (Mw 721) 
[38] [54] 
    Mycoticin A  
    (Flavofungin) 
S. ruber C37H60O10 (Mw 664) 
[55] [56] 
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    Mycoticin B S. flavofungini C36H58O10 (Mw 651) 
[57] [58] 
 
Table 5. Properties of "classical" pentaenes 
Name Producing organism 
Chemical composition 
and molecular weight 
References 
Discovery Chemistry 
Contain mycosamine     
  Eurocidin A Streptomyces albireticuli 
S. reticuli 
C40H65NO15 (Mw 800) 
[59] [60] 
  Eurocidin B S. eurocidicus C39H63NO15 (Mw 787)   
Contain N in 
unspecified form: 
    
  Aliomycin S. acidomyceticus Contains S 
[61]  
  Capacidin Streptomyces sp. C54H85N2O18 (Mw 1,049) 
[62]  
  HA106 Streptoverticillum 
cinnamoneum  var. 
sparsum 
- 
[63]  
  HA 135 Streptoverticillum 
sporiferum 
- 
[63]  
  HA145 Streptoverticillum 
cinnamoneum  var. 
albosporum 
- 
[63]  
  HA 176 Streptoverticillum 
cinnamoneum  var. 
lanosum 
- 
[63]  
  PA 153 Streptomyces sp. C37H61NO14 (Mw 744) 
[18]  
  Pentaene S. effluvius C, 58.4; H, 8.2; N, 2; O, 
21.3 
  
  Compound 616 S. parvisporogenes C, 62; H, 7.8; N, 2.7; O, 
27.5 
  
Insufficient data for 
further classification: 
    
  Distamycin B S. distallicus C22H27N9O4 (Mw 481.5)   
  Fungichromatin Streptomyces sp. No N 
[48]  
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Table 6. Properties of hexanes 
Name Producing organism 
Chemical composition 
and molecular weight 
References 
Discovery Chemistry 
Contains no 
carbohydrate: 
    
  Demostatin S. viridogriseus C, 64.9; H, 9; O, 26.1 
(Mw 572) 
[64] [65] 
Insufficient data for 
further classification: 
    
  Cryptocidin Streptomyces sp. C52H83-86NO17 (Mw 
983-986) 
[66]  
  Endomycin B S. hygroscopicus var. 
enhygrus 
S. endus 
 
[33] [67] 
  Flavacid S. flavus C, 61.6; H, 7.8; N, 1.1; 
O, 36.3 
[68]  
  Fradicin S. fradiae  
[69]  
  Mediocidin S. mediocidicus  
[70]  
  Mycelin S. roseoflavus 
S. diastatochromogenes 
S. fradiae 
N 
no N 
[71]  
  Mycelin IMO S. diastatochromogenes  
[72]  
  Tetrahexin (also 
contains a tetraene 
chromphore) 
Streptomyces sp. ATCC 
14972 
C, 65; H, 8.5; N, 1.3; 
O, 24.7 
[73] [74] 
 
Table 7. Properties of heptaenes without aromatic moiety and heptaenes with N-methyl-p-
aminoacetophenone 
Name Producing organism 
Chemical composition 
and molecular weight 
References 
Discovery Chemistry 
Contain no aromatic 
moiety: 
    
  Amphotericin B Streptomyces nodosus C47H73NO17 (Mw 924) 
[75] [76] 
  Candidin S. viridoflavus C47H71NO17 (Mw 922) 
[77]  [78] 
  Mycoheptin S. netropsis C48H77NO17 (Mw 939) 
[79]  
  X-63 Streptomyces sp.  
[80]  
Contain N-methyl-p-
aminocetophenone: 
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  Candimycin S. echimensis C, 57.2; N, 1.7; H, 8.2 
[81] [82] 
  DJ400B S. surinam C66H96N2O22 (Mw 
1,269) 
[83] [84] 
  Perimycin S. coelicolor var. 
aminophilus 
C47H75N2O14 (Mw 892) 
[85] [86] 
Insufficient data for 
further classification: 
    
  Antifungin 4915 S. paucisporogenes C, 63.6; H, 7.8; N, 2.8; 
O, 24.5 
[87]  
  Eurotin A S. griseus  
[88]  
  Heptane 757 Streptomyces sp.  
[89]  
  Monicamycin Streptoverticillium 
cinnamomeus var. 
monicae 
C, 58.3; H, 7.85; N, 2.2 
[90]  
  Neoheptane Streptomyces sp.  
[91]  
  PA 150 Streptomyces sp. C54H82N2O18 (Mw 
1,047) 
[92]  
 
Table 8. Properties of the heptaenes which contains p-aminoacetophenone 
Name Producing organism 
Chemical composition 
and molecular weight 
References 
Discovery Chemistry 
Ascosin S. canescus  
[93]  
Aureofungin S. cinnamomeus var. 
terricola 
C, 60.4; H, 7.9; N, 2.2 
[94] [49] 
Ayfactin A S. viridofaciens C, 62.6; H, 7.8; N, 2.7 
[95]  
Ayfactin B S. aureofaciens C, 62.5; H, 7.6; N, 2.8 
[95]  
Azacolutin (F-17-C) S. cinnamomeus var. 
azacoluta 
 
[96] [97] 
Candicidin S. griseus Ca. C63H85N2O19 (Mw 
1,200) 
[98] [99] 
DJ 400 B2 S. surinam C58H86N2O21 (Mw 
1,147) 
[84] [84] 
Hamycin S. primprina C, 59.9; H, 7.8; N, 2.2; 
O, 20.1 
[100] [101]  
Heptamycin Streptomyces sp. C59H93N2O22 (Mw 
1,181) 
[102]  
Levorin A S. levoris C62H114N2O22 (Mw 
1,238) 
[103]  
Levorin B S. hachijoensis C61H186N2O21 * 2H2O 
[103]  
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(Mw 1,230) 
Trichomycin A S. abikoensis C58H84N2O18 (Mw 
1,097.29) 
[104] [105] 
 
The polyene antibiotics are characterized by a really low solubility. The solubility 
values for these molecules are less than 1 mg/L at physiological pH (6-7) in water or 
water-free alcohols [106]. 
All the polyenes interact with sterols, change the membrane permeability of eucaryotic 
cells and lead to cell lysis [107]. Even though they have the same mechanism of action, 
their effects on artificial membranes and cells are different. The anion or cation 
selectivity of the membrane pores produced [108, 109], their relative preference for 
cholesterol or egosterol-containing membranes [110-113] and their progressive or "all-
or-none" modes of action differ [114-117]. A lot of interest has been focused on these 
antimycotics during the last decades as they have demonstrated to have synergistic 
antifungal action with other agents  [118], to have antitumoral effects  [119] and some 
of them have been shown to have immunoadjuvant properties [120, 121]. 
Between all these polyene antibiotics, the heptaene non-aromatic polyene amphotericin 
B has been the most studied molecule of all the above described antibiotics. Its wide 
antifungal spectrum of action together with its antiparasitic and immunoadjuvant 
properties made researchers considered this molecule as a lead candidate for the 
treatment of systemic antifungal resistant infections and leishmaniasis. 
1.2. Amphotericin B 
1.2.1. Historical background 
 
Amphotericin B (AmB), a polyene antibiotic with a characteristic yellow color, was 
first isolated in 1959 from cultures of Sreptomyces nodosus [122]. Streptomyces 
nodosus, a soil actinomycete, is an aerial mycelium that forms opened and closed spirals 
[123]. It produces gray spherical to oval spores and the tonality of the spores changes 
according to the composition of the culture media. It is a nonchromogenic SH2-negative 
and strongly proteolitic microorganism. It grows in glucose, mannitol, inositol, xylose, 
rhamnose, fructose, trehalose and melibiose but no growth is detected in adonitol, 
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sorbitol, arabinose, cellulose, sucrose, lactose and raffinose. The optimal temperature 
for the growth of this microorganism is in the range 25-37°C [124]. 
In 1955, the S. nodosus strain was collected along the Orinoco delta in Tembladora, 
Venezuela by W. Gold, and the extracts obtained from this strain were first tested for its 
antifungal activity [125]. 
In 1987 Nicolaou et al. described for the first time the complete synthesis of the 
amphotericin B [126]. Even though this was the first published complete AmB 
synthesis, the high costs and low yields that this synthesis implied could not compete 
with the biotechnological production processes already set up and optimized. This is the 
reason why currently the AmB is only produced from strains of Streptomyces nodosus 
at a large industrial scale. 
1.2.2. Physicochemical properties 
 
1.2.2.1. Chemical structure 
Amphotericin B is a mycosamine-containing, macrocyclic polyene antibiotic. 
Chemically it is a (1S, 3R, 4E, 6E, 8E, 10E, 12E, 14E, 16E, 18S, 19R, 20R, 21S, 25R, 
27R, 30R, 31R, 33S, 35R, 37S, 38R)-3-[(2R, 3S, 4S,5S ,6R)-4-amino-3,5-dihydroxy-6-
methyloxan-2-yl]oxy 19, 25, 27, 30, 31, 33, 35, 37-octahydroxy-18, 20, 21-trimethyl-
23-oxo-22,39-dioxabicyclo[33.3.1] nonatriaconta-4, 6, 8, 10, 12, 14, 16-heptaene-38-
carboxylic acid. Its molecular formula is C47H73NO17 and its molecular weight 924.08 
g/mol.  
It is characterized by the presence of both hydrophobic (polyenehydrocarbon chain) and 
hydrophilic (polyhydroxyl chain) domains which confers the molecule its amphoteric 
nature. As detailed in figure 1, the hydrophilic domain is composed by seven hydroxyl 
groups and an ester, while the hydrophobic domain is constituted by seven double 
bounds. The heptaene chain is responsible for the rigidity of the molecule. Apart from 
the hydrophobic and hydrophilic parts, an internal hemiketal ring is contained. When 
the AmB is in solution the hemiketal is in equilibrium with the ketone opened ring 
[127]. The amphotericin B can behave as base or acid as a function of the pH. The 
carboxyl group (pKa of 5.5) and the amino group located in the mycosamine (pKa of 
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10) are both ionized at physiological pH [128]. The amphoteric character of this drug is 
responsible for its poor solubility in both aqueous and organic solvents. 
Several chemical modifications on the C-16 carboxyl and/or in the 3' amino groups 
located in the mycosamine of the AmB have been extensively studied in order to 
improve the drug solubility. Nevertheless, these new semisynthetic derivates have been 
never marketed [129].  The hydroxyl groups located in the C-7 to C-10 region are key 
for the AmB antifungal activity. Therefore, the new approaches for obtaining 
amphotericin B derivates with higher efficacy and lower side effects are focused on 
changes on the C-7-C-10 region apart from the carboxyl group located in C-16 [130]. 
 
 
Figure 1. Chemical structure of amphotericin B 
As detailed before, the AmB is produced by Streptomyces nodosus. This microorganism 
does not usually produce pure AmB. It generates a mixture of AmB and, in much lower 
amount, its reduced derivative amphotericin A (AmA). The C28-29 double bond in 
AmA is reduced, which implies a decrease in potency [131]. For this reason the 
production of amphotericin B at a large industrial scale should be closely controlled as 
the pharmacopoeias only accept as amphoterin B those products that contains a mixture 
of AmB and AmA in which AmB is at least in a 75% [132]. 
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1.2.2.2. Solubility 
As previously detailed for the polyene antimycotics, amphotericin B has limited 
solubility in water (table 9). At pH 6-7 its solubility is lower than 1 mg/L, reason why 
this drug is almost not orally absorbed (there is almost no gastrointestinal resorption) 
and it has to be parentally administered [106]. Even though at pHs below 2 (pH<2) and 
above 11 (pH˃11) AmB is water-soluble, at this extreme pHs the molecule is not stable 
[133]. The AmB higher solubility at those acidic and alkaline pHs is explained by the 
formation of salts. However this increase in solubility is not only accompanied by a 
decrease in stability but also by a reduction in the antimycotic activity. 
The AmB solubility in organic solvents is slightly higher than in water. Only 
dimethylsulfoxide (DMSO) solubilizes the AmB at more than 3 mg/mL. 
 
Table 9. AmB solubility in different solvents [132].  
Solvent AmB solubility (mg/mL) 
Dimethylsulfoxide 30-40 
Ethylenglycol 2.6 
Dimethylformamide 2-4 
Methanol 2 
Acetic acid 1-2 
Propylenglycol 1-2 
Ethanol 0.5 
Acetone 0.35 
Isopropyl alcohol 0.11 
Alkalin or acidic water 0.1 
Chloroform 0.08 
Cyclohexane 0.02 
Petroleum ether 0.01 
Water at physiological pH <0.001 
 
Many attempts have been performed during the last decades to increase the 
amphotericin B solubility. First attempts were focused on the use of surfactants as 
sodium lauryl sulfate or sodium deoxycholate [132]. These solubilizers increased the 
not only the AmB solubility but also its toxicity [134]. Following attempts considered 
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the AmB solubilization with phospholipids and /or cholesterol [135] and recent attempts 
included the AmB covalently binding to polymers, its loading in particles or 
nanosuspensions, its solubilization in polymeric micelles, etc.  
 
1.2.2.3. Aggregation State 
Amphotericin B can be found in different aggregation states; monomeric, dimeric and 
polyaggregated. Not only the aspect of the AmB changes with the different aggregation 
states but also the activity, pharmacokinetics and drug toxicity are influenced.  
In water suspensions three different AmB forms coexist: monomers, water soluble 
oligomers and non-water soluble aggregates [136-138]. The molecular weight (Mw) of 
these species consequently differs. A polyene antibiotic solution can contain species 
with molecular weights of approximately one thousand dalton (Da) (monomers) to few 
millions Da (colloid-type micelles) [139]. 
AmB molecules in the monomeric state are found at concentrations below 10-7 M. The 
critical aggregation concentration for amphotericin B (CAC) is very low, less than 1 
µg/ml, which means that above those concentrations the molecules, will associate [134, 
140]. These molecules are amphiphatic and thus, in aqueous media and with increasing 
drug concentrations, they have a high tendency to interact ones to each others (head-to-
tail arrangement). The AmB monomeric molecules interaction is lead by hydrophobic 
forces. The interaction of one monomeric molecule with another (dimerization) forms 
dimers (figure 2A). The dimerization is considered as the first step of aggregation [141]. 
The consecutive steps in the aggregation process involves first, the interaction of two 
dimers which generates a tetramer (figure 2B) and secondly, the interaction of dimers 
with tetramers constituting larger aggregates. The AmB monomers and self-associated 
species (oligomers) are water-soluble while the association of oligomers are non-water 
soluble [136]. 
Chemically, the interaction between two monomers (dimer) is stabilized by the 
hydrophobic interactions of the chromophores and the hydrogen bonds formed between 
the hydroxyl group on C35 and the oxygen located in between the C42 and the C19. On 
the other hand, the dimers association into tetramers results from the hydrogen bonds 
formed between the hydroxyl groups in C8 and C3 [142,143]. The external surface of 
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the tetramer is constituted by the polyene hydrophobic chains which allows for the 
interaction with other AmB molecules through van der Waals forces [132]. 
 
Figure 2. Amphotericin B aggregation process 
When the AmB is dissolved as monomers it produces yellow transparent solutions. The 
dimeric aggregation state generates yellow-orangish translucid colloidal dispersions and 
finally, the AmB polyaggregates are found as yellow opaque suspensions. 
The aggregation properties of the AmB are influenced by pH changes [144]. At pH 7.4 
the polyene antibiotic molecules are zwitterions. The dimerization and association 
constants at this pH suggest that the most soluble species are the dimers. On the 
contrary, in acidic and alkaline media, (below pH 2 or above pH 10) the AmB 
molecules have net charge. In this case, the dimerization and association constants 
decrease due to the repulsive forces between molecules with the same sign of net charge 
and therefore the AmB is found mainly as monomers [145]. 
Permeation studies performed by Bolard et al in 1991 demonstrated that only self-
associated AmB induces damage in cholesterol-containing cells [146]. Two self-
association forms of AmB are found in water; one water soluble and another one non-
Monomer Dimer Tetramer 
A B 
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water soluble. In 1992 Legrand et al reported that only the water soluble self-associated 
species were responsible for the AmB toxicity [136]. Both studies were in fair 
agreement with the hyphotesis of Gruda and Dussault [147] based on the lower toxicity 
of the AmB when administered as monomers compared to dimers. Therefore, the AmB 
monomers are non-toxic towards mammalian cells, permeating only fungal cells, while 
the water soluble self-associated species are non selective. They are toxic to both 
mammalian and fungal cells. 
The proportion of these chemical species, as well as the aggreation state, depends not 
only on the AmB concentration but also on the dilution, the AmB solubilizer (organic 
solvent, surfactant or polymer), the mixing method, the mixing temperature, etc. [148]. 
The rate of AmB aggregation, for example, is strongly increased with dilution [149].  
In order to decrease the AmB associated toxicity in water at physiological pH many 
strategies have been developed during the last decades (the dimers are the main species 
found in water at pH 7.4). The use of surfactants that maintain the AmB in the 
monomeric state [150]; the heat of AmB to produce a new self-associated state 
("superaggregates") [151] as well as the inclusion of the polyene antibiotic into carriers,  
are some of the techniques that have acquired a high relevance in the design of new 
AmB formulations. As shown in figure 3, the AmB loading into carriers must assure a 
controlled drug release. Independently of the initial AmB aggregation state, the drug 
delivery system (DDS) should release the AmB as monomers below the critical 
aggregation concentration. If the AmB is slowly released in monomers, the 
rearrangement of AmB molecules into soluble aggregates, once in blood, will not take 
place and the nephrotoxicity and neurotoxicity will be avoided. Any method that 
decreases free AmB concentration in plasma is expected to reduce its direct toxicity 
[151]. Moreover the carriers’ integrity upon dilution is a key factor in the design of non-
toxic formulations. The carriers should maintain their integrity once injected in plasma 
in order to avoid the fast AmB release and molecules re-aggregation [152]. 
Introduction 
 
42 
 
Figure 3. AmB selectivity and toxicity against ergosterol/cholesterol cells depending on the aggregation 
state. On the left side, AmB being release as monomers and damaging ergosterol cells. On the right side, 
AmB being released as aggregates and damaging both cholesterol and ergosterol cells. 
 
1.2.2.4. Ultraviolet-Visible spectroscopy 
As detailed in point 1.2.2.1, the AmB has a heptaene chain on its structure. These seven 
conjugated double bonds have a key role on AmB spectroscopic properties. They 
behave as cromophore.  
The ultraviolet (UV) spectra of the AmB differs with increasing drug concentrations 
(Figure 4) and therefore, the UV spectroscopic analysis are very helpful for the study of 
the different AmB aggregation states (the aggregation state of the AmB varies with 
increasing drug concentrations). 
At very low concentrations (< 10-7 M) the AmB is found as monomer and it spectrum is 
similar to that obtained for the polar organic solvents [139]. The heptaene chromophore 
characteristic absorption spectrum is obtained at these low concentrations. As observed 
in figure 4 (M-AmB), four well-separated bands at 344-350 nm, 363-368, 393-388 and 
406-412 nm are detected [153-155]. 
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Figure 4. Amphotericin B UV-Visible absorption spectra of its different aggregation states: monomer or 
M-AmB ( ___ ), dimer or D-AmB (........) an polyaggregate or P-AmB (_ _ _) [156]. 
 
With increasing AmB concentrations the spectrum changes, and at concentrations above 
10-4 M, a completely new spectrum is defined. This is due to the formation of small 
oligomers, mainly dimers [138].  
The dimeric profile of amphotericin B is characterized by a intense band at 328-340 nm 
due to an hyperchromic shift [157] and less intensive bands at 363-368 nm, 383-388 nm 
and 406-412 nm due to an hypochromic effect. Moreover in this dimeric profile there 
appears a new band located at 415-425 nm (bathochromic shift) (figure 4, D-AmB).  
At higher AmB concentrations, the chomophore groups from the AmB molecules 
interact through hydrophobic forces and form bigger aggregates (polyaggreagates). This 
interaction results in a decrease in bands absorption (hypochromic effect). As shown in 
figure 4 (P-AmB) the bands located at 360-363 nm, 383-385 nm and 406-420 nm have 
almost no absorption. This is in accordance to Rinner et al publication which stated that 
the larger AmB aggregates are almost not detected through the spectroscopic techniques 
[158]. 
1.2.2.5. Infrared spectroscopy 
The first information regarding the infrared spectrum (IR) of amphotericin B was 
published in 1977. Schwartzman et al described two types of forms possibly found in 
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AmB powders. They demonstrated that the IR spectrum of AmB presented at room 
temperature, a mixture of two different forms called Types I and II [159]. The first type 
predominated in hand-ground samples while the second type was mostly found in 
vibrator ground samples. Both types differed in the size of the fragments which were 
smaller for Type II compared to Type I. Type I spectrum (figure 5A) was characterized 
by a sharp C=O stretching band at 1692 cm-1, a C=C stretching band at 1556 cm-1 and 
C-H bands and stretching bands at 850, 1380 and 2680 cm-1. On the contrary, Type II 
spectrum  (figure 5B) showed, in general, broader an less resolved bands which 
included a broad C=O stretching band at 1712 cm-1 and a C=C stretching band at 1566 
cm-1. The bands located near 900, 1233, 2930 and 2970 cm-1 also differed between 
types I and II. The differences found in between samples seemed not to be related to the 
particle size.  
 
Figure 5. IR spectra of amphotericin B. Hand-ground (A) and vibrator-ground AmB powders (B) [159]. 
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Figure 6. FT-IR Spectra of AmB. ν (stretching vibrations), δ (bending vibrations). 
 
These summarized descriptions of the bands have been completed over the last years. 
The recent AmB analyses through Fourier-Transform infrared (FT-IR) spectroscopy 
have been able to detect and identify the main AmB functional groups. From all the 
peaks observed in figure 6,  the ones located at 1689 cm-1 and 1552 cm-1, corresponding 
to stretching vibrations on C=O  and bending vibrations on NH2 respectively, are the 
most important. This is supported by the fact that those functional groups are directly 
related to the physicochemical and pharmacological properties of the AmB [108]. 
 
1.2.2.6. X-ray diffraction analysis 
Amphotericin B is known to have a crystalline structure. The degree of crystallinity in 
AmB at different conditions have been deeply studied so far [159], concluding that not 
only the crystalline structure varies with the preparation process (ground) but also with 
the temperature. 
The X-ray diffraction spectrum of the amphotericin B (unheated or unground) 
demonstrates the crystal structure of the molecule (figure 6A). When the amphotericin 
B is heated or grounded by vibration, the diffraction pattern changes (figure 6B). On 
one hand, the heating at 158ºC (figure 6A) reveals a pattern with less intense peaks, 
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increased background and slight changes in d-spacings (the amorphous fraction is 
increased). On the other hand, the vibrator-ground powder shows very low intense and 
broad peaks (figure 6B). This pattern is typical of amorphous powders. 
 
 
 
Figure 6. X-Ray spectrum of amphotericin B. (A) Unheated versus heated AmB at 158ºC. (B) Vibrator-
ground AmB powder [159]. 
 
1.2.3. Mechanism of action 
 
Amphotericin B mechanism of action is still not well determined. It seems that the AmB 
affects cells at two levels [160]: 
 Binding to the ergosterol contained in the membranes and 
 Inducting oxidative damage. 
A 
B 
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Figure 7. Amphotericin B mechanism of action on fungal cells. At the membrane, pores formation (1) or 
ergosterol sequestrion (2). Inside the cell the AmB can induce oxidative burst through different pathways: 
acting directly as prooxidant (3), first binding to ergosterol and then oxidizing (4) or influencing the 
mitochondrial activity (5). 
 
The amphotericin B effect on the cell membrane can lead to pore formation or 
ergosterol sequestration while, its intracellular effect falls on the induction of oxidative 
stress (figure 7).   
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1.2.3.1. AmB effects on cell membrane 
AmB has the ability to insert into the fungal and parasitic lipid membrane bilayer. This 
insertion takes place through its hydrophobic domains. As a result of this interaction 
multimeric pores are formed in which the hydrophobic domains (polyene chains) of the 
drug are in contact with the membrane lipids. The pores increase the cell permeability to 
small cations such as K+, Ca+ and Mg+, leading to a loss of intracellular ions and 
therefore, cell death.  
AmB does not only bind to ergosterol containing cells but also to others sterols cell 
membranes, such as cholesterol (mammalian cells). However, the affinity of AmB for 
other sterols is lower than for ergosterol. It has to be considered, as detailed in point 
1.2.2.3 that the affinity, and therefore the toxicity of AmB for the different sterols 
depends on its aggregation state.  
AmB binding to ergosterol or cholesterol-containing membranes can take place in two 
different ways (figures 8 and 9).  
Figure 8 (adapted from [161]) shows the hydrogen bonds formed between the sterols 
and the drug. These constitute the first type of interaction. This interaction forms a 
"cage" like structure in which the hydrogen bonds are mainly formed in between the 
hydroxyl groups of the sterol and the carboxyl group in C-18 of the AmB. The presence 
of water is responsible for this type of interaction. The AmB mycosamine amine group 
also participates in this binding; it strengthens the AmB-sterol interaction. As both, 
ergosterol and cholesterol molecules are 3-β-hydroxy sterols, their hydrogen bond 
reaction with AmB is assumed to be similar [161]. 
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Figure 8. Interaction between AmB and sterols through hydrogen bonds. 
 
The second type of interaction (figure 9) is based on the Van der Waals forces that 
might appear between the polyene rigid chain (7 double bonds) of AmB and the whole 
sterol molecule. A study performed in 1989 by Hervé et al., concluded that the greater 
affinity of AmB to ergosterol compared to cholesterol was explained by the double 
bond located in C-22 of ergosterol [162, 163]. The conformational studies of both 
molecules showed that the overall shape of ergosterol conformers was flat while the 
cholesterol flat shape was just one of its possible conformations. The absence of a 
double bond in the side chain of cholesterol (C-22) confers more flexibility to this 
molecule [161,164] . 
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Figure 9. Interaction between AmB and cholesterol or ergosterol through Van der Waals forces. 
 
In 2011, Palacios et al., described two different mechanisms for AmB cell membrane 
damage: sterol sequestration (membrane destabilization) and membrane 
permeabilization (ions depletion) [165]. The sterol, and concretely, the cholesterol 
sequestration by AmB, avoids the interaction of parasite-macrophage in the Leishmania 
infections. This mechanism, even though, will cause damage on the host cells as the 
cholesterol is sequestrated, is considered as a novel and useful AmB mechanism for the 
treatment of visceral Leishmaniasis [166]. Ergosterol is needed in a large number of 
cellular processes: endocytosis, vacuole fusion, stabilization of proteins, etc. [167]. 
AmB binding and sequestration of ergosterol is enough to damage cells due to the 
multiple cell processes in which ergosterol is implied. The pore formation enhances to 
the antifungal efficacy but it is not essential for the fungal cells death [168]. 
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As for the pore formation is concerned, several studies have revealed that AmB forms 
two different kind of pores. The mechanism of AmB pore formation as well the 
mechanism of AmB membrane entrance are still very unclear. Some hypothesize that 
the AmB monomers enter in some way the membrane and form binary complexes with 
the lipids located at this level, generating the channels. This is called "sequential" 
mechanism. Others hypothesize that AmB supramolecular complexes are firstly formed 
in the membrane surface and then enter the membrane producing a membrane 
reorganization towards functional channels. This is considered as the "one step" 
mechanism [169]. 
The two types of AmB pores are formed in different moments and their substrate 
specificity and killing effects are different [160,170]. After cells contact with AmB the 
non-aqueous pores are firstly formed. These pores are permeable to monovalent cations 
but show low affinity for monovalent anions [171]. Later on, the aqueous pores are 
formed. In this case, the pores are permeable to monovalent anions and cations, and 
large electrolytes (eg. glucose). The pore formation is a fast process that usually takes 
place in milliseconds [160]. Depending on the membrane composition (content of 
ergosterol or cholesterol)  and the AmB delivery system, the speed of the process and 
the AmB concentration needed to form the pores differs [172].  
Figure 10, taken from [173] simulates the AmB-cholesterol/ergosterol channels. The 
yellow balls simulate the sterols molecules; the red balls represent the AmB carboxyl 
groups and, the N-P and O-N refer to the interactions that take place between the amine 
group of the AmB and the phosphate of the dimyristoylglycerophosphatidylcholine 
(DMPC), and between the oxygen of the AmB carboxyl group and the amine of the 
DMPC when the distance in between them is lower than 4Å. This model is in fair 
agreement with other previously described simulations in which the AmB-sterol 
channel is composed by eight AmB and sterol molecules non-covanlently associated 
[174,175]. These channels are surrounded by 34 DMPC molecules, have cylindrical 
shape and are solvated in both sides and in the interior by 1666 water molecules [173]. 
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Figure 10. Simulation of AmB channels formed with cholesterol (A) and with ergosterol (B). Figure 
adapted from [173]. 
 
Even though it has been widely accepted that sterol presence in the membrane is 
necessary for the AmB pore formation some studies have revealed that the antibiotic is 
able to conduct channels even in the absence of sterols. Nevertheless, the drug 
concentration required to form pores in these conditions, is much higher than in the 
presence of sterols [176,177]. 
As previously detailed, the small structural differences found for cholesterol and 
ergosterol are enough to produce great disimilarities in AmB affinity. These 
disimilarities can be explained by the fact that many AmB molecules are involved in the 
formation of single membrane channels. The cumulative effect of such slight 
differences can significantly influence the stability of the pore [173]. Apart from the 
non-aqueous and aqueous pores, AmB can form two types of channels; single-length 
channel (SLC) and double-length channel (DLC). The DLCs are formed when two 
SLCs are arranged into a tail-to-tail configuration [178]. The DLCs are only form when 
the antibiotic is added from both sides of the membrane, reason why the SLCs are 
considered as the only possible channels during in vivo administration.  
 
 
A 
B 
B 
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1.2.3.2. Induction of oxidative damage 
Apart from the study performed by Gray et al [168], several other studies have 
demonstrated that pore formation is not enough to produce cell death [160] and that the 
chemical modifications on the AmB domains responsible for the pore formation, do not 
affect its antifungal activity [179]. Therefore, AmB may generate other killing 
mechanisms. Mowat et al [180] and Sokol-Anderson [181] described the AmB 
mechanism of action as complex. It depends not only on the growth phase of fungi but 
also on the presence of oxygen in between other factors. In this sense, as demonstrated 
by Sokol-Anderson, the addition of antioxidants (eg. superoxide dismutase) protects C. 
albicans from the lytic effect of AmB. In 2005, Liu et al [182] published a paper in 
which they described the AmB induction in stress genes expression.  
Many studies have been performed during the last years but the oxidative damage role 
of AmB on its antifungal activity is still unknown. 
 
1.2.3.3. Immunomodulatory properties 
Apart from its antifungal and antiparasitic effect, AmB has also immunostimulatory 
properties [183]. The AmB enhancement of the host immune response offers another 
alternative mechanism of action for this antifungal drug. However, it has an important 
drawback. The immunomodulatory effect has been related to the AmB associated 
toxicity [160]. 
The AmB interaction with endothelial cells, finally leads to an increase in nitric oxide 
(NO). The AmB increases the expression of the inducible isoform of the nitric oxide 
synthase (iNOS) which produces the rise of NO production. NO is implied in the 
vasodilatation and protection processes against pathogens [184]. The proinflammatory 
effect of AmB has been associated with protective effects during infection [160]. 
Opposite to this protective effect some studies have revealed that the increase in 
proinflammatory cytokines is related to the drug toxicity in the host [185]. The AmB 
renal toxicity has been somehow related to modifications in the expression of NO 
synthase and the induction of apoptosis [186]. 
Even though, the drug immunomodulatory mechanism is not well known, the AmB 
seems to interact to the toll-like receptors (TLR), mainly TLR2 and TLR4, and to CD14 
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receptors (figure 11) [160]. When AmB binds TLR2,  there is a release of 
proinflammatory cytokines (IL-6, IL-8, TNFα, MCP-1, MCP-1) while the interaction 
with TLR4 produces a release of anti-inflammatory cytokines (IL-10) [132,160,187]. 
The AmB interaction with CD14, activates the TLR signaling pathway [188]. 
 
Figure 11. Immunomodulatory effects of AmB [160]. 
 
Moreover, the AmB binding to sterols can lead to conformational changes that could 
activate some membrane enzymes as NADPH oxidase, involved in the oxidative stress. 
The enzymes activation will finally generate the accumulation of free radicals with 
antimicrobial properties (reactive oxygen species, ROS) [132]. 
 
1.2.4. Pharmacokinetics 
 
Amphotericin B is considered as a class IV drug according to the Biopharmaceutical 
Classification System (BCS). Class IV drugs are characterized by low solubility and 
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low permeability properties. The amphoteric nature of the drug, which is responsible for 
the low solubility values, together with its high molecular weight (924.09 Da) difficult 
its absorption. AmB is poorly absorbed after oral administration. Several oral 
pharmacokinetic (PK) studies have reported serum concentrations of approximately 
0.04-0.5 µg/mL AmB after oral administration of 1.6-5 g of drug per day during two 
days [189,190]. 
1.2.4.1. Plasma levels 
The serum levels detected after intravenous administration of AmB are dose-related. 
These levels are not only influenced by the dose but also by other parameters such as 
the frequency of administration and the rate of infusion [123]. Independently on the 
dose (one dose daily or twice the daily dose on alternate days), the AmB minimum 
serum concentrations are not modified. Nevertheless, there exist a relationship between 
the dose and the serum levels [191]. AmB fast infusion (45 minutes infusion) increases 
the mean serum concentration values after 1 h of the end of infusion but the 
concentrations do not differ at 18 h and 42 hours post-infusion [192]. 
1.2.4.2. Biodistribution 
The drug distribution was considered initially to follow a three-compartment model 
[193-195]. This model provided the best fit for the observed distribution and elimination 
phases of AmB [196].  However, the model that best fits may differ in between 
formulations. For instance, the liposomal amphotericin B  formulation (AmBisome®) or 
the colloidal AmB dispersion (Amphocil®) best fits to a two-compartment model [197- 
198]. 
The apparent volume of distribution (Vd), as well as the distribution model, varies 
depending on the formulation. While Akitson et al reported in 1978 a Vd value of 4 
L/kg [193], the AmB formulated with sodium deoxycholate, first marketed formulation, 
has been reported to have a different Vd depending on the initial dose administered. For 
instance, the administration of 0.6 and 1 mg/kg AmB led to Vd values of 5.1 and 2.4 
L/kg, respectively [197,199] 
As already mentioned, the apparent volume of distribution, as well as the other 
pharmacokinetic parameters, may differ from one formulation to another. Table 10 
summarizes the pharmacokinetics parameters analyzed in humans after intravenous 
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administration of different amphotericin B commercialized formulations. Cmax, AUC, 
Vd and t1/2 corresponds to maximum concentration, area under the curve, volume of 
distribution and terminal half-life elimination, respectively. 
 
Table 10. Pharmacokinetic properties of the commercialized AmB formulations. Adapted (132). 
Formulation Structure 
Particle 
size 
(µm) 
Dose 
(mg/kg) 
Cmax 
(µg/mL) 
AUC 
(µg*h/mL) 
Vd 
(L/kg) 
t1/2 
(h) 
Ref. 
Fungizone® 
Deoxycholate 
micelles 
0.035 
0.6 1.1 17.1 5.1 - [199] 
1 1.7 18.7 2.4 26.8 [197] 
0.8 1.46 17.2 - - [209] 
Abelcet® 
Lipid complex 
(ribbon-like) 
1.6-11 
5 1.7 9.5 131 173.4 [199,210] 
5 2.39 19.17 132.8 393 [211] 
2.5 1.09 8.9 - - [212] 
Amphocil® 
Cholesterol 
dispersion 
(discs) 
0.11-
0.14 
5 3.1 43 4.3 - [199] 
0.25 0.8 9.4 3.4 86 [196] 
0.5 0.84 21.0 5.5 157 [196] 
1 2.2 46.3 7.6 244 [196] 
1.5 2.5 57.3 8.9 235 [196] 
AmBisome® 
Unilamilar 
liposomes 
0.06-
0.08 
5 83 555 0.11 - [199] 
1 8 27 0.58 10.7 [213] 
2.5 19 65 0.69 8.1 [213] 
5 58 269 0.22 6.4 [213] 
7.5 90 476 0.26 8.5 [213] 
FungisomeTM 
Multilamilar 
liposomes 
2.7-3.5 1 1.012 11.43 2.28 17.2 [214] 
 
AmB is characterized by a high degree of plasma protein binding (91-95%) [200-202]. 
Due to this binding, the AmB unbound fraction in plasma is very low, approximately a 
5-9% (some studies have reported unbound values even lower than 4% [201]. It binds 
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principally to lipoproteins, albumin, cholesterol or cholesterol-containing membranes 
(erythrocytes) [136, 203-205]. The major AmB binding in plasma takes place with β-
lipoprotein [133,206]. However, there is also evidence of AmB binding with high 
affinity to human serum albumin (HSA) and α1-acid glycoprotein (AAG) [151, 207]. 
AmB low permeability explains the fact that this polyene antibiotic is not usually found 
in tissues with the exception of liver, spleen and lung [208]. The amount of drug 
detected in the pleural, synovial and peritoneal fluids is low (approximately half of its 
serum concentration) [123]. Amphotericin B crosses the placental barrier, and low 
concentrations are attained in the amniotic fluid. The drug distribution into breast milk 
has not been yet study in humans. 
1.2.4.3. Metabolism 
Amphotericin B metabolism has not been already well-elucidated [197]. 
Characterization studies performed in urine and feces samples containing AmB, showed 
the absence of metabolites and concluded that AmB was eliminated unchanged [215]. 
1.2.4.4. Elimination 
AmB follows a biphasic elimination profile [193]. The drug is characterized by a fast 
initial serum half-life of 24-48 h followed by a slower elimination phase (terminal half-
life) of up to 15 days [216,217]. The metabolism seems to play a minor role on AmB 
elimination [216] as the AmB is mainly eliminated unaltered. Regarding the AmB 
elimination there is some controversy. In 1980 and 1990, some studies reported that the 
amount of AmB detected in urine after 24 h administration was very low 
(approximately 3%) and that less than half of the dose was biliary or renal excreted 
[123,218]. The unchanged AmB renal excretion was considered a minor elimination 
pathway and therefore, it should not be altered in patients with impaired renal function. 
However, as reported by Bury et al, the AmB plasma clearance increased with 
increasing severity of renal dysfunction. Renal excretion of unchanged AmB was found 
to be lower in the uremic patients with respect to healthy volunteers and also the hepatic 
clearance raised in renal dysfunction [201]. AmB levels in bile and urine were detected 
up to 12 and 27-35 days after administration, respectively [219]. In 2002, Bekersky et al 
reported a 20% unchanged AmB excretion in urine and 40% excretion in feces [207]. 
Urinary and fecal clearance amounted a 75% of the total drug clearance.  
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All the above information refers to AmB in general but, as previously detailed, the 
pharmacokinetic profile differs between formulations. For more detailed information 
each formulation should be discussed separately. 
1.2.5. Spectrum of action and resistance 
 
1.2.5.1. Spectrum of action 
Amphotericin B is a macrolide antibiotic with a broad spectrum of action. It is the only 
polyene agent from approximately 200 known, whose toxicity allows for its intravenous 
administration [220]. As previously detailed, its mechanisms of action is basically based 
on its binding to sterols. This binding causes either disruption of the osmotic membrane 
integrity, disturbance of the oxidative enzymes or leakage of intracellular magnesium 
and potassium. Depending on the microorganism susceptibility and the drug 
concentration in the infection site, the AmB can behave as fungicide or fungistatic 
[221]. Amphotericin B is generally used in the treatment of fungal invasive and 
systemic infections. Particularly, the AmB is useful in treating candidosis, 
cryptococcosis, histoplasmosis, blastomycosis, parococcidiodomycosis, 
coccidiodomycosis, aspergillosis, extracutaneous sporotrichosis and mucormycosis. But 
it is also used in the treatment of some cases of hyalohyphomycosis and 
phaeohyphomycosis [220]. It is worth pointing out that most of the strains are inhibited 
at AmB concentrations in between 0.03 and 1 µg/mL [222].  
Tables 11 and 12 describe the AmB spectrum of action against the most clinically 
important yeasts and molds.  
The MIC90 (mg/mL) refers to the minimum inhibitory concentration (MIC) at which the 
90% of the isolates are inhibited. The data contained in the tables has been compiled 
from the literature and the WCH Mycology Unit. 
 
AmB is not active against bacteria, rickettsias or virus [222]. However, it has activity 
against some protozoos as Leishmania, Trypanosoma, Acanthamoeba, Naegleria or 
Plasmodium [106, 229-232]. 
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Table 11. AmB spectrum of activity against the most clinically relevant yeasts. Adapted from [220]. 
Species  MIC90 (mg/mL) References 
C. albicans 0.25-1 [223, 224] 
C. parapsilosis 1 [223, 224] 
C. glabrata 0.25-2 [223, 225] 
C. tropicalis 0.5-1 [223, 225] 
C. krusei 2 [223, 224, 226]  
C. kefyr 1 [226] 
C. famata 1 [227] 
C. guilliermondi 0.5-1 [224, 228]  
C. lusitaniae 0.5-2 [226] 
C. neoformans 0.25-1 [223, 226] 
M. furfur S  
S. cerevisiae 0.25-1 [225] 
T. beigelii 2 [227] 
 
Table 12. AmB spectrum of action against the most clinically important moulds. Adapted from [220]. 
Species  MIC90 (mg/mL) References 
Histoplasma capsulatum 0.5 [233] 
Coccidioides immitis 0.5-1 [233] 
Blastomyces dermatitidis 0.5 [233,234] 
Paracoccidiodes brasiliensis 0.5 [235] 
A. fumigatus 1-2 [236, 237] 
A flavus 1-1-42 [236, 237] 
A. terreus 1-2 [238] 
A. nidulans 1 [238] 
A. niger 1-˃16 [238] 
S. apiospermum 4-˃16 [239, 240] 
S. prolificans 0.5-4 [239, 240] 
S. schenckii 0.26-˃116 [226] 
Paecilomyces sp. 1-˃4 [241,  242] 
Penicillium sp. 0.5-1 [242] 
Fusarium sp. 0.5-1 [236, 237] 
Bipolaris sp. 1-4 [227] 
Exophiala sp. 0.5-2 [226] 
Cladophialophora sp. 0.5-2 [240, 241] 
Absidia sp. 0.5-2 [240] 
Apophysomyces sp. 0.5-2 [242] 
Cunninghamella sp. 0.5-2 [242] 
Mucor sp. 0.5-2 [242] 
Rhizomucor sp. 0.5-2 [242] 
Rhizopus sp. 0.5-2 [237, 243] 
Saksenaea sp. 0.5-2 [244] 
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1.2.5.2. Resistance 
Resistance to AmB (MIC ˃ 2 mg/mL) is a slow process that usually emerges from 
patients treated for a long period of time with this antibiotic. It is quite rare and it is 
usually caused by either a change in the sterol structure which leads to decreases in 
AmB binding or a decrease in the amount of ergosterol in the plasmalemma [220]. 
Some fungal cells present a mutation in their ergosterol biosynthesis pathway that leads 
to the production of ergosterol-like compounds which have less binding affinity for 
AmB. 
Despite the wide use of amphotericin B over more than 40 years, almost no resistances 
have been developed [245,246].  AmB resistance tends to be specie-dependent. After 
long patient treatments with this polyene antibiotic, some strains of Candida albicans, 
Candida tropicalis, Candida parapsilosis and Candida lusitaniae have developed 
resistance to AmB. Some isolates of Fusarium spp, Sporothrix schenckil and 
Scedosporium apiospermum have shown primary resistance whereas all strains of 
Scedosporium prolificans have demonstrated to be completely resistant to this drug 
[220]. 
The microorganism resistance to amphotericin B can take place through three different 
pathways summarized below [132]. 
1. Decrease in the membrane ergosterol content. The appearance of resistance is 
related to either a mutation in the ergosterol biosynthesis pathway or to changes 
in the components of the cellular membrane wall [247].  It has to be pointed out 
that the co-administration of azoles together with the amphotericin B may cause 
resistance, as the azoles inhibits the ergosterol synthesis [248]. 
2. Modifications in the mitochondrial respiratory chain. Even though there is 
not confirmed evidence, it is assumed that the mitochondrial respiratory chain 
has a key role on the AmB development of resistance. The respiratory chain 
does not only participates in the biosynthesis of ergosterol but also can be 
implied in the accumulation of free radicals inside the cells [249]. 
3. Tolerance to oxidative stress. The yeasts exposure to inhibitory concentrations 
of fluconazole can induce a mechanism that make the yeasts turned more 
resistant to the oxidative and nitrosative stress (caused by ROS or NO). The 
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higher yeast resistant to the stress made then more tolerant to the oxidative stress 
caused by AmB [250,251]. 
1.2.6. Amphotericin B formulations 
 
1.2.6.1. Fungizone® 
In 1958, the first AmB formulation was marketed under the brand Fungizone®. 
Fungizone®, developed and commercialized by Bristol-Myers Squibb, Co. is a micellar 
dispersion of AmB with a bile salt, sodium deoxycholate, in a molar ration 1:2, in a 
phosphate buffer (figure 12) [148]. The lyophilized formulation contains 41 mg sodium 
deoxycholate and 50 mg AmB. The particle size of the micelles is approximately 1 µm 
[252]. Contrary to what it was thought at the beginning, Fungizone® consists of large 
aggregates rather than small mixed micelles (MM) [253].  
 
 
 
 
 
Figure 12. Fungizone® structure. Adapted from [214]. 
When it was first commercialized, Fungizone® had the broadest spectrum of action of 
all available antifungal agents. Even though it had a great efficacy, therapeutic doses 
caused severe sides effects, including pain at the site of injection, fever, chills, nausea, 
vomiting, electrolyte abnormalities, lysis of red blood cells (RBCs) and nephrotoxicity 
[254,255].  These side effects were directly related to the dose. The side effects 
increased with increasing dosage. The infusion-related side effects (fever, rigors, chills) 
are very common but medical management of these symptoms suffices to allow 
continuation of the treatment. However, renal insufficiency in association with 
azotemia, renal tubular acidosis and impaired urinary concentrating ability resulting in 
electrolyte imbalance might be severe enough to reduce the dose or to change to an 
alternate days dosing [256]. The dose-related toxicity is a limiting factor for all patients 
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but most importantly for immunocompromised patients (AIDS and cancer) that are 
undergoing intensive cytoreductive therapy [257]. 
Regarding its nephrotoxicity, Fungizone® has a concentration-dependent profile of 
toxicity and its selectivity depends on its aggregation state [258]. The critical micelle 
concentration (CMC) of Fungizone® (2-6.10-3 M) is responsible for its associated 
toxicity. Once in blood, the formulation suffers a dilution process in which the micelles 
loss their integrity releasing the amphotericin B molecules. The amphotericin B rapidly 
rearrange into soluble aggregates which are not selective against ergosterol, damaging 
either ergosterol or cholesterol cells. Moreover, the high concentration of sodium 
deoxycholate, which is a toxic bile salt, plays an important role in the hemolysis caused 
by this formulation. The sodium deoxycholate is also assumed to be responsible for the 
diarrhea observed in patients after Fungizone® administration [259]. 
This associated toxicity has limited the daily dose of Fungizone® to approximately 1 
mg per kg [260]. 
 
1.2.6.2. Strategies to reduce amphotericin B associated toxicity 
In order to reduce the AmB associated toxicity different tactics have been investigated 
during the last years. Regarding the Fungizone®, first attempts where focused on saline 
loading, dose reduction and alternative day dosing but none of them worked [135]. The 
design and development of novel amphotericin B formulations should be  mainly 
focused on the reduction of nephrotoxicity. As previously mentioned, the amphotericin 
B selectively and therefore, toxicity, is related to its aggregation state, reason why the 
target of the new formulations was centered on the maintenance of low free AmB serum 
concentrations. If the AmB concentration in serum remains low, the drug molecules will 
not rearrange into soluble aggregates and the selectivity against ergosterol containing 
cells will be maintained [151]. To achieve this aim, the AmB was included in carrier 
systems that exhibited controlled drug release.  
In the early 1990s a new generation of AmB formulations were developed. The sodium 
deoxycholate contained in the Fungizone® was replaced by either phospholipids 
(Abelcet®), cholesterol (Amphocil®) or both (Ambisome®). Even though all these 
formulations improved the therapeutic indexes of the AmB included in Fungizone® the 
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cost of these new treatments was 12 to 40 times higher than the latest. Moreover, these 
new formulations did not avoid the need of hospitalization or the side effects associated 
to the treatment (they reduced the side effects but did not remove them).  
Apart from these liposomes (Ambisome®) and emulsions (Abelcet® and Amphocil®), 
other particulate carrier systems were developed during the 90s.  
Besides the above detailed drawbacks, it has to be considered that most particulate 
formulations are rapidly removed from the circulations by the reticulate endothelial 
phagocyte system (RES) cells, leading to a very low serum half-life of AmB combined 
with low bioavailability and irregular distribution in the body. Even though for most the 
pathologies this phenomenon is considered as a disadvantage, in the treatment of 
visceral leishmaniasis, where the parasite reside in this cells, is a great advantage [106]. 
Table 13 summarizes the strategies followed in the design of new amphotericin B 
formulations as well as the microorganisms aim of treatment. 
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Table 13. Strategies for the design of new AmB formulations 
Carrier Composition Microorganism Reference 
Liposomes AmB, hydrogenated soy bean lecithin, phosphocholine, cholesterol, sucrose, α-
tocopherol, sodium succinate hydrate (AmBisome®) 
Leishmania spp [261- 266] 
  
AmBisome® 
 
Candida albicans 
 
[267, 268] 
    
 Nanosomes (AmB, soy phosphatidylcholine sodium cholesteryl sulfate) Aspergillus spp [269] 
Colloidal dispersions and 
emulsions 
AmB cholesterol dispersion = ABCD (Amphocil®) 
 
Leishmania spp [266,270,271] 
    
 Amphocil® Candida spp, Aspergillus spp, 
Mucor spp 
[272, 273] 
    
 AmB lipid complex containing dimyristoylphosphatidylcholine, 
dimyristoylphosphatidylglycerol (Abelcet®) 
Candida spp [274, 275] 
    
 AmB, stearic acid, Tween 80, chitosan Leishmania spp. [276] 
Nanosuspensions AmB, Tween 80, Pluronic F68, sodium cholate Leishmania spp [277] 
  Ballamuthia mandrillaris [278] 
 AmB, Eudragit RS 100 Fusarium spp [279] 
Albumin nanoparticles AmB, human serum albumin, dimethylsulfoxide Leishmania spp [280] 
    
  Candida spp [260] 
 
 
Novel formulations for Amphotericin B delivery 
 
65 
Carrier Composition Microorganism Reference 
Emulsions AmB, fat and phospholipids (EAmB - US Patents 5,576,016) Candida spp. [281] 
    
 AmB, deoxycholate, soya bean oil Leishmania spp [282, 283] 
    
 AmB Intralipid (ILA) emulsions Candida spp. [284, 285] 
    
Micellar systems AmB, sodium deoxycholate L. donovani [264, 286, 287] 
 AmB, poly(ethylene oxide)-block-poly-(L-amino acid=aspartamide) Candida spp, Aspergillus spp, 
Cryptococcus spp. 
[152, 288] 
 AmB, chitosan-g-pluronic F-127 copolymer (CPF) Candida spp, Aspergillus spp [289] 
Cyclodexrins AmB, methyl-beta-cyclodextrin (MβCD) Leishmania spp. [166] 
    
 AmB, gamma-cyclodextrin (γ-CD) Leishmania spp, Candida spp. [290, 291] 
 AmB, hydroxypropyl-γ-CD (vaginal gel) Candida spp  [292] 
Cochleates AmB, phospholipid calcium precipitates Leishmania spp Leishmania spp [293, 294] 
    
  Candida spp. [293, 295] 
    
  Aspergillus spp. [296] 
    
Polymer particles AmB, polylactide-co-glycolide (PLGA) Leishmania spp. [297, 298]  
 
 
 
   
 
 
 
 Aspergillus spp. [299] 
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Carrier Composition Microorganism Reference 
Polymer particles AmB, PLGA, dimercaptosuccinic acid (DMSA) Paracoccidioides brasiliensis [300] 
    
 AmB, Poly(α-glutamic acid) Leishmania spp [301] 
    
 AmB, ethylcyanoacrylate Leishmania spp  [302] 
    
 AmB, polybutylcyanoacrylate Cryptococcus spp [303] 
    
 AmB, sodium alginate  Candida spp [304] 
    
 AmB, sodium alginate, chitosan stearate Leishmania spp [305] 
    
 AmB, polyethylenimine-dextran-sulfate (pendant in vivo results) [306,307] 
    
 AmB, chitosan-dextran-sulfate (pendant in vivo results) [306] 
    
 AmB, gelatin Leishmania spp [308] 
    
 AmB, GCPQ (quaternary ammonium palmitoyl glycol chitosan) Leishmania spp [309] 
    
 AmB, Polyethylene glycol (PEG), lipid nanoparticles (LNP) Aspergillus spp [310] 
    
Inclusion complexes + liposomes AmB, hydroxypropyl/sulfo butyl ether β-CD and cholesterol/L-PC Aspergillus spp, Cryptococcus spp [311] 
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Some of these carriers has not been only used in the treatment of candidiasis and 
leishmaniasis but also in the prophylaxis of invasive fungal infections in 
inmunocompromised patients [312,313]. 
 
1.2.6.3. Commercialized amphotericin B formulations 
Here in, there is a brief description of the main commercialized amphotericin B 
formulations used in therapeutics. 
1.2.6.3.1. AmBisome® 
AmBisome® was the first lipidic AmB marketed formulation. The AmB (50 mg) was 
included into small sonicated unilamellar liposomes (figure 13) composed by 
hydrogenated soy bean lecitine (213 mg), cholesterol (52 mg) and distearoyl 
phosphaidylglycerol (84 mg) [314].  AmBisome® developed by Vestar, Inc., was first 
marketed in Europe in 1989 by NeXstar Pharmaceuticals [148]. Since then and so far 
over 500,000 patients have been treated with AmBisome® [315].  
 
 
 
 
 
 
 
Figure 13. Ambisome® structure. Proposed arrangement of the AmB molecules (black) into the lipid 
bilayer [316]. 
It is commercially available as a lyophilized powder for reconstitution. It has to be 
reconstituted in water (water for injection - WFI) prior to administration. The 
reconstitution generates liposomes with a mean diameter of 60-80 nm [106,317,318]. 
Apart from the lipidic content, the formulation also includes sucrose for obtaining an 
isotonic solution, and α-tocopherol and disodium succinate hydrate. 
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The pharmacokinetic profile of Ambisome® has been reported to be significantly 
superior to that of Fungizone®. The serum elimination half-life is improved, the 
effective plasma concentrations are enhanced and the plasma clearance is therefore, 
reduced [106,278, 319]. After parenteral administration of this formulation most of the 
AmB is retained in liver and spleen but the molecule can also be found in lungs and 
kidneys (the retention in these two organs is much lower). Ambisome® higher 
concentrations in spleen and brain compared to Fungizone® makes this formulation 
suitable for the treatment of Leishmaniasis [320,321,322]. 
It has a less toxic profile than Fungizone® and it is well tolerated by patients at risk, 
including transplant patients [323] and children with cancer [324].  
 
1.2.6.3.2. Abelcet® 
Abelcet® is the first non-liposomal AmB-lipid complex (ABLC) marketed in Europe. 
This non-liposomal formulation contains AmB (100 mg) in a lipidic suspension of 
dimyristoylphosphatidylcholine (68 mg) and dimyristoylphosphatidylglycerol (30 mg) 
[325]. The lipid complexes have a ribbon-like structure (figure 14) with a mean particle 
size of 1-6 µm [326]. 
Compared to Fungizone®, Abelcet® has reduced toxicity but maintains its therapeutic 
efficacy. Abelcet® shows a lower risk of renal disorders than Fungizone® at a dose of 
1-5 mg kg-1 day-1 [326]. 
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Figure 14. Abelcet structure. AmB and lipids are arranged in a 1:1 interdigitated complex [326]. 
The main drawback of this formulation, the fast clearance, is related to its colloidal 
properties. It is quickly removed from the circulation by the cells of the mononuclear 
phagocyte system (eg. Kupfer cells) enhancing the risk of possible hepatic disorders 
[106]. 
 
1.2.6.3.3. Amphocil® 
Amphocil® was the second non-liposomal AmB marketed formulation. It is an AmB 
colloidal dispersion (ABCD) developed by Liposome Technology, Inc and first 
commercialized in 1994 in the United Kingdom. It consists of AmB (50 mg) and 
sodium cholesteryl sulfate (26.4 mg) in equimolar concentrations [325]. The particle 
structure resembles discs (figure 15) of 4 nm thick and a 100 nm mean diameter [327]. 
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Figure 15. Amphocil® structure. The interaction of AmB with the cholesterol sulfate forms rigid and 
tightly packed lipid bilayers [326]. 
As for the other lipid-based formulations, it has also a similar antifungal efficacy than 
Fungizone® but it has reduced cytotoxicity and hemolysis [106].  
 
1.2.6.3.4. FungisomeTM 
FungisomeTM is the most recent AmB marketed formulation. It is a multilamellar 
liposome AmB formulation first commercialized in India in 2003. It is composed by 
phosphatidylcholesterol and cholesterol in a molar ratio of 7:3. It forms multilamellar 
vesicles with a particle size ranging between 2.74 - 3.45 µm (figure 16). It is 
commercialized as a liquid formulation [214]. 
 
Figure 16. FungisomeTM structure 
As well as for AmBisome®, this new liposomal formulation accumulates in liver, 
spleen and, in less degree, in lungs. Nevertheless, the pharmacokinetic profile of this 
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new formulation is completely different to that of AmBisome®. This can be explained 
by their difference in particle size. The FungisomeTM larger particle size, makes it easily 
recognizable by the RES.  
 
1.2.6.4. New approaches in the design of amphotericin B delivery systems  
1.2.6.4.1. Polymeric micelles 
Even though the lipidic systems described above, do not display the high toxicity of 
Fungizone®, their high cost and biopharmaceutical instability are important limiting 
factors to their use [279,311]. Abelcet®, the AmB/lipid complex, is formed by large 
size particles that are rapidly taken up by macrophages thus cumulating in liver and 
spleen, which in one side shortens the circulating period and on the other increases the 
volume of distribution and clearance. Ambisome®, the lyophilized liposomal AmB 
formulation, substantially escapes recognition and uptake by the mononuclear 
phagocyte system but tends to accumulate in high amount in the liver and spleen. 
Finally, Amphotec®, an AmB colloidal dispersion, exhibits dose-limiting infusion-
related toxicities. Interestingly, clinical trials showed that despite the lipid-associated 
formulations were significantly less nephrotoxic than AmB/deoxycholate, they were not 
significantly better than the latter for treatment of several diseases, including AIDS-
associated acute cryptococcal meningitis [328].  
Polymeric micelles have some advantages over lipid-based systems such as easy 
preparation process, higher thermodynamic and kinetic stability (which confers higher 
stability toward dilution in vivo), long shelf-life at room temperature, ability to 
withstand autoclaving for sterilization, prolonged blood circulation due to a lower 
uptake from the reticulo-endothelial system (RES) and low cost of production [288] 
[106]. A few PEG containing polymers have been used to produce AmB pharmaceutical 
products. PEG is indeed a soluble non-toxic, low immunogenic and low antigenic 
polymer widely applied for prolonging the circulation of colloidal drug delivery systems 
as it prevents the massive accumulation in RES organs, namely liver and spleen [310] 
[253], reduces the kidney filtration and avoids the capillary penetration 
[134,329,330,331]. Therefore, these long circulating carriers may be able to increase the 
therapeutic index of AmB at low dose, low risk of toxicity and low cost [332].  Micelle 
formulations obtained using poly(ethylene glycol)-block-poly(-caprolactone-co-
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trimethylenecarbonate) and PEG-DSPE showed that the solubility could increase of 2 
order of magnitude [155]. Interestingly, the physical combination of PEG-DSPE with 
sterol molecules was found to determine both the solubility and the aggregation state of 
AmB. 
Monomeric AmB is known to selectively interact with ergosterol in fungal cell 
membranes, forming channels by the classic barrel stave motif, while aggregated AmB 
preferentially associates with cholesterol, which causes toxicity in mammalian cells. 
Therefore, polymers containing sterol molecules have been hypothesized to be suitable 
materials for preparation of stable AmB colloidal formulations. Typically, PEG-
cholesterol type polymers have been found to produce micelles with about 10-6 M CMC 
[329,331,333,334], which are much more stable compared to sodium deoxycholate 
(CMC 2-6.10-3 M) [334]. Recently, self-assembling polymers obtained by end 
conjugation of cholanic acid to monomethoxypoly(ethylene glycol) chains have been 
investigated for the delivery of proteins and low mol wt drugs [335,336]. These PEG-
cholane polymers were found to associate with proteins by cholanic moiety docking 
into the hydrophobic clefts and interaction with hydrophobic surfaces of proteins 
yielding novel supramolecular systems for protein delivery. Furthermore, preliminary 
unpublished studies showed that PEG-cholane can enhance the solubility of poorly 
soluble drugs, namely tamoxifen and paclitaxel.  
Due to the strong affinity of sterol moieties for AmB and the ability of PEG-cholane to 
dissolve hydrophobic drugs by forming micelles, these polymers seem to possess the 
requisites for obtaining new efficient colloidal systems for delivery of this antifungal 
drug.  
 
Even though the amphotericin B associated nephrotoxicity is the main drawback for the 
use of this molecule in clinic, the fact that this antibiotic is only available for 
intravenous administration also limits its prescription. The development of AmB oral or 
topic formulations with decreased toxicity will allow not only for the treatment of 
systemic fungal infections but also for the treatment of topical mixed-infections 
resistant to conventional treatments. These formulations will improve patient 
compliance and reduce the sanitary cost of the treatment. 
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2. OBJECTIVE AND JUSTIFICATION OF THE NEED OF COLLABORATION 
 
Justification of the need of collaboration 
Taking into account the rising importance and clinical repercussion of the mold 
infections in humans and animals, the development of new formulations that reinforce 
the current therapeutic arsenal is needed. 
As detailed in the introduction the wide spectra of action of amphotericin B together 
with its low appearance of resistance, makes this drug a suitable candidate for the 
treatment of mycosis. Thus, the main objective of the present thesis will be focused on 
the development of new amphotericin B (AmB) formulations, with reduced side effects, 
for the treatment of topical and systemic mycosis.  
To achieve this purpose, the experience of the UCM research group in the development 
and characterization of new amphotericin B formulations was complemented with the 
long experience of the University Javeriana of Bogotá on microbiology and clinical 
practice and  the wide expertise of the University Degli Studi di Padova on chemical 
conjugation. 
Therefore, two collaborations were established alongside this PhD project. The first 
collaboration, set with the University Javeriana of Bogotá, aimed in studying the efficay 
of an AmB nail lacquer. While the second and main collaboration, which was 
established with the University Degli Studi di Padova (Italy) aimed in developing a new 
AmB formulation for the treatment of systemic mycosis. This last collaboration lead to 
the codirection in between Spain-Italy of the present PhD project. 
The PhD project is therefore structured in two main chapters. The first experimental part 
approaches the development of an amphotericin B nail lacquer useful in the treatment of 
onychomycosis while the second experimental part focuses on the solubilization and 
inclusion of amphotericin B in the colloid system formed by the polymer PEG5kDa-
cholane. 
 
 
 Objetive and justification of the need of collaboration 
 
76 
Objective 
As previosly mentioned, the main objetive of the current thesis is the development of 
two amphotericin B formulations. One topical formulation for the treatment of 
onychomycosis and one formulation for the treatment of systemic mycosis. 
The specific objectives are differenciated with regards to the formulation to be 
developed. 
EXPERIMENTAL PART 1 - AmB nail lacquer 
The increasing incidence of concomitant nail infections caused by dermatophytes or 
non-dermatophytes and Candida spp, or by different species of Candida at the same 
time, has raised during the last years. These concomitant infections are an important 
healthy issue as most of the commercialized treatments are not effective against mixed 
infections. Therefore, the development of a formulation able to penetrate the nail and 
effective against dermatophyte, non-dermatophyte molds and Candida spp. is needed.  
Taking into account that amphotericin B is a polyene antibtioc and antifungal drug with 
a broad spectrum of action and low incidence of resistances, we have considered this 
molecule as an alternative for the treatment of nail mixed infections. Thus, the main 
objective of this first chapter is focused on the development and characterization of an 
amphotericin B nail laquer for the treatment of onychomycosis. The efficacy of the nail 
lacquer will be assayed in collaboration with the research group of Dra. Parras from the 
University Javeriana of Bogotá (Colombia). 
To reach this general objective, some specific targets are proposed: 
1. AmB solubility studies on different solvents. 
2. Development of AmB nail lacquers using different film-forming agents. 
3. Characterization of the nail lacquers. 
4. In vitro nail penetration studies 
5. In vitro and in vivo efficacy studies. Determination of the minimum inhibitory 
concentrations and efficacy studies on infected keratinized structures of animal 
origin. 
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EXPERIMENTAL PART 2 - AmB/PEG5kDacholane formulation 
During the last years, the research group from the UCM has designed and developed 
new formulations for amphotericin B (AmB) delivery which are characterized by a great 
therapeutic efficacy. Furthermore, these preparations have lower side effects compared 
to other commercialized formulations. The experience of this group on this research 
topic (amphotericin B) is supported by 8 PhD thesis (Moreno, 2000), (Brime, 2002), 
(Sánchez-Brunete, 2003), (Valdespina, 2007), (Espada, 2008), (Ruiz, 2010), (Serrano, 
2013) and (López, 2015) and by the publication of different articles in specialized 
journals. 
On the other hand, the research group from the University of Padova (lead by Professor 
Caliceti), is a worldwide known reference group on the design of pegylated drug 
carriers. The conjugation with different polyethylene glycols (pegylation), which is one 
of the most important lines of research in the drug delivery field, allows for a higher 
drug bioavailability. Professor Caliceti is a world expert in the synthesis and 
conjugation of different molecules with polyethylene glycols and his group has done 
important scientific contributions related to this topic. 
Based on the promising results obtained on both research groups and taking into 
account the rising importance and clinical repercussion of the mold infections, the main 
objective of this thesis focuses on the development and optimization of an amphotericin 
B pegylated formulation for the treatment of fungal infections. The AmB interactions 
with cholesterol-type molecules are known to favor the drug solubility. In this sense, the 
conjugation of cholesterol-type molecules with different PEGs will allow for the 
encapsulation and solubilization of AmB. 
To achieve this general purpose, some specific objectives conforming the working plan 
are proposed: 
1. Synthesis of different AmB pegylated complexes 
2. Characterization of these complexes by studying their solubility in different 
conditions. The complexes characterization will include DLS, HPLC, DSC,  RX, 
FTIR, CD, ITC and synchrotron analysis. 
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3. Ex vivo characterization of these complexes. Study of  the toxicity by hemolysis 
and study of the antifungal efficacy against Candida albicans 
4. In vivo pharmacokinetic studies after oral and intravenous administration. The 
pharmocokinetic properties of the new AmB formulation will be determined and 
compared to the commercialized formulations Ambisome® and Fungizone®. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DRUG UNIPD AMPHOTERICIN B PEG5KDA-CHOLANE 
FTIR HSM HEMOLYSIS ORAL UCM MONOMER 
POLYAGGREGATES ITC IN VITRO  INTRAVENOUS Ke 
SYNTHESIS mV TNBS RESISTANCE T1/2 NMR XRD 
FORMULATION ACTIVATION IR CANDIDA  HPLC 1959 
EFFICACY SYNCHROTRON CHOLESTEROL pH CMAX 
DIMER ORAL NAIL CHARACTERIZATION ΔH 924Da 
CRITICAL AGGREGATION CONCENTRATION MIC CMC 
CIRCULAR DICHROISM ONYCHOMYCOSIS STABILITY 
RELEASE UV TOXICITY TEA HSA C24 TOPICAL 
ADMINISTRATION AMORPHOUS CONJUGATION AUC 
MIXED INFECTIONS MEMBRANE ΔS PENETRATION 
EXCIPIENTS BETA-SHEET C47H73NO17 KD2 CM-1 
ALPHA-HELIX EF ERGOSTEROL FILM-FORMING 
DERMATHOPHYTE MOLDS AMPHOTERIC PKA 
DISSOCIATION  CRYSTALLINE  INTERACTION BALB/C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. EXPERIMENTAL PART 
  
 
 
 
 
 
 
 
 
 
 
  
N-METHYL-2-PYRROLIDONE AGE NAIL PLASTICIZER   
PEG ENHANCEMENT FACTOR IN VIVO EFFICACY 
CANDIDA SP. COSOLVENTS DRYNESS SODIUM 
DEOXYCHOLATE   PENETRATION SPRAY DRYING H2O    
AMPHOTERICIN B ONYCHOMYCOSIS LACQUER   
ETHANOL MYCOTIC γ-CYCLODEXTRINS   GLYCERIN 
EUDRAGIT® L100  FREEZE DRYING  HPLC  1/S  F11 
PLASDONE K90  CELLULOSE FILM-FORMING SEM 
POLOXAMER DLS  F19 MIXED INFECTIONS   STABILITY 
F13 EX VIVO  UNIVERSITY JAVERIANA  ANIMAL 
ORIGIN PPG TRYCHOPHYTON MENTAGROPHYTES 
ACTIVITY  DERMATOPHYTE  KERATINE  SCANNING 
ELECTRON MICROSCOPY RHEOLOGY MIXED 
INFECTIONS PENETRATION CLSI EFFICACY ADHESIVE 
PARTICLE SIZE BRIGHTNESS PATHOGENS CLSI CFU 
LEAD CANDIDATE   TOE-NAIL  MIC  MOISTURE  YIELD  
3.1. EXPERIMENTAL PART 1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NAIL DERMATOLOGICALLY INNOCOUS ADHESIVE 
FAST DRYING THIN LAYER PLASTICIZER LACQUER 
POLISH FINGER RESINS EUDRAGIT® L100 
DURABILITY PEG FREEZE DRYING VOLATILE 
SOLVENTS  TOE  VARNISH  EASY REMOVAL 
PLURONIC F127 NMP SPRAY DRYING FLEXIBILITY 
DOCNA   EXTENSIBILITY    GT  PPG   VISCOSITY  
EASY REMOVAL    γ-CD   COSOLVENTS    SEM 
PLASDONE K90 UNIVERSITY JAVERIANA OF BOGOTÁ 
BRIGHTNESS IN VIVO  EFFICACY CLSI STRUCTURES 
MINIMUM INHIBITORY CONCENTRATION IN VITRO  
PENETRATION EFFICACY CFU KERATINIZED 
RHEOLOGY ONYCHOMYCOSIS PATHOGENS PAPER 
DISKS 30 DAYS CULTURE MEDIA BRUSH-STROKE 
PHYSICOCHEMICAL CHARACTERIZATION RP-HPLC 
STABILITY   LEAD CANDIDATE   DLS   MOISTURE   ICH  
EXP.1-1. MATERIALS & METHODS 
  
 
Novel formulations for Amphotericin B delivery 
 
85 
EXP1-1. MATERIALS & METHODS 
EXP1-1.1. Nail lacquers 
 
Nail lacquer, also known as nail varnish or nail polish, is a lacquer that can be applied to 
human finger and toenails in order to decorate, protect and/or treat the nails. 
An ideal nail polish should have the properties detailed below; 
- Be dermatologically innocuous to the nail, 
- Avoid compound precipitation with time, 
- Ease of application, covering homogenously all the targeted surface, 
- Adhesive - the film formed has to be resistant and flexible, 
- When colored, the nail lacquer must have the same color in the container than 
over the nail, 
- Relatively fast drying, allowing the application if necessary of three layers of 
lacquer and, 
- Easy removal using appropriate solvents. Once removed, the nail should not be 
colored or stained. 
Not all commercially available lacquers reach all these properties but at least they 
should be innocuous, adhesive, fast-drying and be easily removed. 
EXP1-1.2. Excipients 
 
Nail polishes usually present in their composition the following groups of compounds. 
- Film-forming agents 
- Resins 
- Plasticizers 
- Solvents and cosolvents 
- Colorants and pigments 
- Viscosity modifying agents 
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The excipients used in the development of an AmB nail polish are the film-forming 
agents, the plasticizers, the solvents and the cosolvents. A brief description of each of 
the groups included in the nail polish composition is described below. 
EXP1-1.2.1. Film-forming agents 
Film formers are chemical compounds that generate flexible, cohesive and continuous 
layers when applied to a surface. Depending on their solubility properties they can 
generate permeable or impermeable films.  
The film forming agents studied in the development of an AmB nail polish were 
Plasdone K90®, Eudragit L100®, cellulose acetate phthalate and Pluronic F127®. They 
were included in a 10 to 20 weight (%). Each of the film forming agents used, as well as 
their properties, are detailed in appendix 1 (AP1.2). 
EXP1-1.1.2.2. Plasticizers 
Plasticizers are compounds that improve the flexibility, brightness and durability of the 
film formed. They are present in an amount of 2 to 10% (weight) as higher percentages 
can generate weak layers that are easy breakable. The plasticizer assayed for the new 
AmB-based nail lacquer were polyethyelen glycol (PEG), propylene glycol (PPG), 
glycerin triacetate (GT), diethyl phthalate (DEP), castor oil (CO) and dibutyl sebacate 
(DBS). 
The properties and the chemical structure of the above mentioned plasticizers is detailed 
in appendix 1 section AP1.2. 
EXP1-1.1.2.3. Solvents 
The solvents constitute the volatile part of the nail polish. They are a key factor in the 
polish composition as they directly influence the dryness and ease of application. 
Highly volatile mixtures can cause difficult and non homogenous applications while 
low volatile mixtures produce thin and slow drying layers.  
The solvents used in the AmB nail polish composition were ethanol or a mixture of 
ethanol and water in an amount of 38 to 70 wt. %. 
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EXP1-1.1.2.4. AmB solubilizers 
From a chemically point of view, amphotericin B is an amphiphilic molecule with low 
water solubility. Its low solubility (less than 1 mg/L) in water or water-free alcohols at 
phisiological pH, constitutes the main drawback when developing any kind of 
pharmaceutical formulation (topical, oral or intravenous). To overcome the AmB 
solubility problems, many strategies have been followed during the last years. These 
include the use of sodium deoxycholate (DocNa), gamma cyclodextrin (γ-CD), 
polymers, etc. Here in, it is reported for the first time the use of N-methyl-2-pyrrolidone 
(NMP) and Plasdone® K90 as AmB solubilizer agents.  
For the development of the new AmB lacquer, DocNa, γ-CD, NMP and Plasdone® K90 
were used. Each of them, was able to solubilize the AmB in a different way. 
The composition, properties and chemical structures of the AmB solubilizers is detailed 
in section AP1.2 of the appendix 1. 
EXP1-1.2.5. Cosolvents 
The use of water-soluble polymers, such as Plasdone® K90, in the development of a 
water soluble film forming lacquer, would imply the addition of a co-solvent with short 
evaporation rates in order to achieve dryings time within the range 3-5 minutes (once 
applied over the nail). Due to its properties and compatibility, the ethanol would be the 
selected co-solvent in the water permeable nail lacquers.  
 
EXP1-1.3. Amphotericin B solubility studies 
 
In order to know in which solvents AmB had the highest solubility, the following study 
was performed. The aim of this study was to find the most suitable solvents for the 
development of an AmB topical formulation.  
 
Method 
AmB solubility in acetic acid, acetone, acetonitrile (ACN), cyclohexane, 
dimethylformamide (DMF), dimehtylsulfoxide (DMSO), ethanol, isopropyl alcohol, 
glycol ethylenglycol dimethylether, N-methyl-2-pirrolidone (NMP), and petroleum 
ether was studied. 
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As a low AmB solubility was expected for all the solvents, apart from DMSO and 
NMP, samples were prepared at 5 mg/mL. When DMSO and NMP where assayed the 
samples contained 50 mg/mL of AmB.  
Briefly, 1 mL of solvent was added to the eppendorfs containing 5 or 50 mg AmB and 
vortex for 1 min. Once shaked, they were left stirring in a mechanic oscillator at 25 °C 
for three hours. Afterwards, the samples were centrifuged at 12,000 rpm for 10 min and 
20 μL supernatant were taken. The supernatant was then diluted to 1 mL with methanol 
(MeOH) and centrifuged again at 12,000 rpm for another 10 min. Finally, 50 μL 
supernatant were analyzed by RP-HPLC. The AmB concentration was referred to a 
curve linear in the range 12 ng/mL – 40 μg/mL (r2=0.999). The samples were prepared 
in triplicate. 
EXP1-1.4. Developement of an AmB nail lacquer for the treatment of 
onychomyosis. 
EXP1-1.4.1. Study design 
 
The study design used in the development of an AmB nail lacquer for the treatment of 
onychomycosis is detailed in figure 17.  
The first step implied the bibliographic research. The excipients that were used, as well 
as the amphotericin B solubility method, were selected in basis of the possible 
patentability. The second and third steps consisted of the formulations development and 
their short-term stability studies. The fourth step supposed the selection of three lead 
candidate formulations. These formulations were physicochemical characterized and 
studied during step 5 in terms of in vitro nail penetration and efficacy. The data 
generated on step 5 allowed for the selection of the final lead candidate. This lead 
candidate was sent to Colombia for further in vitro and in vivo studies. 
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Figure 17. Study design for the development of an amphotericin B nail lacquer. 
 
EXP1-1.4.2. Formulation development (second step of the study design) 
20 different nail lacquer compositions were prepared following the information 
compiled from a deep bibliographic research (articles and patents). The formulations 
were studied in terms of physical and chemical stability and the below parameters were 
evaluated using a 1-5 scale, where 1 was the minimum score and 10 the maximum. 
- Water permeability of the film formed,  
- viscosity of the formulation,  
- brightness of the formulation and film formed,  
- film drying time over the nail, 
- stickiness of the film once dried, 
- extensibility of the formulation, 
- homogeneity of the film formed and 
- pH of the formulation 
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The formulations prepared were classified in two main groups according to the type of 
polymer used as film forming agent: water soluble and non-water soluble lacquers. 
 
EXP1-1.4.3. Short-term stability studies (third step in the study design) 
The formulations stability, as well as the AmB concentration, were studied in all the 
formulations during 1 month at room temperature and exposed to light. 
 
EXP1-1.4.4. Pre-selection of three lead candidates (fourth step in the study design) 
Based on the results obtained in the short term stability studies, three formulations were 
selected for the complete characterization. 
 
EXP1-1.4.5. Characterization of the three lead candidates (fifth step in the study 
design) 
The selected formulations were physicochemically characterized and studied in terms 
on in vitro penetration and efficacy. 
 
EXP1-1.4.5.1. Physicochemical characterization 
EXP1-1.4.5.1.1. Dynamic light scattering  
Nail polish (3 mg/g AmB) was prepared as described above and diluted 1:5 with 
purified water in order to have a sample with suitable properties that allow for the 
particle size analyses.  Fresh and reconstituted samples were analyzed at different times 
(0, 7 and 15 days) by dynamic light scattering (DLS) using a Malvern Zetasizer Nano-
ZS (Malvern, Worcestershire, UK). The analyses were performed in triplicate at 25 ºC, 
633 nm wavelength and 173º detection angle to assess the mean particle size and size 
distribution. 
EXP1-1.4.5.1.2. Freeze drying 
The freeze drying technique was used to obtain a dehydrated nail polish powder easily 
redispersible with a mixture of ethanol and water.  
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5 g of 3 mg/g AmB water-permeable nail lacquers (F11 and F13) were prepared as 
described above. However, due to the low freezing temperature of the ethanol, the 
lyophilization process was performed in the absence of this solvent. The samples were 
frozen at -20°C and lyophilized using a Lio-labor® instrument (Telstar, Barcelona, 
Spain) for 48 h. The freezing and sublimation temperatures in the lyophilization 
chamber were -45ºC and from -45 to 25ºC, respectively. The sublimation pressure was 
4.54 10-4 atm. The moisture content in the lyophilized product was determined as weight 
loss after heating at 105ºC using a Mettler PM100 balance equipped with a Mettler 
LP16 infrared drying unit (Mettler Toledo, Greifensee, Switzerland). The end point was 
estimated after 120 s without weight variation.  Reconstitution of the freeze dried 
samples was performed by the addition of a mixture of water and ethanol in different 
proportions depending on the composition of the freeze dried formulation. 
Particle size and AmB concentration analyses of reconstituted solutions were carried out 
at times 0, 7 and 15 days by DLS and RP-HPLC, according to the analytical protocols 
reported above. 
 
EXP1-1.4.5.1.3. Spray drying 
The spray drying technique was used to transform a liquid (the AmB impermeable nail 
lacquer [F19]), into a powder. The aim of this assay was to obtain a powder with 
suitable properties (low humidity and stability) for reconstitution. 
As reported above, the freeze drying is not an appropriate technique for those 
formulations containing organic solvents. This is due to the extremely low freezing 
temperature that should be reached in the chamber when these compounds are included. 
For this reason, the spray drying technique was considered as a good choice for 
obtaining a powder with the Eudragit® based formulations. 
5 g of 3 mg/g AmB water-impermeable nail lacquer were prepared as previously 
reported with modifications. The NMP was substituted for DMSO and the ethanol for 
methanol. The NMP has a high evaporation temperature (202 ºC) that difficult its drying 
with this technique. The DMSO although presents a slightly lower evaporation 
temperature (189 ºC) than NMP; in combination with methanol it evaporates at lower 
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temperatures. Preliminary studies performed by the research group  showed that the 
mixture DMSO-methanol evaporates at 75 ºC (data not shown). 
The study was performed at 2 bars pressure, with an aspiration of 100% and with a flow 
rate of 3 mL/min. The inlet and outlet temperatures were 75 ºC and 60 ºC, respectively. 
Once the formulation was spray dried, the product was removed from the collector and 
weighted in order to calculate the yield. Then, the moisture content in the sample was 
determined as reported in the freeze-drying method. Reconstitution of the spray dried 
formulation was performed by the addition of a mixture of ethanol and NMP in a ratio 
7:1.  
 
EXP1-1.4.5.1.4. Scanning electron microscopy (SEM) 
The superficial characteristics of the film formed by the water permeable and 
impermeable AmB nail lacquers were studied by SEM using a JEOL JSM 6335F 
microscope. One drop of 3 mg/g AmB nail polish was placed on a Formvar® carbon 
coated grid (F196/100 3.05 mm, Mesh 300) and left drying at room temperature for 5 
min. The grids were then covered with a thin gold layer and the samples were analyzed. 
The assay was performed at an accelerating voltage of 15 kV. 
 
EXP1-1.4.5.1.5. Rheological properties 
General considerations 
The nail lacquers must have a viscosity that allows for an easy administration and avoid, 
if included, the precipitation of the pigments or other substances included as suspension. 
Generally, the nail lacquers are known to be Newtonian liquids with viscosity values 
ranging from 200 to 400 cPs. The rheological behavior and the viscosity of the nail 
lacquers vary a lot depending of the nature of the polymer used as film-forming agent. 
Thus, polymers such as Eudragit® generate low viscous liquids (<100 cPs) that are 
suitable for nail application. 
Therefore, the formulations developed were studied in terms of viscosity and 
rheological behavior to check whether or not they were appropriate for nail 
administration.  
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Method 
2 g of 3 mg/g AmB nail lacquer were placed on a thermostated cell and measured in a 
Brookfield DV-III viscometer (MAB industrial, Barcelona).The experiment was 
performed at 5 to 62.5 rpm using a CP41 needle. The interval of shear rate was set from 
at 0 to 125 s-1 and the temperature at 25 ºC. The temperature (25 ± 2 °C) was controlled 
using water bath connected to a Tempette® Junior TE-8J resistance. Prior to sample 
analysis the instrument was calibrated using a Brookfield viscosity standard of 975 cPs 
at 25 ºC. 
The rheological behavior of the samples was studied by plotting the viscosity (mPa.s) 
versus the shear rate (1/s), and the shear stress (Pa) versus shear rate (1/s). 
 
EXP1-1.4.5.2. Stability studies 
Short-term stability studies (15 days) were performed on freshly, freeze dried and spray 
dried AmB nail lacquers. Particle size, moisture content, viscosity and AmB 
concentration were determined at 0, 7 and 15 days.  
Long-term stabilities studies following ICH normative are being carried out at this 
moment (data not shown).  
EXP1-1.4.6. In vitro penetration and efficacy studies 
EXP1-1.4.6.1. In vitro nail penetration studies 
General considerations 
The nail penetration studies aimed in determining the in vitro penetration efficacy of the 
lead candidates. The enhanced penetration of the formulations will be compared to a 
control. The formulation with the higher penetration and activity will be selected as the 
final lead candidate. 
Method 
The penetration study was performed on nails donated by both female and male healthy 
volunteers aged ranging between 25-35 years. The experiments were performed in 
triplicate and in each experiment 5 samples of each formulation were prepared. The 
formulations tested were those that showed the best physicochemical properties for 
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AmB nail delivery. The control used for this study was an AmB suspension at pH 5.5 
that was prepared by the addition of 15 mg AmB to 5 mL purified water at pH 12 
(NaOH 0.1 M) followed by pH decrease to 5.5 with ortophosphoric acid 0.1 M. 
The nails were collected and weighted prior to administration. Nail thickness was also 
measured using a caliper Mitutoyo (Illinois, USA).  
One nail was added to each glass tube containing 0.5 g of formulation and left under 
stirring for 15 min at 25°C. Then, with the help of the tweezers, the nails were removed 
and left drying over a watch glass for 20 min. The nails were again weighted to check 
the increase in weight after treatment and introduced into glass tubes. The racks 
containing the tubes were placed in a thermostatized bath set at 32 ºC, 60 rpm for 24 h. 
Later, the nails were taken out from the tubes, washed three times with water and three 
times with ethanol for the water permeable lacquers, and viceversa for the water 
impermeable lacquers. The AmB from the nails was then extracted using DMSO. 
Briefly, each nail was added to a glass tube containing 1 mL DMSO and left under 
stirring at 25°C for 1 h. 10 μL DMSO containing the AmB were diluted to 1 mL with 
MeOH and analyzed by RP-HPLC.  
The AmB concentration was expressed as μg of AmB per mg of nail (μg AmB/mg nail) 
and the enhancement factor (EF) was calculated. It was calculated, as shown in equation 
1, as the ratio between the μg of AmB that penetrated per mg of nail when applied the 
formulation, and the μg of AmB that penetrate per mg of nail when applied the control. 
 
Equation 1. Calculation of the enhancement factor (EF). 
 
EXP1-1.4.6.2. In vitro efficacy study 
The in vitro antifungal activity of AmB as suspension (control) and AmB included in 
water permeable and impermeable nail polishes (samples), were assessed against the 
yeast Candida albicans CECT1394. The control was prepared by solubilizing 5 mg of 
AmB in 5 mL aqueous solution at pH 12 (NaOH 0.1 M) and then decreasing the pH to 
5.5 using orthophosphoric acid 0.1 M. This 1 mg/mL AmB suspension was then diluted 
to 96 μg/mL using phosphate buffer at pH 10.5. The buffer was prepared by the addition 
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of 3.5 g of potassium phosphate dibasic (0.2 M) to 100 mL deionized water at pH 10.5 
(NaOH 0.1 M). 
Yeast cells were cultured in Petri dishes containing agar Sabouraud (72 h at 30 ºC) and 
then 3 mL of a 0.5 McFarland standard suspension (1-5.106 CFU/mL) were seeded in 
plates of Agar Mueller Hinton supplemented with glucose [337]. Methylene blue was 
used as contrast agent.  
Paper disks, impregnated with the AmB dissolved in DMSO were used as reference (S1 
600 μg/mL; S2 200 μg/mL; S3 96 μg/mL; S4 38.4 μg/mL; S5 18.4 μg/mL). One disk 
impregnated with 20 μL of S3 (reference at the same concentration as the control and 
samples) and one disk with 20 μL of 96 μg/mL control were placed on each petri dish.  
3 mg/g AmB water permeable or impermeable lacquers were diluted to 96 μg/mL using 
0.2 M phosphate buffer (pH 10.5) and DMSO, respectively. The impermeable lacquers 
were diluted with DMSO as they form a precipitate in contact with aqueous solutions.  
Then, papers disks impregnated with 20 μL of 96 μg/mL AmB nail lacquers were 
placed on the plates and incubated at 30 ºC for 48 h. After 48 h of incubation, the 
inhibition zones were accurately measured using a caliper and referred to the standard 
(96 μg/mL AmB, S3). 
 
EXP1-1.4.7. Selection (sixth step on the study design) 
The results generated in the physicochemical characterization together with the in vitro 
penetration and efficacy data, allowed for the selection of the final lead candidate. 
 
EXP1-1.4.8. Collaboration with the University Javeriana of Colombia (seventh and 
last step on the study design) 
The lead candidate formulation was sent to Colombia for further analytics.  
 
The translated instructions sent to Colombia together with the labels to identify the 
content of the different vials included in the shipment is attached at the end of Materials 
and Methods. 
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EXP1-1.4.8.1. Evaluation of the antimycotic effect of an AmB nail lacquer against 
the etiological agents responsible for the onychomycosis 
In collaboration with the research group of Dra. Claudia Parras from the University 
Javeriana of Bogotá (Colombia), the in vitro and in vivo efficacy of formulation 19 
(water impermeable nail lacquer) was assayed. This collaboration aimed in determining  
the in vitro minimum inhibitory concentration (MIC) of amphotericin B against 
dermatophytes and non-dermatophytes molds; as well as, evaluating the nail lacquer 
activity on keratinized structures (animal origin) infected in vitro. 
 
EXP1-1.4.8.1.1. Determination of the minimal inhibitory concentration (MIC) 
The minimal inhibitory concentration (MIC) of AmB included in formulation 19 was 
studied against the main etiological agents responsible for the nail infections. 
Trichophyton rubrum, Trichophyton mentagrophytes, Aspergillus niger, Fusarium 
oxysporum and Fusarium solani were the microorganisms assayed. These molds 
belonged to the Microorganisms Collection of the University Javeriana of Colombia. 
For the in vitro MIC studies, seven disks containing AmB at different concentrations 
(table 14) were prepared from a stock solution of 5 mg/mL AmB. DMSO was used as 
control.  
Table 14. AmB nail lacquer concentrations prepared for the MIC study. 
Standard Dilution 
S1 (2400 µg/mL) 480 µL of stock solution + 520 µL of DMSO  
S2 (960 µg/mL) 400 µL of S1 + 600 µL of DMSO 
S3 (384 µg/mL) 400 µL of S2 + 600 µL of DMSO 
S4 (154 µg/mL) 400 µL of S3 + 600 µL of DMSO 
 S5 (61 µg/mL) 400 µL of S4 + 600 µL of DMSO 
S6 (25 µg/mL) 400 µL of S5 + 600 µL of DMSO 
S7 (9.8 µg/mL) 400 µL of S6 + 600 µL of DMSO 
Control DMSO 
 
The in vitro evaluation was performed according to the parameters detailed on the CLSI 
M38 A2 guideline. Briefly, each microorganism was replicated in PDA tubes (16 x 150) 
and incubated at 28ºC during the times established in the guideline. The inocula were 
prepared using a 0.85% sterile saline solution added of tween 20. The microorganisms 
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loading was adjusted by UV spectroscopy and counted in a Newbauer chamber. The 
conidia concentration used in the experiment was in the range 0.4-5 104 CFU/mL and 1-
3 104 CFU/mL for dermatophytes and non-dermatophytes molds, respectively. 
Once the inoculums were prepared, they were seeded in non-supplemented agar Müller-
Hinton. The seeding was performed following the three-directions seeding method in 
order to cover the maximum surface. Once the plates had been seeded, the disks were 
impregnated with 20µL of the different AmB nail lacquer concentrations detailed on 
table 14. The disks were left dry at room temperature for 15 min and then place over the 
agar. Prior to incubation, the agar plates were refrigerated for 2 hours at 5ºC. After that, 
the dishes were incubated at 30ºC for 48h.  
To note that as quality control, the reference strains Candida parasilopsis ATCC 22019 
and Candida krusei ATCC 6258 were used in the assay. 
 
EXP1-1.4.8.1.2. Evaluation of amphotericin B nail lacquer efficacy in the mycotic 
infections of keratinized structures of animal origin. 
Figure 18 shows the timelines and the steps included in the efficacy study designed to 
probe the AmB nail lacquer efficacy against the main pathogens responsible for the 
onychomycosis. 
In order to evaluate the efficacy of the topical AmB nail lacquer formulation, 
keratinized structures of animal origin (chicken nails) were infected with dermatophyte 
and non-dermatophyte molds. Conidia concentrations of 5 108 CFU/mL were prepared 
for each microorganism. 10 µL of each were inoculated in the surface of the keratinized 
structures. The nails were washed and disinfected prior the applications, and the absence 
of microorganisms was established. After the inoculation, the nails were daily 
monitored during 15 days.  At day 15, the nail was sanded down for infection 
confirmation. The infection was confirmed by the observation of the mycotic structures 
in the direct examination with KOH and the later isolation in agar Sabouraud + 
chloramphenicol and Mycosel. 
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Figure 18 Study design and schedule for the efficacy studies on keratinized structures. 
 
Once the infection was confirmed, the AmB nail lacquer (formulation 19) at 3 mg/mL 
AmB was applied over the nail using a brush. The formulation was reconstituted prior 
to administration and shake in order to assure the correct dispersion (see appendix 2). 
Each brush-stroke contained approximately 50 µL formulation that were directly 
applied over the infected nails. The formulation was applied on alternate days (1-0-1-0-
1-0-1 and 0-1-0-1-0-1-0 from Monday to Sunday). After 30 days treatment the AmB 
nail lacquer efficacy was assayed by means of direct examination and culture. 
In this study design the following groups were included as controls: sterility of the 
culture media, sterility of the topical formulation, sterility of the keratinized structures, 
and growth. 
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EXP1-1.4.8.1.3. Formulation 19 in vivo efficacy studies - A case study 
 Case study of a 20 year-old boy infected by Candida spp. 
The research group of Dra. Claudia Parras in Colombia works in collaboration with 
physicians treating immunosupressed patients with severe infections. One of these 
patients was a 20 year-old boy that presented deep candidiasis infections in mouth and 
throat that were resistant to usual treatments but not to Amphotericin B. As this patient 
did not respond to oral therapies, the drugs were being administered using catheters but 
these catheters were being infected by Candida. In order to be able to successfully 
administer the treatments required by this patient and to avoid more complications, it 
was decided to cover the catheters with formulation 19. As it dries really fast and leaves 
an impermeable AmB thin film, the infections might be avoided. In fact, the patient did 
not have any recurrence due to catheters infections when they were covered by 
formulation 19 leading to treatment accomplishment. Once the catheter was remove it 
was observed and analyzed. The catheter maintained the yellowish color due to the 
lacquer layer applied and there were no signs of candidiasis in the patient.  
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SPRAY DRIED AMB NAIL LACQUER INSTRUCTIONS & LABELS 
 
RECONSTITUTION 
- Each vial contains 1.015 g of spray dried product that has to be reconstituted with 4 mL of the 
reconstitution solution (mixture of ethanol: NMP 7:1). 
 
- Once the 4 mL have been incorporated, the vial has to be shake until complete dissolution. The 
reconstituted product will have the aspect of a translucent yellow-organish lacquer. 
 
- The vials should be securely closed in order to avoid ethanol evaporation. 
 
FINAL ASPECT AND CONTENT AFTER RECONSTITUTION 
- After reconstitution, each vial will contain 5 g of lacquer that will last for 1 week treatment. 
AmB concentration in the final reconstituted product will be 0.3% (3 mg/mL). 
 
HOW TO USE THE LACQUER 
- Before each use/administration, the lacquer should be shake. 
- With the help of a brush, apply a layer of nail lacquer and leave dry for 5 min. 
- The lacquer forms a water impermeable film. If the layer has to be removed, the removal will be 
done with ethanol. 
 
STORAGE 
- Once reconstituted, the lacquer has to be stored at room temperature and protected from light. 
 
Number of vials sent: 4 
Each vial can be used for 1 week treatment 
Treatment duration: 1 month (30 days) 
 
 
 
 
 
 
 
IMPORTANT: 
- The spray dried product has to be REFRIGERATED (2-8ºC) and protected from light. If possible, maintain it 
inside a humid-controlled ambient or in a bag/bottle containing silica. 
 
- The nail lacquer, once reconstituted, can be stored at ROOM TEMPERATURE and protected from light. 
 
Spray dried AmB nail lacquer - Instructions and labels 
 
104 
 
LABELS USED TO IDENTIFY THE CONTENT OF THE VIALS SENT TO COLOMBIA 
 
- RECONSTITUTION SOLUTION 
 
 
 
 
 
 
 
 
- SPRAY DRIED AMB NAIL LACQUER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RECONSTITUTION SOLUTION FOR AMB NAIL 
LACQUER 
Vial content: 10 mL of the mixture ethanol + NMP (7:1) 
Shake before use 
Add 4 mL of this solution to each spray dried lacquer vial 
STORE AT ROOM TEMPERATURE AND PROTECTED 
FROM LIGHT 
DO NOT REFRIGERATE 
 
SPRAY DRIED AMB NAIL LACQUER 
Vial content: 1.015 g 
Each 1.015 g of spray dried product contains 15 mg AmB 
Reconstitute with 4 mL of the mixture Ethanol: NMP. Shake until 
homogenous reconstitution. 
Final concentration: 0.3% AmB (3 mg/mL) 
Content and final aspect: 5 g of AmB nail lacquer. Translucent and 
yellow-orangish lacquer. 
Reconstitution valid for 7 days at room temperature. 
THIS BAG CONTAINS 4 VIALS (1 PER WEEK) FOR 1 MONTH 
TREATMENT 
STORE AT ROOM TEMPERATURE AND PROTECTED 
FROM LIGHT. KEEP INSIDE THE SILICA BAG. 
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EXP1-2. RESULTS 
EXP1-2. 1. Amphotericin B solubility studies 
 
EXP1-2.1.1. Reverse-phase high pressure liquid chromatography (HPLC) 
The AmB concentration in the different samples was determined by RP-HPLC 
following the protocol reported by Espada et al. (2008). Two calibration curves, one for 
the extrapolation of the AmB solubility and another one for the determination of the 
AmB concentration on the nail lacquers and on the human nails treated, were performed 
by analyzing different AmB standards of known concentration. For each calibration 
curve, 13 AmB standards were prepared in triplicate by serial dilution using MeOH as 
solvent and starting from a stock solution containing 100 μg/mL AmB in a mixture of 
DMSO-MeOH (1/10). Tables 15 and 16 show the results obtained for both calibration 
curves.  
The AmB solubility studies were performed in Italy, while the AmB determination on 
the nail lacquers and on the human nails were made in Spain (different instruments were 
used which implied the execution of two different calibration curves). This is the reason 
why there are two different calibration curves. 
The AmB concentration for the solubility studies was extrapolated from a curve linear 
in the range 0.012 – 40 μg/mL [(AmB concentration) =115.1(peak area)-1.665; 
R2=0.99], while the AmB concentration in the nail lacquer samples was extrapolated 
from a curve linear in the range 0.012 – 40 μg/mL [(AmB concentration)=113.2(peak 
area)-3.5076; R2=0.99]. As shown in figures 19 and 20, in order to avoid mistakes when 
extrapolating low AmB concentrations, both curves were divided into two sub-curves; 
one used in the determination of low AmB concentrations and another one used for 
calculating high AmB concentrations.  
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Table 15. Concentration and area under the curve (AUC) of the different AmB standards used for the 
calibration curve employed in the determination of AmB concentration on nail lacquer and in the human 
nails. 
Concentration [μg/mL] AUC/1000 AUC/1000 AUC/1000 Mean AUC SD 
50 Out of range Out of range Out of range NA NA 
40 4,508.5 4,520.8 4,498.1 4,509.13 11.36 
25 2,823.1 2,902.6 2,875.6 2,867.1 40.42 
12.5 1,375.7 1,396.1 1,386.4 1,386.06 10.20 
6.25 690.2 699.7 702.1 697.33 6.29 
3.125 342.8 356.2 339.5 346.16 8.84 
1.5625 162.4 175.4 170.7 169.5 6.58 
0.78125 81.91 80.32 82.1 81.44 0.97 
0.3906 41.75 45.71 43.88 43.78 1.98 
0.1953 20.73 19.85 21.63 20.73 0.89 
0.09765 10.81 11.32 10.36 10.83 0.48 
0.04882 5.34 5.61 5.95 5.63 0.30 
0.02441 2.67 2.98 2.71 2.78 0.16 
0.0122 1.09 1.51 1.36 1.32 0.21 
 
 
Table 16. Concentration and area under the curve (AUC) of the different AmB standards assayed for the 
calibration curve used in the AmB solubility studies. 
Concentration [μg/mL] AUC/1000 AUC/1000 AUC/1000 Mean AUC SD 
50 Out of range Out of range Out of range x x 
40 4,607.61 4,596.99 4,604.38 4,602.99 5.44 
25 2,885.17 2,862.01 2,874.42 2,874.42 11.67 
12.5 1,452.02 1,437.13 1,450.07 1,446.07 7.75 
6.25 708.15 702.03 707.85 706.01 3.45 
3.125 357.49 354.18 358.59 356.75 2.29 
1.5625 177.69 176.04 178.04 177.25 1.06 
0.78125 89.43 86.94 88.42 88.26 1.25 
0.3906 45.14 42.14 45.07 44.11 1.71 
0.1953 23.27 19.98 21.35 21.53 1.65 
0.09765 11.48 9.76 10.17 10.47 0.89 
0.04882 5.67 4.61 5.01 5.09 0.53 
0.02441 2.74 2.19 2.45 2.46 0.27 
0.0122 1.17 1.02 1.08 1.09 0.07 
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Figure 19. Calibration curves used to calculate: (left) high concentrations (y=113.41x-9.11, r2=0.99) and 
(right) low concentrations of AmB (y=107.78x+0.0694, r2=0.99) included in the nail lacquers. 
 
 
Figure 20. Calibration curves used to calculate: (left) high (y=115.22x-3.6765, r2=0.99) and (right) low 
AmB concentrations (y=113.7x-0.454, r2=0.99) on the solubility studies. 
 
EXP1-2.1.2. Solubility studies 
The AmB showed extremely low solubility values in almost all the solvents assayed 
with the exception of acetic acid, dimethyl formamide, DMSO and NMP. Table 17 
shows the RP-HPLC results from the AmB solubility studies. As detailed in section 
EXP.1-1.2. from Materials and Methods, the samples were diluted with methanol prior 
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to injection (20 µL of sample + 980 µL of methanol). In the case of DMSO and NMP, 
as the solubility was expected to be much higher, those samples were diluted twice; first 
20 µL sample were diluted with 4980 µL methanol and then, the resulting solution was 
diluted again as detailed for the other samples. 
The higher AmB solubility in acetic acid compared to the other solvents is due to the 
charges generated on this molecule in the presence of an acidic environment due to its 
amphoteric character.   
Table 17. RP-HPLC results obtained in the AmB solubility studies 
 
 
 
 
 
 
 
 
* These samples were diluted twice prior to injection. 
The highest solubility values were found with NMP and DMSO (see table 18). It is well 
known that AmB is highly soluble in DMSO and it can be found as monomer when 
dissolved on it. However, this solvent is not usually used as AmB solubilizer due to its 
high toxicity.  
On the other hand, the solubility of AmB in NMP had never been studied. This is the 
first data published on AmB solubility in NMP. The NMP has demonstrated to be the 
best solvent for AmB. It solubilizes the drug in its monomeric state (figure 21). 
 
 
 
Solvent Mean AUC (/1000) Retention time (min) 
Acetic acid 3.028.45 8.567 
Acetone 13.54 8.633 
Acetonitrile 21.80 8.600 
Cyclohexane 5.07 8.592 
Dimehtylformamide 2.368.44 8.717 
Dimethylsulfoxide (DMSO) 358.05* 8.575 
Ethanol 95.85 8.608 
 Ethylenglycol dimethylether 24.04 8.658 
Isopropyl alcohol 17.58 8.542 
N-methyl-2-pyrrolidone (NMP) 433.66* 8.542 
Petroleum ether 2.19 8.692 
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Table 18. AmB solubility studies in different organic solvents. 
Solvent AmB (mg/mL) 
Acetic acid 
Acetone 
4.48 ± 0.16 
0.006 ± 0.0003 
Acetonitrile 0.0098 ± 0.00002 
Cyclohexane 0.0024 ± 0.00002 
Dimethylformamide 4.12 ± 0.0708 
Dimethylsulfoxide 39.41 ± 0.0032 
Ethanol 0.0423 ±0.0001 
Ethylenglicol dimethylether 0.0072 ± 0.0001 
Isopropyl alcohol 0.0079 ± 0.0003 
N-metil-2-pirrolydone 47.73 ± 0.022 
Petroleum ether 0.0011 ± 0.00008 
 
 
 
 
 
 
 
 
 
Figure 21.  UV scan (450 -300 nm) of AmB dissolved in NMP. 
EXP1-2.2. Formulation development 
 
Our aim in the development of an amphotericin B nail lacquer was first focused on 
obtaining an appropriate matrix that served as nail polish, and then, on the incorporation 
of amphotericin B on that matrix. Thus, we aimed in obtaining a nail lacquer able to 
form an homogenous film and dry within 5 minutes when applied to the nail.  
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Tables 19 and 20 summarize the aim of the formulations as well as the problems found 
during preparation and/or characterization. Table 19 refers to the water soluble while 
table 20 to the non-water soluble nail lacquers. 
 
Table 19. Summary of the water soluble nail lacquers prepared 
A. Water soluble nail lacquers 
A.1. Water soluble matrix 
Formulation Aim of the formulation Comments 
Formulation 1 Design a water soluble matrix High viscosity 
Formulation 2 Decrease the viscosity of F1 Decreased viscosity 
A.2. Incorporation of AmB in the water soluble matrix using Plasdone K90 as film former 
Formulation Aim of the formulation Comments 
Formulation 3 AmB solubility with NMP NA 
Formulation 4 AmB solubility with γ-CD Stability problems 
Formulation 5 Modifications to increase the stability of F4 Increased stability 
Formulation 6 AmB solubility with Plasdone Long drying times 
Formulation 7 Overcome the drying problems of F6 Long drying times (shorter than 
F6) 
Formulation 8 Overcome the drying problems of F7 Shorter drying times 
Formulation 9 AmB solubility with Fungizone® simile Drying problems 
Formulation 10 Incorporation of urea to F9 Drying problems 
Formulation 11 Shorten drying times of F9 Reduced drying times 
Formulation 12 Incorporation of urea to F11 Increased drying times 
Formulation 13 Reduce the drying time of F12 Reduced drying times 
A.3. Incorporation of AmB in the water soluble matrix using PluronicF127 as film former 
Formulation 14 AmB solubility with Fungizone® simile NA 
Formulation 15 Incorporation of urea to F14 Stability problems 
Formulation 16 Ethanol removal to improve stability 
 of F14 and F15 
NA 
Formulation 17 AmB solubility with γ-CD  
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Table 20. Summary of the water insoluble nail lacquers prepared 
B. Water insoluble nail lacquers 
B.1. Incorporation of AmB in water insoluble matrix using Eudragit®L100 
Formulation 18 AmB and Eudragit dissolution in NMP Drying problems 
Formulation 19 Addition of ethanol to overcome drying 
problems 
Short drying times 
Formulation 20 Incorporation of urea to F19 No soluble 
 
More detailed information on the nail lacquer matrix and the problems found during 
preparation and/or stability can be found in sections AP1.3. and AP1.4. appendix 1. 
EXP1-2.3. Pre-selection of the lead candidate formulations 
 
Between all the water permeable and impermeable lacquers developed, the three lead 
candidates considered as possible carriers for AmB delivery were Formulation 11,  
Formulation 13  (water permeable lacquers) and Formulation 19 (water impermeable 
polish). These formulations were chosen according to their stability, characteristics of 
the film formed and the drying times. 
In the following experiments, these 3 formulations were used. 
 
EXP1-2.4. Characterization of the three lead candidate formulations 
 
EXP1-2.4.1. Physicochemical charaterization 
 
EXP1-2.4.1.1. Lyophilization/spray drying 
As detailed in Materials and Methods (EXP1-1.3.5.1.2 and EXP1-1.3.5.1.3) the water 
soluble nail lacquers were lyophilized in order to obtain a powder for reconstitution. 
This method aimed in generating a product with a longer shelf life compared to the 
freshly prepared formulations. Formulations 11 and 13 were prepared following the 
protocol previously detailed, frozen with liquid nitrogen and lyophilized during 48 h. 
The freeze dried powders obtained were yellowish and slightly electroscopic (figure 
22A). Its water content, measured by IR, was 6.91% and 4.96% for F11 and F13, 
respectively. 
Regarding the water impermeable formulation, F19, a lyophilization process could not 
be performed. The freeze-dried method does not allow for the use of organic solvents. 
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Therefore, another method had to be used for obtaining a F19 stable powder for 
reconstitution. The spray drying technique was used as an alternative to the freeze 
drying. As the solvents included in F19 had high evaporation temperatures, some 
changes were made on the initial F19 composition. The ethanol was substituted by 
methanol and the NMP by DMSO. Even though DMSO had lower evaporation 
temperature compared to NMP, this value was still too high. Experiments performed by 
our research group (data not shown) demonstrated that the mixture DMSO-methanol, at 
low DMSO contents, evaporated at 75ºC. To note that the substitution of ethanol by 
methanol was based not only on the studies performed in terms of evaporation, but also 
to the fact that the mixture DMSO-methanol assures AmB in-process stability. The 
mixture DMSO-methanol has been widely used in our research group for the AmB 
concentration determination, as the AmB is completed solubilized in this mixture 
(monomeric aggregation state). Once the spray drying method was set up, the F19 
powder for reconstitution was obtained with yields ranging between 89-94%. The 
aspect of the recovered product was that of a fluffy, yellowish, non-electrostatic powder 
(figure 22B). As well as for the lyophilized products, the humidity value was measured 
in this powder. The % of humidity was 7.03%. 
 
Figure 22. A. Lyophilized F11 and B. Spray dried F19 
Both methods, freeze drying and spray drying, provided stable powders for 
reconstitution. The addition of water or mixture NMP-Ethanol to F11, F13 and F19, 
generated nail lacquers with the same properties of the freshly prepared formulations. 
The reconstitution lasted less than 5 min and it was favored by agitation. 
 
EXP1-2.4.1.2. Stability studies 
The AmB concentration in freshly prepared and reconstituted formulations was studied 
over the time. As shown in table 21 and figure 23, the AmB content in freshly prepared 
A B 
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formulations remained stable during at least 3 weeks at 25ºC. At week 4 a small 
decrease in AmB content was detected. 
Table 21. Concentration values of F11, F13 and F19 during 28 days storage at 25ºC. 
Formulation 
% AmB (g of amB/100 g formulation)  
0 days 7 days 15 days 21 days 28 days 
F11 0.3001 0.2998 0.2962 0.2959 0.2792 
F13 0.2999 0.2995 0.2951 0.2943 0.2819 
F19 0.3010 0.3005 0.2978 0.2965  0.2854 
 
 
 
 
 
 
 
 
 
Figure 23. AmB concentration on F11, F13 and F19 after 28 days storage at 25ºC. 
Table 22 shows the concentration values obtained for the reconstituted powders (rF11, 
rF13, rF19) during 15 days storage at room temperature. These reconstituted solutions 
were designed to be used only for 1 week treatment and therefore, a stability of 15 days 
is accepted. 
Table 22. Concentration values of rF11, rF13 and rF19 during 28 days storage at 25ºC. 
Formulation 
% AmB (g of amB/100 g formulation)  
0 days 7 days 15 days 
rF11 0.2998 0.2981 0.2977 
rF13 0.2989 0.2978 0.2972 
rF19 0.3008 0.2993 0.2989 
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A complete stability study on the powders for reconstitution has been designed. The 
powders will be exposed to 4ºC, 25ºC and 40ºC and its physicochemical properties as 
well as the AmB concentration will be analyzed over time. 
 
EXP1-2.4.1.3. Dynamic light scattering (DLS) 
Tables 23 and 24 show the particle size in number of the two water permeable lead 
candidates analyzed by DLS. The mean particle size was higher for formulation 13 
compared to 11 for all the assayed period. Both formulations had a mean particle size 
ranging between 20-30 nm which remained stable during at least 15 days after 
reconstitution. The mean particle size was increased after 3 weeks reconstitution (38.03 
± 2.86 nm and 40.15 ± 2.21 nm for F11 and F13, respectively) and some of the 
formulations showed signs of desestabilization at day 35 (four populations with a 
particle size of 1824, 853, 234.4 and 27.41 nm were detected). 
Formulation 19 could not be analyzed by DLS because, in contact with water, the 
polymer precipitates forming a film. 
Table 23. Mean particle size of AmB fresh lacquer over 15 days. 
Formulation 
(fresh formulation) 
Time (days) 
0 7 15  
Formulation 11 20.01 ± 2.56 nm 22.86 ± 1.43 nm 21.57 ± 1.21nm 
Formulation 13 25.80 ± 4.28 nm 30.56 ± 0.89  nm 29.46 ± 2.33 nm 
Formulation 19* - - - 
 
Table 24. Mean particle size of AmB reconstituted lacquer over 15 days. 
Formulation 
(after reconstitution) 
Time (days) 
0 7 15 
Formulation 11 21.98 ± 1.37 nm 23.19 ± 2.75 nm 24.85 ± 1.98 nm 
Formulation 13 26.05 ± 2.24 nm 29.93 ± 3.16 nm 30.17 ± 3.05 nm 
Formulation 19* - - - 
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EXP1-2.4.1.4. Scanning electron microscopy 
The films formed by the different formulations are shown on figure 24.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. SEM microphotographies of the film formed by F11 (A), F13 (B) and F19 (C). 
A 
B 
C 
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Formulation 19 formed a homogenous film while F11 and F13 generated a film in 
which some deposits could be detected. Those deposits were chemically analyzed by 
SEM, concluding that they are not composed by AmB crystals. They might appear as a 
consequence of incomplete dissolution of any of the formulation components. 
Figure 25 shows the amplified zoom of the deposits found on the film formed by 
formulations 11 and 13. 
 
 
 
 
 
 
 
 
 
Figure 25. Amplified picture of the filmed formed by F13. 
 
EXP1-2.4.1.5. Rheological characterization 
Tables 25 and 26 show the viscosity results from F11, F13 and F19 in the fresh and 
reconstituted formulations at 0, 1 and 2 weeks. The viscosity values were recorded in 
cPs.  
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Table 25. Viscosity data (cPs) from F11, F13 and F19 fresh formulations. 
Fresh formulation 
Formulation Time 0 Time 7 days Time 15 days 
Formulation 11 265.85±2.48 245.26±4.21 255.49±1.28 
Formulation 13 326.55±3.60 313.75±3.60 319.88±1.85 
Formulation 19 80.45±1.26 79.38±1.85 89.05±0.95 
 
Table 26. Viscosity data from F11, F13 and F19 reconstituted formulations. 
Reconstituted formulation 
Formulation Time 0 Time 7 days Time 15 days 
Formulation 11 259.85±2.45 251.38±4.27 261.49±1.28 
Formulation 13 323.98±1.95 327.02±1.21 328.58±1.18 
Formulation 19 88.78±0.57 88.82±0.90 89.93±0.57 
 
The viscosity values measured for F11 and F13 where higher than those of F19. The 
higher values obtained for the water permeable lacquers are related to the higher 
molecular weight of the Plasdone® K90 compared to the Eudragit® L100.  
On the other hand, the differences found in between F11 and F13 can be explained by 
the incorporation of urea in the formulation. The addition of 10% urea on F13, entailed 
a 10% decrease on solvents content (5% water and  5% ethanol). This decrease 
generated, as expected, a higher viscous lacquer. 
As shown in table 26, the viscosity values in the reconstituted samples did not differed 
to those of the freshly prepared formulations. Moreover, as for the freshly prepared 
lacquers, the values remained stable during the whole assayed period.  
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Figures 26 and 27 show the rheological behavior of freshly prepared and reconstituted 
F11. 
Figure 26. Viscosity profile of fresh F11 at time 0 (-■-), after 1 week (-□-) and after 2 weeks storage at 
20±2 ºC (-▲-). 
Figure 27. Viscosity profile of reconstituted F11 at time 0 (-●-), after 1 week (-○-) and after 2 weeks 20±2 
ºC (-◊-). 
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Figures 28 and 29 show the rheological behavior of freshly prepared and reconstituted 
F13. 
 
Figure 28. Viscosity profile of fresh F13 at time 0 (-■-), after 1 week (-□-) and after 2 weeks storage at 
20±2 ºC (-▲-). 
 
 
Figure 29. Viscosity profile of reconstituted F13 at time 0 (-●-), after 1 week (-○-) and after 2 weeks 20±2 
ºC (-◊-). 
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And finally, figures 30 and 31 show the rheological behavior of freshly prepared and 
reconstituted F19. 
 
Figure 30. Viscosity profile of fresh F19 at time 0 (-■-), after 1 week (-□-) and after 2 weeks storage at 
20±2 ºC (-▲-). 
Figure 31. Viscosity profile of reconstituted F19 at time 0 (-●-), after 1 week (-○-) and after 2 weeks 20±2 
ºC (-◊-). 
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All three lead candidates (F11, F13 and F19) showed Newtonian flow properties 
regardless the formulation preparation (freshly or reconstituted). This was in accordance 
to other nail antifungal formulations used in the treatment of onychomycosis [338]. 
EXP1-2.5. In vitro nail penetration and efficacy studies 
 
EXP1-2.5.1. In vitro nail penetration studies 
The in vitro efficacy studies on the three lead candidates were performed on female 
human nails. The nails were donated by healthy female students whose age ranged 
between 25-35 years old. 
Formulations 11, 13 and 19 were those that showed the best physicochemical properties 
and therefore, these were the ones assayed in vitro in terms of penetration, activity and 
efficacy.  
As indicated in Materials and Methods (EXP1-1.3.6.1), 5 nails were used for each 
formulation on each of the experiments. The nails, whose weight differed between 
donors and in between the same donor, were weighted prior and after incubation with 
0.5 g of the different formulations. The nails weight was found to be in the range 2.8-8 
mg. As the µg of AmB that penetrated into the nail were expressed as function of the 
nail weight, this variability did not affect the final results. Not only the weight of the 
nails was checked, but also the amount of formulation added (0.5001- 0.05104 g). 
Once the nails containing the lacquer, were incubated at 32ºC for 24 hours, their 
superficial lacquer film was removed in order to assure that the AmB concentration 
detected by HPLC was extracted only from inside the nail. The washing was performed 
following the protocol described in Materials and Methods (EXP1-1.3.6.1).  
The AmB extraction was first assayed with NaOH. The literature describes the addition 
of high molarities NaOH solutions as the best mechanism to dissolve the nails. 
Nevertheless, this method generated some problems. First of all, the AmB at high pH 
not only get dissolves but also gets degraded. This degradation produced low, almost no 
detectable, peaks in the HPLC (false negatives). Secondly, the nail dissolution 
generated many compounds which did not allow for a proper AmB UV determination. 
The spectra (300-450 nm) showed new peaks which absorbed at the same AmB 
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wavelengths. Finally, the HPLC did not work either. When neutralizing the samples for 
injection, some molecules precipitated and even though the samples were filtered, new 
peaks were found to overlay the AmB monomer peak at 406 nm. Several changes were 
performed on this method (different NaOH solutions, filtrations, addition of AmB 
solvents in the dissolved nails followed by centrifugation, modifications on the mobile 
phase composition, insertion of gradients, etc.) but none of them worked.  
As an alternative to nail dissolution with sodium hydroxide and, as a result of some 
observations made by our research group during this project, the addition of DMSO was 
considered as an acceptable method for AmB nail extraction. A study performed on 
nails exposed to DMSO during 48 hours showed that this solvent attacks the nail and 
generates similar degradation products to those detected with NaOH treatment. As this 
method worked slower and was not so aggressive as NaOH (the nail is not dissolved), 
the AmB that penetrated the nail was successfully recovered and analyzed.  
Once the extraction method was set up, the in vitro penetration studies were design. 
Figures 32 shows a scheme of the planned studies. 
 
Figure 32. In vitro nail penetration study design. 
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The first in vitro study aimed to establish the different penetration efficacies of a control 
(an AmB suspension) and F11, F13 and F19 formulations. The experiments were 
performed in triplicate and 5 nails were used for each formulation on each experiment. 
The in vitro penetration nail studies are known to have a wide variability and therefore, 
the higher the number of nails used and the higher the number of experiments 
performed, the better.  
Table 27 shows the µg of AmB extracted from mg of nail (µg that theoretically 
penetrated the nail) as well as the enhancement factor (EF). The EF measures the higher 
or lower penetration of a formulation with respect to a control. Usually the control is a 
commercialized formulation, but in this case it was an AmB suspension (no excipients 
added). 
 
Table 27. First in vitro penetration study. µg of AmB per mg of nail and enhancement factor. 
Formulation µg AmB/mg nail (mean) SD EF 
Control 0.2928 0.005 NA 
F11 0.221 0.065 0.75 
F13 0.192 0.079 0.66 
F19 0.571 0.055 1.95 
SD, standard deviation; EF, enhancement factor 
 
The results of this first experiment demonstrated that F19 was the formulation with 
highest enhanced penetration. Surprisingly, F11 and F13 showed lower nail penetration 
(EF<1) values. Not only F19 penetrated more but also the NMP efficacy as penetrating 
enhancer was demonstrated to be higher than that of urea (F13). 
The  second study (second and third experiments) was conducted in order to check the 
reproducibility and variability of the EF value obtained for F19, and therefore, of the 
method. In these experiments, the control and the F19 were the only samples analyzed. 
Tables 28 and 29 show the results for the second and third experiments. Both 
experiments, as previously stated, were performed in triplicate. 
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Table 28. Second in vitro penetration study. µg of AmB per mg of nail and enhancement factor for F19. 
Experiment 2. 
Formulation µg AmB/mg nail (mean) SD EF 
Control 0.0853 0.05 NA 
F19 0.151 0.04 1.77 
 
Table 29. Second in vitro penetration study. µg of AmB per mg of nail and enhancement factor for F19. 
Experiment 3. 
Formulation µg AmB/mg nail (mean) SD EF 
Control 0.2571 0.14 NA 
F19 0.4341 0.064 1.69 
 
The three experiments performed on different nails, gave an EF value of 1.69-1.95 for 
F19. In the three cases the values were similar and always higher than those of the 
control.  
Once the method reproducibility was tested another three experiments (experiment 4, 5 
and 6) were designed to confirm the in vitro penetration of the reconstituted F19 (rF19) 
compared to the freshly prepared formulation. Tables 30, 31 and 32 show the EF values 
obtained for both F19 and rF19. 
 
Table 30. Third in vitro penetration study. µg of AmB per mg of nail and enhancement factor for F19 and 
rF19. Experiment 4. 
Formulation µg AmB/mg nail (mean) SD EF 
Control 0.2232 0.03 NA 
F19 0.4181 0.14 1.87 
rF19 0.4648 0.12 2.02 
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Table 31. Third in vitro penetration study. µg of AmB per mg of nail and enhancement factor for F19 and 
rF19. Experiment 5. 
Formulation µg AmB/mg nail (mean) SD EF 
Control 0.1659 0.05 NA 
F19 0.3120 0.05 1.88 
rF19 0.3282 0.07 1.98 
 
Table 32. Third in vitro penetration study. µg of AmB per mg of nail and enhancement factor for F19 and 
rF19. Experiment 6. 
Formulation µg AmB/mg nail (mean) SD EF 
Control 0.1722 0.03 NA 
F19 0.3139 0.05 1.83 
rF19 0.3137 0.05 1.82 
 
The EF values obtained for F19 and rF19 were really similar. Regardless the small 
differences due to method accuracy, both formulations behaved identically. The spray 
drying process did not alter the physicochemical properties of F19 nor its nail 
penetration. 
The EF values calculated along all the studies, were in the range [1.73-1.92] and [1.82 - 
2.09] for F19 and rF19, respectively. 
At this point and pending on the in vitro efficacy studies, the F19 was considered as 
possible lead candidate for the following experiments planned with the scientists of 
Colombia. 
It is worth noting that the best method to study the in vitro nail penetration is based on 
the use of Franz cells. The research group is currently setting up the conditions for this 
experiment (data not generated yet). 
 
EXP1-2.5.2. In vitro efficacy against Candida albicans CECT1394 
The efficacy of the three lead candidates (F11, F13 and F19) was studied against 
Candida albicans CECT1394. As described in materials and methods, the 3 
formulations were diluted to 96 µg/mL using phosphate buffer or DMSO. The water 
permeable lacquers (F11 and F13) were diluted with phosphate buffer, while the water 
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impermeable lacquer (F19) was diluted with DMSO. As previously mentioned, the film 
forming agent included in F19 (Eudragit® L100) forms a solid film in contact with 
water, reason why it cannot be diluted with phosphate buffer. 
Once the dilutions were prepared, the paper disks where loaded with 20 µL sample, 
placed over the agar containing the Candida and incubated at 30ºC for 48 h. The 
inhibition halos generated for F11, F13 and F19, as well as the formulations efficacy 
compared to the standard (S3, standard with the same concentration), are detailed in 
table 33. An AmB suspension was used as control.  
The experiment was performed in triplicate and what is detailed on table 33 is the mean 
of the three experiments. Each experimental value was generated from the measurement 
of 5 inhibition zones. 
Table 33. Inhibition halos (mm) and % of activity obtained with F11, F13 and F19. 
Formulation Mean inhibition halo (mm) SD % Activity compared to S3 
Control 14.25 0.52 64.6 
S3 22.06 0.13 100 
F11 20.90 0.71 103.1 
F13 18.01 0.18 94.7 
F19 22.75 0.73 81.65 
 
As shown in table 33, F19 was the formulation that generated the higher inhibition 
zones (22.75 mm) in all three experiments. The slightly higher activity of F19 compared 
to S3 can be related to the presence of NMP on the formulation. The antifungal activity 
of the AmB included in this formulation might be increased by the penetrating effect 
conferred by NMP. These assumptions would be accepted or rejected when more 
experimental data would be generated (following experiments). 
The results obtained in the efficacy study, provided the information necessary to select 
the final lead candidate formulation. All the data allow us to conclude that F19, was the 
selected formulation. 
In order to check that the spray dried F19 nail lacquer had the same activity than the 
freshly prepared formulation, the efficacy study was performed again in triplicate. In 
this case, the control, the fresh F19, the reconstituted formulation (rF19) and the S3 
standard were assayed. Table 34 shows the results obtained from this study. 
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Table 34. Inhibition halos (mm) and % of activity obtained with freshly prepared and reconstituted F19 
(rF19) 
Formulation Mean inhibition halo (mm) SD % Activity compared to S3 
Control 14.19 0.48 64.5 
S3 21.98 0.04 100 
F19 22.26 0.03 101.3 
rF19 22.31 0.12 101.5 
 
This in vitro efficacy study showed that both, fresh and reconstituted F19, had the same 
activity. The spray drying did no modify the formulation efficacy.  
Moreover, the differences previously found in activity for F19 compared to S3, 
decreased in this experiment. These small differences were related to the method 
accuracy and not to a real higher F19 efficacy. 
In order to compare the activity of F19 and rF19 to commercially available AmB disks 
(Neo-sensitabs®), a third experiment was performed. In this case, the control, the S3, 
the Neo-sensitabs®, F19 and rF19 were assayed against Candida albicans CECT1394. 
The results obtained are indicated in table 35.  
To note that the F19 and rF19 disks were impregnated with 20 µL of 96 µg/mL AmB 
(load=1.92 µg AmB) while the AmB content of the Neo-sensitabs® disks was 10 µg. 
The experiment was performed with a higher initial AmB concentration on Neo-
sensitabs® disks. 
Table 35. Inhibition zones (mm) and % of activity obtained with freshly prepared and reconstituted F19 
(rF19) compared to Neo-sensitabs® 
Formulation Mean inhibition halo (mm) SD % Activity compared to S3 
Control 14.51 0.67 66.0 
S3 21.98 0.06 100 
Neo-sensitabs® 21.68 0.23 98.6 
F19 22.44 0.07 102.1 
rF19 22.48 0.17 102.3 
 
Even though the initial AmB concentration on the Neo-sensitabs® disks was 5 times 
higher than in the other formulations, its inhibition zone, as well as its percentage (%) of 
activity, was lower than for F19, rF19 and S3.  
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In all three in vitro activity studies performed, the highest inhibition zone and the 
highest percentage of activity was found for both fresh and reconstituted F19. 
EXP1-2.6. Lead candidate selection 
 
The better performance of F19 compared to F11 and F13 (higher in vitro nail 
penetration and efficacy against Candida albicans) together with its high stability and 
novelty, are some of the reasons why it was selected as lead candidate. Formulation 19 
was sent to the Colombia scientists for establishing the minimum inhibitory 
concentrations (MICs) against the etiological agents responsible for the onychomycosis 
as well as for the in vitro efficacy studies against infected keratinized structures. 
 
EXP1-2.7. Evaluation of the antimycotic effect of an AmB nail lacquer against the 
etiological agents responsible for the onychomycosis - In vitro studies performed in 
Colombia. 
AmB efficacy studies against the dermatophyte and non-dermatophyte molds 
responsible for the onychomycosis, as well as the in vitro efficacy against an infected 
model, were performed in collaboration with University Javeriana of Bogotá 
(Colombia). A summary of the results generated is indicated below. 
 
EXP1-2.7.1. Determination of the minimal inhibitory concentration (MIC). AmB 
efficacy 
For the determination of the amphotericin B activity, several concentrations ranging 
between 9.8 to 2,400 µg/mL were prepared. Two of those concentrations being higher 
that the ones described in the guideline CLSI. The samples prepared correspond to those 
concentrations in which there is the appearance of an inhibition halo. 
Method validation 
In order to evaluate the validity of the test, two strains of Candida were used as 
reference; Candida parapsilosis ATC22019 and Candida krusei ATCC6258. Both 
strains were evaluated against all the concentrations prepared for the study. As the 
commercially available disks contain 25 µg/mL AmB, the concentration used for the 
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method validation was also 25 µg/mL. Figures 33 and 34 show the results obtained from 
the reference strains. 
 
Figure 33. MIC test validation using two reference strains of Candida. 
At an AmB concentration of 25 µg/ml the inhibition zones obtained for Candida krusei 
and Candida parapsilosis were 14-25 mm and 17-29 mm, respectively. These values 
were in accordance with the cut points detailed on CLSI guideline (M44 A2). Therefore, 
the test demonstrated its validity for MIC determination. 
 
 
 
 
 
 
 
Figure 34. Method validation using C. parapsilosis and C. Krusei. Inhibition zones (mm) generated by 
both strains 
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To note that the zones of inhibition obtained for the rest of the concentrations are in fair 
agreement with the expected results, as the inhibition zones diameter might be directly 
related to the drug concentration. 
 
EXP1-2.7.1.1. AmB activity against dermatophyte and non-dermatophyte molds 
EXP1-2.7.1.1.1. Activity against dermatophyte molds 
The evaluation of the amphotericin B activity against Trichophyton mentagrophytes and 
Trichophyton rubrum was determined by means of the inhibition halo generated 
(measured in mm) against each microorganism. The AmB inhibition halos for both spp 
are detailed in figure 35. 
 
 
Figure 35. Inhibition halos generated by AmB on T.mentagrophytes and T rubrum cultures. 
 
As detailed in the Candida assays, it can be observed how the AmB efficacy against 
dermatophyte molds is directly related to the concentration administered. Nevertheless, 
AmB efficacy against T. rubrum was found to be higher than for T. mentagrophytes 
(p=0,0). As for T. rubrum is concerned, all the inhibitions zones generated with AmB 
concentrations ranging between 61-2,400 µg/mL were higher than 20 mm, while in T. 
mentagrophytes, an inhibition halo of 22 mm was only found at 2,400 µg/mL. 
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EXP1-2.1.1.2. Activity against non-dermatophyte molds 
AmB activity against non-dermatophyte molds (Aspergillus niger, Fusarium solani and 
Fusarium oxysporum) is detailed on figure 36.  
 
Figure 36. Inhibition halos generated by AmB on A. niger, F. solani and F. oxysporum 
 
The study of the AmB activity against non-dermatophyte molds showed a greater AmB 
efficacy against F. solani compared to F. oxysporum, being these differences 
statistically significant (p<0.05). The inhibition halos obtained for F. solani were found 
to be higher than 15 mm for 25 µg/mL and all the above concentrations.  
The results obtained for F. oxysporum showed that at concentrations below 154 µg/mL  
(61, 25 and 9.8 µg/mL) the microorganism is resistant to AmB. The inhibition halos 
obtained for concentrations higher than 61 µg/mL were directly related to the 
concentrations. The more AmB concentration, the higher the inhibition halo. However, 
none of the inhibition halos measured were above 15 mm. 
The inhibition zones obtained for A. niger, showed an homogenous behavior for all the 
concentrations included in the range 9.8-960 µg/mL. These concentrations showed 
inhibition halos below 15 mm. Only when the discs were loaded with 2,400 µg/mL 
AmB, the inhibition halos obtained had 20 mm. 
Figure 37 shows the inhibition halos obtained with different AmB concentrations. 
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Figure 37. Inhibition zones (mm) caused against different dermatophyte and non-dermatophyte molds 
when several concentrations of AmB were tested. 
 
EXP1-2.7.2. AmB efficacy against mycotic infections on keratinized structures  
The evaluation of the therapeutic effect of AmB in the treatment of the onychomycosis 
located in keratinized structures of animal origin (chicken nails) was studied as 
described in Materials and Methods (EXP1-1.3.8.1.2). Briefly, the nails were drilled and 
inoculated with different conidia suspensions (depending on the type of microorganism 
to be infected with). Total nail infection was confirmed at 15 days post-inoculation. The 
infection was verified by direct examination using 30% KOH as well as by means of the 
etiological agent isolation in agar Sabouraud + Cloranfenicol + Mycosel (figure 38). 
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Figure 38. Fungal infection on keratinized structures (direct examination and culture). 
 
The nail lacquer was applied in alternate days during 30 days. At day 30, the efficacy 
was evaluated by direct examination and culture, as previously described. Figures 39 
and 40 show the infection of the keratinized structures and its resolution after 30 days 
treatment with formulation 19. 
 
 
 
 
Microorganism Direct examination Culture 
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Figure 39. Culture of infected nails prior and after 30 days administration of F19. 
KOH CULTURE CULTURE 
 
 
 
 
 
 
 
Mycosel Sab+CLO Mycosel Sab+CLO 
  
 
Figure 40. Direct examination (KOH) and culture of infected nails prior and after F19 administration for 
30 days. 
Microorganism Before After 
Sterility 
control 
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As shown in figure 39, the formulation assayed (3 mg/mL AmB nail lacquer) was active 
against both dermatophyte and non-dermatophyte molds after 30 days treatment. The 
use of NMP did not only increase the amphotericin B solubility, but also enhanced its 
penetration through the nail.  
 
The results of the in vitro efficacy study conducted with F19 on keratinized structures, 
supported the in vitro inhibition results. The inhibition zones caused on fungal cultures 
were found to be in agreement with the sensitivity data, regardless the differences found 
on some of the microorganisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
IN VIVO EFFICACY CANDIDA SP. COSOLVENTS 
DRYNESS SODIUM DEOXYCHOLATE   PENETRATION 
SPRAY DRYING H2O  N-METHYL-2-PYRROLIDONE 
AGE NAIL PLASTICIZER   PEG ENHANCEMENT FACTOR  
AMPHOTERICIN B ONYCHOMYCOSIS LACQUER   
ETHANOL FILM-FORMING SEM POLOXAMER DLS  F19 
MIXED INFECTIONS STABILITY F13 EX VIVO  
UNIVERSITY JAVERIANA  ANIMAL ORIGIN PPG 
TRYCHOPHYTON MENTAGROPHYTES ACTIVITY  
DERMATOPHYTE BRIGHTNESS TOE-NAIL MIC  
PATHOGENS ADHESIVE LEAD CANDIDATE   MOISTURE  
YIELD KERATINE MYCOTIC GLYCERIN EUDRAGIT® 
L100  FREEZE DRYING    PLASDONE K90  CELLULOSE 
γ-CYCLODEXTRINS HPLC SCANNING ELECTRON 
MICROSCOPY RHEOLOGY MIXED INFECTIONS 
PENETRATION CLSI EFFICACY PARTICLE SIZE 1/S  F11  
EXP.1-3. DISCUSSION 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Novel formulations for Amphotericin B delivery 
 
141 
EXP1-3. DISCUSSION 
 
Amphotericin B solubility studies using different organic solvents (acetic acid, acetone, 
acetonitrile, cyclohexane, dimethylformamide, ethanol, ethylenglycol dimethylether, 
isopropyl alcohol, dimethylsulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP) and 
petroleum ether) provided information on the maximum amount of drug that could be 
dissolved on them. The highest AmB solubility values were obtained for DMSO and 
NMP (39 mg/mL and 47.73 mg/mL, respectively). While DMSO solubilizing effect on 
AmB had been widely studied, this is the first time that the AmB solubility in NMP is 
reported. NMP not only solubilizes higher amounts of AmB but also avoids the toxicity 
associated to DMSO administration. Furthermore, the studies of AmB aggregation on 
both solvents demonstrated that the AmB is found in its monomeric state when 
dissolved with either DMSO or NMP.  
Different water permeable and impermeable nail lacquer formulations were prepared. 
The drying time, viscosity, aspect of the film, extensibility, brightness, AmB 
incorporation and pH were studied. From all the formulations developed (20), three of 
them were selected for further characterization and in vitro studies. F11, F13 and F19 
were the formulations that showed the best physicochemical properties. These three 
formulations were selected as lead candidates. 
Even though formulations 11, 13 and 19 overcame the AmB low solubility problems, 
the short-term stability of these formulations was still an issue. Preliminary stability 
studies showed that the formulations were stable up to 1 month at room temperature. 
The strategy used to overcome the short AmB stability was focused on obtaining 
powders for reconstitution. These powders would be stored at 2-8ºC and protected from 
light and humidity. 
The freeze drying (for F11 and F13) and spray drying (for F19) methods generated 
stable lyophilized and spray dried products easily redispersable. Immediately after 
solvent addition, formulations with the same physicochemical properties than the 
freshly prepared F11, F13 and F19 were obtained and the water content detected by IR 
was lower than 8% regardless the method and the formulation prepared. The spray 
drying technique provided an alternative method for obtaining an F19 powder for 
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reconstitution. The method was successfully set up and the yields obtained were in the 
range 89-94% for all the experiments performed. The AmB concentration detected by 
HPLC was 0.3% in the freshly prepared F11, F13 and F19. After 1 month storage at 
25ºC the concentration decreased up to 0.28%. The reconstituted formulations 
demonstrated its stability during 15 days storage in the same conditions. Further 
stability studies are currently on going.  
The particle size of the freshly prepared and reconstituted F11 and F13 was in the range 
20-30 nm. The dimensions of the freshly prepared formulations remained stable during 
15 days at 25ºC. On the contrary, the particle size of the reconstituted formulations 
slightly increased with increasing exposure times. The small increase in size was not 
considered as an indicative of instability as in none of the formulations the size was 
greater than 30 nm.  F19 could not be analyzed by DLS due to its water impermeable 
properties. 
SEM images of the film formed by F11, F13 and F19 provided information on the 
differences found in between formulations. While SEM microphotographies of F19 
showed a continuous, homogenous and smooth film, the film formed by F11 and F13 
presented some deposits. The chemical composition of the deposits was analyzed by 
SEM and it was concluded that they were no generated by the accumulation of AmB 
crystals. The deposits might me related to incomplete solubilization of any of the 
components included in the formulation. 
The viscosity values obtained for F11, F13 and F19 were different. The higher viscosity 
values recorded for the water permeable formulations are explained by the higher 
molecular weight of the Plasdone® K90 compared to the Eudragit® L100. The 
differences detected in between F11 and F13 were related to higher solids content on 
F13. The viscosity values were, in all cases, stable during 15 days at 25ºC and no 
significant differences were observed in between them. The rheological behavior was 
identical for all three formulations. Regardless the initial differences in viscosity, F11, 
F13 and F19 showed Newtonian flow properties. Even though the pseudoplastic flow 
properties are believed to confer the nail lacquer improved film stability and therefore, 
are preferred, there are some studies that support that Newtonian flow properties are 
adequate for nail delivery [338]. 
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In vitro nail penetration studies on female human nails, demonstrated the higher nail 
penetration reached with F19 compared to F11, F13 and to the control. The EF value for 
F19 (EF=1.95) was almost twice the value of the control (EF=1) and approximately 
three times the value of F11 and F13.  Despite the assumed experimental variability 
given by the use of human keratinized structures, the method generated close-related 
results. The EF value was not influenced by the formulation preparation process (fresh 
or reconstituted lacquers). Although the protocol used in these in vitro penetration 
studies provided useful information for the selection of a lead candidate, it has to be 
taken into account that the most reliable penetration data would be obtained in a Franz 
cells experiment.  
The in vitro efficacy studies against Candida albicans showed that the most active 
formulation was F19 (103%). The greater % of activity found for F19 compared to the 
control was considered to be related to the method accuracy. No differences in activity 
between F19 and its reconstituted product were found. The activity of this formulation 
compared to Neo-sensitabs® (commercialized AmB loaded disks) demonstrated that 
F19 was more effective than the latest, even at 5 times less concentration. The study of 
the in vitro efficacy of this formulation was of great importance as the main objective of 
the present chapter was to develop and AmB nail lacquer effective against 
dermatophyte, non-dermatophyte, candidal onychomycosis and, most importantly, 
against mixed infections. 
Taking into account all the above summarized results (physicochemical characterization 
and in vitro penetration and efficacy studies), F19 was selected as lead candidate.  
F19 powder for reconstitution was sent to the University Javeriana of Bogotá 
(Colombia) for analysis. The group of Dra. Parras, determined the minimum inhibitory 
concentration (MIC) and the F19 efficacy on keratinized infected structures of animal 
origin. The efficacy was assayed on nails infected with T. mentagrophytes, T. rubrum, 
F. solani, F. oxysporum and A. niger, main etiological agents responsible for the 
onychomycosis. 
The new AmB formulation was effective against dermatophyte and non-dermatophyte 
molds. Even though there are some studies that report the absence of AmB activity 
against dermatophyte molds and, some clinical trials in which the AmB administration 
has produced treatment failures, the data obtained from the MIC studies, support the 
Exp1-3.Discussion 
 
144 
AmB efficacy. This activity was greater against T. rubrum compared to the other 
dermatophyte molds, and in general to all the microorganisms assayed. This is in 
accordance with the studies performed by Lu Yu, et al., [338] and Yenisehirli et al., 
[340].  
The AmB was active against F. solani at almost all the concentrations assayed, but it 
had limited activity against F. oxysporum. Only at high AmB concentrations, the 
molecule was effective. These data differed from those included in the studies carried 
out by Wildfeuer et al., [244] and Lalitha et al. [341]. These studies supported the 
highly efficacy of AmB against different Fusarium spp. Moreover, the studies 
performed by Pujol et al.; Azor et al.; O'Donnell et al. and Alastruey et al. [342-345] 
stated that the AmB was the most active drug against Fusarium spp. The MIC results 
should be, therefore, validated against different isolations of the same Fusarium spp. in 
order to determine the MICs (the guidelines does not detail the cut points for the 
determination of sensitivity or resistant). 
The small inhibition zones obtained when AmB formulation was applied to Aspergillus 
niger cultures could be explained by the difficulties found in the treatment of this 
microorganism. Even though A. niger is not the most commonly responsible etiological 
agent for the non-dermatophyte onychomycosis, when it is the causative agent, its 
treatment should not be performed with AmB. The A. niger reduced sensitivity against 
AmB has been previously reported by García-Martos et al [346]. On the contrary, other 
studies conducted by Pfaller [347] and Wildfeuer [348]  showed that the AmB was 
effective against Aspergillus spp. 
The AmB nail lacquer was active against the dermatophyte and non-dermatophyte 
infections located on keratinized structures. 30 days treatment with F19, administered in 
alternate days, once daily, cleared up the infections caused by T. mentagrophytes, T. 
rubrum, A. niger, F.oxysporum and F.solani. After 30 days of treatment no 
microorganisms were found nor in the culture media neither in the direct examination. 
These results were in fair agreement with the in vitro penetration studies performed on 
human nails supporting the enhanced AmB nail penetration due to the presence of NMP 
in the formulation. 
The in vivo application of F19 was described as a case study. The water impermeable 
AmB layer generated on the surfaces of the catheters avoided their contamination. After 
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patient treatment success and removal of the catheters, it could be observed how the 
yellowish AmB film remained intact. 
The selection of a lead candidate formulation for AmB nail delivery was conducted 
through a screen study of more than 20 formulations. Short-term stability and AmB 
concentration studies were performed on 20 of those formulations. The results obtained 
in these studies provided valuable information for the initial selection of three lead 
candidates. The physicochemical characterization and the in vitro penetration and 
efficacy studies, demonstrated the better performance of the water impermeable lacquer 
compared to the other two formulations. Based on those results, F19 was chosen as lead 
candidate and further in vitro and in vivo efficacy studies were performed. The 
formulation was effective against the main etiological agents responsible for the 
onychomycosis, resolving the in vitro infections within 30 days treatment.  
 
 
In sum, an AmB nail lacquer effective in the treatment of onychomycosis has been 
developed for the first time. This new nail lacquer constitutes a promising alternative 
for AmB nail delivery. However, further in vivo efficacy studies as well as futher 
studies related to its application over catheters should be performed. 
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EXP2-1. MATERIALS & METHODS 
EXP2-1.1. Materials 
 
Amphotericin B (AmB) was purchased from Azelis (Barcelona, Spain), Fungizone® 
from Bristol-Myers Squibb (Madrid, Spain) and Ambisome® by Gilead Sciences 
(Madrid, Spain). Globulin free human serum albumin, naproxen and 5β-cholanic acid 
were supplied by Sigma-Aldrich (Milan, Italy). 5 kDa amino-terminating 
monomethoxy-terminating poly(ethylene glycol) (PEG5kDa-NH2) and hydroxyl-
terminating monomethoxy-terminating poly(ethylene glycol) (PEG5kDa-OH) were 
supplied by Iris Biotech GmbH (Marktredwitz, Gemany). Heparinized capillaries (75 
mm) were purchased from Heinz Herenz (Hamburg, Germany) and heparine 5000 UI 
from Rovi. Dialysis membranes (Spectra/Por®Float-A-lyzer®G2 MWCO: 3.5-5kDa) 
were supplied by Spectrum®Labs (Wurzburgo, Germany). Certified Candida albicans 
strain (CECT1394) was a gift of Dr. Pérez Carrasco from Centro de Análisis Químico y 
Microbiológico (CAQYM), Universidad Alcalá de Henares (Madrid, Spain). Culture 
media were purchased from Pronadisa-Conda Lab (Madrid, Spain). Technical grade and 
HPLC grade solvents and salts were purchased from Merck (Milan, Italy). In this thesis 
the purified water was always obtained from MilliQ, Millipore (USA). 
 
EXP2-1. 2. Methods 
EXP2-1.2.1. Synthesis and characterization of the poly(ethylene glycol)-cholane 
bioconjugate 
 
Monomethoxy-poly(ethylene glycol)-cholane (PEG5kDa-cholane) was synthesized 
according to the protocol reported in the literature with modifications [335]. The 
synthesis was based on a two step reaction where the first step consisted on the 
activation of the carboxyl group from the cholanic acid while the second step included 
the conjugation of the activated group with a monomethoxy-poly(ethylene glycol)amine  
of 5  kDa molecular weight (MeO-PEG5kDa-NH2) (figure 41). The two steps of the 
reaction are summarized in figure 41. 
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Figure 41. Chemical synthesis of PEG5kDa-cholane. 
 
EXP2-1.2.1.1. Activation of the carboxyl group 
It is important to point out that for this step the maintenance of the anhydrous conditions 
not only in the cabinet but also in the products and the material needed for the reaction 
is a key factor. A high degree of activation will be expected if these conditions are 
maintained.   
The activation (figure 42) was performed by the addition of thionyl chloride (524 μL, 
7.2 mmol) in a ratio 1:10 (cholanic acid: thionyl chloride) to a flask containing the 5β-
cholanic acid (260 mg, 0.72 mmol) dissolved in 6 mL CH2Cl2. The bottom of the flask 
was slightly submerged into a glycerin bath set at 50 ºC. The temperature was manually 
adjusted in order to control the boiling and therefore the reflux. The mixture was 
refluxed under nitrogen atmosphere for three hours. During the process the reaction was 
controlled in order to assure that the micelle was not getting dried. When necessary, 
some drops of CH2Cl2 were added. After the three hours, the distillation column was 
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assembled and the unreacted thionyl chloride was removed by distillation. Finally, to 
assure the complete solvent removal, the product was left in a rotavapor for 1 h.  
 
Figure 42. Chemical activation of the carboxyl group from the cholanic acid. 
Once activated, the product generated was analyzed by nuclear magnetic resonance in 
order to check the degree of activation. 
 Degree of activation by nuclear magnetic resonance (NMR) 
After solvent evaporation an aliquot of the activated cholane was reacted with 200 μL 
CH3OH (figure 19). The methyl ester of the cholanic acid was first vortex for 5 min and 
then centrifuged at 10000 rpm for another 5 min using a Sigma centrifuge D-37520 
(Osterode am Harz, Germany). 150 μL of the micelle were added to an eppendorf and 
placed under vacuum using a Heto Vacuum Centrifuge VR-mini St. a.-1 (Allerod, 
Denmark) during one and a half hours in order to eliminate the excess of CH3OH. 
Finally, 700 μL deuterated chloroform were added (figure 43) and the product was 
analyzed by 1H-NMR spectrometry using a Bruker Spectrospin 300 spectrometer 
(Bruker, Fallanden, Switzerland) to estimate the activation degree. By the integration of 
the peaks corresponding to the 3H from the CH3 of the methanol that sterifies the 
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cholanic and the 3H from the CH3 placed in position 19 of the cyclopentane perhydro 
phenanthrene ring and by using the following equation (equation 1) the degree of 
activation can be estimated. 
 
 
Equation 1. Calcule of the carboxyl group degree of activation 
 
The knowledge of the degree of activation was necessary to proceed with the next step 
of the reaction.  
 
Figure 43. Sample preparation for NMR analysis 
 
EXP2-1.2.1.2. Conjugation with MeO-PEG5kDa-NH2 
The conjugation was performed taking into account that the stoichiometry of the 
reaction was 1:3:2 (MeO-PEG5kDa-NH2 : cholanyl chloride : triethylamine (TEA)) and 
considering a certain degree of cholanyl activation (previously calculated).  
Cholanyl chloride (218 mg, 0.576 mmol) in 1 mL CH2Cl2 was added of 53.5 μL TEA 
(0.384 mmol) and 4 mL CH2Cl2 of 242.7 mg/mL PEG5kDa-NH2 (970.8 mg, 0.192 mmol) 
(figure 44). The reaction solution was maintained overnight under stirring at room 
temperature and then dropwise added to 35 mL of diethyl ether. The precipitate, 
immediately generated, was refrigerated at 4 ºC (left in the fridge for 10 min) to 
enhance the polymer precipitation and then, recovered by centrifugation at 4000 rpm for 
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15 min and re-dissolved in 5 mL CH2Cl2. The precipitation was repeated three times. 
The precipitate was desicated under vacuum and finally lyophilized in a Hetossic 
equipment (HETO Lab, Birkerod, Denmark).  
 
 
Figure 44. Cholanyl chloride conjugation with 5 kDa amino-terminating monomethoxy-terminating 
poly(ethylene glycol). 
 
The degree of PEG-NH2 derivatization with cholanyl chloride was evaluated by the 
TNBS colorimetric assay, which allows for determination of unreacted amino groups   
[349] and by 1H NMR spectrometry. 
 
 TNBS colorimetric assay 
The 2,4,6-trinitrobenzene sulfonic acid, known as TNBS,  is a highly sensitive and fast 
chemical used in the quantification of free amino groups. The reaction of TNBS with 
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primary amines generates highly chromogenic products that can be measured by UV 
[350]. 
For this assay, also known as Snyder test, 30 mL of a 0.1 M borate buffer were prepared 
by the addition of 185.5 mg of boric acid (61.3 g/mol) in purified water at pH 9.3 
(NaOH 0.5 M). Then, a stock solution of MeO-PEG5kDa-NH2 (reference) and PEG5kDa-
cholane (synthesized product) were prepared at 2.157 mM. 5 mg of both MeO-PEG5kDa-
NH2 (9.89 10
-4 mmol, mol wt 5056 Da) and PEG5kDa-cholane (9.232 10
-4 mmol, mol wt 
5416 Da) were added of 456.2 μL and 428 μL of borate buffer, respectively. For the 
sample preparation, 30 μL of TNBS diluted in borate buffer (1:30) and 940 μL of borate 
buffer were added to both 30 μL of MeO-PEG5kDa-NH2 stock solution and 30 μL of 
PEG5kDa-cholane stock solution. After 30 min reaction, the samples were measured by 
UV spectroscopy in a Perkin Elmer Spectrophotometer Lambda 25 (Massachusetts, 
USA) set at 420 nm (wavelength of maximum absorption for the compound generated 
as a consequence of the reaction with TNBS). The blank used for the experiment was 
borate buffer (940 μL) added of 30 μL TNBS. The samples were prepared in triplicate.   
The degree of derivatization was calculated from the equation 2. 
 
 
 
Equation 2. Calcule of the degree of derivatization by TNBS 
 
 Degree of conjugation by NMR 
The degree of conjugation was also confirmed by 1H NMR spectrometry. The samples 
were prepared following the same protocol reported above. The yield was calculated by 
dividing the integration of the peak corresponding to the 3H from the CH3 placed in 
position 19 of the cyclopentane perhydro phenanthrene ring by the 3H from the CH3 of 
the last methoxy group located in the PEG chain. 
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Equation 3. Calcule of the degree of conjugation by NMR 
The polymer synthesized was stored in a freezer at -20ºC until use. 
EXP2-1.2.2. Amphotericin B dissolution studies with PEG5kDa-cholane 
 
AmB dissolution studies with PEG5kDa-cholane were carried out according to three 
different methods: Direct dissolution; Co-solvent dissolution and Dissolution/pH 
change. The aim of this assay was to find the method that produces the maximum AmB 
dissolution with the polymer.  
 
EXP2-1.2.2.1. Direct dissolution 
Samples of 4 mg AmB in 500 µL CH3OH where desiccated using a speed-vac system. 
The dried samples were added of 500 µL of 0.5, 1, 1.5, 2, 3 and 6 mg/mL PEG5kDa-
cholane or PEG5kDa-OH in water, pH 7.2, and maintained overnight under top-down 
mixing. The samples were centrifuged at 12000 rpm for 10 min. The AmB 
concentration in the supernatant was determined by the RP-HPLC method previously 
described.  
 
EXP2-1.2.2.2. Co-solvent dissolution 
Samples of 4 mg of AmB in 500 µL CH3OH were added of 100 µL of 2.5, 5, 7.5, 10, 15 
and 30 mg/mL PEG5kDa-cholane or PEG5kDa-OH in water, pH 7.2. The mixtures were 
dried in speed-vac and the residues were re-dispersed in 500 µL water at pH 7.2 and 
maintained overnight under top-down mixing. The samples were centrifuged at 12000 
rpm for 10 min and the AmB in the supernatant was analyzed by RP-HPLC as reported 
above. 
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EXP2-1.2.2.3. Dissolution/pH change 
The AmB dissolution was performed according to the method described by Higuchi and 
Connors [351]. Briefly, 20 mg of AmB were dissolved in 1 mL of 0.5, 1, 1.5, 2, 3 and 6 
mg/mL PEG5kDa-cholane or PEG5kDa-OH in 0.05 N NaOH. The pH was then shifted to 
7.2 with 0.1 M ortophosphoric acid and the suspensions were centrifuged at 12000 rpm 
for 10 min. The AmB in the supernatant was analyzed by RP-HPLC as reported above. 
 
EXP2-1.2.3. Physicochemical characterization of the AmB/PEG5kDa-cholane 
complex 
 
EXP2-1.2.3.1. Reverse-phase high pressure liquid chromatography  
The AmB concentration in the different samples was determined by reverse-phase 
chromatography (RP-HPLC) using a Thermo Hypersil BDS® C18 column (200 x 4.6 
mm, 5 μm) operated on a Jasco HPLC system equipped with a Jasco PU-1580 pump 
and UV-visible detector set at 406 nm (Jasco, Tokyo, Japan). The column was 
isocratically eluted at a flow rate of 1 mL/min with 52:4.3:43.7 v/v/v acetonitrile/acetic 
acid/water mobile phase [352]. The AmB concentration in the samples was determined 
on the basis of the elution peak area (AmB is eluted after 8 min), which was referred to 
a titration curve obtained by eluting AmB samples at concentrations in the range of 
0.012-40 μg/mL [(AmB concentration)=115.1(peak area)-1.665; R2=1]. When 
analyzing biological samples, the AmB concentration was referred to a curve linear in 
the range 0.012-50 μg/mL [(AmB concentration)=113.7(peak area)-12.45; R2=0.99]. In 
order to avoid mistakes in the extrapolation of low AmB concentrations, both curves 
where divided in two sub-curves; one for low AmB concentrations (from 0.012 to 
1.5625 μg/mL R2=0.999) and another for high AmB concentrations (from 0.78125 to 40 
or 50 μg/mL R2=0.999). After sample analysis, the column was isocratically washed 
with MeOH:H2O (60:40) at 0.4 mL/min, 406 nm, for 1 hour when analyzing non-
biological samples and, with a gradient of ACN(TFA 0.05%) and H2O(TFA 0.05%) at 1 
mL/min, 220 nm, for 1 hour after biological samples analysis. The gradient used was 
40% ACN, 60% H2O from 0 to 3 min; from min 3 to min 12 the amount of ACN was 
increased from 40 to 90% and the water content decreased from 60 to 10%; from min 12 
to min 15 the washing phase consisted of 90% ACN and10% H2O, from min 15 to min 
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18 the ACN was decrease to 40% and the H2O increased to 60% and from min 18 to 20 
the phase remained as 40% ACN, 60% H2O. 
When necessary, a 5 M HCl Guanidine solution was injected to remove the plasma 
proteins attached to the column.  
 
EXP2-1.2.3.2. Dynamic light scattering and zeta potential analyses 
AmB/PEG5kDa-cholane aqueous solutions (1 mg/mL AmB, 12:1 AmB/PEG5kDa-cholane 
molar ratio) prepared by dissolution/pH change were analyzed at different times (0, 7, 
14, 21, 28, 35, 42, 49, 56 and 63 days) by dynamic light scattering (DLS) using a 
Malvern Zetasizer Nano-ZS (Malvern, Worcestershire, UK). The analyses were 
performed in triplicate at 25ºC, 633 nm wavelength and 173º detection angle to assess 
the mean particle size, size distribution and zeta potential. Particle size, size distribution 
and zeta potential of unloaded micelles (0.5 mg/mL PEG5kDa-cholane aqueous solutions) 
were also studied.   
 
EXP2-1.2.3.3. Freeze drying 
AmB/PEG5kDa-cholane samples (10 mL of 1 mg/mL AmB, 12:1 AmB/PEG5kDa-cholane 
molar ratio) were prepared by dissolution/pH change, frozen with liquid N2 and 
lyophilized using a Lio-labor® instrument (Telstar, Barcelona, Spain) for 48 h. The 
freezing and sublimation temperatures in the lyophilization chamber were -45ºC and 
from -45 to 25ºC, respectively. The sublimation pressure was 4.54 10-4 atm. The 
moisture content in the lyophilized product was determined as weight loss after heating 
at 105 ºC using a Mettler PM100 balance equipped with a Mettler LP16 infrared drying 
unit (Mettler Toledo, Greifensee, Switzerland). The end point was estimated after 120 s 
without weight variation.  Reconstitution of the freeze dried samples was performed by 
the addition of 10 mL of 10 mM phosphate buffer, 0.15 M NaCl (PBS), pH 7.2. Particle 
size and AmB concentration analyses of reconstituted solutions were carried out at 
times 0, 7, 14, 24 and 31 days by DLS and RP-HPLC, respectively, according to the 
analytical protocols reported above. 
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EXP2-1.2.3.4. Isothermal titration calorimetry 
Description of the technique 
Isothermal titration calorimetry (ITC) is a technique used to measure the energetic of 
molecular interactions or biochemical reactions [353]. It is the most direct method to 
measure the heat change on formation of a complex at constant temperature. The basics 
of this technique are simple. The experiment is performed at a constant temperature by 
titrating one binding partner (“titrant”), placed on the syringe, into a solution containing 
the other binding partner (‘titrand’), located in the sample cell of the calorimeter. Both, 
titrant and titrand solutions should have the same buffer composition. After each 
addition of a small aliquot of titrant, the heat released or absorbed in the sample cell is 
measured with respect to a reference cell filled with the  buffer. If the interaction is 
exothermic, the ITC uses less energy to heat the cell; if the interaction is endothermic, 
the ITC uses more energy to heat the cell. The heat change is expressed as the electrical 
power (J s-1) required to maintain a constant small temperature difference between the 
sample cell and the reference cell, which are both placed in an adiabatic jacket. The 
addition of the titrant is automated and occurs from a precision syringe driven by a 
computer-controlled stepper motor. Precise measurement of the energy required to 
maintain temperature of the cell during the course of several injections leads to the 
calculation of free energy, enthalpy (ΔH), entropy (ΔS), dissociation constant (Kd), and 
stoichiometry of binding from one single experiment. In commercially available 
instruments volumes of sample cells are in the range 0.2–1.5 ml. The amount of titrand 
required per experiment depends on the magnitude of the heat change [354]. 
Method 
ITC analyses were carried out using an MSC-ITC instrument (Microcal Inc., 
Northampton, MA). AmB solutions were prepared by dissolution/pH change and their  
concentration was determined by RP-HPLC prior to sample analysis. AmB (1.1 10-5 M) 
and PEG5kDacholane (0.6 10
-3 M) solutions in water at pH 3.5, 5.5, 7.2, 8.5 and 11.0, 
were degassed and thermostated at 25 ºC before the analysis. At 5 min intervals, 5 μL 
volumes of PEG5kDa-cholane solutions were injected in 10 s into the calorimeter cell 
containing 1.5 mL AmB solutions at the same pH. Each assay was performed in 
triplicate and the data was analyzed with the Microcal Origin 3.5 software. 
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EXP2-1.2.3.5. Structural characterization  
Samples of AmB, PEG5kDa-OH, PEG5kDa-cholane, lyophilized AmB/PEG5kDa-cholane 
(12:1 AmB/PEG5kDacholane molar ratio) prepared by dissolution/pH change and 
AmB/PEG5kDa-cholane physical mixtures (12:1 AmB/PEG5kDa-cholane molar ratio) 
obtained by mixing AmB and PEG5kDa-cholane dry powders were analyzed by 
differential scanning calorimetry, hot stage microscopy, X-ray diffractometry and 
Fourier-transformed infrared spectroscopy in order to characterized the new system 
developed. 
 
EXP2-1.2.3.5.1. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) analyses were performed using a Mettler 
TA3000 differential scanning calorimeter DSC 20 (Mettler Toledo, Greifensee, 
Switzerland). Samples (10 mg) were placed on a pinhole aluminum lidded pan and 
heated in atmospheric air at a rate of 10ºC/min from 30 to 250ºC.  
 
EXP2-1.2.3.5.2. Hot stage microscopy 
Hote stage microscopy (HSM) analyses were performed by placing the samples on a 
microscope covered slide and heated at a rate of 2ºC/min from 25 to 250ºC. Microscopy 
determinations were carried out using a Thermo Galen microscope fitted with the Kofler 
stage (Leica, Wien, Austria) [355]. 
 
EXP2-1.2.3.5.3. X-ray diffractometry 
X-Ray diffractometry (XRD) analyses were carried out with an X-ray diffractometer 
Philips®X’ Pert–MPD (PANalytucal, Amelo, Netherlands). The samples were placed on 
a carrier, irradiated with monochromatized CuK α-radiation and analyzed between 2 
angles of 5º and 50º with 0.04º steps of 1 s. The assay was performed at 30 mV voltage 
and 30 mA intensity. 
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EXP2-1.2.3.5.4. Fourier-transformed infrared spectroscopy (FT-IR) 
Fourier-transformed infrared spectroscopy (FT-IR) spectra were recorded over the range 
4000-400 cm-1 using a FT-IR Nicolet Magna 750 spectrometer (0.5 cm-1 resolution) 
equipped with an attenuated total reflectance (ATR) Spectra Tech Performer with 
diamond crystal (Thermo Fisher Scientific, Waltham, MA USA). The data were 
analyzed with Thermo software. 
 
EXP2-1.2.3.6. Synchrotron 
In order to analyze the superficial characteristics of the AmB/PEG5kDa-cholane micelles 
and the interactions that take place between the AmB and the polymer, some samples 
were prepared and analyzed by synchrotron. This analysis was performed in 
collaboration with the group of Milan University Bicocca that has access to the 
instrument placed in Geneve. 
For the synchrotron analysis, the polymer and each single component of the formulation 
has to be prepared at a concentration of 10 mg/mL in order to assure the highest 
resolution.  
As previous studies showed that PEG5kDa-cholane in the presence of AmB, NaOH and 
orthophosphoric acid jellifies at 7.5 mg/mL, a 5 mg/mL PEG5kDa-cholane solution and a 
10 mg/mL AmB in AmB/ PEG5kDa-cholane micelles containing 5 mg/mL polymer were 
prepared. 
The medium was obtained by the addition of 40 μL NaOH 0.1 M and 30 μL 
ortophosphoric acid 0.1 M to 4.930 mL purified water. 1 mL medium was used to 
solubilize 5 mg of PEG5kDa-cholane. The AmB/PEG5kDa-cholane micelles (10 mg/mL 
AmB, 5 mg/mL PEG5kDa-cholane) were prepared by the pH/change method. The 
samples were centrifuged at 4500 rpm for 5 min using a Hermle Z- 306 centrifuge 
(Wehingen, Germany) to ensure complete solubilization and to eliminate air bubbles. 
As the solution containing the AmB/PEG5kDa-cholane micelles was slightly viscous, 
another formulation with fewer amounts of AmB and PEG5kDa-cholane was prepared. 
This second formulation contained half AmB half polymer. In order to perform the 
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experiment not only the formulation but also a sample of the polymer alone at 2.5 
mg/mL was prepared.  
1 mL of each sample was placed in an eppendorf, frozen with liquid nitrogen and stored 
in freezer at -20 ºC until expedition. 
 
EXP2-1.2.3.7. Transmission electron microscopy 
Samples for negative-stain transmission electron microscopy (TEM) analysis were 
prepared by depositing one drop of AmB/PEG5kDa-cholane (12:1) micelles, prepared by 
dissolution/pH change, stained with 1% phosphotungstic acid for 20 seconds into 
Formvar/carbon-coated TEM copper grids (size 3.05 mm) for 30 s. The grids were left 
drying at room temperature for 15 min before the analysis. The samples were examined 
and photographed in a Jeol JEM 1010 transmission electron microscope (Jeol Ltd, 
Tokyo, Japan) equipped with a Megaview II imaging camera and operating at 100 kV 
(resolution 0.35 nm). 
 
EXP2-1.2.3.8. Human Serum Albumin circular dichroism analyses 
Description of the technique 
Circular dichroism (CD) spectroscopy is a spectroscopic technique used to study chiral 
molecules. The basics of this method are referred to the differential absorption of the 
left and right circularly polarized components of equal magnitude of the plane-polarized 
radiation. If after passing through the sample that is being examined, the left and right 
components are not absorbed or equally absorbed, the recombination of both would 
regenerate polarized radiation in the original plane. However, if both are differently 
absorbed, the resulted radiation would be said to possess elliptical polarization (figure 
45) [356]. A CD signal is generated when a chromophore is chiral (optically active) 
either intrinsically by reason of its structure; by being covalently linked to a chiral 
centre or by being placed in an asymmetric environment [357].  
 
CD instruments measure the difference in absorption between the left and right 
circularly polarized components (ΔA= AL-AR) and usually express this measurement as 
ellipticity in degrees [356]. 
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Figure 45. Circular Dichroism bases. Image taken from [356]. 
 
In figure 45, the scheme A part I show the behavior of the two components  when they 
both have the same amplitude while part II refers to the resultant of the difference 
between the two components (dashed line) when they are elliptically polarized. In the 
scheme B, as shown in the spectra, the absorption bands can generate different signals 
on the CD depending on the left and right absorption. The higher left absorption 
compared to the right, generates a positive band in the CD (band 1); the higher right 
absorption compared to the left, produces a negative band (band 2) while the achiral 
chromosphere doesn’t generate a signal (band 3).  
 
CD spectroscopy is widely used to study chiral molecules of all types and sizes, but it is 
in the study of large biological molecules where it finds its most important applications. 
It is mainly used in the analysis of the secondary structure or conformation of 
macromolecules, particularly proteins. As protein secondary structure is sensitive to its 
environment, temperature or pH, CD can be used to observe how secondary structure 
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changes with environmental conditions or on interaction with other molecules. 
Structural, kinetic and thermodynamic information about macromolecules, as well as, 
aggregation and stability information about small molecules, can be derived from 
circular dichroism spectroscopy.  
Method 
Circular dichroism analyses were performed either in the far or near UV. The far UV 
was used to detect possible changes in the human serum albumin (HSA) secondary 
structure caused by the presence of AmB included in different systems. Changes in the 
protein structure could possibly lead to side effects when administered this formulation 
in vivo. On the other hand, the CD analyses in the near UV were performed in order to 
get information about the AmB aggregation state in the presence or in the absence of 
HSA. It is well known that formulated AmB in the presence of HSA disaggregates and 
joins the protein in a monomeric state [151]. The speed at which this process takes place 
is directly related to the toxicity of the formulation.  
 Far UV 
Human serum albumin (HSA) solution (1.5 10-7 M) in PBS, pH 7.2, in the absence or in 
the presence of 1.37 10-7 M AmB or equivalent AmB concentration of Fungizone®, 
heated Fungizone® (obtained by 30 min heating  Fungizone® at 70ºC) or 
AmB/PEG5kDa-cholane micelles (12:1 AmB/PEG5kDa-cholane molar ratio) prepared by 
dissolution/pH change were analyzed by CD in the far UV (200-300 nm, 50 nm/s with 8 
s response and 2 nm band width) using a J-810 Jasco spectrodichrograph (Jasco, Tokyo, 
Japan). The spectra were processed by Dicroprot software and the protein secondary 
structure was calculated by KD2 analysis. CD analyses were performed after sample 
incubation at 37ºC for 15 min [151].  
 Near UV 
HSA solutions (2.3 10-4 M) in PBS, pH 7.2, in the absence or in the presence of 5 10-6M 
AmB or AmB equivalent concentration of Fungizone®, heated Fungizone® and 
AmB/MeO-PEG5kDacholane (12:1 AmB/PEG5kDa-cholane molar ratio) samples were 
incubated at 37 ºC for 15 min [151] and then analyzed by circular dichroism (CD) in the 
near UV (300-450 nm).  
Exp2-1.Materials & Methods 
 
166 
 
EXP2-1.2.3.9. Absorption and kinetics studies 
The AmB aggregation in the different formulations, at different temperatures and in the 
presence and absence of HSA, as well as, the kinetics of the AmB disaggregation 
process in the presence of HSA, were studied as described below.  
AmB (5 10-5M) or AmB equivalent concentration of Fungizone®, heated Fungizone® 
and AmB/PEG5kDa-cholane micelles (12:1 AmB/PEG5kDa-cholane molar ratio) prepared 
by dissolution/pH change in PBS, pH 7.2, were 1:10 diluted with a 2.3 10-4 M HSA in 
the same buffer and spectrophotometrically analyzed by UV absorption in the range of 
300- 450 nm at 25 and 37ºC using an Evolution 201 UV-Visible spectrophotometer 
equipped with a single cell peltier system (Thermo Fisher Scientific). Absorption 
spectra were recorded at 0, 1, 2, 5, 10, 20 and 45 min. Kinetic analysis were performed 
recording the absorption at 413 nm, at 15 s intervals for the first 5 min and then at 1 min 
intervals for further  40 min [358].  
 
EXP2-1.2.3.10. Dialysis studies 
The AmB release from the core of the PEG5kDacholane micelles was studied by dialysis.  
One milliliter of 30 μg/mL AmB or AmB equivalent AmB/PEG5kDacholane micelles 
(12:1 AmB/ PEG5kDacholane molar ratio) in PBS, pH 7.4, was dialyzed at 25 ºC against 
PBS buffer, pH 7.4 using a Float-A-Lyzer® G2 system, 3.5-5 kDa cut-off. The AmB 
concentration inside the dialysis bag was determined at fixed time points by RP-HPLC. 
The analysis was performed in triplicate and the data was elaborated to find the best fit 
according to different mathematical models (table 36). 
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Table 36. Mathematical models used in the study of the AmB kinetic release profile 
Model Equation 
Zero order Qt =Q0 + kt 
First order log Qt =log Q0 +kt/2,303 
Hixon-Crowel Qt = kt1/2 
Higuchi Q∞1/3-Qt1/3 = kt 
Baker-Lonsdale 3/2[1-(-1(Qt/Q∞))2/3]-(Qt/Q∞)=kt 
Korsmeyer-Peppas Qt/Q∞=ktn  
 
EXP2-1.2.4. Stability studies 
 
ICH stability studies 
The stability studies were designed following the International Conference of 
Harmonisation guidelines (ICH) [359]. The stability guideline (ICHQ1A), exposes that 
the conditions for the accelerated studies for those drugs that should be stored at 4 ºC, 
are 6 months analysis at 25 ± 2 ºC with a relative humidity (RH) of 60 ± 5%.   
Following the ICH, 15 mL of 1 mg/mL AmB, 12:1 AmB/PEG5kDa-cholane solution and 
FD micelles were prepared for the stability studies. 200 μL AmB/PEG5kDa-cholane 
solution and re-dispersed product were added to 60 vials and stored in a desiccator at 25 
± 2 ºC and 60% RH. The temperature was controlled three times a week and the RH 
was obtained by the addition of a saturated solution of NaCl. 
At each sampling time, three vials from both formulations were analyzed by RP-HPLC 
in order to determine the remaining AmB concentration. 
  
Gastric mimicking fluid stability studies 
AmB/PEG5kDa-cholane stability studies in gastric mimicking fluid (GMF) were 
performed in order to get information about the percentage of AmB still available in the 
formulation after being exposed to these extreme conditions. The aim of the study was 
to check whether or not the new formulation could be orally administered.  
The GMF was prepared according to the European pharmacopeia [360]. Briefly, 0.2 g 
of NaCl and 0.32 g of pepsin 800/2500 U/mg were added to 100 mL of deionized water 
at pH 1.2 (7 mL of 0.1 M HCl). The gastric mimicking fluid was kept at 37 ºC and 
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under stirring during the entire assay (4 hours).  At time 0, 5 mL of 1 mg/mL AmB in 
AmB/PEG5kDa-cholane micelles (12:1 AmB/PEG5kDa-cholane molar ratio) were added 
to the GMF.  At fixed times, 100 μL media were taken and analyzed by RP-HPLC. 
The analysis was performed in triplicate and the data was elaborated to find the best fit 
according to different mathematical models (table 14). 
EXP2-1.2.5. In vitro toxicity studies 
 
EXP2-1.2.5.1 Hemolysis 
The hemolytic effect of AmB included in Fungizone® and PEG5kDa-cholane micelles 
(12:1 molar ratio) was studied as reported elsewhere [330]. 
Blood was collected from Sprague Dowley rats.  Blood was collected from the tail vein 
and added of sodium citrate (3.8%) to avoid coagulation. 
2 mL of non-coagulated blood were diluted with 8 mL PBS buffer, pH 7.2, and 
centrifuged at 1500 rpm for 5 min. Then, the pellet was washed 5 times with PBS in 
order to obtain a clear supernatant and the hematocrit was adjusted to 5% (w/v) in PBS. 
Two control samples were prepared. As for the negative control 1 mL PBS was added 
of 30 μL red blood cells (RBC) (0% hemolysis). With regards to the positive control, 
this was prepared by the addition of 30 μL RBC to 1 mL purified water (100% 
hemolysis). 
To study the AmB hemolytic effect, 30 μL of RBC were added of 1 mL of 0, 2.5, 5, 10, 
20, 30, 40, 50 and 60 μg/mL AmB included in the different formulations prepared in 
PBS. Samples were incubated in a water bath at 37ºC for 5 h. The hemolysis was 
stopped by decreasing the temperature to 0ºC using ice and the unlyzed RBC were 
removed by centrifugation at 1500 rpm for 4 min. The supernatant was analyzed by 
UV/VIS spectroscopy at 541 nm.  
The study was performed in triplicate and the percentage of hemolysis was calculated 
from the following equation: 
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Where Abs, Abs0 and Abs1 are the sample absorbance, control absorbance with 0% 
hemolysis and control absorbance with 100% hemolysis, respectively. 
EXP2-1.2.6. In vitro efficacy studies 
 
In vitro antifungal activity of AmB and AmB/PEG5kDa-cholane micelles (12:1 AmB/ 
PEG5kDa-cholane molar ratio) in PBS, pH 7.2, prepared by dissolution/pH change, was 
assessed against Candida albicans CECT1394.  Yeast cells were cultured in Petri dishes 
containing agar Sabouraud medium for 72 h at 30 ºC and then 3 mL of a 0.5 McFarland 
standard suspension (1-5.106 CFU/mL) were seeded in plates of Agar Mueller Hinton 
supplemented with glucose [337]. Methylene blue was used as contrast agent. Paper 
disks, impregnated with the AmB dissolved in DMSO were used as reference (S1 600 
μg/mL; S2 200 μg/mL; S3 96 μg/mL; S4 38.4 μg/mL; S5 18.4 μg/mL). Twenty 
microliters of 96 μg/mL AmB or equivalent AmB concentration of 
AmB/PEG5kDacholane in 0.2 M phosphate buffer, pH 10.5, were placed onto the paper 
disk that was then placed on the plates and incubated at 30ºC. After 48 h of incubation, 
the inhibition zones were accurately measured using a caliper and referred to the 
reference (96 μg/mL AmB, S3). 
 
EXP2-1.2.7. In vivo studies 
 
The analysis of biological samples requires the addition of an internal standard to assure 
the efficiency during sample preparation, or the performance of drug recovery studies to 
detect the amount of drug that can be recovered in plasma.  
Both, the use of an internal standard and the drug recovery studies, were considered and 
studied before performing the in vivo oral and intravenous pharmacokinetic studies in 
animals. 
It is important to point out that all the in vivo experiments were conducted following the 
European guidelines... 
 
Exp2-1.Materials & Methods 
 
170 
EXP2-1.2.7.1. Internal standard 
General considerations  
The internal standard can be defined as a chemical compound added to a sample at a 
known concentration in order to provide a basis for comparison in quantification. The 
addition of known quantities of internal standard to biological samples is used to assure 
the efficiency of the sample preparation. The ratio obtained between the area of the drug 
and the area of the internal standard allow for the determination of the drug 
concentration in the biological samples.  
In the choice of the internal standard some factors may be considered [361]: 
- The compound must be detected at the same wavelength as the drug, 
- It has to be eluted near the peaks of the sample but it has to be well-resolved 
from the drug, 
- It must be available in pure form, 
- It should be a stable compound and no react with the sample,  
- And ideally, its physicochemical properties should be similar to the drug object 
of study. 
Due to the large experience of the research group in Padua using naproxen, this drug 
was selected as candidate for the the internal standard studies. 
Internal standard calibration curve 
A naproxen stock solution of 50 mg/mL was prepared by the addition of 25 mg 
naproxen to 0.5 mL methanol. From this stock solution, 14 samples were prepared by 
serial dilution ranging from 0.003 to 50 mg/mL and analyzed by RP-HPLC at 406 nm 
starting from the more diluted sample. The analysis was performed in triplicate. 
 
EXP2-1.2.7.2. AmB recovery studies in plasma 
Drug recovery studies are necessary when working with biological samples. Sample 
preparation protocols usually include several steps (centrifugation and precipitation) 
where some of the drug can be lost. Moreover, even the solvent used to precipitate the 
plasma proteins is selected as function of the drug solubility; part of the drug can 
precipitate if joined with the proteins. Therefore, the knowledge of the amount of drug 
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lost during sample preparation allows the extrapolation of the real amount of drug 
contained in blood.  
Samples preparation and analysis 
1 mg/mL stock solutions of AmB in DMSO, AmB in dextrose (5% w/v), Fungizone®, 
Ambisome® and AmB/PEG5kDa-cholane were diluted in order to obtain 6 samples with 
1, 2, 4, 6, 8 and 10 μg/mL concentration. Then, 5 μL of each sample were added of 100 
μL blood; slightly shake in order to avoid the hemolysis and centrifuged at 3500 rpm for 
3 min. After centrifugation, 30 μL of supernatant were withdrawn, added of 100 μL 
MeOH (to induce faster protein precipitation the samples were stored 10 min at 4 ºC) 
and centrifuged at 12000 rpm for 5 min. Finally, 100 μL supernatant (plasma without 
proteins) were withdrawn and 30 μL of those, analyzed by RP-HPLC. 
The blood (2 mL) was extracted from Balb/c female mice, age ten weeks, following the 
protocols established by the animal facilities of the University of Padua.  
By plotting the AmB initial concentration versus the AmB concentration detected in 
plasma, a regression equation (y=a+bx) was obtained. The “b” value which corresponds 
to the slope of the curve multiplied by 100 was the percentage of recovery. This value 
was used to extrapolate the real AmB concentration in blood.  
 
EXP2-1.2.7.3. Oral pharmacokinetic studies 
Introduction 
AmB is a class four drug (low solubility and low permeability) whose log P (0.95) and 
molecular weight (924.09 g/mol) are responsible for its low oral absorption. In spite of 
these disadvantages the oral administration of AmB will, not only enhance the 
therapeutic patient compliance, but also allow for the interruption of the treatment if 
severe side effects are detected. Moreover, in the undeveloped countries, where the 
infections caused by of Candida and Leishmania are severe, an oral AmB formulation 
will solve the problems related to the treatment access (the intravenous therapies 
requires long-term hospitalization).  
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The high stability of the AmB included in the PEG5kDa-cholane micelles as well as the 
integrity of the system at a wide range of pHs (3-5-8.5), make this new formulation 
suitable for oral administration.  
In order to check whether or not the AmB in the PEG5kDa-cholane micelles reaches a 
comparable Cmax value to that obtained with other commercialized formulations (eg. 
Fungizone® and Albelcet®) the following oral in vivo study was designed. 
 
Method 
The oral pharmacokinetic experiments were performed in healthy female BALB/c mice, 
age ten weeks and 20 g body weights. 5 mg/kg AmB were administered via gavage 
using 1 mL syringes fitted with an appropriate needle which allowed the formulation to 
directly reach the stomach. The different formulations (AmB in 5% dextrose w/v, 
Ambisome®, Fungizone® and AmB/PEG5kDacholane) were prepared at a concentration 
of 1 mg/mL AmB in purified water. Blood samples (100 μL) were extracted at each 
sampling time (0.5, 1, 2, 4, 8 and 24 h) from the right eye of each mouse (via seno retro-
orbital) using heparinized capillary tubes. The blood was added to an eppendorf 
containing 2 μL heparine and slightly moved to avoid blood coagulation. Blood was 
centrifuged at 4500 rpm for 5 min and the supernatant (plasma) was removed, frozen in 
liquid nitrogen and kept at -20°C until sample analysis. 
 
Protocol for sample preparation 
Samples were prepared following the 10-steps protocol detailed below.  
1. The formulations, 2 per day, were prepared on the day of adminitration at 
1mg/mL AmB using water for injection (WFI) as vehicle.  
 
2. The theoretical AmB concentration contained in the formulations was analyzed 
by RP-HPLC before administration. Briefly, 30 μL of each formulation were 
diluted with 970 μL methanol and analyzed by RP-HPLC. 
 
3. BALB/c mice were divided into different cages - 4 mice per formulation on each 
cage. The tail of the animals was marked in blue or red depending on the 
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formulation, with and indelible marker. In order to avoid mistakes, each mouse 
had a different number on its tale (“I”, “II”, “III”, IIII”). 
 
4. Prior to administration each mouse was weighted.  The AmB dose was adjusted 
as function of the animal weight in order to achieve the correct dose (5 mg/kg). 
Assuming an animal weight of approximately 20 g, 100 μL of 1 mg/mL AmB 
formulations should be administered.  
 
5. The 1 mL syringes (without needle) used for the oral administration were 
charged with 650 μL formulation. After loading, the needle was fitted into the 
syringes and 150 μL formulation were displaced (50 μL discarded, and 100 µL 
charged in the needle).  
 
6. At time 0, 100 μL formulations were orally administered to each mouse as 
shown in figure 46. 
 
7. Prior to blood extraction, 24 eppendorfs (0.5 mL capacity) containing 2 μL 
heparine were prepared for each formulation. Heparine was used to avoid later 
blood coagulation. 
 
8. At each sampling time (scheme 1), using heparinized capillary tubes, 
approximately 100 μL blood was extracted from the right eye of the mice via 
seno retro-orbital and deposited into the heparinized eppendorfs. The eye of the 
mice was then cleaned and the animals were again left in the cage. 
 
9. Blood samples were centrifuged at 4500 rpm for 5 min. Then, 45 μL plasma 
were added to the empty eppendorfs, frozen with liquid nitrogen and kept at -
20°C until RP-HPLC analysis. 
 
10. RP-HPLC analysis - Prior to HPLC analysis, the samples were thawed at room 
temperature. Once thawed, 45 μL methanol were added in order to precipitate 
the proteins and the eppendorfs were first vortex for 30 s and then centrifuged at 
12000 rpm for 15 min. The supernatant was finally analyzed by HPLC. During 
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samples analysis, the mobile phase was eluted at 1 mL/min and the elution time 
was fixed at 30 min*. 
*The extended elution time with respect to the non-biological samples was due to the 
plasma peak detected at 20-21 min (λ=406 nm) during the recovery studies. To avoid 
possible interferences with the AmB peak, the elution time was increased up to 30 min 
instead of 12 min. 
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Scheme 1. Study design of the oral pharmacokinetics experiments performed in female BALB/c mice. 
Day 1. Oral administration of 5 mg/kg AmB in Dextrose (5% w/v) and 5 mg/kg AmB as Ambisome® to 
four mice. Day 2. Oral administration of 5 mg/kg AmB as Fungizone® and AmB/PEG5kDacholane to four 
mice. 
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Day 2 
Fungizone®                                           AmB/PEG5kDa-cholane (12:1) 
                                                                                                                                    
 0.5 h      1 h         2 h         4 h       8h       24h 
  
1 
2 
3 
4 
 
 0.5 h      1 h         2 h         4 h       8h       24h 
  
1 
2 
3 
4 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
33 
34 
35 
36 
41 
42 
43 
44 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
37 
38 
39 
40 
45 
46 
47 
48 
29 
30 
31 
32 
 0.5 h      1 h         2 h         4 h       8h       24h 
  
1 
2 
3 
4 
 
  1 
  2 
  3 
  4 
  5 
  6 
  7 
  8 
  9 
 10 
 11 
12 
33 
34 
35 
36 
41 
42 
43 
44 
 13 
14 
15 
16 
 0.5 h      1 h         2 h         4 h       8h       24h 
  
1 
2 
3 
4 
 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
37 
38 
39 
40 
45 
46 
47 
48 
29 
30 
31 
32 
Exp2-1.Materials & Methods 
 
176 
EXP2-1.2.7.4. Intravenous pharmacokinetics studies 
Introduction 
The intravenous (iv) administration of AmB is still nowadays the main route of 
administration for this antibiotic. Between all the AmB commercialized formulations 
(Fungizone®, Ambisome®, Abelcet®), the lipidic formulations are the ones whose use 
is more spread [269,311,362,363]  . This is due to the low sides effects associated to its 
administration. Nevertheless, these lipidic formulations have a high cost that 
significantly increases the cost of the treatment with respect to the non-lipidic 
formulations (Fungizone®) [364-367]. Therefore,  the development of an iv AmB 
formulation whose efficacy is comparable, if not higher, to the lipidic formulations 
(Ambisome®); its side effects are lower and the price is decreased, could significantly 
reduce the cost of the treatment. 
The efficacy of the AmB/PEG5kDacholane micelles was assayed intravenously as 
detailed above. This new formulation will potentially decrease by seven the actual 
treatment cost. 
 
Method 
The intravenous pharmacokinetics experiments were performed in healthy female 
BALB/c mice, age ten weeks (born on 16.02.15) and 20 g weight. A dose of 1 mg/kg 
AmB (0.020 mg AmB – 80 μL of 0.25 mg/mL AmB in NaCl 0.9%/Dextrose 5% w/v 
(1:1)) was administered intravenously in the lower part of the tail. At time 1 min, 5 min, 
10 min, 30 min, 1 h, 2 h, 4 h, 8 h and 24 h, 80-100 μL of blood were extracted from the 
right eye of each mouse via seno retro-orbital using heparinized capillary tubes. For 
each formulation 6 mice were used (for AmB/PEG5kDacholane 7). The blood was added 
into an eppendorf containing 2 μL heparine (5000 UI), centrifuged at 4500 rpm during 
15 min and then, 45 μL supernatant for Ambisome® and Fungizone® and 40 μL for 
AmB/PEG5kDa-cholane were placed in a new eppendorf, frozen with liquid nitrogen and 
kept in the freezer (-20ºC) until analysis. For the RP-HPLC analysis, the plasma 
samples were first thawed and then added of 45 μL methanol. After methanol addition 
the samples were vortex in order to precipitate the proteins and centrifuged at 12000 
rpm for 15 min. The supernatant was finally analyzed by RP-HPLC. 
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Protocol for sample preparation 
As for the oral pharmacokinetic experimernts, samples were prepared following a 10-
steps protocol. 
1. Formulations were prepared on the same day of the experiment (2 one day and 
the other the next day) at 1 mg/mL AmB using WFI as vehicle. Prior to 
administration, the samples were diluted to a final concentration of 0.25 mg/mL 
using a mixture (1:1) of NaCl 0.9% and Dextrose 5% w/v (formulations were 
prepared 1 h before the experiment started).  
 
2. The theoretical AmB concentration was checked by RP-HPLC before 
administration. 30 μL f each formulation were diluted with 970 μL methanol and 
analyzed by HPLC.  
 
3. BALB/c mice were divided into different cages -6 mice per formulation with the 
exception of AmB/PEG5kDa-cholane. 7 mice were used for the latest. The tail of 
the animals was marked on its upper part in blue or red, depending on the 
formulation, with an indelible marker. In order to avoid mistakes, each mouse 
had a different number on its tale (“I”, “II”, “III”, IIII, IIIII and IIIIII”). 
 
4. Prior to administration each mouse was weighted and the AmB dose was 
adjusted as function of the animal weight in order to achieve the correct dose (1 
mg/kg). Assuming an animal weight of approximately 20g, 80 μL of 0.25 
mg/mL AmB formulations in a mixture (1:1) of NaCl 0.9% and dextrose 5% 
w/v were iv administered. 
 
5. 1 mL syringes (insulin-type) were loaded with 150 μL formulation. The needle 
was then fitted and 70 μL were discarded in order to display the air and have the 
correct dose in the syringe. 
 
6. At time 0, 80 μL of each formulation were intravenously administered in the 
lower part of the mouse tail. 
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7. 33 eppendorfs (0.5 mL capacity) were prepared for each formulation by adding 2 
μL heparine. The heparine was added in order to avoid later blood coagulation. 
 
8. At each sampling time (tables 37-39), using heparinized capillary tubes, 
approximately 80-100 μL blood were extracted from the right eye of each mice 
via seno retro-orbital and deposited into the heparinized eppendorfs. The eye of 
the mice was then cleaned and the animals were again left in the cage. The 
mandibular extraction (via mandibular vein) using a needle was also assayed. 
This technique is known to be less painful for the mice but the amount of blood 
recovered was really low and therefore, the extraction was performed through 
the eye. 
 
9. Blood samples were centrifuged at 4500 rpm for 15 min and then, 45 μL (for 
Ambisome® and Fungizone®) or 40 μL (AmB/PEG5kDa-cholane) plasma were 
added to empty eppendorfs, frozen with liquid nitrogen and kept at -20°C until 
HPLC analysis. 
 
10. RP-HPLC analysis - The samples were thawed at room temperature and once 
thawing was completed, 50 μL methanol were added in order to precipitate the 
proteins. After methanol addition, the eppendorfs were first vortex 30 s, stored 
in the fridge for 5 min in order to induce faster protein precipitation and then 
centrifuged at 12000 rpm for 15 min. The supernatant (20 or 30 μL depending 
on the sampling time) was precipitated again with methanol (100, 50 or 60 μL) 
and vortex for 30 s. After 5 min in the fridge the samples were centrifuged again 
at 12000 rpm for 15 min. The final supernatant was analyzed by RP-HPLC. 
During sample analysis the mobile phase was eluted at 1 mL/min and the elution 
time was fixed at 30 min* 
*the extended elution time with respect to the non-biological samples analysis was due 
to the plasma peak detected at 20-21 min (λ=406 nm) during the recovery studies 
performed with plasma. 
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Table 37. Protocol design for blood extraction after iv administration of 1 mg/kg Ambisome® 
Time Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 
Injection 09:51 10:02 10:09 10:23 10:32 10:54 
1 min 09:52 (1) 10:03 (2) 10:10 (3) 10:24 (4) 10:33 (5) 10:55 (6) 
5 min 09:56 (7) 10:07 (8) 10:14 (9) - - - 
10  min - - - 10:33 (10) 10:42 (11) 11:04 (12) 
30 min 10:21 (13) 10:32 (14) 10:39 (15) - - - 
1 h - - - 11:23 (16) 11:32 (17) 11:54 (18) 
2 h 11:51 (19) 12:02 (20) 12:09 (21) - - - 
4 h - - - 14:23 (22) 14:32 (23) 14:54 (24) 
8 h 17:51 (25) 18:02 (26) 18:09 (27) - - - 
24 h 09:51 + 1 day (28) 10:02 + 1 day (29) 10:09 + 1 day (30) 10:23 + 1 day (31) 10:32 + 1 day (32) 10:54 + 1 day (33) 
 
Table 38. Protocol design for blood extraction after iv administration of 1 mg/kg Fungizone® 
Time Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 
Injection 09:54 10:05  10:14 10:27 10:48 10:58 
1 min 09:55 (34) 10:06 (35) 10:15 (36) 10:28 (37) 10:49 (38) 10:59 (39) 
5 min 09.59 (40) 10:10 (41) 10:19 (42) - - - 
10  min - - - 10:37 (43) 10:58 (44) 11:08 (45) 
30 min 10:24 (46) 10:35 (47) 10:44 (48) - - - 
1 h - - - 11:27 (49) 11:48 (50) 11:58 (51) 
2 h 11:54 (52) 12:05 (53) 12:14 (54) - - - 
4 h - - - 14:27 (55) 14:48 (56) 14:58 (57) 
8 h 17:54 (58) 18:05 (59) 18:14 (60) - - - 
24 h 09:54 + 1 day (61) 10:05 + 1 day (62) 10:14 + 1 day (63) 10:27 + 1 day (64) 10:48 + 1 day (65) 10:58 + 1 day (66) 
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Table 39. Protocol design for blood extraction after iv administration of 1 mg/kg AmB/PEG5kDa-cholane 
Time Mouse 1 Mouse 2 Mouse 3 Mouse 4 Mouse 5 Mouse 6 Mouse 7 
Injection 09:41  09:57 10:01 10:11 10:17 10:24 10:43 
1 min 09:42 (67) 09:58 (68) 10:02 (69) 10:12 (70) 10:18 (71) 10:25 (72) 10:44 (100) 
5 min 09:46(73) 10:02 (74) 10:06 (75) - - - - 
10  min - - - 10:21 (76) 10:27 (77) 10:34 (78) 10:53 (101) 
30 min 10:11 (79) 10:27 (80) 10:31 (81) - - - - 
1 h - - - 11:11 (82) 11:17 (83) 11:24 (84) 11:43 (102) 
2 h 11:41 (85) 11:57 (86) 12:01 (87) - - - - 
4 h - - - 14:11 (88) 14:17 (89) 14:24 (90) 14:43 (103) 
8 h 17:41 (91) 17:57 (92) 18:01 (93) - - - - 
24 h 09:41 + 1 day (94) 09:57 + 1 day (95) 10:01 + 1 day (96) 10:11 + 1 day (97) 10:17 + 1 day (98) 10:24 + 1 day (99) 10:43 + 1 day (104) 
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EXP2-2. RESULTS 
EXP2-2. 1. Synthesis and characterization of the poly(ethylene glycol)-cholane 
bioconjugate 
 
EXP2-2.1.1. Activation of the cholanic acid 
The degree of cholanic acid derivatization with thionyl chloride was measured by 128H-
NMR and the spectra were proceeded with MestreNova software. Figure 46 shows the 
spectrum obtained for the treated cholanyl chloride sample.  
By the integration of the peak at 0.64 ppm and the peak at 3.66 ppm the degree of 
activation was calculated as detailed below.  
 
Knowing that there is an activation of 79% and that the stoichiometry of the reaction is 
1:3:2 (MeO-PEG5kDa-NH2 : cholanyl chloride : triethylamine (TEA)) the amount of 
reagents needed for the following step (conjugation) was calculated. 
 
EXP2-2.1.2. Conjugation with MeO-PEG5kDa-NH2 
The degree of cholanyl chloride conjugation with MeO-PEG5kDa-NH2 was calculated by 
two different techniques: 128H-NMR and TNBS colorimetric assay. 
Figure 47 shows the spectra obtained for the NMR analysis of the conjugated sample. 
The two main peaks, 0.64 ppm (CH3 in position 19) and 3.38 ppm (CH3-O in ended 
position of PEG5kDa chain), were integrated in order to calculate the degree of 
conjugation.  
 
As reported in the above equation, the degree of conjugation calculated by NMR was 
found to be 95%. 
Exp2-2.Results 
 
184 
Figure 46. 128H-NMR spectrum of the activated cholanic acid 
Figure 47. 128H-NMR spectrum of the conjugated cholanyl chloride 
3.66 
0.64 
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The TNBS colorimetric assay was performed as a complementary experiment to 
corroborate the degree of activation and therefore, the success of the reaction. The NMR 
itself is reliable but as the integration of the peaks is made manually, some small errors 
can be generated. To make sure that the data obtained by NMR were totally reliable, the 
TNBS was carried out. 
Table 40 shows the absorbance values obtained for the reference sample (PEG5kDa-NH2) 
and the conjugated (PEG5kDa-cholane) when treated with TNBS.  
Table 40. Absorbance values for the reference sample and conjugate. 
 Reference Conjugate 
Absorbance 1 0.9161 0.0398 
Absorbance 2 0.9264 0.0469 
Absorbance 3 0.9178 0.0375 
 
The degree of activation by TNBS was calculated as detailed in the following equation. 
 
The values obtained for the three samples were 95.6%, 94.9% and 95.9%, respectively. 
The mean of those values gave a percentage of conjugation of 95.4% ± 0.51%.  
The values of conjugation calculated by both techniques were found to be similar. 95% 
versus 95.4% with NMR and TNBS, respectively. 
EXP2-2.2. Amphotericin B dissolution studies with PEG5kDa-cholane 
 
Solubility studies were carried out at pH 3.5, 5.5, 7.2, 8.5 and 11.0 by combining fixed 
amounts of AmB with increasing amounts of PEG5kDa-cholane according to three 
different experimental protocols: 1. direct dissolution; 2. co-solvent dissolution; 3. 
dissolution/pH change. For comparison, the solubility of AmB in the presence of 
increasing amounts of PEG5kDa-OH was also examined. 
Preliminary studies showed that in the absence of PEG5kDa-cholane and PEG-OH, the 
direct AmB dissolution yielded lower drug concentrations than co-solvent dissolution 
and dissolution/pH change. This behavior was observed at all examined pHs (figure 48 
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and table 41) and was in fair agreement with studies reported in the literature [145]. The 
UV spectra of dissolved AmB (figure 49) showed that the three dissolution methods 
yielded different physical forms of dissolved AmB, namely monomers and soluble 
aggregates such as dimers and tetramers. According to the literature, the absorption at 
322 nm (Aλ322) and 413 nm (Aλ413) were elaborated to estimate the content of 
monomeric and nanoaggregated AmB in solution [288,358,368]. The lower Aλ322/Aλ413 
ratio obtained by direct dissolution indicated that the monomeric form was the 
predominant AmB specie in solution. On the contrary, the higher Aλ322/Aλ413 ratio 
obtained by co-solvent dissolution and dissolution/pH change indicated that in such a 
case the main specie in solution was the nanoaggregated AmB. Therefore, AmB 
dissolved by direct dissolution tends to be in the monomeric form while AmB dissolved 
by dissolution/pH change and co-solubilization was mainly in aggregated form. 
 
 
 
 
 
 
 
 
Figure 48. AmB solubility (µg/mL) at different pHs by dissolution/pH change (-▲-) and by direct 
dissolution (-■-). 
 
 
 
 
3 4 5 6 7 8 9 10 11 12
0
10
20
30
40
50
750
800
850
900
950
1000

g
/m
L
 A
m
B
pH
Novel formulations for Amphotericin B delivery 
 
187 
Table 41. Concentration of AmB dissolved at different pHs by direct dissolution and dissolution/pH 
change. 
 
 
 
 
 
 
Figure 49. UV-Vis spectra of AmB (A) and AmB/PEG5kDa-cholane (B) solutions prepared by co-solvent 
dissolution or dissolution/pH change (__) and by direct dissolution (…..). 
 
The solubility profiles reported in Figure 50 show that PEG5kDa-OH has not relevant 
effect on the AmB solubility, which increased from 6 µg/mL to 17 µg/mL as the 
polymer concentration increased from 0.5 to 6 mg/mL (table 42). Furthermore, similarly 
to AmB in the absence of polymers, the dissolution method did not affect remarkably 
the AmB solubility (data not shown). On the contrary, PEG5kDa-cholane dramatically 
increased the drug solubility and the dissolution method was found to significantly 
affect the AmB solubility (table 43). The direct dissolution yielded less than 0.5:1 
AmB/PEG5kDa-cholane molar ratio while the co-solvent dissolution and the 
pH 
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dissolution/pH change protocols resulted in 12:1 AmB/PEG5kDa-cholane molar ratio, 
with identical dissolution profiles. 
 
 
 
 
 
 
 
 
 
Figure 50. Solubility profile of AmB with: PEG5kDa-cholane by direct dissolution (-♦-); PEG5kDa-cholane 
by dissolution/pH change and by co-solubilization (-■-); PEG5kDa-OH by dissolution/pH change (-●-). 
 
Table 42. Concentration of AmB (µg/mL) dissolved by the dissolution/pH change method using increased 
amounts of PEG5kDa-OH. 
PEG5kDa-OH (mg/mL) AmB dissolved (μg/mL) 
0.5 6.29±0.04 
1 13.34±0.12 
1.5 16.64±0.09 
2 17.80±0.14 
3 17.09±0.07 
6 17.44±0.25 
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Table 43. Concentration of AmB (µg/mL) dissolved by direct dissolution and dissolution/pH change 
using increased amounts of PEG5kDa-cholane. 
PEG5kDa-cholane 
(mg/mL) 
AmB (μg/mL) dissolved by direct 
dissolution 
AmB (μg/mL) dissolved by 
dissolution/pH change 
0.5 41.66±0.77 1010±4.58 
1 58.29±0.71 2005±7.09 
1.5 83.56±2.38 3001±2.64 
2 106.42±2.74 3999±7.63 
3 125.35±1.43 6002±3.60 
6 154.58±3.88 12001±1.52 
 
The UV analysis of the AmB/PEG5kDa-cholane obtained by direct dissolution (figure 
49B) showed that the dissolved AmB was mainly in the monomeric form while the high 
absorption at 322 nm of samples obtained by co-solvent dissolution and dissolution/pH 
change demonstrated that in these samples nanoaggregated AmB specie predominated.  
The maximal solubility of AmB with PEG5kDa-cholane could not be determined because 
high polymer concentrations produced viscous dispersions that prevented the accurate 
analysis of dissolved AmB. 
 
EXP2-2.3. Physicochemical characterization of the AmB/PEG5kDa-cholane complex 
 
EXP2-2.3.1. Reverse-phase high pressure liquid chromatography 
The AmB concentration in the different samples was determined by RP-HPLC 
following the protocol reported by Espada et al. Two calibration curves, one for non-
biological samples and another one for biological samples, were performed by 
analyzing different AmB standards of known concentration. 13 AmB standards were 
prepared in triplicate for each calibration curve by serial dilution using MeOH as 
solvent starting from a stock solution of 100 μg/mL AmB in a mixture of DMSO-
MeOH (1/10). Tables 44 and 45 show the results obtained for both calibration curves.  
The AmB concentration in non-biological samples was extrapolated from a curve linear 
in the range 0.012 – 40 μg/mL [(AmB concentration)=115.1(peak area)-1.665; R2=1] 
while the AmB concentration in biological samples was extrapolated from a curve linear 
in the range 0.012 – 50 μg/mL [(AmB concentration)=113.7(peak area)-12.45; 
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R2=0.99]. As shown in figures 51-54 both calibration curves were divided into two sub-
curves, one for low AmB concentrations and another one for high AmB concentrations 
in order to avoid mistakes when extrapolating low AmB concentrations.  
Table 44. Concentration and area under the curve (AUC) of the different AmB standards assayed for the 
calibration curve used in the non-biological samples. 
Concentration [μg/mL] AUC/1000 AUC/1000 AUC/1000 Mean AUC SD 
50 Out of range Out of range Out of range x x 
40 4607.61 4596.99 4604.38 4602.99 5.44 
25 2885.17 2862.01 2874.42 2874.42 11.67 
12.5 1452.02 1437.13 1450.07 1446.07 7.75 
6.25 708.15 702.03 707.85 706.01 3.45 
3.125 357.49 354.18 358.59 356.75 2.29 
1.5625 177.69 176.04 178.04 177.25 1.06 
0.78125 89.43 86.94 88.42 88.26 1.25 
0.3906 45.14 42.14 45.07 44.11 1.71 
0.1953 23.27 19.98 21.35 21.53 1.65 
0.09765 11.48 9.76 10.17 10.47 0.89 
0.04882 5.67 4.61 5.01 5.09 0.53 
0.02441 2.74 2.19 2.45 2.46 0.27 
0.0122 1.17 1.02 1.08 1.09 0.07 
 
Table 45. Concentration and area under the curve (AUC) of the different AmB standards assayed for the 
calibration curve used in the biological samples. 
Concentration [μg/mL] AUC/1000 AUC/1000 AUC/1000 Mean AUC SD 
50 5705.01 5664.78 5693.92 5687.90 20.77 
25 2837.72 2800.49 2829.76 2822.65 19.60 
12.5 1392.24 1380.03 1378.19 1383.48 7.63 
6.25 682.73 655.53 676.81 671.69 14.30 
3.125 330.82 327.94 332.7 330.48 2.39 
1.5625 157.79 161.19 159.63 159.53 1.70 
0.78125 78.92 78.41 78.79 78.70 0.26 
0.3906 38.97 38.15 38.67 38.59 0.41 
0.1953 18.71 18.42 18.54 18.55 0.14 
0.09765 9.01 8.91 8.99 8.97 0.05 
0.04882 4.70 4.57 4.59 4.62 0.07 
0.02441 2.64 2.54 2.56 2.58 0.05 
0.0122 1.21 1.18 1.20 1.19 0.01 
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Figure 51. Calibration curve for high AmB concentrations in non-biological samples. 
 
 
 
 
 
 
 
 
 
Figure 52. Calibration curve for low AmB concentrations in non-biological samples. 
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Figure 53. Calibration curve for high AmB concentrations in biological samples. 
 
 
 
 
 
 
 
 
 
Figure 54. Calibration curve for low AmB concentrations in biological samples. 
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EXP2-2.3.2. Dimensional, morphological and surface characterization of 
AmB/PEG5kDa-cholane formulations  
Dynamic light scattering (DLS) and transmission electron microspcopy (TEM) analyses 
were performed to evaluate the dimensional, morphological and surface features of the 
AmB/PEG5kDa-cholane formulations obtained by dissolution/pH change. The DLS 
profile reported in figure 55A showed that the AmB association with PEG5kDa-cholane 
forms monodisperse size distribution micelles with mean diameter of 33.2±1.2 nm (PDI 
0.16), which is in good agreement with the dimensional values obtained with AmB free 
PEG5kDa-cholane formulations [369]. DLS analyses of AmB/PEG5kDa-cholane 
formulation performed in the pH range of 3.5-11.0 yielded similar dimensional profiles 
while AmB/PEG5kDa-OH mixtures did not show micelle formation at all pHs. The 
particle size of AmB loaded and unloaded PEG5kDa-cholane micelles remained stable in 
all the pH range assayed (table 46).  
The TEM image reported in figure 55B confirms the dimensional features obtained by 
DLS. The AmB/PEG5kDa-cholane micelles have circular shape and gray shadow around 
the micelles due to the negative-staining of the PEG chain by phosphotungstic acid. 
 
Figure 55. Dynamic light scattering profile (A) and transmission electron microscopy image (B) of 
AmB/PEG5kDa-cholane formulations. 
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Table 46. Particle size of AmB loaded and unloaded PEG5kDa-cholane micelles at different pHs. 
pH 
Particle size (nm) 
AmB loaded PEG5kDa-cholane micelles AmB unloaded PEG5kDa-cholane micelles 
3.5 32.93±1.26 16.63±0.44 
5.5 33.05±0.95 18.18±1.06 
7.2 33.31±1.14 18.42±2.13 
8.5 32.86±1.81 18.15±2.22 
11 33.58±2.29 19.89±1.95 
 
Figure 56A and table 47 show the zeta potential of the micelles at different pHs. At pH 
5.5-7.2 the overall micelle surface was nearly neutral. At pH below 5.5 the zeta 
potential shifted to slightly positive values and above pH 7.2 to negative values. Similar 
zeta potential values were obtained with AmB free PEG5kDa-cholane micelles (figure 
56B, table 47). 
 
Table 47. Zeta potential values of loaded and unloaded PEG5kDa-cholane micelles at different pHs. 
pH 
Loaded PEG5kDa-cholane micelles Unloaded PEG5kDa-cholane micelles 
Zeta potential (mV) SD Zeta potential (mV) SD 
3.5 2.79 0.45 3.81 0.84 
5.5 -0.07 0.09 0.54 0.43 
7.4 -0.43 0.18 0.387 0.46 
9.5 -7.23 0.29 -8.92 0.11 
12 -13.26 1.11 -12.96 2.05 
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Figure 56. Zeta potential profiles of AmB loaded (A) and unloaded (B) PEG5kDa-cholane micelles at 
different pHs.  
 
EXP2-2.3.3. AmB/MeO-PEG5kDa-cholane formulation lyophilisation and stability 
The lyophilization of AmB/PEG5kDa-cholane formulations obtained by dissolution/pH 
change produced yellowish, fluffy and slightly electrostatic powders (figure 57, insert 
A). The moisture content in the lyophilized product was 7%. The lyophilized powder 
rapidly re-dissolved in buffer at pH 7.2 to regenerate a clear yellow colloidal dispersion 
(figure 57, insert B).  
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After re-dispersion, at 25°C, the micelle size of the colloidal system was 32.2±3.4 nm 
and AmB was completely re-dissolved. Figure 31 shows that both micelle size and 
AmB concentration remained stable over 1 month. The chemical degradation during the 
first month was less than 5%. After 2 months storage neither the micelle size nor the 
size distribution changed while the AmB concentration decreased on an 8±0.3%. 
Similar results were obtained with freshly prepared micelles.  
 
 
 
 
 
 
 
 
 
Figure 57. Micelle size (-●-) and residual AmB content (-□-) time course profiles of lyophilized 
AmB/PEG5kDa-cholane formulation re-dispersed in buffer at pH 7.2. Insert A lyophilized formulation; 
insert B re-dispersed formulation.  
 
EXP2-2.3.4. Isothermal titration calorimetry assays 
Isothermal titration calorimetric (ITC) analyses were performed to investigate the AmB 
interaction with PEG5kDa-cholane at different pHs: 3.5, 5.5, 7.2, 8.5 and 11.0. The ITC 
study was carried out by injecting volumes of polymer solutions into the cell containing 
the AmB solutions. The operative conditions were selected on the basis of the results 
obtained by the solubility studies. Blank runs were carried out by injecting polymer 
solutions into the cell containing AmB free buffer or by injecting buffer into the cell 
containing AmB solutions. 
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The buffer injection into AmB solutions did not elicit significant thermal effect. Instead, 
the injection of aliquots of polymer solutions into the cell containing buffer produced 
pH independent bimodal exothermic ITC profiles, which was due to the demicellisation 
and polymer dilution as reported elsewhere [336]. The thermal profiles reported in 
figure 58 show that the polymer interaction with AmB occurs according to a multimodal 
pH-dependent behavior. The calorimetric raw data subtracted of the values obtained 
with the corresponding blanks were found to fit a three sequential binding site fitting 
model, with good correlation (Chi^2). The association parameters derived from the 
analysis are summarized in table 48. 
 
Figure 58. Isothermal calorimetry profiles of AmB titrated with PEG5kDa-cholane at pH 3.5 (A), 5.5 (B), 
7.2 (C), 8.5 (D) and 11.0 (E). 
 
In all cases, the binding affinity constants (K) were found to decrease from the first to 
the third binding site and the drug/polymer interactions occurred according to strong 
exothermic contributions (ΔH). The first binding was found to occur with high enthalpic 
and entropic contribution (ΔH1 and ΔS1, respectively). The second binding occurred 
with the lowest enthalpic contribution (ΔH2) even though it was strongly favored by a 
positive entropic change (ΔS2). The third binding was characterized by the lowest 
affinity constant (K3) and entropic contribution (ΔS3) but the highest enthalpic 
contribution (ΔH3). To note that at pH 11.0, the third binding occurred with negative 
ΔS. 
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Table 48. Calorimetric parameters obtained by AmB titration with PEG5kDa-cholane at pH 3.5, 5.5, 7.2, 
8.5 and 11.0: affinity constant (K), differential enthalpy (ΔH) differential entropy (ΔS), Chi squared 
(Chi^2/DoF). 
 
 
EXP2-2.3.5. Structural characterization 
Comparative structural characterizations of AmB, PEG5kDa-cholane, PEG5kDa-OH, 
lyophilized AmB/PEG5kDa-cholane micelles and physical AmB/PEG5kDa-cholane 
mixture were performed by differential scanning calorimetry (DSC), X-Ray 
diffractometry(XRD), Fourier transformed infrared (FTIR), .  
The DSC profiles (figure 61) showed the typical water loss, melting and decomposition 
behaviors of the various samples. Unformulated AmB (figure 59A) exhibited the 
characteristic endothermic peak of this drug at 104.6ºC corresponding to the water loss 
process [364] and the characteristic decomposition peak above 160ºC, namely at 
188.6ºC [370]. PEG5kDa-cholane (figure 59B) showed a sharp endothermic peak at 
58.9ºC, corresponding to the polymer melting as observed by hot stage microscopy (60 
°C), followed by an exothermic event at 171.3ºC, which corresponds to the polymer 
decomposition. Similarly to PEG5kDa-cholane, PEG5kDa-OH (figure 59C) melted at 
 pH 
 
3.5 5.5 7.2 8.5 11.0 
K1 105 M-1 9.83±0.46 1.54±0.069 7.87±0.28 3.31±0.096 2.36±0.12 
ΔH1 -2349±14.3 -1071±9.36 -1101±3.64 -1414±7.99 -3206±47.0 
ΔS1 19.5 20.1 23.3 20.5 13.8 
      
K2 105 M-1 1.22±0.088 0.554±0.023 0.356±0.027 0.435±0.016 1.52±0.12 
ΔH2 -485.4±24.5 -769.1±21.4 -964.5±29.3 -104.9±19.3 -125.5±56.4 
ΔS2 
 
21.6 19.1 17.6 20.9 23.3 
K3 105 M-1 0.149±0.009 0.531±0.022 0.234±0.012 0.246±0.008 0.062±0.004 
ΔH3 -5251±134 -1061±23.8 -2053±50.8 -3127±27.2 -6924±277 
ΔS3 
 
1.49 18.1 13.1 9.60 -5.87 
Chi^2/DoF 114.7 17.87 18.29 19.19 142.5 
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64.1ºC and decomposed at 155.0°C. The thermal profile of the physical AmB/PEG5kDa-
cholane mixture (figure 59D) showed two endothermic peaks at 60.9ºC and 92.9ºC, and 
an exothermic peak at 178.5ºC, which were in fair agreement with AmB melting and 
PEG5kDa-cholane melting and decomposition. The DSC profiles of AmB/PEG5kDa-
cholane micelles (figure 59E) showed only one endothermic peak at 172.5ºC, 
corresponding to the PEG5kDa-cholane decomposition.  
 
Figure 59. Differential scanning calorimetry profiles of AmB (A), PEG5kDa-cholane (B), PEG5kDa-OH (C), 
physical AmB/PEG5kDa-cholane mixture (D) and lyophilized AmB/PEG5kDa-cholane vesicles (E). 
 
The X-Ray diffractometric (XRD) spectra (figure 60) showed the characteristic peaks of 
the crystalline form of unformulated AmB (figure 60A) at diffraction angles of 
2θ 14.82º, 17.22º, 18.38º, and 21.66º [292,364,371]. PEG5kDa-cholane (figure 60B) 
displayed broad peaks at 19.02º and 23.38º while the AmB/PEG5kDa-cholane physical 
mixture (figure 60C) showed the peaks corresponding to both crystalline AmB and 
PEG5kDa-cholane. The lyophilized AmB/PEG5kDa-cholane micelle formulation (figure 
60D) did not show the characteristic peaks of AmB and PEG5kDa-cholane while 
exhibited two peaks at 22.11º and 26.14º. 
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Figure 60. X-Ray diffractometric index patterns of AmB (A), PEG5kDa-cholane (B), physical 
AmB/PEG5kDa-cholane mixture (C) and lyophilized AmB/PEG5kDacholane micelles (D). 
 
The Fourier transformed infrared (FTIR) spectra (figure 61) provided additional 
information about the physical AmB/PEG5kDa-cholane interaction in the micelle 
lyophilized product. The unformulated AmB spectrum showed the typical signals 
reported in the literature [292,364,371]. The spectrum of the physical AmB/PEG5kDa-
cholane mixture showed the signals corresponding to both AmB, i.e. at 1039 cm-1,[ν(C-
O-C)] pyranose, and PEG5kDacholane, i.e. at 1465 cm
-1[δ(CH2)], 1359 cm-1[δ(CH)],  
840.43 cm-1 [δ(C-H)] cyclic. The lyophilized AmB/PEG5kDa-cholane micelles displayed 
the same signals of the other samples. However, below 1700 cm-1 the main peaks 
characteristic of AmB [i.e. 1689.37 cm-1, ν(C=O); 1552.55 cm-1, δ(N-H); 1006.68 cm-1, 
δ(=C-H)] [373, 374] and PEG5kDa-cholane [i.e. at 1465cm-1, δ(CH2); 1342 cm-1, δ(C-O); 
1097 cm-1, ν(C-N); 960 cm-1, δ(C-H)] were missing. 
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Figure 61. Fourier transformed infrared profiles of: unformulated AmB (---); PEG5kDa-cholane (---); 
Physical mixture (---) and Freeze dried product (---). 
 
Tables 49-52 summarize the main signals (cm-1) of unformulated AmB, PEG5kDa-
cholane, physical AmB/PEG5kDa-cholane mixture and lyophilized AmB/PEG5kDa-
cholane micelles, respectively. The “ν” refers to the stretching vibrations and the “δ” to 
the bending vibrations 
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Table 49. Main FTIR signals of unformulated AmB. 
 
 
 
 
 
 
 
 
 
 
 
Table 50. Main FTIR signals of PEG5kDa-cholane. 
Signal (cm-1) % Transmission Functional Group 
2881.18 26.13 [ν(CH2, CH3)] alquil 
1650.80 93.52 [ν(C=O)amide] 
1540.87 94.56 [δ(N-H)] 
1465.66 59.98 [δ(CH2)] 
1359.59 67.69 [δ(CH)] 
1342.24 33.76 [δ(C-O)] 
1241.95 64.99 [ν(C-N)amide] 
1147.46 53.81 [ν(C-O-C)] 
1097.32 6.06 [ν(C-N) amine] 
1060.67 29.76 [ν(C-O)ether] 
840.83 41.40 [δ(C-H)cyclic]  
 
 
 
Signal (cm-1) % Transmission Functional Group 
3359.44 55.44 [ν(N-H, O-H)] 
2939.03 66.82 [ν(CH2, CH3)] 
2877.32 71.66 [ν(CH2, CH3)] 
1689.37 73.72 [ν(C=O)] 
1552.44 69.30 [δ(N-H)] 
1403.95 69.56 [δ(C-H)] 
1384.66 71.78 [δ(CH3)] 
1322.95 74.04 [δ(C-O)] 
1164.81 73.16 [ν(C-O-C)] 
1066.46 55.16 [ν(C-O)alcohol] 
1039.46 59.88 [ν(C-O-C)pyranose] 
1006.68 42.98 [δ(=C-H)] 
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Table 51. Main FTIR signals of AmB/PEG5kDa-cholane physical mixture. 
Signal (cm-1) % Transmission Molecule Functional Group 
3359.44 65.33 AmB [ν(N-H, O-H)] 
2881.18 48.81 PEG5kDacholane [ν(CH2, CH3)] alquil 
1689.37 79.29 AmB [ν(C=O)] 
1650.80 86.56 PEG5kDacholane [ν(C=O)amide] 
1556.30 75.58 PEG5kDacholane/AmB [δ(N-H)] 
1465.66 72.73 PEG5kDacholane [δ(CH2)] 
1403 75.14 AmB [δ(C-H)] 
1359.59 70.89 PEG5kDacholane [δ(CH)] 
1342.24 55.65 PEG5kDacholane [δ(C-O)] 
1241.95 75.57 PEG5kDacholane [ν(C-N)amide] 
1170.60 78.69 AmB [ν(C-O-C)] 
1147.46 67.43 PEG5kDacholane [ν(C-O-C)] 
1097.32 37.21 PEG5kDacholane [ν(C-N) amine] 
1060.67 47.69 PEG5kDacholane [ν(C-O)ether] 
1039.46 58.70 AmB [ν(C-O-C)pyranose] 
1006.68 49.54 AmB [δ(=C-H)] 
840.43 63.92 PEG5kDacholane [δ(C-H)cyclic] 
 
Table 52. Main FTIR signals of the lyophilized AmB/PEG5kDa-cholane micelles. 
Signal (cm-1) % Transmission Molecule Functional Group 
3347.87 42.67 AmB [ν(N-H, O-H)] 
2881.18 48.52 PEG5kDacholane [ν(CH2, CH3)] alquil 
1241.95 65.43 PEG5kDacholane [ν(C-N)amide] 
1103.10 30.34 PEG5kDacholane [ν(C-N) amine] 
1070.32 29.31 AmB [ν(C-O)alcohol] 
1039.46 32.16 AmB [ν(C-O-C)pyranose] 
998.96 41.09 AmB [δ(=C-H)] 
865.90 38.97 PEG5kDacholane [δ(C-H)cyclic] 
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EXP2-2.3.6. Synchrotron 
Synchrotron analysis are not yet completed. Preliminary results show that the 
AmB/PEG5kDa-cholane presents an ordered structure. 
 
EXP2-2.3.7. Human Serum Albumin circular dichroism analyses 
Circular dichroism studies were carried out to investigate the interaction of AmB with 
plasma proteins, which can either alter the protein structure or induce drug 
disaggregation [358,151]. The study was comparatively performed by using AmB, 
Fungizone®, heated Fungizone® and AmB/PEG5kDa-cholane. 
Table 53 reports the secondary protein structure obtained by the KD2 elaboration of the 
far UV CD spectra shown in figure 62A. The results reported in the table show that the 
secondary protein structure was not significantly altered by AmB regardless the 
formulation. 
 
Table 53. Secondary structure (α-helix and β-sheet content) of human serum albumin (HSA) and HSA 
incubated with AmB, Fungizone®, Heated Fungizone® and AmB/MeO-PEG5kDa-cholane 
 α-helix β-sheet 
HSA 0.67 0.04 
AmB 0.63 0.06 
Fungizone® 0.63 0.06 
Heated Fungizone® 0.64 0.05 
AmB/MeO-PEG5kDacholane 0.69 0.04 
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Figure 62. Circular dichroism spectra. A. Far UV spectra of HSA incubated with AmB (__), Fungizone® 
(···); heated Fungizone® (- -) and AmB/PEG5kDa-cholane micelles (·-·) B. Near UV spectra of 
AmB/PEG5kDa-cholane micelles in the absence of HSA (1); AmB/PEG5kDa-cholane micelles in the 
presence of HSA (3); Fungizone® in the absence of HSA (2); Fungizone® in the presence of HSA (4). 
 
Figure 62B reports the near UV CD spectra of AmB/PEG5kDa-cholane micelles and 
Fungizone® showing the typical doublet (intense biphasic dichroic signals) of AmB in 
the absence or in the presence of HSA. The wavelengths of maximum (λmax) and 
minimum (λmin) ellipticity and the maximum-minimum ellipticity amplitude intensity 
(Ai) represent the AmB aggregation: the lower λmax and λmin, the higher the AmB 
aggregation; the higher Ai, the higher AmB aggregation [151]. 
In the comparative study (figure 63), AmB in solution presented the highest λmax and 
λmin, and the lowest Ai either in the absence or in the presence of HSA (λmax327nm, 
λmin353nm and Ai 83.8 θ in the absence of HSA; λmax 326 nm, λmin 351 nm and Ai 44.4 
θ in the presence of HSA). In the absence of HSA the λmax, λmin and Ai of 
AmB/PEG5kDa-cholane were 316.5 nm, 333.8 nm and 134.3 θ respectively, while in the 
presence of HSA λmax, λmin and Ai were 321.4 nm, 340.2 nm and 129.9 θ, respectively. 
In the absence of HSA, Fungizone® showed 319.5 nm λmax, 341.3 nm λmin and 139.71 θ 
Ai while in the presence of HSA λmax, λmin and Ai were 324 nm 345.3 nm 138.66 θ. 
Heated Fungizone® showed the lowest λmax and λmin and the highest Ai (λmax 313 nm, 
λmin 330 nm and Ai 175.7 θ in the absence of HSA; λmax 314nm, λmin 332 nm and Ai 
184.59 θ in the presence of HSA). Accordingly, the spectra obtained with Fungizone® 
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and AmB/PEG5kDa-cholane micelles showed a higher presence of aggregated AmB 
[151]  either in the absence or in the presence of HSA compared to unformulated AmB. 
In both cases, the λmax and λmin of the doublet of Fungizone® was 3-8 nm higher 
compared to the ones obtained with AmB/PEG5kDa-cholane micelles indicating that 
AmB in Fungizone® was less aggregated than in the PEG5kDa-cholane micelles. The 
addition of HSA was found to red-shift of 4-7 nm the doublet of AmB formulated with 
PEG5kDa-cholane and Fungizone® indicating that in both cases HSA promotes the AmB 
disaggregation [375-377].  
 
Figure 63. Circular dichroism profiles in the absence (A) and presence (B) of HSA of: AMB (1); 
Fungizone® (2); Heated Fungizone® (3) and AmB/PEG5kDa-cholane micelles (4) at 37ºC. 
 
EXP2-2.3.8. Absorption and kinetics studies 
UV-Vis absorption spectroscopic studies were performed in the range 300-450 nm to 
determine the time course profile of AmB disaggregation in presence of HSA. The 
studies were comparatively performed with AmB, Fungizone®, heated Fungizone® and 
AmB/PEG5kDa-cholane micelles at 25°C and 37°C and the AmB disaggregation was 
determined by Gaussian fit of peak IV. The increase of the absorption area of peak IV 
(λ 413 nm), which represents the monomeric state of AmB, indicates the drug 
disaggregation. 
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The time course profiles reported in figure 38 show that at 37°C the unformulated AmB 
undergoes significant disaggregation. Fungizone® disaggregation was found to occur at 
less extent than free AmB while heated Fungizone® was pretty stable as its 
disaggregation was very low. The extent of AmB disaggregation from the 
AmB/PEG5kDa-cholane micelles was found to be in between Fungizone® and heated 
Fungizone®. After 45 min, the peak IV area was 2.1 and 1.7 for Fungizone® and 
AmB/PEG5kDa-cholane, respectively. 
The curves reported in figure 64 were found to fit a first order kinetic and were 
elaborated to get information on AmB dissociation rate. At 37°C, the disaggregation 
half-life time (t1/2) was 194, 335, 463 and 618 s for unformulated AmB, Fungizone®, 
heated Fungizone® and AmB/PEG5kDa-cholane micelles, respectively. The t1/2 values 
calculated from disaggregation profiles obtained at 25ºC (figure 65) were 397, 507, 573 
and 997 s for AmB in solution, Fungizone®, heated Fungizone® and AmB/PEG5kDa-
cholane micelles, respectively. 
 
 
 
 
 
 
 
 
Figure 64. Disaggregation profiles at 37°C of AmB (-▼-), Fungizone® (-◊-), heated Fungizone® (-●-) 
and AmB/PEG5kDa-cholane micelles (-□-) incubated with HSA. 
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Figure 65. Disaggregation profiles at 25°C of AmB (-▼-), Fungizone® (-◊-), heated Fungizone® (-●-) 
and AmB/PEG5kDa-cholanemicelles (-□-) incubated with HSA. 
 
EXP2-2.3.9. Dialysis studies 
The AmB release from the PEG5kDa-cholane micelles was studied using dialysis. Figure 
66 shows a biphasic profile where 70% AmB was released within 10 hours and 90% in 
96 h.  
 
 
 
 
 
 
 
 
Figure 66. Percentage of AmB released from the PEG5kDa-cholane micelle core over time. 
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In order to understand which mechanism (diffusion, erosion, relaxation of the polymer 
chains, etc.) governs the release of the AmB from the core of the PEG5kDa-cholane 
micelles, the data obtained from the dialysis experiment was elaborated to find the best 
fit according to different mathematical methods (table 54).  
Table 54. Results obtained with the different mathematical methods 
 
Model 
 
AmB/PEG5kDacholane 
0-10 h 
 
AmB/PEG5kDacholane 
24-96 h 
R2 K R2 K 
Zero order 0.887 1.344 0.867 0.002 
First order 0.749 0.156 0.847 0.002 
Hixon-Crowel 0.930 0.071 0.917 0.007 
Higuchi 0.988 4.772 0.923 0.942 
Baker-Lonsdale 0.598 0.033 0.767 0.001 
Korsmeyer-Peppas (n=0.58) 0.988 0.156 0.923 0.038 
 
As shown in table 54, the two steps of release were determined by diffusion. The 
differences found in the rate and in the K constant indicate that the structural conditions 
are different in the two moments of release. 
EXP2-2.4. Stability studies 
 
ICH Stability studies 
This study is being currently on going and therefore no complete results are already 
generated. The results from the 2 months stability have been summarized in section 
EXP2-2.3.3. 
 
Gastric mimicking fluid stability studies 
AmB/PEG5kDa-cholane micelles oral stability was studied as described in 
pharmacopoeia using simulated gastric mimicking fluid at pH 1.2 (see materials section 
EXP2-1.2.4). The aim of the study was to evaluate the integrity of the new formulation 
at low pH in the presence of pepsin during 4 hours. The assay was performed in 
triplicate. 
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The residence time of the drug in the stomach varies depending on many different 
factors but in general the mean residence time is around 1.5-2 h. As reported in table 55, 
after 90 minutes at pH 1.2, there was still a 51.75 ± 0.96% of intact AmB available to be 
absorbed. Figure 67 shows the behavior of the AmB included in PEG5kDa-cholane 
micelles during all the assayed period.  
As reported in table 56, the stability data in GMF was elaborated to find the best fit 
according to different mathematical models (zero, first and second order, Higuchi, 
Korsmeyer-Peppas, Baker Lonsdale and Hixon-Crowel). The AmB/PEG5kDa-cholane 
micelles degradation kinetics was found to best fit to Higuchi and Korsmeyer-Peppas 
models with an r2 of 0.996 and 0.994, respectively. The "n" value (n=0.392) in the 
Korsmeyer-Peppas fitting was calculated by plotting the log t versus log Mt/M0 for 
those values with less than a 60% AmB degradation.  
 
Table 55. AmB/PEG5kDa-cholane micelles degradation in GMF at 37 ºC 
Time (h) 
Concentration [μg/mL] 
Mean [μg/mL] Mean % AmB SD 
1 2 3 
0 31.483 30.173 33.048 31.568 100 0 
0.5 32.849 33.740 35.487 34.025 67.83 1.37 
1 29.762 30.096 29.655 29.838 60.27 0.46 
1.5 25.598 26.106 25.150 25.618 51.75 0.96 
2 22.516 22.029 21.408 21.984 44.41 1.11 
2.5 18.517 18.473 17.900 18.297 36.96 0.69 
3 16.117 15.943 15.457 15.839 31.99 0.69 
3.5 14.013 13.674 13.658 13.782 27.81 0.42 
4 11.798 11.250 11.710 11.586 23.40 0.59 
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Figure 67. AmB/PEG5kDa-cholane micelles stability in GMF at 37 ºC during 4 hours. 
 
Table 56.  AmB/PEG5kDa-cholane micelles degradation kinetics adjusted to different mathematical models 
Model A-value B-value Correlation coeficient (r2) 
Zero order 17.43 16.59 0.888 
First order 0.499 0.105 0.943 
Second order 82.39 16.75 0.880 
Higuchi 2.104 37.86 0.996 
Korsmeyer-Peppas 0.019 0.447 0.994 
Baker-Lonsdale 1.743 0.08 0.504 
Hixon-Crowel 0.237 0.396 0.962 
 
EXP2-2.5. In vitro toxicity studies 
 
EXP2-2.5.1. Hemolysis 
 
Prior to in vivo administration of AmB/PEG5kDa-cholane micelles, the hemolytic effect 
of this new formulation was studied and referred to Fungizone®. It was referred to 
Fungizone® due to the structural similarities of both colloidal systems. 
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The results for the hemolysis study performed with AmB/DMSO, Fungizone®, 
AmB/PEG5kDa-cholane micelles, AmB/PEG5kDa-stearic,  and AmB/PEG5kDa-arachidonic 
are detailed on table 57 and figure 68.  
 
 
 
 
 
 
 
 
 
Figure 68. Hemolytic effect of AmB in DMSO (-▼-), Fungizone® (-◊-), AmB/ PEG5kDa-arachidonic (-●-
), AmB/ PEG5kDa-stearic (-■-) and AmB/PEG5kDa-cholane micelles (-□-) at different concentrations. 
 
Table 57. Hemolytic effect of AmB included in different formulations at increasing concentrations. 
AmB [µg/mL] 
% Hemolysis 
AmB 
in DMSO 
Fungizone® 
AmB/PEG5kDa-
cholane 
AmB/PEG5kDa-
stearic 
AmB/PEG5kDa-
arachidonic 
0 0±0 0±0 0±0 0±0 0±0 
2.5 40±0.8 3±1.7 0±0 2.46±0.8 7.45±1.1 
5 60±1.2 5±1.2 0±0 15.3±1.2 15.3±1.2 
10 80±2.5 10±2.5 0±0 31.28±2.5 35.17±2.7 
20 100±3.5 15±2.9 1.3±0 70.2±3.5 50.3±3.3 
30 100±2.5 25±3 2.87±0.5 94.22±2.5 79.44±2.1 
40 100±0.9 50±4 6.50±1 97.3±0.9 85.03±1.0 
50 100±1.3 60±2 15.2±1.2 99±1.3 91.09±1.6 
60 100±2 100±1 31.07±3 100±2 97.29±2.3 
 
The hemolytic effect was, as expected, concentration-dependent. Higher amounts of 
AmB caused higher hemolysis. At low AmB concentration (2.5 µg/mL) the AmB 
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dissolved in DMSO showed a 40% hemolysis while Fungizone® and AmB/PEG5kDa-
cholane micelles had barely hemolytic effect. At 10 µg/mL, AmB in DMSO produced 
an 80% hemolysis, Fungizone® a 10% and AmB/PEG5kDa-cholane did not showed any 
hemolytic effect. At 40 µg/mL, AmB in DMSO caused 100% hemolysis, Fungizone® 
close to 50% and AmB/PEG5kDa-cholane just an 8%. Finally, at 60 µg/mL both AmB in 
DMSO and Fungizone® produced 100% hemolysis while AmB/PEG5kDa-cholane 
caused just 30% hemolysis. 
The results from the hemolysis studies allowed for the in vivo administration of the 
AmB/PEG5kDa-cholane micelles. This formulation was found to be less hemolytic than 
the already commercialized Fungizone®. 
EXP2-2.6. In vitro efficacy studies 
 
In vitro antifungal studies of AmB and AmB/PEG5kDa-cholane micelles were performed 
against C. albicans [378]. The diameters of the inhibition halos were, for both 
formulations, higher than 15 mm (18.47±0.185 for AmB and 20.48±0.238 mm for 
AmB/PEG5kDa-cholane micelles), indicating that they are active against Candida 
albicans [379-380].  The results reported in figure 69 show that AmB/PEG5kDa-cholane 
micelles were 15% less active than the standard solution of AmB and 15% more active 
than AmB in buffer. 
 
 
 
 
 
 
 
Figure 69. C. albicans inhibition in the presence of AmB/PEG5kDa-cholane, AmB in buffer (suspension) 
and AmB in DMSO (p<0.01). 
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EXP2-2.7. In vivo studies 
 
EXP2-2.7.1. Internal standard 
Naproxen, widely used as internal standard, was prepared at different concentrations 
ranging from 3 ng/mL to 50 mg/mL and analyzed by RP-HPLC. Table 58 shows the 
results for the three calibration curves performed at 406 nm with this compound. The 
naproxen retention time was found to be 4.5 min and the peak was well resolved from 
the AmB peak. 
As shown in Figure 70 the calibration curve was not linear in the assayed range 
(y=5.601-0.618x, r2=0.822). The non-linearity was found to be related to the 
wavelength used in the analysis. Although at 406 nm naproxen was detected, when 
performing the same analysis at other wavelengths (300, 270 and 200 nm) the 
integration of the peaks eluted at 4.5 min was higher than that obtained at 406 nm with 
the same concentration.  
Table 58. Concentration and area under the curve (AUC) of the different naproxen standards 
Naproxen [mg/mL] 
AUC/1000 
Mean AUC/1000 
1 2 3 
50 32.141 32.009 32.208 32.12 
25 24.89 25.02 25.63 25.18 
12.5 18.442 18.26 18.54 18.41 
6.25 14.784 15.18 14.92 14.96 
3.125 12.432 12.64 12.59 12.55 
1.5625 9.696 9.38 9.47 9.52 
0.78125 6.237 6.99 6.71 6.65 
0.3906 4.013 4.45 4.392 4.29 
0.1953 2.429 2.54 2.46 2.48 
0.09765 1.526 1.44 1.539 1.50 
0.04882 0.932 0.904 0.924 0.92 
0.02441 0.476 0.425 0.461 0.45 
0.0122 0.357 No detection No detection x 
0.0061 No detection No detection No detection x 
0.00305 No detection No detection No detection x 
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.  
 
 
 
 
 
 
 
 
Figure 70. Calibration curve of naproxen at 406 nm. 
As naproxen was discarded as internal standard, the recovery studies were then 
performed in order to have an indicator of drug loss during biological sample 
preparation.  
 
EXP2-2.7.2. AmB recovery studies in plasma 
AmB recovery studies from plasma were performed in order to calculate the AmB loss 
during sample preparation. AmB in DMSO and in dextrose (5% w/v), Fungizone®, 
Ambisome® and AmB/PEG5kDa-cholane micelles were prepared and added of blood. 
Plasma samples were obtained as reported in methods (EXP2-1.2.7.2) and analyzed by 
RP-HPLC. 
Tables 59-63 show the recovery values obtained for the different AmB formulations 
assayed orally and/or intravenously. 
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Table 59. AmB recovery in plasma from AmB/DMSO. 
AmB [μg/mL] 
Theoretical 
AmB [μg/mL] 
Recovered in Blood 
AmB [μg/mL] 
Recovered in Plasma 
AmB [μg/mL] 
1 0.04761 0.2088 0.1148 
2 0.09523 0.2982 0.1640 
4 0.18957 0.3472 0.1909 
6 0.28571 0.5388 0.2963 
8 0.3809 0.6978 0.3837 
10 0.47612 0.8221 0.4521 
 
Table 60. AmB recovery in plasma from AmB/Dextrose (5% w/v). 
AmB [μg/mL] 
Theoretical 
AmB [μg/mL] 
Recovered in Blood 
AmB [μg/mL] 
Recovered in Plasma 
AmB [μg/mL] 
1 0.04761 0.1834 0.1008 
2 0.09523 0.2672 0.1469 
4 0.18957 0.3781 0.2079 
6 0.28571 0.4925 0.2708 
8 0.3809 0.6732 0.3701 
10 0.47612 0.8104 0.4457 
 
Table 61. AmB recovery in plasma from Ambisome®. 
AmB [μg/mL] 
Theoretical 
AmB [μg/mL] 
Recovered in Blood 
AmB [μg/mL] 
Recovered in Plasma 
AmB [μg/mL] 
1 0.04761 0.1337 0.0735 
2 0.09523 0.2220 0.1221 
4 0.18957 0.3111 0.1711 
6 0.28571 0.4315 0.2373 
8 0.3809 0.5380 0.2958 
10 0.47612 0.8081 0.4444 
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Table 62. AmB recovery in plasma from Fungizone®. 
AmB [μg/mL] 
Theoretical 
AmB [μg/mL] 
Recovered in Blood 
AmB [μg/mL] 
Recovered in Plasma 
AmB [μg/mL] 
1 0.04761 0.1509 0.0829 
2 0.09523 0.2324 0.1278 
4 0.18957 0.3701 0.2035 
6 0.28571 0.4397 0.2418 
8 0.3809 0.6433 0.3538 
10 0.47612 0.7798 0.4288 
 
Table 63. AmB recovery in plasma from AmB/PEG5kDa-cholane micelles. 
AmB [μg/mL] 
Theoretical 
AmB [μg/mL] 
Recovered in Blood 
AmB [μg/mL] 
Recovered in Plasma 
AmB [μg/mL] 
1 0.04761 0.1615 0.0882 
2 0.09523 0.2895 0.1592 
4 0.18957 0.4818 0.2649 
6 0.28571 0.5093 0.2801 
8 0.3809 0.6756 0.3715 
10 0.47612 0.8229 0.4525 
 
The % of AmB recovered in plasma from the different formulations was calculated by 
plotting the initial theoretical AmB concentration versus the AmB recovered in plasma. 
The slope of the curves, expressed as percentage, was assumed as the recovery value for 
each individual formulation. 
Table 64 shows the regression curves and the percentages of recovery for all 
formulations assayed. The results showed that there were no significant differences 
between the recovery values obtained with the different AmB formulations. Therefore, a 
79% (0.79) recovery was used for the determination of AmB concentration in biological 
samples regardless the formulation. 
Table 64. Percentage of AmB recovered in plasma for each formulation. 
Formulation Equation % Recovery 
AmB in DMSO y=0.793x+0.071, r2=0.984 79.3% 
AmB in dextrose (5% w/v) y=0.7932x+0.061, r2=0.994 79.32% 
Fungizone® y=0.789x+0.045, r2=0.987 78.9% 
Ambisome® y=0.79x+0.029, r2=0.961 79% 
AmB/PEG5kDa-cholane y=0.79x+0.075, r2=0.969 79% 
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EXP2-2.7.3. Oral pharmacokinetic studies 
Study design 
As described in methods, the oral pharmacokinetic studies of the different AmB 
formulations were performed on two non-consecutive days. On day 1, AmB/Dextrose 
and AmBisome® were tested and on day 2 Fungizone® and AmB/ PEG5kDa-cholane 
were assayed. 
Mice behavior  
Independently of the formulation administered the mice behavior was almost exactly the 
same. For all the orally administered formulations the mice felt discomfort due to the 
insertion of a syringe directly into their stomach. After administration and for less than 
3 minutes, the mice remained quiet and seemed afraid. Then, they started to move and 
act normally. At time 4 hours, the mice that have received 5 mg/kg of  Fungizone® and 
Ambisome® showed signs of suffer and their hair was slightly frizzy while those 
receiving AmB/Dextrose and AmB/PEG5kDa-cholane continued to act normally. It is 
worth pointing out that the mice that had received 5 mg/kg AmB/PEG5kDa-cholane were 
moving faster and were more active than those receiving AmB/Dextrose. 
Pharmacokinetic data treatment 
 General considerations 
A non-compartmental independent model was used to estimate the area under the curve 
between 0 and 24 h (AUC0-24). The apparent elimination constant (Ke) was estimated 
with the last two plasma concentrations values available (8 and 24 h) for Fungizone®, 
Ambisome® and AmB/Dextrose formulations and with the last three points (4, 8 and 24 
h) for the AmB/PEG5kDa-cholane formulations. The half-life (t½) was calculated as the 
ratio between 0.693 and Ke. Cmax and Tmax values were taken directly from the 
experimental data. The median of the Tmax values were used for comparative studies. 
The area under the curve between 24 h and the infinite (AUC24-∞) was calculated as the 
ratio between the concentration at time 24 h (C24) and the Ke. The area under the curve 
between 0 and the infinite (AUC0-∞ ) was estimated as the sum of AUC0-24 plus AUC24-
∞. Absolute bioavailability (F) was obtained with the following equation: 
F = 100 x (AUCoral 0-24 x DoseIV) / (AUCiv 0-24 x Doseoral) 
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The comparison of the results obtained with the different formulations assayed was 
performed using ANOVA and t-Student data treatments (Excel, Microsoft Office 2007). 
 Results 
Figure 71 shows the results of the four orally tested formulations (AmB/Dextrose, 
Ambisome®, Fungizone® and AmB/PEG5kDa-cholane) after administration of a dose of 
5 mg/kg of AmB. 
Tables 65-68 show the pharmacokinetic parameters obtained on each mice after 
administration of AmB/Dextrose, Ambisome®, Fungizone® and AmB-PEG 
formulations, respectively. 
 
Figure 71. Mean and standard deviation of the plasma concentrations obtained after oral administration of  
AmB dextrose  (-◊-),  Ambisome® (-□-), Fungizone® (-■-), and AmB-PEG5kDa-cholane (-▲-). 
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Table 65. Pharmacokinetic results obtained after oral administration of AmB/Dextrose at 5 mg/kg AmB. 
AmB dextrose 
Mice 
Mean SD 
1  2  3 4  
Ke (h) 0.04 0.07 0.04 0.03 0.04 0.02 
t½ (h) 15.41 10.62 18.43 24.37 17.21 5.75 
AUC0-24 (µg h/ml) 4.74 4.14 5.12 6.27 5.07 0.90 
AUC24-infinite 2.90 1.22 4.08 7.86 4.02 2.82 
AUC0-infinite 7.64 5.36 9.20 14.13 9.08 3.72 
Extrapolation (%) 38.00 22.78 44.33 55.62 40.18 13.70 
Cmax (µg/ml) 0.27 0.28 0.28 0.35 0.30 0.04 
T max (h) 8.00 4.00 8.00 8.00 8.00 2.00 
 
Table 66. Pharmacokinetic results obtained after oral administration of Ambisome® at 5 mg/kg AmB. 
Ambisome® 
Mice 
Mean SD 
1 2 3 4 
Ke (h) 0.02 0.04 0.03 0.01 0.03 0.01 
t½ (h) 33.62 16.35 22.80 52.48 31.31 15.81 
AUC0-24 (µg h/ml) 7.32 4.59 5.87 6.79 6.14 1.20 
AUC24-infinite 11.62 3.68 6.02 18.82 10.03 6.74 
AUC0-infinite 18.94 8.27 11.89 25.60 16.18 7.69 
Extrapolation (%) 61.35 44.48 50.64 73.49 57.49 12.74 
Cmax (µg/ml) 0.33 0.31 0.31 0.33 0.32 0.01 
T max (h) 8 4 4 4 4 2 
F (%) 8.42 5.28 6.75 7.81 7.07 1.37 
 
Table 67. Pharmacokinetic results obtained after oral administration of Fungizone® at 5 mg/kg AmB. 
Fungizone® 
Mice 
Mean SD 
1 2 3 4 
Ke (h) 0.06 0.02 0.01 0.04 0.04 0.02 
t½ (h) 10.84 28.91 52.11 15.69 26.89 18.47 
AUC0-24 (µg h/ml) 5.14 6.11 5.89 5.60 5.68 0.42 
AUC24-infinite 1.61 8.22 16.68 3..49 7.50 6.72 
AUC0-infinite 6.75 14.32 22.57 9.08 13.18 7.02 
Extrapolation (%) 23.88 57.36 73.91 38.38 48.38 21.85 
Cmax (µg/ml) 0.29 0.35 0.27 0.31 0.31 0.03 
T max (h) 8 4 8 8 8 2 
F (%) 16.90 20.09 19.37 18.41 18.69 1.38 
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Table 68. Pharmacokinetic results obtained after oral administration of AMB/PEG5kDa-cholane at 5 mg/kg 
AmB. 
AMB/PEG5kDa-cholane 
Mice 
Mean SD 
1 2 3 4 
Ke (h) 0.01 0.01 0.02 0.04 0.02 0.01 
t½ (h) 133.16 53.62 34.28 18.30 59.84 50.97 
AUC0-24 (µg h/ml) 6.31 4.85 4.69 4.94 5.20 0.75 
AUC24-infinite 51.32 14.79 8.74 3.48 19.58 21.66 
AUC0-infinite 57.63 19.65 13.43 8.42 24.78 22.38 
Extrapolation (%) 89.05 75.30 65.07 41.32 67.69 20.14 
Cmax (µg/ml) 0.31 0.27 0.31 0.32 0.30 0.02 
T max (h) 4.00 4.00 4.00 4.00 4.00 0.00 
F (%) 10.94 8.42 8.13 8.57 9.01 1.30 
 
Figures 72-76 show the mean half-life, AUC0-24, Cmax, Tmax and Absolute 
bioavailability (F) obtained for the four orally tested formulations. 
Due to the high AUC24-infinite values (higher than 5%) only AUC0-24 was used in the 
comparative studies. 
Tables 69-73 show the results from the ANOVA tests performed on the different 
formulations. The half-lives (t½), AUC0-24, Cmax, Tmax and Absolute bioavailability 
(F) were studied. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72. Mean and standard deviation of the half-lives (t½) obtained after oral administration of AmB 
dextrose, Ambisome®, Fungizone® and AmB-PEG5kDa-cholane. 
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Figure 73. Mean and standard deviation of the AUC0-24 values obtained after oral administration of AmB 
dextrose, Ambisome®, Fungizone® and AmB-PEG5kDa-cholane. 
 
 
 
 
 
 
 
 
Figure 74. Mean and standard deviation of the Cmax obtained after oral administration of AmB dextrose, 
Ambisome®, Fungizone® and AmB-PEG5kDa-cholane. 
 
 
 
AmB/Dextrose Ambisome Fungizone AmB/PEG5kDa-cholane
0
1
2
3
4
5
6
7
8
9
10
A
U
C
0
-2
4
 (

g
 h
/m
L
)
AmB Formulations
AmB/Dextrose Ambisome Fungizone AmB/PEG5kDa-cholane
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
C
m
a
x
 (

g
/m
L
)
AmB Formulations
Novel formulations for Amphotericin B delivery 
 
223 
 
 
 
 
 
 
 
Figure 75. Mean and standard deviation of the tmax obtained after oral administration of AmB dextrose, 
Ambisome®, Fungizone® and AmB-PEG5kDa-cholane. 
 
 
 
 
 
 
 
 
Figure 76. Mean and standard deviation of the Absolute Bioavailability (F) obtained after oral 
administration of Ambisome®, Fungizone® and AmB-PEG5kDa-cholane. 
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Table 69. ANOVA test on the half-life constants of AmB Dextrose, Ambisome®, Fungizone® and 
AmB/PEG5kDa-cholane. NS (P-value is higher than 0.05). 
One-factor ANOVA 
    
       
SUMMARY  
      
Groups Counts Sum Mean Variance 
  
AmB Dextrose 4 68.82 17.21 33.11 
  
Ambisome® 4 125.25 31.31 249.90 
  
Fungizone® 4 107.54 26.89 341.00 
  
AmBPEG 4 239.36 59.84 2598.05 
  
       
       
ANALYSIS OF VARIANCE 
     
Variation origin 
Sum of 
squares 
Degrees of 
freedom Mean of squares F Probability 
Critical value 
for F 
Between groups 4,029.59 3 1,343.20 1.67 0.23 3.49 
In between groups 9,666.18 12 805.51 
   
     
.
 
 
Total 13,695.77 15 
     
 
Table 70. ANOVA test on the AUC0-24 results of AmB Dextrose, Ambisome®, Fungizone® and 
AmB/PEG5kDa-cholane. NS (P-value is higher than 0.05). 
One-factor ANOVA 
    
       
SUMMARY 
      
Groups Counts Sum Mean Variance 
  
AmB Dextrose 4 20.27 5.07 0.81 
  
Ambisome® 4 24.57 6.14 1.43 
  
Fungizone® 4 22.73 5.68 0.18 
  
AmBPEG 4 20.79 5.20 0.56 
  
       
       
ANALYSIS OF VARIANCE 
     
Variation origin 
Sum of 
squares 
Degrees of 
freedom 
Mean of 
squares F Probability 
Critical 
value for F 
Between groups 2.89 3 0.96 1.29 0.32 3.49 
In between groups 8.92 12 0.74 
   
       
Total 11.80 15 
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Table 71. ANOVA test on the Cmax results of AmB Dextrose, Ambisome®, Fungizone® and 
AmB/PEG5kDa-cholane. NS (P-value is higher than 0.05). 
One-factor ANOVA 
    
       
SUMMARY 
      
Groups Counts Sum Mean Variance 
  
AmB Dextrose 4 1.18 0.30 0.00 
  
Ambisome® 4 1.29 0.32 0.00 
  
Fungizone® 4 1.22 0.31 0.00 
  
AmBPEG 4 1.21 0.30 0.00 
  
       
       
ANALYSIS OF VARIANCE 
     
Variation origin 
Sum of 
squares 
Degrees of 
freedom Mean of squares F Probability 
Critical value 
for F 
Between groups 0.00 3 0.0005 0.65 0.60 3.49 
In Between groups 0.01 12 0.0008 
   
       
Total 0.01 15 
     
 
Table 72. ANOVA test on the tmax results of AmB Dextrose, Ambisome®, Fungizone® and 
AmB/PEG5kDa-cholane. NS (P-value is higher than 0.05). 
One-factor ANOVA 
    
       
SUMMARY 
      
Groups Counts Sum Mean Variance 
  
AmB Dextrose 4 28 7 4 
  
Ambisome® 4 20 5 4 
  
Fungizone® 4 28 7 4 
  
AmBPEG 4 16 4 0 
  
       
       
      
Variation origin 
Sum of 
squares 
Degrees of 
freedom Mean of squares F Probability 
Critical 
value for F 
Between groups 27 3 9 3 0.07 3.49 
In between groups 36 12 3 
   
       
Total 63 15 
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Table 73. ANOVA test on the Absolute Bioavailability (F) results of Ambisome®, Fungizone® and 
AmB/PEG5kDa-cholane. S (P-value is lower than 0.001). 
One-factor ANOVA 
     
       
SUMMARY 
      
Groups Counts Sum Mean Variance 
  
Ambisome® 4 28.26 7.07 1.89 
  
Fungizone® 4 74.78 18.69 1.91 
  
AmBPEG 4 36.06 9.01 1.68 
  
       
       
ANALYSIS OF VARIANCE 
     
Variation origin Sum of squares 
Degrees of 
freedom Mean of squares F Probability 
Critical 
value for F 
Between groups 310.27 2 155.13 84.89 0.000001 4.26 
In between groups 16.45 9 1.83 
   
       
Total 326.72 11 
     
The above summarized statistic results show that only significant (P<0.01) differences 
were found among formulations in terms of the absolute bioavailability (F). The 
Fungizone® formulation had higher F values compared to Ambisome® and AmB-
PEG5kDa-cholane.  
It is important to point out that all the oral AUC0-24 values were very similar regardless 
the formulation (figure 73). 
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EXP2-2.7.4. Intravenous pharmacokinetics studies 
Study design 
The intravenous pharmacokinetic studies of the different AmB formulations were 
performed on two non-consecutive days. On day 1, AmBisome® and Fungizone® were 
tested and on day 2, AmB/ PEG5kDa-cholane was assayed. The number of sampling 
points (see study design on EXP2-1.2.7.4) together witht the number of operators did 
not allowed for the complete study in one day.  
Mice behavior 
The mice behavior was different depending on the formulation administered. The 
behavior of the female BALB/c after iv administration of 1 mg/kg Fungizone®, 
AmBisome® and AMB/PEG5kDa-cholane is detailed below. 
 Fungizone® 
The intravenous administration of 1mg/kg Fungizone® caused discomfort and suffer on 
the mice. During the first 15 minutes after administration, the mice remained unmoved 
in a corner of the cage and in a position in which they seemed a ball. They were all 
together; really close ones to the others and even, ones over the others. Their hair got 
slightly frizzy . After 15 min, the mice started to move but the movements were slow 
and the mice seemed afraid.  
This behavior is supported by the hemolysis found in most of the samples collected 
during the intravenous pharmacokinetic study. 
 Ambisome® 
The IV administration of Ambisome® caused less pain in the mice than the 
administration of Fungizone®. The mice showed signs of suffer but not so pronounced 
as for Fungizone®. Moreover, the mice recovery time after injection was shorter for 
Ambisome®. After 8 minutes, the mice started to move and behave normally, even 
though there were still some signs of suffer.  
When preparing the samples for the HPLC analysis, some of them were found to be 
hemolyzed. 
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 AmB/PEG5kDa-cholane 
Immediately after Intravenous administration of 1 mg/kg AmB included in PEG5kDa-
cholane micelles, the BALB/c mice showed a normal behavior. They were active and 
continued to walk, jump, play, eat and wash themselves. There were no signs of suffer 
and their hair remained nice.  
The mice just felt a little bit of pain when extracting the blood from the eye at each time 
point.  
Pharmacokinetic data treatment 
 General considerations 
A non-compartmental independent model was used to estimate the area under the curve 
between 0 and 24 h (AUC0-24). The initial concentration (C0) was extrapolated using the 
first two plasma samples available adjusted to a fist-order kinetic. 
The apparent elimination constant (Ke) was estimated with the last three plasma 
concentrations values available (4, 8 and 24 h). The regression coefficients calculated 
with those three values are reported in tables 74-76. The half-life (t½) was calculated as 
the ratio between 0.693 and Ke.  
The area under the curve between 24 h and the infinite (AUC24-∞) was calculated as the 
ratio between the concentration at time 24 h (C24) and the Ke. The area under the curve 
between 0 and the infinite (AUC0-∞) was estimated as the sum of AUC0-24 plus AUC24-∞. 
The results obtained with the different formulations assayed were compared using 
ANOVA and t-Student data treatments (Excel, Microsoft Office 2007). 
 Results 
Figure 77 shows the results of the three intravenously tested formulations (Ambisome®, 
Fungizone® and AmB/PEG5kDa-cholane) after administration of a dose of 1 mg/kg of 
AmB. 
Tables 74-76 summarize the pharmacokinetic parameters obtained on each mouse after 
iv administration of AmBisome®, Fungizone® and AmB-PEG formulations, 
respectively. 
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Figure 77. Mean and standard deviation of the plasma concentrations obtained after iv administration of 
Ambisome® (-□-), Fungizone® (-■-) and AmB-PEG5kDa-cholane (-▲-) 
 
Table 74. Pharmacokinetic results obtained after IV administration of Ambisome® at 1 mg/kg AmB. 
AmBisome® 
Mice 
Mean SD 
1 2 3 4 5 6 
Ke (h-1) 0.135 0.127 0.127 0.126 0.136 0.137 0.131 0.005 
t½ (h) 5.117 5.443 5.443 5.491 5.110 5.067 5.278 0.199 
r -0.987 -0.987 -0.990 -1.000 -0.991 -0.986 -0.990 0.005 
AUC0-24 (µg h/ml) 16.179 16.486 18.164 17.853 18.476 17.155 17.385 0.931 
AUC24-∞ (µg h/ml) 0.565 0.732 0.706 0.691 0.627 0.574 0.649 0.071 
AUC0-∞ (µg h/ml) 16.744 17.219 18.869 18.544 19.103 17.730 18.035 0.951 
Extrapolation (%) 3.373 4.253 3.740 3.726 3.281 3.240 3.602 0.386 
C24 (µg/ml) 0.076 0.093 0.090 0.087 0.085 0.079 0.085 0.006 
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Table 75. Pharmacokinetic results obtained after IV administration of Fungizone® at 1 mg/kg AmB. 
 
 
Table 76. Pharmacokinetic results obtained after IV administration of AMB/PEG5kDa-cholane at 1 mg/kg 
AmB. 
AmB-PEG5kDa-cholane 
Mice 
Mean SD 
1 2 3 4 5 6 7 
Ke (h-1) 0.032 0.033 0.032 0.034 0.045 0.048 0.051 0.039 0.007 
t½ (h) 21.447 21.311 21.739 20.240 15.561 14.298 13.561 18.308 3.294 
r -0.931 -0.999 -0.960 -0.970 -0.999 -0.971 -0.984 -0.973 0.026 
AUC0-24 (µg h/ml) 10.348 10.924 11.377 12.834 11.417 11.853 11.978 11.533 0.845 
AUC24-∞ (µg h/ml) 8.277 7.971 9.302 9.015 5.221 4.970 4.560 7.045 1.895 
AUC0-∞ (µg h/ml) 18.626 18.895 20.680 21.849 16.638 16.823 16.537 18.578 2.067 
Extrapolation (%) 44.441 42.184 44.982 41.261 31.379 29.544 27.572 37.337 6.755 
C24 (µg/ml) 0.267 0.259 0.297 0.309 0.233 0.241 0.233 0.263 0.030 
 
Interestingly, AmB/PEG5kDacholane samples were the less hemolyzed of all tested 
formulations and the mice behavior was normal showing no signs of suffer. 
Extrapolation of the AUC24-∞ for the Fungizone® and the AmB/PEG5kDacholane 
formulations was higher than 5%, and for this reason, only AUC0-24 was used for 
comparative purposes. 
AmB pharmacokinetics is usually defined as multiexponential, non lineal and dependent 
on the drug formulation administered, even after simple in bolus administration [153]. 
. 
Data reported in figure 77 and in tables 74-76 show that the pharmacokinetic behavior 
Fungizone® 
Mice 
Mean SD 
1 2 3 4 5 6 
Ke (h-1) 0.055 0.057 0.038 0.048 0.056 0.048 0.050 0.007 
t½ (h) 12.491 12.153 18.346 14.551 12.362 14.449 14.059 2.356 
r -0.864 -0.877 -0.728 -0.932 -0.993 -0.888 -0.880 0.088 
AUC0-24 (µg h/ml) 5.903 5.728 5.683 5.943 6.985 6.236 6.080 0.485 
AUC24-∞ (µg h/ml) 2.005 1.909 3.748 2.739 2.157 2.887 2.574 0.699 
AUC0-∞ (µg h/ml) 7.908 7.637 9.431 8.682 9.142 9.123 8.654 0.728 
Extrapolation (%) 25.353 25.001 39.745 31.550 23.596 31.649 29.482 6.101 
C24 (µg/ml) 0.111 0.109 0.142 0.130 0.121 0.138 0.125 0.014 
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of AmB depends on the type of formulation administered. Therefore, ANOVA tests 
were performed to study the possible statistically significant differences among the 
different formulations assayed. 
 
It is reasonable that the apparent elimination constant and the half-life were found to be 
different depending on the drug formulation. Figures 78 and 79 show the mean apparent 
elimination constants and the half-lives associated to the three different formulations. In 
order to obtain a more reliable elimination constant value, more sampling points would 
be required. Nevertheless, as the aim of the present study was to test different AmB 
formulations and analyze their different pharmacokinetic behavior, the sampling points 
available are enough. 
 
The apparent elimination constants were calculated with the last three available 
concentrations for each formulation and the regression coefficients are reported in tables 
74-76.  
 
Tables 77 and 78 summarize the results from the ANOVA tests performed on the three 
intravenously administered formulations. The statistical tests show significant 
differences among the formulations for the apparent elimination constants (Ke) and the 
half-life (t½) parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 78. Mean apparent elimination constant (Ke) and standard deviation of Ambisome®, Fungizone® 
and AmB/PEG5kDa-cholane after IV administration of 1 mg/kg AmB. 
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Figure 79. Mean half-life (t½) (h) and standard deviation of Ambisome®, Fungizone® and AmB/PEG5kDa-
cholane after IV administration of 1 mg/kg AmB. 
 
Table 77. ANOVA test on the apparent elimination constants (Ke) of AmBisome®, Fungizone® and 
AmB/PEG5kDa-cholane. P-value is lower than 0.001. 
One-factor ANOVA 
   
 
      
 
SUMMARY 
     
 
Groups Count Sum Mean Variance 
 
 
AmBisome® 6 0.789 0.131 0.00002463 
 
 
Fungizone® 6 0.302 0.050 0.00005494 
 
 
AmB/PEG5kDa-chlolane 7 0.275 0.039 0.00007104 
 
 
      
 
ANALYSIS OF VARIANCE 
    
 
Variation origin 
Sum of 
squares 
Degrees of 
freedom Mean of squares F Probability 
Critical value 
for F 
Between groups 0.032 2.000 0.016 305.902 1.8 10-13 
3.634 
In between groups 0.001 16.000 0.000 
  
 
Total 0.032 18.000 
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Table 78. ANOVA test on the half-lives (t½) of AmBisome®, Fungizone® and AmB/PEG5kDa-cholane. P-
value is lower than 0.001. 
One-factor ANOVA 
   
 
      
 
SUMMARY 
     
 
Groups Counts Sum Mean Variance 
 
 
AmBisome® 6 31.670 5.278 0.040 
 
 
Fungizone® 6 84.352 14.059 5.549 
 
 
AmB/PEG5kDa-cholane 7 128.156 18.308 13.422 
 
 
      
 
ANALYSIS OF VARIANCE 
    
 
Variation origin 
Sum of 
squares 
Degrees of 
freedom 
Mean of 
squares F Probability 
Critical value 
for F 
Between groups 561.272 2.000 280.636 41.394 
4.73 10 -7 3.634 
In between groups 108.474 16.000 6.780 
  
 
Total 669.746 18.000 
   
 
 
Figures 80 and 81 show the values of AUC0-24 and C24 for the different tested 
formulations. The concentration of AmB circulating in blood after 24 h was 0.263 
μg/mL for the AmB-PEG5kDa-cholane formulation, twice that of Fungizone® or 
Ambisome® (0.1252 μg/mL and 0.085 mg/mL, respectively). Tables 79 and 80 show 
the results from the ANOVA tests performed on both parameters (AUC0-24 and C24). 
 
 
 
 
 
 
 
 
 
Figure 80. Mean AUC0-24 (µg h/mL) and standard deviation for the different tested formulations. 
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Figure 81. Mean C24 (µg/mL) and standard deviation for the different tested formulations. 
 
Table 79. ANOVA test on the AUC0-24 of AmBisome®, Fungizone® and AmB/PEG5kDa-cholane. P-value 
is lower than 0.001. 
One-factor ANOVA 
   
 
      
 
SUMMARY 
     
 
Groups Counts Sum Mean Variance 
 
 
AmBisome 6 104.313 17.385 0.866 
 
 
Fungizone 6 36.477 6.080 0.235 
 
 
AmBPEG 7 80.732 11.533 0.634 
 
 
      
 
ANALYSIS OF VARIANCE 
    
 
Variation origin Sum of squares 
Degrees of 
freedom Mean of squares F Probability 
Critical value 
for F 
Between groups 383.647 2.000 191.823 329.671 
9.9 10-14 3.634 
In between groups 9.310 16.000 0.582 
  
 
Total 392.956 18.000       
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Table 80. ANOVA test on the C24 of AmBisome®, Fungizone® and AmB/PEG5kDa-cholane. P-value is 
lower than 0.001. 
 
In order to study a possible relationship between the apparent elimination constant (Ke) 
with the AUC0-24 and the C24 a t-Student test was applied. The results are shown in 
tables 81 and 82 and figures 82 and 83. 
Table 81. t-Student test with different variances for Ke and AUC0-24. 
  Ke (h-1) AUC0-24 (µg h/ml) 
Mean 0.071877004 11.6590439 
Variance 0.00179644 21.8309061 
Observations 19 19 
Hypothetical difference between the 
means 0 
 
Degrees of freedom 18 
 
t-statistic -10.8093683 
 
P(T<=t) one tail 1.3307 10-9 
 
t-critical value (one tail) 1.734063592 
 
P(T<=t) two tails 2.66141E-09 
 
t-critical value (two tails) 2.100922037   
 
There is a significant relationship between both variables with a P-value lower than 
0.001. 
One-factor ANOVA 
   
 
      
 
SUMMARY 
     
 
Groups Counts Sum Mean Variance 
 
 
AmBisome 6 0.510 0.085 0.000 
 
 
Fungizone 6 0.752 0.125 0.000 
 
 
AmBPEG 7 1.838 0.263 0.001 
 
 
      
 
ANALYSIS OF VARIANCE 
    
 
Variation origin Sum of squares 
Degrees of 
freedom 
Mean of 
squares F Probability 
Critical 
value for 
F 
Between groups 0.114 2.000 0.057 1360.154 
9.9 10-11 3.634 
In Between groups 0.007 16.000 0.000 
  
 
Total 0.121 18.000       
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Table 82. t-Student test with different variances for Ke and C24. 
  Ke (h-1) C24 (µg/ml) 
Mean 0.071877 0.163168383 
Variance 0.00179644 0.006732092 
Observations 19 19 
Hypothetical difference between the means 0 
 
Degrees of freedom 27 
 
t-statistic 4.308929837 
 
P(T<=t) one tail 9.73034 10-5 
 
t-critical value (one tail) 1.703288423 
 
P(T<=t) two tails 0.000194607 
 
t-critical value (two tails) 2.051830493   
 
There is a significant relationship between both variables with a P-value lower than 
0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82. Significant relationship (P<0.01) between AUC0-24 and the apparent elimination constant (Ke). 
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Figure 83. Significant relationship (P<0.01) between C24 and the apparent elimination constant (Ke). 
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EXP2-3.DISCUSSION 
 
The results reported in this thesis show that PEG5kDa-cholane can increase more than 10
5 
times the AmB solubility according to a linear [dissolved drug]/[polymer concentration] 
correlation. Solutions up to 12 mg/mL AmB (6 mg/mL PEG5kDa-cholane) were obtained 
without significant change of buffer viscosity. Higher drug/polymer concentrations 
increased the viscosity, which prevented the accurate determination of the maximal 
AmB solubility. However, neither AmB separation nor inhomogeneity were observed 
up to 60 mg/mL AmB (30 mg/mL PEG5kDa-cholane). PEG5kDa-OH was not found to 
significantly affect the AmB solubility indicating that the drug solubility was due to the 
supramolecular PEG5kDa-cholane self-association into micelles as previously reported 
[335]. 
The remarkable effect of PEG5kDa-cholane on AmB solubility is due to a combination of 
effects, which include the ability of PEG5kDa-cholane to form stable micelles with a low 
CMC [335] and the affinity of AmB for sterol molecules. AmB displays in fact its 
antifungal activity and cytotoxicity by interaction with ergosterol and cholesterol 
located in membranes of fungi and mammalian cells, respectively [168,381]. To note 
that a study reported in the literature showed that sterols in DSPE-PEG micelles favor 
the formation of soluble AmB aggregates [382].This study showed that either AmB 
solubility or aggregation depend on the chemical structure and content of sterols in the 
DSPE-PEG vesicles. 
The high AmB solubility obtained by using little amounts of excipients, namely 
solubilizing agents, is an important requisite for the development of safe products easily 
manageable in clinical practice. The use of high amounts of excipients may in fact be 
associated to toxic effect, in particular in parenteral administrations, namely infusion. 
Little amounts of PEG5kDa-cholane yielded very high AmB concentration solutions 
whilst commercial products, namely Fungizone® and Ambisome®, and other 
formulations described in the literature contain high amounts of solubilizing excipients 
[155]. In Fungizone® and Ambisome®, for example, 50 mg AmB are formulated with 
41 mg sodium deoxycholate and 350 mg phospholipids/cholesterol/tochopherol, 
respectively [362], which are re-constituted in 15 mL saline solution resulting in 3.33 
mg/mL AmB. The same amount of AmB could be dissolved with 25 mg of PEG5kDa-
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cholane in about 4 mL buffer to yield 12.5 mg/mL AmB. It is worth to note that 
previous cell culture studies showed that PEG5kDa-cholane has negligible toxicity even 
at high doses. Furthermore, preliminary studies showed that, oppositely to sodium 
deoxycholate used in Fungizone®, PEG5kDa-cholane does not display significant 
hemolytic effect [335].  
The different capability of PEG5kDa-cholane to solubilize AmB observed with different 
dissolution methods can be explained by the effect of the dissolution conditions in the 
formation of monomeric and multimeric soluble species, typically dimers and tetramers 
[145]. According to the UV and CD spectrometric data, the direct AmB dissolution 
process produces low drug concentrations where AmB is mainly associated in the 
monomeric form with PEG5kDa-cholane. On the contrary, the spectra obtained with 
AmB/PEG5kDa-cholane prepared by co-solvent dissolution or by dissolution/pH change 
showed the typical profile of aggregated AmB. Therefore, the high drug concentration 
obtained by these methods can be ascribed to the formation of AmB nanoaggregates, 
which are promptly stabilized by the polymer interaction. 
Dynamic light scattering (DLS) and transmission electron microscopy (TEM) 
confirmed that the AmB/PEG5kDa-cholane association forms micelles with 
homogeneous size. The particles size was similar to other nanoformulations such as 
nanosomal AmB (34.6 nm) [269] or Ambisome® (35-70 nm) [106,156,362]. The 
structure of the AmB/PEG5kDa-cholane micelles was confirmed by the TEM analyses, 
which showed the polymeric chains exposed on the vesicle surface, while the 
hydrophobic cholane moieties are localized inside the micelles. The similar zeta-
potential of AmB free and AmB loaded micelles indicates that the AmB ionization does 
not affect the overall surface charge of the micelle confirming that the drug was 
localized in the micelle core. 
The high affinity of AmB for PEG5kDa-cholane observed by isothermal calorimetry 
(ITC) is in agreement with the high affinity of this drug for steroidal polycycles 
described in the literature, which is responsible for its antifungal activity and 
cytotoxicity [168,381]. However, the isothermal calorimetry (ITC) highlighted the 
complexity of the PEG5kDa-cholane interaction with AmB, which takes place with 
different AmB soluble species, namely monomers, dimers, tetramers, and other 
multimeric nanoaggregates, of which abundance depends on the pH. It has been 
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reported that the presence of a net charge in the antibiotic molecule is the main factor 
that induces the solubility of AmB through the formation of the monomeric specie. 
AmB pKa values are 5.7 for the carboxyl group and 10.0 for the amino group. 
Therefore, at pH 11.0 AmB is mainly in the monomeric highly soluble anionic form 
[145]. As the pH decreases to the isolectric point, the AmB anionic form and the drug 
solubility decrease with concurrent formation of less soluble nanoaggregates. At pH 3.5 
the AmB solubility slightly increases with the increase of the cationic specie, which was 
found to be less soluble than the anionic form. The similar thermal profile obtained at 
pH 5.5 and 7.2 and the similar ones obtained at 3.5 and 8.5 seem to indicate that the 
polymer interaction with the drug is strictly related to the solubility of AmB and hence 
to the relative abundance of the mono- or multimeric species. 
The three different binding sites calculated by ITC analyses reasonably result from the 
PEG5kDa-cholane interaction with different AmB species through hydrophobic 
interactions between the cholane moiety and the heptaene side of the drug molecule to 
form different supramolecular structures. These results are in agreement with studies 
reported in the literature, which showed that the aggregation state of AmB depends on 
the sterol content physically incorporated in DSPE-PEG micelles. However, in all cases, 
the AmB/PEG5kDa-cholane interaction is enthalpically favored, regardless the binding 
site and the pH, indicating that the cholane interaction with AmB is thermodynamically 
favored as expected by the interaction of hydrophobic moieties in aqueous solution. 
The first and second bindings are also strongly entropically contributed suggesting that 
in these steps the polymer interaction with the drug provokes the disruption of ordered 
structures, namely AmB nanoaggregates, dimers and tetramers or by displacement of 
water molecules coordinated with the polymer and the drug. We hypothesize that these 
interactions occur by insertion of the cholanic moiety in between the heptaenic sides of 
coupled molecules in multimeric forms, dimers and tetramers. 
The affinity constant for the third binding site (K3) was remarkably lower than that 
calculated for the other sites. Despite the strongest enthalpic contribution, the entropic 
contribution to this interaction was lower than the first two interactions, especially at 
high and low pHs. At pH 11.0, the ΔS was negative indicating that this interaction can 
occur with the formation of ordered structures. This seems to be in agreement with the 
RDX spectra, which showed that the AmB incorporation into the polymer micelles 
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occurs with the destruction of the typical crystalline form of AmB while novel ordered 
structures are formed. 
Importantly, the AmB/PEG5kDa-cholane formulation was found to be pharmaceutically 
stable. The lyophilization process produced a fluffy powder with low moisture content 
without cake formation. The lyophilized product was stable throughout the time as 
AmB/PEG5kDa-cholane solutions could be perfectly reconstituted by physiological 
buffer addition in few seconds, even without shaking, to yield a colloidal dispersion 
with the same physicochemical features of the freshly prepared formulation. It is worth 
to note that the reconstituted formulation was physically and chemically stable over 1 
month at room temperature.  
The spectrometric and thermal analyses performed on lyophilized AmB/PEG5kDa-
cholane provided information about the physical structure of the dried formulation. The 
Fourier transform infrared (FTIR) analysis showed new signals for the AmB/PEG5kDa-
cholane micelle formulations, while the AmB/PEG5kDa-cholane physical mixture 
showed all the signals corresponding to the drug and the polymer. Similarly, the 
differential scanning calorimetry and X-ray diffraction (XRD) analyses evidenced the 
intimate AmB/PEG5kDa-cholane interaction with the disappearance of the typical 
thermal and diffraction signals of crystalline AmB and PEG5kDa-cholane. On the 
contrary, the AmB/PEG5kDa-cholane physical mixture showed all signals of drug and 
polymer. However, it should be noted that as reported above the XRD spectrum of the 
lyophilized AmB/PEG5kDa-cholane micelles showed new signals suggesting that novel 
non-amorphous species are formed. 
The CD studies showed that, similarly to Fungizone® and heated Fungizone®, 
AmB/PEG5kDa-cholane micelles did not induce structural alterations of human serum 
albumin (HSA). This indicates that the formulation shouldn’t have detrimental effect on 
native proteins after administration. In the presence of HSA, the AmB nanoaggregates 
in the PEG5kDa-cholane micelles are more stable and less rapidly disaggregated than in 
non-heated Fungizone®, which can result in lower toxicity. The AmB displacement 
from the PEG5kDa-cholane micelles is higher than from heated Fungizone®. Actually, 
heated Fungizone® was reported to contain higher amount of aggregated AmB 
compared to normal Fungizone®, which results in a more stable and less toxic product 
[383,384,385]. Nevertheless, the therapeutic effect of heated Fungizone® is less 
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reproducible than non-heated Fungizone® [386]. Therefore, the aggregation results 
seem to indicate that PEG5kDa-cholane formulation can yield a product with higher AmB 
stability and lower toxicity compared to Fungizone® and enhanced reproducibility 
compared to heated Fungizone®. 
The dialysis results showed a biphasic pattern where 70% of the drug was release in 10 
h and 90% in 96h. Both steps of release were controlled by diffusion (the best fittings 
were obtained with the Higuchi and Korsmeyer-Peppas model) but the rate and the K 
constant showed that the structural conditions were different for each step of release.  
The AmB stability in gastric mimicking fluid demonstrated that after 1.5 h at pH 1.2 in 
the presence of pepsin there is still a 51.7% AmB available to be absorbed. This study 
was performed in order to demonstrate that the oral administration of AmB/PEG5kDa-
cholane could lead to systemic adsorption of AmB. Even though the absorption values 
are not expected to be high, the oral administration of AmB would avoid the problems 
related to the parenteral treatment compliance and parenteral treatment cost.  
The use of naproxen as internal standard in the treatment of blood samples was 
discarded. Although naproxen is detected at 406 nm and eluted near the AmB but well-
resolved from it, there was non linearity between its concentration and its absorbance at 
406 nm. Therefore, the recovery studies in plasma were performed. 
The AmB recovery studies in plasma showed similar values for all the formulations 
studied (AmB in DMSO, AmB in dextrose, Fungizone®, Ambisome® and  
AmB/PEG5kDa-cholane). The percentage of AmB recovered was 79% regardless the 
formulation. When manipulating the blood samples containing the AmB for obtaining 
the plasma there was a 20% AmB loss. This loss can be explain by the high binding 
affinity of AmB to proteins. The protocols for blood sample preparations include 
several steps (centrifugation and precipitation) where the AmB can be lost. If during 
sample preparation the AmB joins the proteins contained in the blood, the solvents add 
to precipitate those proteins could led to AmB loss. This 79% recovery value is in 
agreement with previously reported values (74% recovery) [387]. 
The hemolysis studies confirmed that the AmB/PEG5kDa-cholane micelles were less 
hemolytic than Fungizone®. Even at concentrations in which the Fungizone® caused 
100% hemolysis, the new formulation produced not more than 30% hemolysis. These 
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results are in fair agreement with the toxicity studies performed with PEG5kDa-cholane  
by Salmaso et al. [335]. The lower hemolytic effect of AMB/PEG5kDa-cholane 
compared to Fungizone® is explained by the solubilizer agent. The sodium 
deoxycholate found in Fungizone® produces hemolytic effects itself [134,148, 152 
259]. Moreover, its CMC value (10-3) makes the micelles susceptible to in vivo dilution 
processes when being intravenously administered. Dilution with plasma, which may 
happen in a time-scale of µsec, lead to the disappearance of the deoxycholate micelles, 
the continuous loss of deoxycholate from the AmB-deoxycholate aggregates and 
consequently, the rapid release and reaggregation of the AmB [148,253]. These AmB 
aggregates are not selective against fungal cells damaging either fungal or mammalian 
cells and being therefore, responsible for the higher hemolytic effect of Fungizone®. 
The biological in vitro studies showed that the AmB formulated with PEG5kDa-cholane 
maintains high antimicrobial activity, which is very close to AmB in solution. This 
confirms that the drug is released from the micelles to interact with the cell membrane. 
The slightly lower activity of AmB/PEG5kDa-cholane compared to the standard may be 
ascribed to the drug release process from the micelles while the drug in solution is 
immediately available. Similarly, the higher activity of the micelle formulation 
compared to the AmB suspension may be attributed to the fastest drug release from the 
former than the dissolution from the solid dispersion. Moreover, considering that the 
mechanism for AmB activity seems to be related to the formation of multimeric drug 
associations, it could possible that the drug released from the micelles is partially in the 
conformation for the interaction with the target. Furthermore, AmB in solution is 
obtained with DMSO, a solvent and absorption enhancer that also has irritant effects. 
The new formulation of AmB presented in this work shows a similar antimicrobial 
activity without DMSO suggesting interesting practical applications. 
The oral administration of 5 mg/kg AmB demonstrated that the new formulation 
developed had the highest half-life of all assayed formulations. While the AUC0-24 
values were similar for all tested formulations the oral absolute bioavailability (F) was 
dependent on the formulation and varied in between 7-19%.  
Finally, The IV administration of 1 mg/kg AmB in Ambisome®, Fungizone® and 
AmB/PEG5kDa-cholane showed that the new formulation developed had a significantly 
(P<0.01) lower apparent elimination constant and consequently, a higher half-life 
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compared to the marketed formulations Ambisome® and Fungizone®. This higher "t1/2" 
value is in agreement with the fact that the PEGylated polymers used as carriers, 
prolong the drug circulation time in blood. The PEGylation decreases the uptake, and 
therefore the accumulation in RES organs, liver and spleen. This is due to the steric 
stability impart by the PEG chains which minimize protein adsorption to hydrophibic 
surfaces, avoiding renal clearance [288,310,317,331,335,388-390], The PEG-cholane 
acts as a nanoscopic carrier capable of releasing the AmB slower over the time, which is 
supported by the higher C24 value obtained for AmB/PEG5kDa-cholane compared to 
Fungizone® and Ambisome®. The higher AmB concentration found in blood after 24 h 
is due to the longer time-dependent relaxation effects of PEG-cholane compared to 
other low molecular weight surfactants as sodium deoxycholate (Fungizone®) [329].  
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4. APPENDIX  
4.1. COMPLEMENTARY INFORMATION 
 
Note 
Appendix 1 includes complementary information on the amphotericin B nail lacquer 
developed for the treatment of onychomycosis.  
Section AP1.1 contains a general introduction of the onychomysis. The etiology, 
indicence, prevalence, predisposition factors, pathophysiology, clinical types of 
onychomycosis, the nail permeability as well as the possible treatments are discussed in 
this section.  
Section AP1.2 includes the detailed description of the excipients studied during 
formulation development.  
Section AP1.3 comprises the composition of the formulations developed 
Ansd finally, Section AP1.4 details the troubleshooting found during formulation 
preparation.  
 
 
 
 
 
 
 
 
 
Complementary information 
 
254 
AP1.1. ONYCHOMYCOSIS INTRODUCTION 
AP1.1.1. General Considerations 
 
Onychomycosis, also known as tinea ungium, is an infection of the fingernails or 
toenails caused by dermatophytes, yeasts or non-dermatophyte molds. It is responsible 
for approximately 50% of consultations for nail disorders [391-393] and represents 
about 30% of diagnosed superficial fungal infections [394].  Even though the 
onychomycosis can affect both finger and toenails, the later are more commonly 
affected [391,395] (the onychomycosis in the toenails are 4-25 times more widespread 
than the infections located in the fingernails [396] . The infections may involve other 
components of the nail including the matrix, the nail bed or the nail plate [396]. 
Onychomycosis is the most common nail disorder and it is reported to be age and 
gender-related. The prevalence of onychomycosis is higher in men, in the younger age, 
but this prevalence increases with age in both genders [391,392,395-399]  
AP1.1.2. Etiology 
 
The etiology of the onychomycosis varies depending on the zone affected (toe or 
fingernails) [395]. In most cases, the pathogens responsible for the toenail infections are 
dermatophytes. Between all the dermatophytes, Trichophyton rubrum is the most 
common cause of onychomycosis worldwide (causing 60% of the dermatophyte 
onychomycosis) followed by Trichophyton mentagrophytes (that causes 20% of the 
infections) and Epidermophyton floccosum (responsible for the 10%) 
[391,392,398,399]. Apart from the dermatophytes, the non-dermatophyte molds such as 
Aspergillus sp. and Scopulariopsis brevicaulis, can be also involved in the nails 
infections as main responsible (primary pathogens) or as secondary pathogens 
(contaminant agents) [391,400,401]. Other molds that have been isolated from the 
infected nails, although are not commonly found in the affected areas, are Fusarium 
spp., Acremonium spp., Alternaria spp. and Neoscytalidium sp [391, 402]. An estimated 
2-15% of the nails infections are due to non-dermatophyte molds [391,403-405]. Yeast, 
such as Candida albicans and Candida parapsilosis, glabrata, C. guillermondii, C. 
krusei, and C. tropicalis represent the third cause of fungal toenail infection [406]. 
Infections caused by Candida spp. occur almost only when predisposing factors are 
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present (diabetes or immunosuppression), as Candida is just able to penetrate the toenail 
if there is an altered immune response [394]. 
Conversely, the onycohomycosis located in the fingernails are mainly caused by yeasts 
belonging to the genus Candida (C. albicans, parapsilosis and tropicalis) [395, 407]. 
These being responsible for the 60% of the infections located at this level [408,409, 
410]. Nevertheless, the fingernail infections can also be produced by dermatophytes 
(Trichophyton rubrum and mentagrophytes) and non-dermatophytes molds 
(Scopulariopsis brevicaulis and Mucor spp). 
AP1.1.3. Incidence 
 
The incidence of the onychomycosis has increased during the last years owing to factors 
such as ageing of the population, increased number of immunocompromised patients 
and increase in sports participation [391,394,395,397,399]. Firstly, as the population 
ages, there is a parallel increase in chronic health problems (diabetes) and poor 
peripheral circulation. Secondly, the number of persons that are immunocompromissed 
due to infections with HIV and the use of immunosuppressive therapy, cancer 
chemotherapy or antibiotics, continue to expand. Finally, the rise in sport participations 
has increased the use of health clubs, commercial swimming pools and occlusive foot 
wears for exercise [400]. Just in a small percentage of people, onychomycosis may be 
caused by a genetic defect that causes an alteration in the immune function. 
AP1.1.4. Prevalence 
 
Not only the incidence of onychomycosis has increased in the last decade but also the 
prevalence of the infections has changed. Even though, Trichophyton rubrum is known 
to be the main ethological agent responsible for the onychomycosis, the nail infections 
caused by yeasts, and in particular by Candida spp, are actually in increase [410]. 
Candida genus is not only responsible for approximately 51-70% of the fingernails 
infections, but also for many of the toenails onychomychosis. Moreover, the incidence 
of concomitant infections caused by dermatophytes or non-dermatophytes and Candida 
spp (figure 84) [411], or by different species of Candida at the same time, has raised 
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during the last years. These concomitant infections are an important healthy issue as 
most of the commercialized treatments are not effective against mixed infections. 
 
Figure 84. Mixed cultures of different infections caused by dermatophytes/non-dermatophytes and 
Candida spp. Culture of infected nails by T. mentagrophytes and Candida spp. (left), and by T. rubrum, 
Scopulariopsis and yeasts (right). Image taken from [411]. 
AP1.1.5. Predisposing factors 
 
Onychomycosis predisposing factors can be classified into personal or environmental 
factors. The first group includes nail trauma, male gender (men are 1.7 to 3 times more 
likely to have a fungal nail infections compared to women); age (the prevalence of 
onychomycosis in patients younger than 19 years of age is 0.7%, in patients ranging 20-
39 years of age is 3.1%, in patients ranging 40-59 years of age is 9.5% and in patients 
above 60 years is 18.32%) [412]; genetic predisposition; hyperhydrosis, peripherical 
vascular diseases (lower extremity venous disease); microcirculatory disorders; 
Raynaud's phenomenon; collagen diseases; diabetes; HIV; finger deformities; 
dystrophic nails; chronic skin diseases such as psoriasis, ichthyosis and atopic 
dermatitis; cancer; monocutaneous candidiasis; long-term use of antibiotics and 
immunosuppressors; poor hygiene and tinea pedis [391,392,394-396,413]. Regarding 
the second group, the environmental factors, the most important risk factors are tropical 
or subtropical climate; occlusion and excessive sweating on the hands or feet; repeated 
trauma; detergents; abrasive liquids and food handling; wearing boots and closed shoes; 
contact with contaminated tools and equipment for cosmetic treatment of the hands and 
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finger/toenails (manicure and pedicure); smoking and contact with animals such as 
family pets [402]. The increasing exposure to the pathogens in public bathrooms and 
swimming pools, together with the habit of wearing other people's shoes, increases the 
risk of contracting onychomycosis. 
In order to understand the different clinical types of onychomycosis, a brief description 
of the pathophysiology of this infection is included below. 
AP1.1.6. Pathophysiology of onychomycosis 
 
As detailed in figure 85, the nail structural components include the proximal and lateral 
folds, cuticle, matrix, plate, bed and hyponichium [412]. 
The proximal fold refers to the skin folded over the part of the nail plate attached to the 
finger while the lateral fold, scientifically known as paronychium, is the soft tissue 
surrounding the border of the nail [414]. 
The cuticle is the semi-circular layer of non-living skin cells that cover the back of the 
visible nail plate. It consists of modified stratum corneum that is originated at the 
junction of the dorsal and ventral epithelial surfaces and proceeds along the nail surface 
[415]. The main function of the cuticle is to protect the matrix from infections caused 
by microorganisms [412]. 
The matrix, commonly known as the growth center of the nail, is located under the 
cuticle at the proximal end [415-417]. It contains nerves, lymph, blood vessels and basal 
cells that migrate into the nail plate, where they divide and differentiate, forming the 
hard, keratinized component of the nail plate. The length, size and thickness of the 
matrix determine the width and the thickness of the nail plate. The matrix would 
continue to grow as long as it would received nutrition. 
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Figure 85. Nail structural composition (taken from [412]). 
 
The nail plate is the largest structure of the nail unit and it is attached to the top of the 
nail bed [415]. It is a transparent structure that is gradually replaced as it grows. It is 
composed by several layers of dead, compacted cells that confers the nail strength and 
flexibility [418] This structure is completely renewed every 6 months on fingers and 
every 10-18 months on toes [412]. The growth speed is usually faster on the longer 
digits which are the ones usually involved in the trauma.  
The nail bed, located under the nail plate, consists of epidermal grooves and ridges that 
contain small blood vessels [419]. Due to its location, a bacterial infection in the nail 
bed increases the possibilities of developing osteomyelitis [275,412]. 
Finally, the hyponychium is the epithelium located beneath the nail plate at the junction 
between the free edge and the skin of the fingerprint fingerprint [412,420].  
 
AP1.1.7. Progression of fungal infection 
 
There are some studies suggesting that the skin is the main source of fungal organisms 
that infect the nail [421-423]. Initially the fungal microorganisms invade the part 
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located in between the nail plate and the nail bed through an opening in the subungual 
space of the hyponychium, close to the distal groove. The infection usually starts 
distally and then progresses proximally except in those cases in which there is a nail 
trauma. The trauma would allow for the direct entry of the microorganisms. 
Onychomycosis is usually considered as a superficial infection as the growth of fungal 
hyphae occur on the nail bed (below the nail plate) [412].  
The susceptibility to the onychomycosis as well as the progression of the disease, once 
the nails have been infected, depends on the interaction of several factors (fungal agent, 
host and environmental factors)  [424]. Even though the disease has a low overall 
prevalence, this is much higher in certain groups of population such as older people and 
immunocompromised patients. The onychomycosis, usually considered as a nuisance 
but not really important health problem, can cause morbidity in all population groups 
but mainly in high-risk patients (diabetics, HIV, patients with acquired 
immunodeficiency syndrome [AIDS] and patients with other types of 
immunosuppression [i.e. long-term corticosteroid therapy and transplant recipients]. 
The impact of the onychomycosis in these types of patients may be really significant. 
For example, in the case of the diabetic patients, if the infection is not treated and the 
natural course of this process continues, a cellulitic or osteomyelitic stage can take 
place. This can be followed by necrosis and finally, major lower-limb amputation. 
Figure 86 shows the natural course of the onychomycosis in non-treated high-risk 
patients. 
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Figure 86. Natural course of onychomycosis and potential sequelae in non-treated high-risk patients. 
 
AP1.1.8. Clinical types of onychomycosis 
 
There are different clinical types of onychomycosis depending on the area that is 
affected and on the modality of the nail invasion. The patients can be affected by one 
subtype of onychomycosis or a combination of various subtypes.  
The most commonly detected clinical types of onychomycosis are the distal lateral 
subungual onychomycosis (DLSO); the white superficial onychomycosis (WSO); the 
proximal subungual onychomycosis (PSO); the endonyx onychomycosis (EO); the total 
dystrophic onychomycosis (TDO) and the candidal onychomycosis (CO). 
Below there is a brief description of each of the subtypes. 
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 Distal lateral subungual onychomycosis (DLSO) 
The distal subungual onychomycosis is the most common variant of the infection (in  a 
case study performed by Kolonchenko et al in 2013, approximately the 89% of the 
patients included in the trial presented DLSO [425]. It is characterized by an invasion of 
the nail bed where fungi reach the nail through the hyponychium and invade the 
undersurface of the nail unit plate being spread proximally [400]. This invasion results 
in subungual hyperkeratosis (thickening of the nail plate) and onycholysis (separation of 
the nail plate from the nail bed) [407,423]. The nail plate appears yellow-white as a 
consequence of the onycholysis, the nail becomes cornified and the normal nail contour 
is lost [394]. Not so frequently, a brown, black or orange discoloration of the 
onycholytic nail can be detected. DLSO can be associated to black pigmentation of the 
nail when the pathogen responsible for the infection is the Melanoids variant of  
Trichophyton rubrum or other melanin-producer fungi such as Aspegillus niger or 
Neoscytalidium dimidiatum [391]. DLSO usually affects one or both of the great 
toenails and it is usually associated to tinea pedis. 
Even though DLSO is the most common presentation of dermatophyte nail infection 
[395], it can be also produced by non-dermatophytes [411]. DLSO is usually caused by 
the dermatophyte T. rubrum, although T. mentagrophytes, T. tonsurans and E. 
floccosum are also known to be causative [415]. The DLSO associated with non-
dermatophytes is usually characterized by a marked periungual inflammation [403].  
 White superficial onychomycosis (WSO) 
The white superficial onychomycosis is less common than the DLSO (10% estimated 
number of onychomycotic patients) [423]. It appears when fungi directly invade the 
superficial layers of the nail plate. Fungi invade the dorsal nail plate and form colonies 
that appear as white opaque formations easily scraped away [391]. These colonies, 
located on the surface of the nail, has the appearance of white patches ("white islands") 
with distinct edges [394,396].  
The classical WSO, non-invasive infection, is the most detected onychomycosis in 
children [395] and it  is caused by dermathophytes (Trichophyton interdigitale, T. 
mentagrophytes) which colonize the most superficial layers of the nail plate without 
penetrating the nail (the fungal microorganisms initially grow on the top of the nail 
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plate) [412]. On the contrary, the molds (Fusarium, Acremonium and Aspergillus spp) 
usually cause a WSO with a deeper nail invasion [399,400]. 
 Proximal subungual onychomycosis (PSO) 
In the proximal subungual onychomycosis the infections begins by the fungi invasion of 
the cuticle and the ventral portion of the proximal nail fold and spreads to the newly 
forming nail plate which results in subungual hyperkeratosis, proximal onycholysis and 
destruction of the proximal nail plate [394]. PSO caused by dermatophytes is very 
strange and it appears as a white area under the proximal nail plate, in the lunula area 
[426]. Although it is the less common presentation of dermatophyte onychomycosis in 
general population, it is common in persons with AIDS (it has been sometimes 
considered an useful marker of HIV infection [395,411, 412]. PSO is usually associated 
to non-dermatophyte mold infections caused by Aspergillus spp and Fusarium spp in 
which the nail plate presents discoloration that might be associated with acute 
periungual inflammation, and in some cases with purulent discharge [403]. 
 Endonyx onychomycosis (EO) 
The endoxyn onychomycosis could be considered as a variant of the DLSO in which the 
fungi nail plate invasion takes place directly via the skin (the fungus immediately 
penetrates the nail plate keratin) [395,425]. It is characterized by a massive nail plate 
invasion in the absence of nail bed involvement. Clinically, the nail plate show lamellar 
splitting, a milky-white discoloration [394] and, conversely to DLSO, there are no signs 
of subungual hyperkeratosis or onycholysis [391]. It is produced by microorganisms 
that usually produce endothrix scalp infections (e.g. T. soudanense or violaceum). 
 Candidal onychomycosis (CO) 
The candidal onychomycosis usually occurs in patients with chronic monocutaneous 
candidiasis [415]  and in the 70% of the cases it is caused by C. albicans [400]. Both 
toenails and fingernails can be involved. Candida sp invade directly the nail plate and 
produce C. paronychia, C. granuloma or C. onycholysis. In between all, Candida 
paronychia is the predominant variant and it is characterized by swelling and erythema 
of the proximal and lateral nail folds. This variant is also known as whitlow. Candida 
granuloma is really uncommon and is characterized by direct invasion and thickening 
of the nail plate with associated paranonychia. Finally, Candida onycholysis occurs 
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when the nail plate separates from the nail bed. The distal subungual hyperkeratosis can 
be appreciated as a yellowish-grey mass lifting of the nail plate [394]. 
 Total dystrophic onychomycosis (TDO) 
Finally, the total dystrophic onychomycosis is considered as the most severe stage of 
onychomycosis and it can be a result of long-standing DLSO or PSO. It consists of the 
total destruction of the nail plate  [395]. The nail plate is diffusely thickened, friable and 
yellowish. There are two main forms of TDO: secondary total dystrophic 
onychomycosis and primary total dystrophic onychomycosis [427]. The secondary TDO 
results from a complete progression of any of the previously mentioned destructive nail 
dystrophies, while the primary TDO occurs in those cases of chronic monocutaneous 
candidiasis where all tissues of the nail apparatus may be involved simultaneously, 
including the nail folds [428]. 
 
Once the clinical types of onychomycosis have been described and before considering 
the possible treatments, one should take into account which factors influence the drug 
transport through the nail plate and which techniques are currently available to enhance 
the drug penetration. 
 
AP1.1.9. Nail permeability 
 
AP1.1.9.1. Factors that influence the drug transport into and through the nail plate 
There are many factors that should be considered before designing a treatment helpful 
for the onychomycosis therapy. The molecular size of the drug, the hydrophilicity and 
lipophilicity, the nature of the vehicle as well as the pH of the vehicle and the solute 
charge, are the most relevant factors [429]. 
AP1.1.9.1.1. Molecular size of diffusing drug 
The molecular size of the drug is really important for the topical treatment of 
onychomycosis. There is an inverse relationship between the size of the drug and the 
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penetration into the nail plate. The larger the molecule size, the harder the molecule 
diffusion through the keratin [395,430,431]. 
AP1.1.9.1.2. Hydrophilicity/Lipophilicity of the diffusing molecule 
The use of nail lacquers containing alcohols, that allow to obtain systems that rapidly 
dry once applied to the nail, is well known. The increased lipophilicity of a diffusing 
alcohol molecule reduces the permeability coefficient until a certain point after which 
further increase in lipophilicity results in increased permeation. Nevertheless, except for 
methanol, the permeability coefficient of net alcohols (water-free) is approximately five 
times smaller than the permeability coefficient of diluted alcohols [432]. When an 
aqueous solution is used, the nails swell as water is taken up into the nail plates. As a 
consequence, the keratin network expands which leads to the formation of larger pores 
through which diffusing molecules can permeate more easily [416,429] 
AP1.1.9.1.3. Nature of the vehicle 
Water hydrates the nail plate which consequently swells. Considering the nail plate to 
be an hydrogel, swelling results in increased distance between the keratin fibers,  the 
formation of larger pores through which permeating molecules can diffuse and hence, 
increased permeation of the molecules. Replacing water with non-polar solvents, which 
do not hydrate the nail, is therefore expected to reduce drug permeation into the nail 
plate [416,429,432]. 
AP1.1.9.1.4. pH of the vehicle and solute charge 
It seems that the pH of the formulation has a distinct effect on the drug permeation 
through the nail plate. Uncharged species permeate to a greater extent compared to 
charged ones [416,432]. 
 
AP.1.1.9.2. Techniques for enhancing transungual drug delivery 
Nail is said to be composed by approximately 25 layers of tightly bound keratinized 
cells. It is approximately 100 folds thicker than subcutaneous and therefore, the trans-
nail penetration of drugs is really challenging. In order to overcome the nail barrier and 
to be able to transport the antifungal drugs above the minimal inhibitory concentration 
(MIC), different chemical, physical and mechanical methods have been used [429,433].  
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AP1.1.9.2.1. Chemical methods to enhance drug penetration 
From a chemically point of view, drug permeation into the nail plate, can be assisted by 
breaking the physical and chemical bounds responsible for the stability of nail keratin 
which would destabilize the keratin, compromise the integrity of the nail barrier and 
allow penetration of drug molecules. Some potential targets of the chemical enhancers 
are the disulphide, peptide, hydrogen and polar bonds in keratin. 
 Keratolytic enhancers or nail softening agents 
In 1998, the paper published by Quintanar-Guerrero et al., described the effect of some 
keratolytic agents (urea, salicylic acid and papain) on the permeability of three 
imidazole antifungal drugs (miconazole, ketoconazole and itraconazole). Both urea and 
salycilic acid were found not only to hydrate and soften the nail plate but also to 
damage the surface of the nail plates, resulting in fractured surfaces. The use of urea 
followed by an oxidizing agent (H2O2) dramatically improved the human nail 
penetration. All three, urea, papain and salicylic acid, act via disruption of the keratin 
disulphide bonds resulting in the formation of pores that provide "open" drug transport 
channels [434,435]. 
 Compounds containing sulfhydryl groups 
Compounds which contain sulfhydryl (-SH) groups such as acetylcysteine, cysteine or 
mercaptoethanol, can reduce and, therefore cleave the disulphide bonds in nail proteins. 
These chemicals have been found to produce structural alterations in nail plate by 
breaking the disulphide bounds which are responsible for nail integrity and therefore 
influence drug transport. However, post-treatment barrier integrity studies performed in 
the nails treated with these enhancers have demonstrated that the changes induced in the 
nail keratin matrix are irreversible. The disulphide broken bonds produce irreversible 
structural changes in the nail plate [436]. 
 Keratinolytic enzymes 
Due to the great abundance of keratin filaments, the use of keratinase for the hydrolysis 
of keratinic tissues such as the stratum corneum (SC), has been considered as an 
alternative for drug penetration enhancement. Mohorcic et al described for the first time 
the efficacy of keratinase administration over the nail plate. These authors designed 
permeation studies using modified Franz diffusion cells and metformin hydrochloride as 
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a model of drug, and they found that the keratinase markedly enhanced the drug 
penetration [433,437] 
 
AP1.1.9.2.2. Physical methods to enhance nail penetration 
The physical methods for drug penetration enhancement are usually preferred to the 
chemical methods in the delivery of hydrophilic and macromolecular drugs (these 
methods obtain a higher drug permeation). 
 Iontophoresis 
This method involves the delivery of a compound across a membrane using an electric 
field. Several are the factors that enhance the drug diffusion through the hydrated 
keratin of the nail: electrorepulsion/electrophoresis; interaction between the electric 
field and the charge of the ionic permeant; electroosmosis; convective solvent flow in 
preexisting and newly created charged pathways; and permeabilization/electroporation, 
electric field-induced pore induction. The type of transport varies depending on the 
charge of the molecule. If the transport of a neutral drug has to be enhanced, the 
permeation will rely on an electroosmotic process. On the contrary, if there is the need 
to enhance the permeation of a charged molecule, the transport will rely on 
electrophoresis and electroosmosis. In all cases, the iontophoresis has a reversible effect 
on the nails [438-440]. 
 Etching 
The "etching" basically consists on the formation of profuse microporosities. These 
microporosities are known to increase the wettability and the surface area and to 
decrease the contact angle. As stated by Repka et al. the presence of microporosities 
improves the interpenetration and bonding of a polymeric delivery system and 
facilitates the interdiffusion of a therapeutic agent [441]. Once the nail plate surface has 
been "etched", a sustained release, hydrophilic, polymer film drug delivery system can 
be applied. This "etching" or roughness of the nail plate results in increased surface area 
which improves the polymer chains inter-diffusion, increasing the bioadhesion and the 
retention of the delivery system. 
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 Carbon dioxide laser 
The use of carbon dioxide as a penetration enhancer can produce positive but 
unpredictable results. This method enhances the nail plate penetration and therefore the 
laser nail radiation has to be followed by daily topical antifungal treatment [442]. 
 Hydration and occlusion 
The hydration of the nail plate results in an increase of the pore size of the nail matrix 
and consequently in enhanced drug permeation [431] Hydrated nails are well known to 
be more elastic and permeable. Sometimes, due to the onychomycosis, there is a 
decrease in transonychial water loss, ceramide concentration and water binding 
capacity. In these cases, and in order to enhance the drug transport, the occlusion could 
be an option. The reconstitution of water and lipid homeostatisis in distrophic nails 
would allow for a higher drug permeation  [416,429,432,443].    
 
AP1.1.9.2.3. Mechanical methods to enhance drug penetration 
The mechanical methods include nail abrasion and nail avulsion. Even though these 
methods have been widely used by dermatologists and podiatrists over the last decades, 
they are considered invasive and potentially painful [432]. The reason why we have 
reserved these enhanced penetration methods for the end relies on the fact that they 
should only be used if none of the previously described chemical or physical penetration 
methods work. 
 Nail abrasion 
The nail abrasion implies the sanding of the nail plate in order to reduce its thickness or 
to completely destroy it. Sanding, using sandpaper number 150 or 180, must be done on 
the edges of the nail in order not to cause discomfort. Nail abrasion thins the nail plate 
which decreases the fungal mass onychomycosis and exposes the nail bed, enhancing 
consequently the action of the drug. 
 Nail avulsion 
Nail avulsion, total or partial, involve surgical removal of the entire or partially affected 
nail plate. The avulsion has to be done under local anesthesia. A chemical/non-surgical 
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nail avulsion can be also performed using urea or a combination of urea and salicylic 
acid at high concentrations. 
Onychomycosis is an infectious disorder that deserves prompt and appropriate care. As 
onychomycosis management remains a clinical challenge from the medical point of 
view, the treatment plan has to be carefully chosen in order to provide the best potential 
for cure [444]. Before initiating the onychomycosis therapy several factors might be 
taken into account; the pathogen agent responsible for the infection, its susceptibility to 
the antifungal drugs, the patient co-morbidities,  the possible interaction with other 
drugs or diet, the side effects derivate from the  antifungal administration, the patient's 
age and the cost of the therapy. An evaluation of the extension and the severity  of the 
disease would be also helpful [399]. 
AP1.1.10. Treatment 
 
Onychomycosis treatments are mainly classified into: pharmacological treatments, 
which include topical and systemic antifungal therapies; and non-pharmacological 
treatments, which include laser and photodynamic therapy, chemical or surgical 
abrasion and mechanical debridement. 
AP1.1.10.1. Pharmacological therapies 
 
As stated above, the pharmacological treatment encompasses the topical and oral 
antifungal therapies (figure 87). As the topical administration is usually considered as 
first line treatment, it would be the first described. 
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Figure 87. Pharmacological treatments of onychomycosis 
 
AP1.1.10.1.1. Topical treatment 
The topical therapy aims to apply the drug directly into the nail. The administration of 
different antifungal drugs included in a matrix (usually a nail lacquer) into the nail plate 
are the bases of this treatment. 
Penetration of topical antifungals through the nail plate requires a vehicle that is 
specifically formulated for transungual delivery. The poor nail unit penetration limits 
the use of topical antifungal agents and therefore, relapses and re-infections are 
common, occurring in at least 20-25% of the patients. 
The topical antifungal therapy is basically focused on the application of nail lacquers. 
The nail lacquers are effective, when used in monotherapy, in the treatment of WSO and 
DLSO limited to the distal nail. These lacquers should only be used in those cases in 
which the infection involves less than half of the distal nail plate or in patients unable to 
tolerate systemic treatment. 
The possible topical treatments include: 
 Amorolfine 
The amorolfine, a morpholine-derived antifungal drug (figure 88) with a broad spectra 
of action acts blocking the delta 14 reduction and delta 7-8 isomerization, resulting in 
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the depletion of ergosterol and the accumulation of ignosterol in the fungal 
cytoplasmatic membrane. The cell wall becomes thicker and chitin deposits are formed 
inside and outside  the fungal cell wall. The amorolfine has fungistatic and fungicidal 
properties against dermatophytes, non-dermatohytes molds and yeasts.  Amorolfine 5% 
(w/vol) nail lacquer is recommended for onychomycosis without matrix involvement 
and mild cases of distal and lateral subungual onychomycosis that affect up to two nails 
[396,398,399,433,445,446]. 
 
Figure 88. Chemical structure of amorolfine 
 
Amorolfine 5% in non-water soluble nail lacquer is applied once a week. The film, a 
water-insoluble film-forming polymer, seals the drug, which remains in the nail until 
next application. The treatment with amorolfine lasts until the nail has grown, 
approximately 9-12 months in toenails and 6 months in fingernails.  
 Ciclopirox  
Ciclopirox is a drug that structurally belongs to the hydroxypyridine family (figure 89). 
Its mechanisms of action is related to the inhibition of metal-dependent enzymes by 
chelating of polyvalent cations (Fe3+, Al3+) which affects the intracellular energy 
production and produce toxic peroxide degradation. It also acts inhibiting the fungal 
nutrient uptake, resulting in a decrease in nucleotides and a reduction in protein 
synthesis. Ciclopirox has fungicidal, anti-inflammatory and anti-allergic activity. 
Novel formulations for Amphotericin B delivery 
 
271 
 
Figure 89. Chemical structure of ciclopirox 
 
Ciclopirox olamine 8% (w/vol) in non-water and water soluble nail lacquer solutions 
should be applied daily covering the total nail plate surface and 5 mm of the 
surrounding skin. The treatment usually lasts 12 months [395,398,433,445-448]. 
 Tioconazole 
Tioconazole is one of the antifungal derived imidazoles agents (figure 90) first 
developed by Pfizer. It is effective against dermatophytes and yeasts (T. rubrum and 
Candida albicans). It is marketed as Trosyl® nail solution which contains 28% w/w 
tioconazole in a solution of ethylacetate and undecylenic acid [449]. Nowadays, the use 
of tioconazole 28% is limited, as the amorolfine and ciclopirox has demonstrate better 
treatment success and avoidance of the allergic contact dermatitis derived from its 
application [395,396]. 
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Figure 90. Chemical structure of tioconazole 
 
 Efinaconazole 
Efinaconazole was the first topical triazole (figure 91) developed specifically for the 
treatment of onychomycosis and approved by the FDA. It was approved in June 2014 
for the topical treatment of dermatophyte-induced toenail onychomycosis. Its 
mechanism of action is based on the inhibition of lanosterol 14α-demethylase, an 
enzyme involved in the ergosterol biosynthesis. It is believed that the accumulation of 
14α-methyl sterols and the consequent lost of ergosterol (which affects membrane 
function and integrity and therefore inhibits grow leading to cell death) might be 
responsible for the fungicidal and fungistatic activity seen in this molecule. The 
efinaconazole has demonstrated to be more effective than itraconazole against T. 
mentagrophytes and than clotrimazole against C. albicans [395,450-452].   
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Figure 91. Chemical structure of efinaconazole 
 
This new triazole, in a 10% (w/vol) topical solution applied once daily, was developed 
for the treatment of mild to moderate DLSO and it has shown to be effective avoiding 
nail debridement. 
 Tavaborole  
Tavaborole is the first member of a new class of pharmaceutical antifungal agents with 
a novel chemical structure (boron-liked) (figure 92) and mechanism of action [453]. It is 
an oxaborole compound that has been designed to be a lightweight, highly water soluble 
compound that maintains a broad-spectrum antifungal activity in the presence of 
keratin. It has been shown to retain its pharmacological antifungal activity in the 
presence of keratin which suggests that it would be effective after permeating the nail 
plate. Compared to other antifungals, tavaborole mechanism of action is completely 
different. It acts on aminoacyl-transfer RNA (tRNA) synthetases by specially binding to 
the editing site of the tRNA. This binding prevents the synthesis of leucine-charged 
tRNAs and consequently, the fungal activity is suppressed [453]. 
. 
 
 
Complementary information 
 
274 
 
 
Figure 92. Chemical structure of tavaborole 
This compound has demonstrated a great ability to penetrate the nail (its low molecular 
weight allows for a high amount of penetration through full-thickness human nail 
plates) which avoids the aggressive debridement required with other lacquers. Due to its 
broad spectrum antifungal activity against dermatophytes, molds and yeasts it is 
indicated in the topical treatment of toenail onychomycosis. In July 2014, it has been 
approved as a 5% topical solution by the FDA [454]. 
 Antifungal drugs under clinical trial 
Other possible topical treatments include the terbinafine (figure 93) nail solution and 
spray (TDT 067) and other two terbinafine formulations (MOB-015 and TMI-358) 
which are under clinical trials. The topical application of luliconazole 10%, an 
imidazole molecule (figure 94) with fungicide and fungistatic activity, has already 
completed phase 1 and phase 2a for the treatment of moderate to severe distal subungual 
onychomycosis with excellent tolerability and safety profile [391,392,455]. 
 
 
Figure 93. Chemical structure of terbinafine 
Novel formulations for Amphotericin B delivery 
 
275 
 
 
Figure 94. Chemical structure of luliconazole 
 
The topical treatment of onychomycosis requires several months (from 6 to 12 months), 
as the nail growth is very slow. Even though the treatment lasts long, in most of the 
cases, and more in the elderly, the topical treatment is the first line treatment for patients 
presenting DLSO due to dermatophytes involving one or two of the great toe nails. In 
these particular cases, the topical antifungal administration is recommended to be 
associated, whenever possible, with periodic removal of the affected nail plate.  
The indications for topical treatment of onychomycosis were summarized by Iorrizo et 
al [446] as follows: 
 Distal subungual onychomycosis affecting <50% of the nail without matrix area 
involvement, without the presence of yellow streaks along the lateral margin of 
the nail and without yellow onycholytic areas in the central portion of the nail 
(dermatophytoma) 
 "Classical" white superficial onychomycosis (WSO) (excluding cases of deep 
WSO) 
 Onychomycosis due to molds (except for those caused by Aspergillus sp.). This 
onychomycosis usually do not respond to systemic antifungal administration. 
 Patients unwilling or unable to tolerate oral therapy. 
 Patients requiring maintenance therapy after the course of an oral therapy. The 
topical treatment administration after a systemic therapy is sometimes also 
considered as an alternative useful for avoiding recurrence in patients cured by 
these oral therapies [398]. 
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Even though the topical treatment of onychomycosis is widely spread, there are some 
infections in which a systemic administration is highly recommended. The DLSO 
extending to the proximal nail, the PSO due to dermatophyte and the deeply infiltrating 
WSO are some of the onychomycosis that require a drug systemic administration.  
 
AP1.1.10.1.2. Systemic treatment 
The systemic therapy of onychomycosis consists on the oral administration of 
antifungal drugs during several months. Usually, the drug is administered until cure is 
achieve or side effects and/or resistant appear. The drugs commonly included in the 
systemic therapy belong to the family of the azoles and alkylamines and they can be 
administered continuously or in pulse manner [399]. 
The drugs usually administered in the systemic therapy include the terbinafine, 
itraconazole and fluconazole. It has been demonstrated that the systemic administration 
of these drugs has a good safety profile and produce 90% of mycological cure in the 
fingernails infections and 80% in the toenails infections [391]. 
 
 Terbinafine 
The terbinafine is an alkylamine drug first synthesized in 1979 (figure 95), that acts 
blocking the biosythesis of ergosterol and therefore, damaging the fungal cell wall 
integrity. It is a strong lipophilic molecule that has demonstrated to be well distributed 
in the skin, fat and nails. This fungicidal drug penetrates the nail through the nail matrix 
and the nail bed. Terbinafine is generally well tolerated and has fewer interactions with 
other drugs than azoles [395]. 
The terbinafine can be administered at a dose of 250 mg/day in a continuous treatment 
of 12 weeks or as pulse therapy in which the first 4 weeks the patient would receive 500 
mg/day and then the following 4 weeks the patient would not receive any treatment 
[393]. 
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 Itraconazole 
Itraconazole is an azole compound (figure 97) developed in the late 1980s that is 
effective against dermatophytes, yeasts and other fungal infections. It acts differently to 
terbinafine. In this case, the drug inhibits the fungal cell CYP450 enzyme, 14-α-
demethylase which is responsible for the transformation of lanosterol to ergosterol, 
affecting the synthesis of the fungal cells wall. It is a highly lipophilic drug that is well 
absorbed in the presence of food and acidic pH.  
 
Figure 95. Chemical structure of itraconazole. 
 
It is usually administered at a dose of 200 mg/daily for 6 weeks in the fingernails and 
for 12 weeks in the treatment of the toenails onychomycosis. It can also be administered 
in pulse therapy at 400 mg/day (200 mg twice a day) during one week per month.  A 
total of two pulses (2 months treatment) and three pulses (three months treatment) are 
necessary for the fingernails and toenails treatment, respectively 
[395,398,403,415,444,456]. 
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 Fluconazole 
Fluconazole is a hydrophilic and keratoniphilic bistriazole (figure 96) that acts similarly 
to itraconazole, affecting also the synthesis of ergosterol. Nevertheless, in this case, the 
flucanozole has almost no effect on human sterol byosynthesis and its absorption is not 
related to food uptake or pH. It has demonstrated to be effective against dermatophyte 
and many Candida spp but its administration is limited due to the important interactions 
with other drugs (it acts at the level of the CYP450) [395,444,457]. 
 
 
Figure 96. Chemical structure of fluconazole. 
It is used in the treatment of dermatophyte onychomycosis at a dose of 150-300 
mg/week during at least 6 months. 
The continuous terbinafine and the pulse itraconazole therapies have demonstrated to be 
effective in the treatment of toenails onychomycosis in patients with diabetes. 
Treatment with fluconazole is less effective than the treatments with terbinafine and 
itraconazole and therefore, these two are preferred in the systemic administration. 
Apart from the drugs already described, the voriconazole, posaconazole, ravuconazole 
and albaconazole are new drugs with similar efficacy to terbinafine. Some of these 
azoles are still on clinical trials but there is a lot of interest focused on them as new 
possible onychomycosis systemic therapies. 
Novel formulations for Amphotericin B delivery 
 
279 
 Voriconazole 
Voriconazole is a molecule which structure is really similar to that of fluconazole 
(figure 97). It was approved by the FDA in 2002 and it can be found as suspension for 
oral administration (40 mg/mL), as tablets (200 mg) or as intravenous infusion (50 mg). 
It has been reported to be effective against Scopulariopsis brevicaulis, Fusarium spp. 
and Scytalidium dimidiatium. It might be useful in resistant cases of onychomycosis but 
it has not been yet studied in clinical trials of nail fungal infections infections 
[395,396,399,446,458,459]. 
 
Figure 97. Chemical structure of voriconazole 
 
 
 Posaconazole 
As well as the other azoles compounds, posaconazole (figure 98), inhibits the CYP450 
14-α-demethylase but its enzyme's inhibition is stronger than that produced by 
itraconazole, especially in the infections caused by Aspergillus spp. It is available as an 
oral suspension (40 mg/mL) and not only its spectrum of action is broader than that of 
fluconazole but also it is more active than the latest. It is effective against Zygomycetes, 
Candida spp and molds. A comparative blinded clinical trial carried out with 
posaconazole and terbinafine showed that the number of patients receiving 
posaconazole at  200 mg/24weeks and 400 mg/24 weeks with complete cure and 
treatment success was higher than for terbinafine 250 mg/12 
(393,395,396,399,403,446,460). Even though the success was greater, the cost of the 
Complementary information 
 
280 
treatment and the dose might be considered before this drug would be approved for the 
treatment of onychomycosis. 
 
Figure 98. Chemical structure of posaconazole 
 
 Ravuconazole 
Ravuconazole, which is structurally similar to fluconazole and voriconazole (figure 
101), acts also inhibiting the 14-α-demethylase. Its potency is similar to that of 
itraconazole and it is active against Candida spp, Cryptococcus neoformans, .A 
fumigatus, dermatophytes and dematiaceous fungi. Its spectra of action as well as its 
success in the treatment of onychomycosis is still under study [395,399,461]. 
 
Figure 99. Chemical structure of ravuconazole 
Several new azoles such as isavuconazole (figure 100) (which has similar activity to 
terbinafine), pramiconazole (figure 101) (which has shown to have a long half-life and 
its posology could be possibly once/daily) and albaconazole (figure 102) (new azole 
with broad spectra of action and excellent oral bioavailability) are being studied as 
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possible alternatives to flucanozole and itraconazole when there is a resistance to 
Candida spp and in the infections caused by non-dermatophytes molds.  
 
Figure 100. Chemical structure of isavuconazole. 
 
 
Figure 101. Chemical structure of pramiconazole. 
 
 
Figure 102. Chemical structure of albaconazole. 
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Before systemically administering an antifungal, the diagnosis should be clear as the 
non-dermatophyte molds are usually not susceptible to systemic therapies and therefore, 
the best treatment would imply the topical therapy combined with the periodical 
removal of the nail plate affected area. In the case of onychomycosis caused by Candida 
spp it should be taken into account that these infections usually appears in diabetic 
patients and in immunodepressed patients and that some systemic drugs, as terbinafine, 
are not active against yeasts.  
The systemic therapy is in general successful but there are still some treatment failures. 
These can be related to the clinical characteristics of the onychomycosis (the drug is 
unable to reach the affected area in active concentration in the total onychomycosis, in 
the very thick subungual onychomycosis and in the dermatophytoma), to the etiological 
agents involved (some non-dermatophyte such as Neoscytalidium, Scopulariopsis and 
Fusarium sp. do not respond to systemic antifungals) and to the patients concomitant 
infections or immunodepressions (other drugs that these patients might take would 
reduce the antifungal blood levels and therefore the drug wouldn't be any more 
effective). 
In order to reduce the number of treatment failures, combined therapies of systemic and 
topical antifungals are usually administered (even though there are almost no studies 
showing the greater efficacy of this combined therapy).  
Despite all the efforts and the combined therapies, the onychomycosis recurrence and 
reinfections are really common. Up to 20% of the cured patients are estimated to have 
recurrence infections. 
AP1.1.10.2. Non-pharmacological treatment 
 
The non-pharmacological treatment approaches include the laser treatment, the 
photodynamic therapy, the chemical or surgical nail avulsion and the mechanical 
debridement. The use of these treatments is usually limited and reserved to those cases 
in which the pharmacological therapies are not effective or to those situations in which 
the combination of pharmacological and non-pharmacological treatments has shown to 
be more effective than the use of those therapies separately.  
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AP1.1.10.2.1. Laser treatment 
The laser therapy can be used as a primary treatment for the onychomycosis due to its 
ablative properties or as a adjunct to topical treatments providing a higher drug 
penetration through the nail plate to the nail bed where the fungal growth is located 
[397]. The laser therapy involves the use of carbon dioxide laser, the Nd:YAG laser 
[398] and the diode 870 nm, 930 nm laser. All these lasers have been approved by the 
FDA due to their low-invasive nature [425] and the reduce number of sessions 
requested (the dual wavelength laser 870/930 nm has demonstrated a 100% eradication 
of bacteria, fungi and yeast [395,462]. The laser therapy is considered as a safe and 
cost-effective treatment modality in which the side effects of the drugs are avoided. The 
inhibitory effects of laser on fungal growth have been widely studied [463]. 
AP1.1.10.2.2. Photodynamic therapy (PDT) 
Photodynamic therapy (PDT) is the most studied light therapy for onychomycosis. It 
involves the use of a photosensitizer and a light source [432]. When using PDT for 
onychomycosis, the pathogen absorbs the photosensitizing agent, making it more 
susceptible for destruction [397]. The use of both, the photosensitizer and the light 
source, generate reactive oxygen species that lead to chemical destruction of nail fungi. 
The photosensitizers that are more commonly used are the 5-aminolevulanic acid 
(ALA) [433], the methyl-aminolevulinate (MAL), the porphyrins and the phenothiazine 
dyes (methylene blue or toluidine blue). This treatment has shown to be effective 
against many fungi (e.g. T. rubrum) [398] but the high number of sessions that it 
implies (3 to 12) is an important inconvenience and raises the cost of the therapy [391]. 
The PDT is indicated for those patients with a contraindication for systemic therapy 
[399]. 
AP1.1.10.2.3. Chemical or surgical nail avulsion 
Nail avulsion involves the removal of the affected nail plate which can be performed 
either surgically or chemically using 40% urea, 30% salicylic acid or 50% potassium 
iodide [412,428]. Those solutions have to be applied over the affected nail and keep 
under occlusion during 7 to 14 days [399,445]. After those days, the nail becomes softer 
and it is more easily removable. After nail removal, a topical antimycotic agent, such as 
bifonazole, is applied for 4 weeks in order to treat the zone. Apart from bifonazole, 
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other topical agents such as tioconazole 28%, amorolfine, ciclopirox 8% lacquer or 
terbinafine gel (this last under study) could be applied once removed the nail for 6 to 12 
months.  
The nail plate removal causes discomfort to the patient and therefore it is restricted to 
cases in which the treatment success depends on the removal of the nail plate. 
AP1.1.10.2.4. Mechanical debridement 
The aim of this technique is to reduce pressure and fungal load by mechanically 
reducing nail thickness [398]. As the mechanical debridement removes a large amount 
of onychomycotic material from the nail, this technique is useful since it enhances the 
effectiveness of other therapies, mainly those ones involving the use of antifungal 
agents [449,464]. 
 
 
Event though there exist a wide variety of possible treatments for the onychomycosis, 
most of them are not effective against concomitant infections. 
The raise of mixed infections caused by dermatophytes or non-dermatophytes and 
Candida sp., together with the increase appearance of resistance and the long duration 
of the treatments, make the development of new antimycotic formulations a neccesity.  
In this sense, the development of new formulations including antifungal agents with 
broad spectra of action, high potency and reduced resistances (such as amphotericin B) 
will be an alternative to the conventional treatments. The reduction of treatment 
duration will also increase patient compliance.  
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AP1.2. Description of the excipients assayed for the AmB nail lacquer. 
The composition, properties and structure of the film-forming agents, plasticizers, 
solvents, AmB solubilizers and cosolvents used in the nail laquer matrix is detailed 
below. 
AP1.2.1. Film-forming agents 
 Plasdone K90® 
Plasdone® is the commercial name of povidone. It is a synthetic homopolymer 
containing 1-vinyl-2-pirrolidinone as a monomer (figure 103). The degree grade of 
polymerization (n) results in a wide range of different molecular weight polymers.  
It is a white (or creamy) colored, odorless and hygroscopic powder that in solution 
produces viscous media. It is soluble in water although its solubility is limited to the 
viscosity of the resulting solution; it is soluble in acids, chloroform, ethanol, ketones 
and methanol. It is an amphiphilic polymer that is widely used as film-former, adhesive, 
binder, solvent, suspensor, stabilizer and viscosity increasing agent. 
  
Figure 103. Chemical structure of povidone 
 
 Eudragit L100® 
Eudragit L100® is an anionic copolymer of methacrylic acid and methyl acrylate in a 
ratio 1:1 (carboxyl groups:ester groups) (figure 104).  It is commercially available as a 
white redispersable powder. It is freely soluble in acetone, ethanol, isopropyl alcohol 
and methanol, and insoluble in water. When dissolved, and in contact with water it 
precipitates, forming white plastic films. 
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It is mainly used as film-forming agent, binder and diluent.  
 
 
Figure 104. Chemical structure of Eudragit L100® 
 
 Cellulose acetate phthalate  
Cellulose acetate pthalate (CAP) (figure 105) is a hygroscopic, tasteless and odorless 
white powder, granule or flake. It is insoluble in water, alcohols and chlorinated and 
unchlorinated hydrocarbons, but soluble in some ketones, esters, ether alcohols, cyclic 
ethers and in certain mixtures of solvents. It is widely used as a film coating agent or as 
a matrix binder. 
 
Figure 105. Chemical structure of cellulose acetate phthalate. 
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 Pluronic F127® 
Pluronic®, also known as poloxamer, is a block copolymer of ethylene oxide and 
propylene oxide (figure 106). The two ethylene blocks are repeated 101 times and the 
propylene block 56 times. It is a white solid, freely soluble in water, in ethanol and in 2-
propanolol.  
It is a nonionic polyol surfactant used as film-forming, dispersing, emulsifying, 
solubilising, lubricant and wetting agent.  
 
Figure 106. Chemical structure of poloxamer. 
 
AP1.2.2. Plasticizers 
 Polyethylene glycol  
Polyethyleneglycols (PEGs) (figure 107) are stable and hydrophilic substances that are 
non irritant to the skin. According to the molecular weight (Mw), there exist a wide 
variety of PEGs.  
PEGs with molecular weights ranging between 200-600 Da (Mw) are clear, colorless or 
pale yellow, viscous liquids; PEGs in the range 1000-5000 Da (Mw) are white pastes or 
waxy flakes depending of the molecular weight, and PEG above 6000 can be found as 
white powders. All grades of PEGs are water soluble and miscible in all proportions 
with other PEGs. Liquid PEGs are soluble in alcohols, acetone, benzene, glycerin and 
glycols; while solid PEGs are soluble in acetone, dichloromethane, ethanol and 
methanol, and slightly soluble in aliphatic hydrocarbons and ether. They are mainly 
used as plasticizers, solvents, lubricants and suspensors. 
The PEGs used in the nail polish composition were PEG400, PEG600 and PEG6000 in a 
proportion ranging between 2-10% 
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Figure 107. Chemical structure of polyethylene glycol. 
  
 Propylene glycol  
Propylene glycol (PPG) (figure 108) is a hygroscopic, colorless, odorless, clear and 
viscous liquid that is stable up to 40 ºC. It is miscible with acetone, chloroform, ethanol, 
glycerin and water. It is commonly used as plasticizer in aqueous film-forming 
formulations but it also acts as antiseptic, disinfectant, humectant, solvent, stabilizing 
agent and water-miscible cosolvent. It has been widely used in different pharmaceutical 
dosage forms including the topicals and parenterals.  
 
Figure 108. Chemical structure of propylene glycol. 
 
 Glycerin triacetate 
Glycerin triacetate (GT) (figure 109) also known as triacetin, is a colorless viscous 
liquid with a slightly fatty odor. It is miscible with chloroform, ethanol, ether, and 
toluene and with water in a ratio 1:14. It is used as hydrophilic plasticizer, solvent or 
fixative. 
 
Figure 109. Chemical structure of glycerin triacetate. 
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 Diethyl phthalate  
Diethyl phthalate (DEP) (figure 110) is a compound included in the group of the low 
molecular weight (<250 Da) esters of phthalic acid which have low viscosity and high 
volatility. It is a clear, colorless, practically odorless oily liquid that is insoluble in water 
but miscible with ethanol, ether and other organic solvents. It is used as plasticizer but 
also as film-forming agent, solvent, vehicle and alcohol denaturant.  
 
Figure 110. Chemical structure of diehtyl phthalate. 
 
 Castor Oil 
Castor oil (CO) (figure 111) also known as ricini oleum is a triglyceride of fatty acids 
composed by 87% ricinoleic acid, 7% oleic acid, 3% linoleic acid, 2% palmitic acid, 1% 
stearic acid and by traces of dyhydroxystearic acid. It is a colorless or light yellow 
viscous oil with a slight odor. It is insoluble in water, soluble in ethanol and miscible 
with chloroform, diethyl ether, ethanol, glacial acetic acid and methanol. CO is used as 
plasticizer and as solvent. 
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Figure 111. Chemical structure of castor oil. 
 
 Dibutyl Sebacate  
Dibutyl Sebacate (DBS) (figure 112) is a colorless, clear oily liquid with a slight butyl 
odor that is practically insoluble in water but soluble in ethanol, ether, mineral oils and 
toluene. It is used as plasticizer together with film-forming agents.  
 
Figure 112. Chemical structure of dibutyl sebacate. 
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AP1.2.3. AmB solubilizers 
 Sodium deoxycholate 
Sodium deoxycholate (DocNa) (figure 113) is a water soluble anionic detergent 
commonly used as surfactant. It is a secondary bile acid produced by the action of the 
bacterial enzymes over glycocholic and taurocholic acid, salts released in the bovine 
intestine. This chemical is not only used as surfactant but also as intermediate in the 
production of corticosteroids; in the preparation and formulation of certain 
microbiological diagnostic media, and as biological detergent to lyse cells and to 
solubilize cellular and membrane components.  
 
Figure 113. Chemical structure of sodium deoxycholate. 
It has the ability to self-assembly in solution and form mixed aggregates with 
hydrophobic drugs. This effect together with its physiological compatibility resulted in 
its wide application as controlled drug delivery carriers. The micelle structure formed 
by sodium deoxycholate and other bile salts, differs from one generated with the typical 
micelle-forming surfactants. Bile salts have a rigid hydrophobic moiety of a steroid 
nucleus with hydrophilic parts of two or three hydroxyl groups and an anionic head of a 
carboxylate group. The spatial arrangement of hydrophilic and hydrophobic groups 
determines the facial amphiphilicity of the molecules of these compounds since they 
have convex hydrophobic and concave hydrophilic surfaces. The critical micelle 
concentration (CMC) of the bile salts is in the range 1-10.10-3 M having sodium 
deoxycholate a CMC value of 2x10-3 M.  
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Sodium deoxycholate has been widely used as amphotericin B solubilizer for many 
years. Thus, Fungizone®, was the first amphotericin B commercialized product in 
which sodium deoxycholate was used as AmB solubilizer and as carrier.  
 Gamma cyclodextrins 
Gamma cyclodextrin (γ-CD) (figure 114), is a cyclic alpha-(1-4)-linked oligosaccharide 
composed by eight molecules of glucose. It is a white, almost odorless, fine crystalline 
powder with a slightly sweet taste. It solubility in water is limited;  1part of γ-CD in 4.4 
parts of water at 20ºC and 1 in 2 parts of water at 45ºC. γ-CD, as well as other 
cyclodextrins, is able to form inclusion complexes with a large variety of molecules, 
resulting in improvements to dissolution and bioavailability owing to enhanced 
solubility and improved chemical and physical stability. Its ability to form these 
complexes is explained by the less polarity of the inner side of the torus-like molecule 
compared to outer side [465]. This is due to the arrangement of hydroxyl groups within 
the molecule. This arrangement allows the γ-cyclodextrin to accommodate a guest 
molecule within the cavity, forming an inclusion complex. The cavity diameter of the γ-
CD is in the range 7.5-8.3 A.  
 
Figure 114. Chemical structure of γ -cyclodextrin 
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Gamma cyclodextrins are widely used in oral, topical and parental formulations due to 
their great solubilizing properties. Its solubilizing effect on amphotericin B was first 
described on 1985 [466] and from this date, this molecule has been used in many 
different AmB formulations such as vaginal gels, ointments, eye drops and solutions 
(AmB forms a soluble inclusion complex with γ-CD in which the AmB solubility can 
be enhanced up to 200-fold) . γ-CD has shown a synergistic effect on membrane 
destabilization with AmB. The combination of AmB- γ-CD  in topical formulations 
have shown a greater antifungal activity than AmB dissolved in other solvents [290]. 
 
  N-methyl-2-pyrrolidone 
N-methyl-2-pyrrolidone (NMP) (figure 115) is a hygroscopic colorless organic solvent 
with a mild amine odour, miscible with ethanol, propanol and water. It is also miscible 
with organic solvents such as benzene, carbon disulfide, chloroform, ether and ethyl 
acetate. Its high stability is only decreased by a slow oxidation process when it contacts 
with air [467]. This polar aprotic solvent is used as penetration enhancer (NMP 
increases partiotioning of drugs into the skin), plasticizer, solvent and as solubilizer 
agent. It has microbiological activity against Gram positive (G+) and Gram negative (G-
) bacteria and some molds.  
 
Figure 115. Chemical structure of N-methyl-2-pirrolidone 
Its ability to penetrate the tissues is based on the modification of the solvent nature of 
the membranes. For this reason, it has been used to generate reservoirs within skin 
membranes. NMP dermal penetration through human skin has been shown to be fast 
[468]. Its use as penetration enhancer in many topical formulations at concentrations up 
to 40% has been reported not to generate any skin sensitization [469]. Due to the 
solvent effects and to its permeability properties, this molecule was assayed for the first 
time as a possible AmB solubility enhancer. 
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 Plasdone K90® 
Plasdone K90®, previously described, it is not only used for its film-forming properties 
but also for its amphiphilic character. At basic pH (pH=12) it interacts with the charged 
AmB, forming a complex in which the drug remains soluble even after neutralization 
(pH 5-7). 
AP1.2.4. Cosolvents 
 Ethanol 
The ethanol was used either as solvent or cosolvent in all the below described 
formulations. This is due to its fast dryness which confers the nail lacquers the capacity 
of generating homogenous films in just a few minutes (≤ 5 minutes). The ethanol 
incorporated was ethanol 96%.  
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AP1.3. Nail lacquer formulations 
AP1.3.1. Water soluble nail lacquers 
Due to the film forming properties of the polyvinyl pyrrolidone molecule, the first 
matrix formulation (without drug incorporation) was prepared using Plasdone® K90 as 
film forming agent. The choice of this polymer was based first, on the information 
obtained from different patents (i.e [470] and secondly, on the possibility of having a 
system in which the AmB solubilization did not imply the addition of extra-excipients. 
The AmB solubility in Plasdone® was assayed. 
AP1.3.1.1. Preparation of a water soluble matrix 
 Formulation 1 
This formulation implies the preparation of a water soluble matrix able to constitute a 
nail lacquer. 
Composition 
Plasdone K90®……………………....20 % 
Urea…………………………………..10 % 
Glycerin triacetate…………………….4 % 
Ethanol……………………………….20 % 
Water…………………………………46 % 
 
Protocol followed for preparation 
5 g formulation was prepared by adding 1 g of Plasdone K90® to 2.3 mL of deionized 
water containing 0.5 g of urea. Once dissolved, 0.2 g of glycerin triacetate and 1 g of 
ethanol were supplied. The formulation was stored in a sealed glass vial to avoid 
ethanol evaporation. 
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Evaluation 
Using a scale from 1 to 5 (1 is the minimum value and 5 the maximum), the following 
parameters were evaluated. 
- water permeability of the film formed,  
- viscosity of the formulation,  
- brightness of the formulation and film formed,  
- film drying time over the nail, 
- stickiness of the film once dried, 
- extensibility of the formulation, 
- homogeneity of the film formed and 
- pH of the formulation 
These parameters were evaluated in all the formulations prepared (1-20) 
 
 Formulation 2 
Formulation 1 was found to be highly viscous. In order to decrease the overall viscosity 
of this formulation the amount of polymer was decreased and the urea was removed. 
Composition 
Plasdone K90®……………………....10 % 
Glycerin triacetate…………………….4 % 
Ethanol……………………………….36 % 
Water…………………………………50 % 
 
Protocol followed for preparation 
5 g formulation was prepared as reported in formulation 1 without the addition of urea. 
The formulation was stored in a sealed glass vial to avoid ethanol evaporation. 
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AP1.3.1.1.1. Incorporation of amphotericin B in the water soluble nail lacquers 
using Plasdone® K90 as film forming agent. 
 
 Formulation 3 
The incorporation of AmB into the water permeable nail lacquer, was assayed for the 
first time with NMP. 
Composition 
AmB………………………………….0.3 % 
NMP…………………………………..10 % 
Plasdone K90®…………………..…....10 % 
Glycerin triacetate……………..……….5 % 
Ethanol……………………….……..24.7 % 
Water…………………………………50 % 
 
Protocol followed for preparation 
15 mg AmB were added of 0.5 g NMP (A) and left under magnetically stirring for 15 
min. Meanwhile, 0.5 g of Plasdone K90® were dissolved with 2.5 mL deionized water 
and added of 0.25 g of glycerin triacetate (B). Then, A was added to B and 1.235 g 
ethanol was incorporated. The formulation was stored as described above. 
 
 Formulation 4 
The AmB solubility with γ-CD (instead of NMP) was assayed in formulation 4. It is 
important to consider that the γ-CD maximum solubility in water is 23.3 g/100 mL 
[471]. When a formulation contains γ-CD, its solubility value limits the amount of the 
other components that can be included in the formulation. 
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Composition 
AmB………………………………….0.3 % 
γ-CD……………………………………9 % 
Plasdone K90®……………………......10 % 
Glycerin triacetate…………………..….5 % 
Ethanol………………………….…..25.7 % 
Water……………………………….…50 % 
NaOH 0.1 M……………………..……...c.s. 
Orthophosphoric acid 0.1 M…….....…....c.s. 
 
Protocol followed for preparation 
The first step was the AmB dissolution. For this purpose, the γ-CD in a ratio 30:1 
(CD:AmB) was used as solubiliser. 0.45 g of γ-CD dissolved in 2.5 mL purified water 
were added of NaOH 0.1 M. When the pH was 12, 15 mg AmB were dissolved and the 
pH was immediately decreased to 5.5 using orthophosphoric acid 0.1 M. Then, 0.5 g of 
Plasdone K90® were added to the AmB-CD complex and left under magnetically 
stirring for 15 min. Finally, 0.25 g of glycerin and 1.285 g ethanol were incorporated.  
The formulation was stored as above indicated 
Formulation 4, both in the presence and in the absence of AmB, showed a precipitate 
after two days preparation. In order to study the factors responsible of this effect, 
different changes in the composition were performed. 
 
 Formulation 5 
Due to the precipitation observed at 48 h and to overcome this problem, some changes 
in F4 were done. 
 
 
 
Novel formulations for Amphotericin B delivery 
 
299 
Composition 
AmB………………………………….0.3 % 
γ-CD…………………………………..15 % 
Plasdone K90®……………………......10 % 
PEG400………………………….….….5 % 
Water…………………………….….69.7 % 
NaOH 0.1 M……………………..……...c.s. 
Orthophosphoric acid 0.1 M……….........c.s. 
 
Protocol followed for preparation 
The same protocol described in formulation 4 was used to prepare 5 g of this 
formulation. In this case, a higher amount of γ-CD and water was used. The formulation 
was prepared without the addition of ethanol.  
 
 Formulation 6 
In formulation 6, the solubilizing effect of Plasdone® K90 on AmB was studied. 
Composition 
AmB………………………………….0.3 % 
Plasdone K90®………………..……....10 % 
PEG 400……………………….……….5 % 
Water……...………………….……..84.7 % 
NaOH 0.1 M……………………..……...c.s. 
Orthophosphoric acid 0.1 M……….........c.s. 
 
As described in the literature, the polyvinylpyrrolidone (Plasdone®) is an amphiphilic 
molecule. In this formulation, the Plasdone® was not only used as film-forming agent 
but also as a possible AmB solubilizer.  
Protocol followed for preparation 
0.5 g of Plasdone K90® were dissolved in 4.235 mL of deoinized water at pH 5.5. The 
pH was increased up to 12 with NaOH 0.1 M and then 15 mg of AmB were added. 
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When dissolved, the pH was decreased again to 5.5 with orthophosphoric acid. Finally, 
0.25 g of PEG400 was added.  
 
 Formulation 7 
As the drying time for F6 (once applied to the nail) was longer than expected, some 
modifications were done on F6 to obtain a formulation with a shorter drying time (F7). 
Formulation 6 showed that although Plasdone K90® interacts with the AmB at pH 12 
and maintain the molecule in solution at lower pHs, the formulation had some 
disadvantages that had to be improved. The drying time when applied to the nail was 
too long due to the high water content. In this formulation, approximately a 20% of the 
water was replaced by ethanol. 
Composition 
AmB………………………………….0.3 % 
Plasdone K90®………………..……....10 % 
Glycerin triacetate……………..……….4 % 
Ethanol……………………….……….20 % 
Water……...………………….……..65.7 % 
NaOH 0.1 M…………………..………...c.s. 
Orthophosphoric acid 0.1 M….....……....c.s. 
 
Protocol followed for preparation 
15 mg AmB dissolved in 3.285 mL of deionized water at pH 12 (NaOH 0.1M) were 
added of 0.5 g of polymer. The pH was then decreased to 5.5 (orthophosphoric acid 
0.1M) and the rest of the components (ethanol and plasticizer) were added. Following 
this protocol, AmB was found to be totally soluble. The formulation was stored in a 
sealed glass vial hermetically as reported elsewhere. 
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 Formulation 8 
F8 was designed to improve the drying problems still found on F7. 
Composition 
AmB…………………………….…….0.3 % 
Plasdone K90®…………………...…....10 % 
Glycerin triacetate…………..….……….4 % 
Ethanol……………………..…....…….30 % 
Water……...………………..………..55.7 % 
NaOH 0.1 M………………...…………...c.s. 
Orthophosphoric acid 0.1 M…......……....c.s. 
 
Although the modifications performed on formulation 7 improved the drying properties 
of formulation 6, there were still some aspects to be improved. The drying time in the 
nail was shorter than before, but not short enough to constitute a nail lacquer. For this 
reason, the percentage of water was decreased and the amount of ethanol increased. 
Protocol followed for preparation 
The formulation was prepared as described for formulation 7. 
 
 Formulation 9 
The Amb solubility as simile of Fungizone® that is, dissolved with sodium 
deoxycholate was studied in F9. 
Composition 
AmB………………………………….0.3 % 
DocNa……………………….…….0.246 % 
Plasdone K90®…………..…………....10 % 
PEG 400……………….……………….5 % 
Water……...…………..……….....84.454 % 
NaOH 0.1 M……………..……………...c.s. 
Orthophosphoric acid 0.1 M.....………....c.s. 
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In order to check the improved stability and the physichochemical properties of the nail 
lacquer with the AmB incorporated as simile of Fungizone®, the formulation detailed 
above was prepared.  The ratio DocNa:AmB used was the one described for Fungizone® 
(0.82:1) [325]. 
Protocol followed for preparation 
12.3 mg of DocNa were dissolved in 2 mL of deionized water and the pH was checked 
(pH 7.6). Then, 20 μL of NaOH 0.1 M were added (pH 12) and 15 mg of AmB were 
dissolved. Just after solubilization, 40 μL of orthophosphoric 0.1 M acid were used to 
decrease the pH to 7.5 (pHs lower than 7 makes the DocNa precipitate). The water 
volume was completed to 4.227 g and 0.5 g of Plasdone K90® were added. A slightly 
viscous solution was obtained. Finally, 0.25 g of PEG400 were incorporated.  
Formulation 9 was modified in order to add a keratolytic agent to the composition (see 
Formulation 10) 
 
 Formulation 10 
The previously developed formulation (F9) showed adequate physicochemical 
properties as nail lacquer (even though the drying time was not as short as expected). In 
order to increase its permeation through the nail, a 10% (weight) urea was added as 
keratolytic agent. 
Composition 
AmB……………………….………….0.3 % 
DocNa…………………………..….0.246 % 
Plasdone K90®……………...………....10 % 
PEG 400……………………..………….5 % 
Urea…………………………..………..10 % 
Water……...………………...….....74.454 % 
NaOH 0.1 M…………………...………...c.s. 
Orthophosphoric acid 0.1 M…......……....c.s. 
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In this formulation a 10% urea was added. At this % or at higher concentrations the urea 
has keratolytic effect. It softens the tissues and enhances the drug penetration through 
the nail [472].  
Protocol followed for preparation 
The formulation was prepared as described in formulation 9. The addition of urea was 
performed right after polymer dissolution. 
 
 Formulation 11 
Formulation 11 was designed as an alternative to Formulation 9. This formulation aims 
in decreasing the drying time over the nail. For this purpose, approximately a 35% of 
water content was replaced by ethanol. 
Composition 
AmB………………………….……….0.3 % 
DocNa………………………..…….0.246 % 
Plasdone K90®………………...……....10 % 
PEG 400..............………….....………….4 % 
Ethanol…………………...……..…35.454 % 
Water……...………………...…............50 % 
NaOH 0.1 M……………...........………...c.s. 
Orthophosphoric acid 0.1 M……......…....c.s. 
 
Protocol followed for preparation 
12.3 mg of DocNa were dissolved in 2 mL of deionized water and the pH was checked 
(pH 7.6). Then, 20 μL of NaOH 0.1 M were added (pH 12) and 15 mg of AmB were 
dissolved. Immediately after solubilization, 40 μL of orthophosphoric 0.1 M acid were 
used to decrease the pH to 7.5, and the water volume was completed to 2.5 mL. Then, 
0.5 g of Plasdone K90® were incorporated to the previous solution and, once dissolved, 
1.772 g of ethanol were added. Finally, 0.20 g of PEG400 were incorporated. The 
formulation was stored in a sealed glass vial hermetically to avoid ethanol evaporation. 
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 Formulation 12 
The amount of ethanol added on formulation 11 was enough to get the required drying 
times over the nails. Therefore, the incorporation of urea was assayed in F12. 
A 10% urea was incorporate to formulation 11. For this purpose, the amount of ethanol 
was decreased in the same proportion (10%). 
Composition 
AmB………………………………….0.3 % 
DocNa………………….………….0.246 % 
Plasdone K90®………..……………....10 % 
PEG 400..............……...……………….4 % 
Urea…………………….……………..10 % 
Ethanol……………..…………..…25.454 % 
Water……...………...…………............50 % 
NaOH 0.1 M…………...………………...c.s. 
Orthophosphoric acid 0.1 M……......…....c.s. 
 
Protocol followed for preparation 
The formulation was prepared as reported for formulation 11. The urea was added 
before the polymer. 
 
 Formulation 13 
The high decrease in the ethanol content in F12 caused longer dryings times. To avoid 
the problems with the drying, in the new formulation (F13), both water and ethanol 
were decrease in a similar proportion (5%). 
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Composition 
AmB………………………….……….0.3 % 
DocNa…………………………..….0.246 % 
Plasdone K90®………………...……....10 % 
PEG 400..............……………....……….4 % 
Urea………………………..…………..10 % 
Ethanol……………………..…..…30.454 % 
Water……...……………...……............45 % 
NaOH 0.1 M………………...…………...c.s. 
Orthophosphoric acid 0.1 M……......…....c.s. 
 
Protocol followed for preparation 
The formulation was prepared as reported for formulation 12. 
 
AP1.3.1.1.2.   Incorporation of amphotericin B in the water soluble nail lacquers 
using Pluronic® F127 as film forming agent. 
 Formulation 14 
In addition to Plasdone® K90, the efficacy of Pluronic® F127 on the generation of a 
water soluble film was also studied. 
Composition 
AmB………………………………….0.3 % 
DocNa……………………….…….0.246 % 
Pluronic F127®……………..………....20 % 
Glycerin triacetate…………..………….4 % 
Ethanol…………………..……..…30.454 % 
Water……...……………...……............45 % 
  
The use of Pluronic F127 (poloxamer) as film-forming agent has been previously 
reported elsewhere. (i.e. [473]).  
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Protocol followed for preparation 
The simile of Fungizone® was prepared as previously described. Then, half of the 
Pluronic F127® (0.5 g) was added. As the polymer took long to dissolve (approximately 
45 minutes), the ethanol (1.523 g) was added to the solution prior to the other 0.5 g of 
polymer in order to have more volume to dissolve the polymer. Finally, 0.2 g of 
glycerin triacetate were incorporated. The formulation was stored in a sealed glass vial 
to avoid the ethanol evaporation. 
 
 Formulation 15 
The feasibility of the new water permeable lacquer containing Pluronic F127, was 
studied after addition of a 10% urea as keratolytic agent. 
AmB………………………………….0.3 % 
DocNa……………………………..0.246 % 
Pluronic F127®………….………….....20 % 
Glycerin triacetate…………..………….4 % 
Urea……………………….…………..10 % 
Ethanol…………………….…..…25.454 % 
Water……...……………..……............40 % 
 
Protocol followed for preparation 
The formulation was prepared as detailed in formulation 14. The addition of urea was 
performed just after the simile preparation. 
 
 Formulation 16 
Formulation 16 was prepared as an alternative to F14 and F15. The aim of this 
formulation was to improve the stability problems detected on F14 and F15. 
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Composition 
AmB………………………………….0.3 % 
DocNa………………………….….0.246 % 
Pluronic F127®………………..……....20 % 
Glycerin triacetate…………..………….4 % 
Water……...………………..….....75.454 % 
 
Aiming to solve the stability problems found on formulations 14 and 15, the removal of 
ethanol and urea were considered as an alternative to improve the stability of the 
formulations. 
Protocol followed for preparation 
The formulation was prepared as reported in formulation 14. All the water was added at 
the beginning. 
 
 Formulation 17 
To improve the stability of F16, the AmB was dissolved with γCD and the ethanol was 
removed from the formulation.  
The stability problems associated to formulations 14 and 15 were not solved with the 
modifications applied on formulation 16. For this reason, the replacement of DocNa for 
γ-CD and the elimination of ethanol were considered as good alternatives. 
Composition 
AmB………………………………….0.3 % 
γCD……………………………….…..15 % 
Pluronic F127®…………………..…....20 % 
Glycerin triacetate……………..……….4 % 
Water……………………….…….…70.7 % 
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Protocol followed for preparation 
AmB (15 mg) was added to 0.75 g of γ-CD in 3.25 mL of deionized water at pH 12 
(NaOH 0.1 M). When the AmB was dissolved, the pH was decreased to 5.5 with 
orthophosphoric acid 0.1 M and the amount of water was adjusted to 3.535 mL. 1 g 
poloxamer was then dissolved on this solution and finally, 0.2 g of plasticizer was 
added.  
 
AP1.3.2. Water insoluble nail lacquers 
AP1.3.2.1.  Preparation of a water insoluble nail matrix and incorporation of AmB 
Considering the fact that the topical treatment against onychomycosis implies the 
administration of the antifungal lacquer not more than once daily, the preparation of a 
water impermeable nail lacquer will improve the efficacy of the treatment. With a non-
water soluble lacquer, the patient would not have to be worried about being in 
prolonged contact with water.  
 
 Formulation 18 
F18 was designed based on an already patented formulation [474] in which the 
Eudragit®  (water impermeable film-forming polymer) was used as film forming agent. 
The AmB solubility results reported in EXP1-2.1 showed that NMP was able to 
solubilize this drug. NMP is considered as a penetration enhancer suitable for topical 
and intravenous administration. For this reason, the NMP was assayed as solvent for 
both the polymer and the AmB in this formulation. 
Composition 
AmB………………………….……….0.3 % 
Eudragit L100®…………………..…....15 % 
PEG 400…………………………..…….5 % 
NMP……………………….………...79.7 % 
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Protocol followed for preparation 
15 mg of AmB were dissolved in 3.985 g of NMP. Then, 0.75 g Eudragit were added 
and the resulted solution was left stirring for 1 h. After 60 min, 0.25 g of PEG400 were 
added and the final formulation was stored in a sealed glass vial to avoid NMP 
hydration.  
 
 Formulation 19 
F19 was designed to avoid the drying problems found with F18. Formulation 18, 
containing only NMP as solvent, was not getting dried once applied to the nail. In order 
to solve this problem, ethanol was included in formulation 19 as polymer solubiliser. 
The ethanol evaporates easily assuring the film formation.  
Composition 
AmB………………………….….…….0.3 % 
NMP…………………………..………..10 % 
Eudragit L100®……………..….……....15 % 
PEG 400……………………...…....…….5 % 
Ethanol……………………...………..69.7 % 
 
Protocol followed for preparation 
0.75 g of Eudragit L100® were left stirring 30 min in a close vial containing 3.485 g 
ethanol (A) (it took quite a long time to dissolve all the Eudragit). Meanwhile, 15 mg of 
AmB were dissolved with 0.5 g NMP (B). This solution was vortex for 15 min until 
final dissolution of AmB. Once it was dissolved in NMP, the resultant AmB solution 
turned orangish transparent and the AmB molecules were found in its monomeric state.  
Then, B was added of A while stirring. Finally, 0.25 g of PEG400 were supplied and 
vortex for 1 min. The formulation was stored as previously described. 
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 Formulation 20 
Taking into account that formulation 19 showed adequate properties for nail 
administration, the incorporation of urea as keratolytic agent was studied.  
Although urea is known to be insoluble in ethanol, the solubilization in a mixture of 
ethanol and NMP was assayed. 
Composition 
AmB………………………………….0.3 % 
NMP…………………………………..10 % 
Eudragit L100®………….…………....15 % 
PEG 400………………….…………….5 % 
Urea…………………….……………..10 % 
Ethanol……………….……………..59.7 % 
 
Protocol 
15 mg of AmB were dissolved in 0.25 g of NMP and left under magnetically stirring for 
15 min (A). Then, 0.5 g of urea and 0.75 g of Eudragit L100® were added to a mixture 
of ethanol and NMP (12:1) (B). A was added of B while stirring and finally, 0.25 g of 
PEG400 were incorporated. The formulation was stored as reported elsewhere. 
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AP1.4. Formulation preparation and troubleshooting 
AP1.4.1. Water soluble nail lacquers 
AP1.4.1.1. Preparation of a water soluble matrix 
 Formulation 1  
The first formulation was selected according to the patents ES 2 260 093 T3 published 
in 2006 entitled "Preparados para la eliminación ungueal atraumática" and the patent 
USP00746396B2 published in 2009 and titled "Composition for removing abnormal 
keratinous material". In both patents the authors used polyvinylpyrrolidone (PVP) as 
film forming agent. Just by the addition of water, the polymer was completely dissolved 
generating an homogenous solution that once applied to the nail formed a film. The 
polymer concentrations detailed in these patents were 10% and 20% respectively, and  
the molecular weights of the PVPs used were 11.5 kDa and 25 kDa for the Spanish 
patent and 11.5 kDa for the American.  
Taking into account these patents, the first polymer used as film forming agent was 
polyvinylpyrrolidone (PVP). Between all the PVPs available, Plasdone K90® with a 
molecular weight of 1,300 kDa was the one selected. As detailed in its technical data 
sheet, this polymer is biocompatible and can be used as an hygroscopic, adhesive, 
amphiphlic, binder and film forming agent. 
For this fist formulation the concentration of Plasdone K90® used was 20%. Based on 
the patents, the urea was added as keratolytic agent, the glycerin triacetate as plasticizer, 
the ethanol (added in order to reduce the amount of water in the formulation and, to 
favor and speed up the drying process) as cosolvent and the water as polymer solvent. 
Plasdone K90®………………….…....20 % 
Urea…………………………………..10 % 
Glycerin triacetate…………….……….4 % 
Ethanol……………………………….20 % 
Water…………………………………46 % 
 
As detailed in materials and methods, the formulation was prepared by the dissolution 
of the polymer in the water containing the keratolytic agent and the subsequent addition 
of the other components.  
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Once the polymer was dissolved, the solution obtained was really viscous. It seemed 
more a gel than a solution. When applied to the nail it did not formed an homogenous 
film. As a consequence of the high viscosity of the solution, the drying time was over 5 
minutes, which was our upper limit.  
Table 83 details the results from the parameters evaluated for this first formulation 
where 1 is the minimum and 5 is the maximum. 
 
Table 83. Evaluation of the physicochemical properties of formulation 1 (scale 1-5) 
Parameter 
Evaluation 
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely removed 
Viscosity 5 The solution is highly viscous 
Brightness 3 N/A 
Drying time in the nail ≥ 5 min 7 min 
Stickiness 4 4 when applied and 2 when it gets dried 
Extensibility 2 The viscosity difficults the extensibility 
pH 5.5-6 Measured with paper bands 
 
 Formulation 2 
The composition of formulation 2 differs to 1 not only in the percentage of polymer 
used but also in the absence of urea. The percentage of polymer was decreased up to 
10% in order to obtain a low viscous solution.  
It was decided not to go ahead with the urea since it is a component that might not be 
included in our final lead formulations for AmB delivery. As it is not a basic component 
on the nail lacquer matrix, the urea was not included in formulation 2. 
Plasdone K90®………………….…....10 % 
Glycerin triacetate…………………….4 % 
Ethanol……………………………….36 % 
Water…………………………………50 % 
 
The reduction on polymer concentration and the elimination of urea, resulted in an 
increase of 4% water and 16% ethanol in formulation 2 compared to 1. The increase on 
ethanol respect to water is a strategy to decrease the drying time over the nail.  
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When preparing the formulation, we realized that after the addition of glycerin triacetate 
there were some oily drops remaining on the surface of the solution. Those drops 
completely disappeared after ethanol incorporation. The final solution was transparent. 
As for formulation 1, table 84 summarizes the results from the evaluation of 
formulation 2. 
Table 84. Evaluation of the physicochemical properties of formulation 2 (scale 1-5) 
Parameter 
Evaluation 
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 2-3 The solution has an appropriate viscosity 
Brightness 3 N/A 
Drying time in the nail ≤ 5 min 4 min 
Stickiness 3 3 when applied and 1 when it gets dried 
Extensibility 4 It is easily extensible 
pH 5.5-6 Measured with paper bands 
 
 
AP1.4.1.1.1. Incorporation of amphotericin B in the water soluble nail lacquers 
using Plasdone® K90 as film forming agent. 
 Formulation 3 
Once obtained an appropriate matrix for the AmB lacquer, a first attempt to include the 
amphotericin B was performed.  
In formulation 3, the amphotericin B (0.3%) and N-methyl-2-pyrrolidone (NMP) (10%) 
were included. The addition of those components implies a reduction of the percentage 
of ethanol up to 24.7%.  
To improve the elasticity of the film, glycerin triacetate (plasticizer) was increased up to 
5%.  
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AmB………………………………….0.3 % 
NMP…………………………………..10 % 
Plasdone K90®………………..……....10 % 
Glycerin triacetate………………..…….5 % 
Ethanol………………………..……..24.7 % 
Water………………………….………50 % 
 
Formulation 3 was prepared as detailed in Materials and Methods. Briefly, the AmB 
was first dissolved in NMP and then added to the polymer water solution containing the 
plasticizer. It is worth noting that the AmB dissolution in NMP is not an immediate 
process, it can last up to 15 min. At the beginning of the dissolution process the solution 
had a yellowish opaque aspect and, when vortexing for some minutes, the solution 
turned orangish transparent. The aspect of the final AmB dissolved in NMP was the 
same as for the AmB in DMSO (figure 37). The AmB aggregation state on NMP was 
also checked by UV finding the AmB as monomers (figure 36). 
The aspect of the final formulation (after addition of ethanol) was yellow-orangish 
translucent even though the solution seemed perfectly dispersed. When applied to the 
nail, the solution left an orangish film.  
In order to determine what was producing the change from the transparent to the 
translucent solution, an aliquot of NMP containing AmB was added of water. The NMP 
solution which was initially transparent turned slightly translucent after water addition. 
The addition of water to the mixture AmB-NMP was responsible for this change. 
Table 85 summarizes the results from the evaluation of formulation 3. 
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Table 85. Evaluation of the physicochemical properties of formulation 3 (scale 1-5) 
Parameter 
Evaluation 
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 2-3 The solution has an appropriate viscosity 
Brightness 3 N/A 
Drying time in the nail ≤ 5 min 4 min 
Stickiness 3 3 when applied and 1 when it gets dried 
Extensibility 4 It is easily extensible 
pH 5.5-6 Measured with paper bands 
 
 Formulation 4 
In formulation 4, the nail lacquer matrix described above was used but in this case, 
instead of dissolving the AmB in NMP, it was dissolved using gamma cyclodextrins (γ-
CD) in a ratio 1:30 (AmB: γ-CD). Thus, the percentage of γ-CD used was 9%. 
AmB………………………………….0.3 % 
γ-CD……………………………………9 % 
Plasdone K90®…………………….......10 % 
Glycerin triacetate………………...…….5 % 
Ethanol………………………..……..25.7 % 
Water………………………..…………50 % 
NaOH 0.1 M………………...…………...c.s. 
Orthophosphoric acid 0.1 M………..........c.s. 
 
In order to form the complex AmB: γ-CD, 0.1 M sodium hydroxide and 
orthophosphoric acid solutions were used. The complex was formed by the addition of 
AmB to a γ-CD water solution at pH 12 (NaOH 0.1 M). The subsequent decrease of the 
pH value to 5.5 was achieved with orthophosphoric acid. The polymer and plasticizer 
were added to this AmB- γ-CD complex resulting in a transparent solution that turned 
translucent immediately after ethanol addition.  
Once applied to the nail, the drying time compared to formula 3, was increased up to 7 
minutes. Moreover, the film formed was not homogenous since the AmB was not 
uniformly distributed within the lacquer.   
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Table 86 summarizes the results from the evaluation of formulation 4. 
Table 86. Evaluation of the physicochemical properties of formulation 4 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 2-3 The solution has an appropriate viscosity 
Brightness 2 N/A 
Drying time in the nail ≥ 5 min 7 min 
Stickiness 3 3 when applied and 1 when it gets dried 
Extensibility 3 It is easily extensible 
pH 5.5-6 Measured with paper bands 
 
 Formulation 5 
Taking into account that the ratio 1:30 AmB: γ-CD did not generate an homogenous 
AmB dispersion on the nail lacquer, we decided to increase the amount of γ-CD up to 
50% having a ratio 1:50. The amount of γ-CD that can be used in the formulation is 
limited by its solubility in water (2.32 g in 10 mL). For this reason, a maximum of 1.5% 
γ-CD can be included in the formulation.  
The increase on the percentage of γ-CD was accompanied by an increase on the water 
content in order to cover the cyclodextrins solubility. The ethanol was removed from 
the formulation due to the increase of both water and γ-CD. The glycerin triacetate was 
replaced for another plasticizer (PEG400) that does not generate oily drops in water. As 
previously stated, those drops disappeared after the addition of ethanol. In this case, 
since the formulation does not contain ethanol, the plasticizer was changed. 
AmB………………………………….0.3 % 
γ-CD…………………………………..15 % 
Plasdone K90®……………..………....10 % 
PEG400………………….………….….5 % 
Water……………………..………….69.7 % 
NaOH 0.1 M…………...………………...c.s. 
Orthophosphoric acid 0.1 M……......…....c.s. 
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The formulation was prepared following the same protocol used for formulation 4. In 
this case, the solution obtained was highly viscous in such a way that it could be 
considered more a gel than a solution. When applied to the nail, due to its high 
viscosity,  it did not leave an homogenous film. Furthermore, once it got dried, the film 
surface was rough.  
Table 87 summarizes the results from the evaluation of formulation 5. 
 
Table 87. Evaluation of the physicochemical properties of formulation 5 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 5 The solution is highly viscous 
Brightness 2 N/A 
Drying time in the nail ≥ 5 min 10 min 
Stickiness 3 3 when applied and 1 when it gets dried 
Extensibility 1 It is not easily extensible 
pH 5.5-6 Measured with paper bands 
 
From the first five formulations the following conclusions can be drawn: 
- Plasdone K90® produces homogenous films when used at 10%. 
- The best solvent to dissolve AmB is NMP. 
- The drying time depends on the formulation composition. The longest times 
were found in those formulations containing γ-CD. 
- The addition of ethanol to the above formulations made the solutions turned 
slightly translucent. 
 
 
 Formulation 6 
In this formulation the AmB dissolution was performed with Plasdone K90®. As 
detailed on Materials and Methods, this polymer is an amphiphilic molecule that may 
behaves as  AmB solubilizer without the need of any other solubilizing agent. In order 
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to check whether Plasdone® was able to solubilize the AmB or not, the following 
formulation was prepared. 
 
AmB………………………………….0.3 % 
Plasdone K90®………………..……....10 % 
PEG 400…………………….………….5 % 
Water……...……………….………..84.7 % 
NaOH 0.1 M…………………..………...c.s. 
Orthophosphoric acid 0.1 M…….....…....c.s. 
 
Briefly, the polymer water solution adjusted at pH 12 (0.1M NaOH) was added of 
AmB. Once the solution was transparent, the pH was shifted down to 5.5 and the 
plasticizer was then added. The solution was slightly translucent but it seemed well-
dispersed. Once applied to the nail it dried but it took longer than the formulations 
containing ethanol.  
This formulation remained stable after 1 month storage at 20ºC. There existed an 
interaction between the polymer and the drug which made the amphotericin B remained 
stable in solution for long periods of time. 
Table 88 summarizes the results from the evaluation of formulation 6. 
Table 88. Evaluation of the physicochemical properties of formulation 6 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 2-3 The solution has an appropriate viscosity 
Brightness 2 N/A 
Drying time in the nail ≥ 5 min 10 min 
Stickiness 3 3 when applied and 1 when it gets dried 
Extensibility 4-5 It is easily extensible 
pH 5.5-6 Measured with paper bands 
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 Formulation 7 
Formulation 7 has almost the same composition than Formulation 6 but in this case the 
water content was decreased because of the ethanol addition. The ethanol is necessary to 
decrease the dying time when applied to the nail. 
 
AmB………………………………….0.3 % 
Plasdone K90®………………..……....10 % 
Glycerin triacetate……………..……….4 % 
Ethanol………………………….…….20 % 
Water……...…………………….…..65.7 % 
NaOH 0.1 M……………………..……...c.s. 
Orthophosphoric acid 0.1 M…….....…....c.s. 
 
As expected, the drying time was decreased from 10 to 7 min. Even though there was a 
considerably reduction on the drying time, 7 minutes was still above the defined upper 
limit of 5 min.  
Table 89 summarizes the results from the evaluation of formulation 7. 
 
Table 89. Evaluation of the physicochemical properties of formulation 7 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 2-3 The solution has an appropriate viscosity 
Brightness 2 N/A 
Drying time in the nail ≥ 5 min 7 min 
Stickiness 3 3 when applied and 1 when it gets dried 
Extensibility 4-5 It is easily extensible 
pH 5.5-6 Measured with paper bands 
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 Formulation 8 
Formulation 8 differs from formulation 7 on the percentage of ethanol. In this 
formulation the ethanol was increased in a 10% and the water content was decreased in 
the same percentage. 
AmB………………………………….0.3 % 
Plasdone K90®……………………......10 % 
Glycerin triacetate…………………..….4 % 
Ethanol………………………………...30 % 
Water……...………………………....55.7 % 
NaOH 0.1 M…………………………......c.s. 
Orthophosphoric acid 0.1 M………..........c.s. 
 
The film formed by Formulation 8 got dried within 4 minutes once applied to the nail.  
Table 90 summarizes the results from the evaluation of formulation 8. 
 
Table 90. Evaluation of the physicochemical properties of formulation 8 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 2-3 The solution has an appropriate viscosity 
Brightness 1-2 N/A 
Drying time in the nail ≤ 5 min 4 min 
Stickiness 3 3 when applied and 1 when it gets dried 
Extensibility 4-5 It is easily extensible 
pH 5.5-6 Measured with paper bands 
 
 
 
 Formulation 9 
In formulation 9 the AmB was dissolved using sodium deoxycholate (DocNa). The ratio 
used for the AmB dissolution was the same as for Fungizone®, that is 1:0.82 
AmB:DocNa. 
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AmB………………………………….0.3 % 
DocNa……………………….…….0.246 % 
Plasdone K90®………………..……....10 % 
PEG 400……………………….……….5 % 
Water……...………………….......84.454 % 
NaOH 0.1 M……………………..……...c.s. 
Orthophosphoric acid 0.1 M…….....…....c.s. 
 
The sodium deoxycholate has the ability of complexing the AmB inside the micellar 
system tha it is formed in contact with water. DocNa is able to maintain the AmB in 
solution even after pH decrease (pH 7.4). The only disadvantage related to the use of 
DocNa is its poor stability at pHs lower than 7.4. Below pH 7.4 this bile salt is not 
anymore stable and it starts to precipitate.  
This formulation was stable at pH 7.4 for at least 4 weeks. During the assayed period 
the solution remained transparent. 
 
Table 91. Evaluation of the physicochemical properties of formulation 9 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 2-3 The solution has an appropriate viscosity 
Brightness 2-3 N/A 
Drying time in the nail ≥ 5 min ≥ 10 min 
Stickiness 2 2 when applied and 1 when it gets dried 
Extensibility 4 It is easily extensible 
pH 7.4 Measured with paper bands 
 
 
 Formulation 10 
Even though formulation 9 took long to get dried over the nail, its aspect and long 
stability made us consider it as a good candidate for AmB delivery. In order to improve 
the drying time some modifications were performed on formulation 9. 
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The first modification was based on the addition of a keratolityc agent, the urea, at a 
10%. As previously stated, at 10% or higher concentrations the urea is able to soften the 
tissues and enhance the drug penetration. 
AmB………………………………….0.3 % 
DocNa……………………….…….0.246 % 
Plasdone K90®…………………..…....10 % 
PEG 400………………………….…….5 % 
Urea……………………………….…..10 % 
Water……...………………….......74.454 % 
NaOH 0.1 M………………………..…...c.s. 
Orthophosphoric acid 0.1 M……….........c.s. 
 
The preparation protocol for Formulation 10 is detailed on Materials and Methods. It is 
worth pointing out that during preparation we realized that the addition of urea made the 
solution turned translucent. 
Table 92. Evaluation of the physicochemical properties of formulation 10 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 3 The solution has an appropriate viscosity 
Brightness 2 N/A 
Drying time in the nail ≥ 5 min ≥ 10 min 
Stickiness 2 2 when applied and 1 when it gets dried 
Extensibility 4 It is easily extensible 
pH 7.4 Measured with paper bands 
 
 
 Formulation 11 
The second modification performed on formulation 9, which was focused on the 
addition of ethanol, made us considered formulation 11 as a lead candidate for AmB 
delivery. 
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AmB………………………………….0.3 % 
DocNa……………………….…….0.246 % 
Plasdone K90®………………..……....10 % 
PEG400...............……………...……….4 % 
Ethanol………………………...…35.454 % 
Water……...…………………..............50 % 
NaOH 0.1 M……………………..……...c.s. 
Orthophosphoric acid 0.1 M……....…....c.s. 
 
The addition of ethanol was performed in order to decrease the drying time. 
 
Table 93. Evaluation of the physicochemical properties of formulation 11 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 3 The solution has an appropriate viscosity 
Brightness 2 N/A 
Drying time in the nail ≤ 5 min 3-4 min 
Stickiness 1 N/A 
Extensibility 4 It is easily extensible 
pH 7.4 Measured with paper bands 
 
 
 Formulation 12 
Formulation 12 came out from the combination of the two modifications carried out on 
formulation 9 and 11. Those are the incorporation of urea and the addition of ethanol. 
The percentage of ethanol was decreased in a 10% (from 35.454% to 25.454%) due to 
the incorporation of urea in the formulation. 
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AmB………………………………….0.3 % 
DocNa………………….………….0.246 % 
Plasdone K90®…………..…………....10 % 
PEG 400..............………...…………….4 % 
Urea……………………….…………..10 % 
Ethanol…………………….…..…25.454 % 
Water……...………………..…............50 % 
NaOH 0.1 M…………………...………...c.s. 
Orthophosphoric acid 0.1 M……......…....c.s. 
 
Both, the addition of ethanol and the urea produced a changed in the aspect of the 
formulation. The formulation, initially transparent, turned slightly translucent after 
addition of ethanol and/or urea, but it remained stable without signs of precipitation at 
least during 2 weeks. 
The drying time with formulation 12 was increased approximately 1 minute compared 
to formulation 11 due to the reduction on ethanol percentage.  
 
Table 94. Evaluation of the physicochemical properties of formulation 12 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 3 The solution has an appropriate viscosity 
Brightness 2 N/A 
Drying time in the nail ≤ 5 min 4-5 min 
Stickiness 1 N/A 
Extensibility 4 It is easily extensible 
pH 7.4 Measured with paper bands 
 
 Formulation 13 
In order to decrease the drying time to 3-4 minutes, formulation 12 was modified. The 
ethanol was increased in a 5% and the water content was decreased in the same 
percentage. In this way, and compared to formulation 11, the amount of solvent and 
cosolvent (water and ethanol) were decreased in the same proportion (5%) and a 10% 
urea was added.  
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AmB………………………………….0.3 % 
DocNa………………………….….0.246 % 
Plasdone K90®…………………..…....10 % 
PEG 400..............………………...…….4 % 
Urea……………………………….…..10 % 
Ethanol………………………...…30.454 % 
Water……...…………………..............45 % 
NaOH 0.1 M……………………...…......c.s. 
Orthophosphoric acid 0.1 M……….........c.s. 
 
The readjustment on the amount of ethanol and water on formulation 13 reduced, just 
slightly, the drying time over the nail (from 4.5 minutes to 4 minutes). 
 
Table 95. Evaluation of the physicochemical properties of formulation 13 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 4 The viscosity is slighter higher 
Brightness 2 N/A 
Drying time in the nail ≤ 5 min 4 min 
Stickiness 1 N/A 
Extensibility 4 It is easily extensible 
pH 7.4 Measured with paper bands 
 
 
AP1.4.1.1.2. Incorporation of amphotericin B in the water soluble nail lacquers 
using Pluronic® F127 as film forming agent. 
 Formulation 14 
For this formulation a new polymer was used as film forming agent. Based on the data 
reported by Nogueiras-Nieto et al. [473] we decided to design a nail lacquer containing 
Pluronic® F127 as film forming agent. The percentage of Pluronic® F127 used was 
20% and the AmB was dissolved using DocNa. 
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AmB………………………………….0.3 % 
DocNa……………………………..0.246 % 
Pluronic F127®…………………….....20 % 
Glycerin triacetate………………….….4 % 
Ethanol………………………..….30.454 % 
Water……...…………………..............45 % 
 
The dissolution of Pluronic® F127 during sample preparation took around 45 minutes, 
which slowed down and difficulted the formulation process. The aspect of the solution 
obtained after the addition of all the components was yellowish translucent.  
The application of Formulation 14 over the nail, left a non homogenous film which 
dried slowly (9 minutes). 
 
Table 96. Evaluation of the physicochemical properties of formulation 14 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 3 The solution has an appropriate viscosity 
Brightness 4 N/A 
Drying time in the nail ≥ 5 min 9 min 
Stickiness 1 N/A 
Extensibility 5 It is easily extensible 
pH 7.4 Measured with paper bands 
 
 
 Formulation 15 
In order to check if there were some improvements on the film formed by F14 with the 
additon of a keratolytic agent, a 10% urea was included.  The amount of ethanol and 
water were decreased in the same proportion, 5% each. 
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AmB………………………………….0.3 % 
DocNa……………………………..0.246 % 
Pluronic F127®……………………......20 % 
Glycerin triacetate……………….….….4 % 
Urea………………………….………..10 % 
Ethanol………………………...…25.454 % 
Water……...…………………..............40 % 
 
The film formed with this new formulation did not present any advantage compared to 
Formulation 14, even more, the drying time was increased in almost 1 minute. 
 
Table 97. Evaluation of the physicochemical properties of formulation 15 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum)) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 3 The solution has an appropriate viscosity 
Brightness 3 N/A 
Drying time in the nail ≥ 5 min 10 min 
Stickiness 1-2 N/A 
Extensibility 5 It is easily extensible 
pH 7.4 Measured with paper bands 
 
Formulations 14 and 15 precipitated after two days storage at 20ºC and consequently, 
they were discarded. 
 
 Formulation 16 
The stability problems found with formulations 14 and 15 were managed through the 
removal of ethanol from the composition. Even though that decision would carried out a 
longer drying time, we wanted to check whether or not the formulation stability was 
improved.  
 
 
Complementary information 
 
328 
AmB………………………………….0.3 % 
DocNa………………………….….0.246 % 
Pluronic F127®………………..……....20 % 
Glycerin triacetate……………..……….4 % 
Water……...………………..….....75.454 % 
  
The elimination of ethanol from the formulation did not only resulted in longer drying 
times (≥10 min) but also in a highly viscous solution. In the absence of ethanol the 
polymer solubility took even longer (approximately 60 min). 
 
Table 98. Evaluation of the physicochemical properties of formulation 16 (scale 1-5) 
Parameter 
Evaluation 
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 
In contact with water the film is completely 
removed 
Viscosity 5 The solution was highly viscous 
Brightness 3 N/A 
Drying time in the nail ≥ 5 min ≥ 10 min 
Stickiness 1-2 N/A 
Extensibility 5 It is easily extensible 
pH 7.4 Measured with paper bands 
 
 Formulation 17 
The stability problems found on formulations 14 and 15 can be explained by an 
incompatibility between the sodium deoxycholate and the polymer. For this reason, in 
formulation 17, the AmB was dissolved using γ-CD. The ratio AmB: γ-CD used was 
1:50.  
AmB………………………………….0.3 % 
γCD……………………………….…..15 % 
Pluronic F127®………………….…....20 % 
Glycerin triacetate……………….…….4 % 
Water…………………………….…70.7 % 
 
In this case, the pH of the formulation was decreased up to 5.5 as the γ-CD are stable 
over a wide range of pHs. The resulting formulation was extremely viscous. It did not 
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almost have mobility within the vial in which it was prepared. At pH 12 there was an 
interaction between the γ-CD and the poloxamer that made the polymer jellify when 
neutralizing the solution. 
 
Table 99. Evaluation of the physicochemical properties of formulation 17 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 5 In contact with water the film is completely 
removed 
Viscosity 5* The solution extremely viscous. It jellified. 
Brightness 3 N/A 
Drying time in the nail ≥ 5 min The gel did not get dried 
Stickiness 4-5 N/A 
Extensibility 1 It is hard to extend due to its high viscosity 
pH 5.5 Measured with paper bands 
 
The above formulations (formulations 1 to 17) have in their composition a water soluble 
polymer. The polymers used, Plasdone K90® and Pluronic F127® form a film that it is 
immediately dissolved when in contact with water. This water solubility is a great 
advantage as the lacquer can be easily removed from the nails without the need of 
organic solvents. Nevertheless, there is an important disadvantage associated to the use 
of these water soluble lacquers which can lead to treatment failure. Once the lacquer is 
applied and dried over the nail (overall when applied to the fingernails), if the patients 
wash their hands, or the nails are exposed to high humid ambients, the film can be 
broken without leaving enough time for the amphotericin B to penetrate the nail and 
therefore, to make its therapeutic action. 
The development of an AmB water impermeable lacquer is, therefore, an important 
issue for the treatment of onychomycosis and patient therapeutic compliance.  
The following formulations, Formulations 18 to 20 have in their composition a water  
impermeable polymer that assures the film integrity over the nail even in contact with 
water.  
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AP1.4.2. Water insoluble nail lacquers 
Based on a deep bibliographic research including papers and patents (i.e. 
US20110200544 A1 (2009) patent entitled "Urea-based film forming solution for 
treating nail psoriasis"), a water impermeable nail lacquer was prepared. Following 
what is described in those publication (the use of different types of Eudragits in a 
percentage ranging 5-15% as film forming agent), the Eudragit L100® was selected as 
film forming agent for the development of a water impermeable nail lacquer. 
 
 Formulation 18 
Apart from Eudragit L100® as film forming agent, in the composition of this 
formulation, the PEG400 was used as plasticizer and the NMP as solvent, AmB 
solubilizer and penetration enhancer.  
Even though, the use of NMP as Eudragit L100® solubilizer had not been previously 
reported, it was decided to assay the polymer solubility on this solvent. As reported in 
section AP4.1.2, the NMP was the solvent in which the AmB showed its highest 
solubility. The NMP has been widely used in different pharmaceutical formulations as 
penetration enhancer, providing the drug to reach its site of action.  
AmB………………………………….0.3 % 
Eudragit L100®…………………..…....15 % 
PEG 400…………………………..…….5 % 
NMP………………………………....79.7 % 
  
As detailed in materials and methods, the NMP was first used to dissolved the AmB and 
then the polymer. Once both were dissolved, the PEG400 was added. The final solution 
had a yellowish-transparent aspect and was slightly viscous. When applied to the nail, 
the film did not got dried due to the long evaporation time of the NMP.  
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Table 100. Evaluation of the physicochemical properties of formulation 18 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 1 In contact with water the film remains intact 
Viscosity 3 The solution was slightly viscous 
Brightness 3-4 N/A 
Drying time in the nail ≥ 5 min It did not get dried 
Stickiness NA Not evaluable as the film is not getting dry 
Extensibility 5 It is easily extendible  
pH 5.5-6 Measured with paper bands 
 
 
 Formulation 19 
The drying problems associated to the use of NMP as unique solvent for both AmB and 
polymer, were resolved by the addition of ethanol as Eudragit L100® solvent.  
AmB………………………………….0.3 % 
NMP…………………………………..10 % 
Eudragit L100®………………..……....15 % 
PEG 400………………………..……….5 % 
Ethanol…………………………..…..69.7 % 
 
Briefly, the formulation was prepared by the addition of the AmB dissolved in NMP to 
the ethanol solution containing the Eudragit L100®. The last step was the PEG400 
incorporation.  
The solution obtained was yellow-orangish translucent and when applied to the nail 
using a brush it quickly dried (within 3 minutes) forming a colored film. 
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Table 101. Evaluation of the physicochemical properties of formulation 19 (scale 1-5) 
Parameter Evaluation  
(1 minimum; 5 maximum) 
Observations 
Water permeability 1 In contact with water the film remains intact 
Viscosity 2-3 The solution extremely viscous. It jellified. 
Brightness 3 N/A 
Drying time in the nail 2-3 min It quickly dries 
Stickiness 2 1 when it gets dry  
Extensibility 5 It is easily extendible 
pH 5.5-6 Measured with paper bands 
 
 Formulation 20 
Even though formulation 19 showed great properties as impermeable nail lacquer, we 
considered to improve the formulation by the addition of a queratolytic agent, the urea. 
The urea is well known to be insoluble in ethanol but we wanted to check whether or 
not we were able to include it in the formulation using the mixture ethanol-NMP. 
In order to include the urea in the formulation, the percentage of ethanol was decreased 
in a 10%. 
AmB………………………………….0.3 % 
NMP…………………………………..10 % 
Eudragit L100®…………………..…....15 % 
PEG 400…………………………..…….5 % 
Urea………………………………..…..10 % 
Ethanol…………………………….....59.7 % 
 
As expected, the urea was not getting dissolved in the mixture ethanol-NMP. Therefore, 
this formulation was not considered as a candidate. 
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A B S T R A C T 
 
A novel formulation for amphotericin B (AmB) delivery has been developed using micelle-forming 5 kDa monomethoxy-
polyethylene glycol functionalized with cholanic acid (PEG5kDa-cholane). This polymer was found to increase 10
3
 times the 
AmB solubility witha12:1AmB/PEG5kDa-cholane molar ratio (2:1 w/wratio). Dynamic light scattering and transmission 
electron microscopy analyses showed that PEG5kDa-cholane associated with AmB to form 30 nm micelles. Isothermal 
titration calorimetry analyses performed at different pH showed that PEG5kDa-cholane interacts with AmB according to 
multiple-site association profiles. Affinity constants and enthalpy and entropy changes were found to depend on pH, 
suggesting that the polymer interaction depends on the AmB ionization and aggregation. The freeze-dried product could be 
promptly re-dispersed forming a colloidal dispersion with the biopharmaceutical features of the freshly prepared micelles, 
namely AmB solubility and micelle size. The dispersion was stable over one month incubation at room temperature. FT-
infrared spectrometry, differential scanning calorimetry and X-ray diffractometry showed that in the freeze-dried product, 
AmB intimately interacts with PEG5kDa-cholane. In presenceofserum albumin, AmB formulatedwith PEG5kDa-cholane 
wasfoundto undergo less extensive and slower disaggregation than in Fungizone
1
. Antifungal activity studies performed using 
Candida albicans showed that AmB/PEG5kDa-cholane was 15% more active than AmB in buffer. 
 
ã 2015 Elsevier B.V. All rights reserved. 
 
 
 
1. Introduction 
 
Amphotericin B (AmB) is a macrolide antibiotic with broad spectra of 
action widely used in the treatment of systemic fungal infections since more 
than 40 years (Gray et al., 2012; Gagos and Arczewska, 2010). Even though 
several new antifungal drugs have been developed, AmB remains the drug of 
choice for treatment of severe systemic fungal diseases as it does not cause 
microbial resistance (Gray et al., 2012), and for treatment of visceral 
leishmaniasis when the parasite develops resistance to antimonial compounds 
(Larabi et al., 2003; Brajtburg and Bolard, 1996; Volmer et al., 2010). 
Nevertheless, AmB administration is often associated with severe dose-
limited toxicity, namely nephrotoxicity, anemia, phlebitis and general malaise 
side effects,which strongly limititsuse (Lemke et al., 2005; Yu et al., 1998b). 
Furthermore, the AmB aggregation is responsible of unspecific cytotoxic 
effects towards 
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ã 2015 Elsevier B.V. All rights reserved. 
 
 
 
cells with ergosterol/cholesterol rich membranes (Gaboriau et al., 1997). 
 
The poor AmB solubility is the main drawback to the development of 
pharmaceutical formulations. So far, many attempts have been made to 
develop AmB formulations with enhanced therapeutic profiles, including solid 
lipid nanoparticles, polymeric nanoparticles, liposomes, micelles and polymer 
bio-conjugates (Vandermeulen et al., 2006; Elgart et al., 2010). 
 
Fungizone
1
, in which micelle forming sodium deoxycholate was used as 
solubilizer, is the first commercialized AmB formulation (Rajagopalan et al., 
1986; Oka and Kamimori, 2013; Fukui et al., 2003). However, the intrinsic 
toxicity of this low molecular weight surfactant was found to enhance the 
nephrotoxic and hemolytic effects of AmB (Yu et al., 1998a; Oka and 
Kamimori, 2013). Moreover, the high critical micelle concentration (CMC) of 
sodium deoxycholate is responsible for in vivo micelle instability that results 
in AmB release and aggregation with consequent non-selective channel 
formation damaging cells with high content of ergosterol or cholesterol 
(Brajtburg and Bolard, 1996). 
Publication 
 
336 
 
42 C. Luengo-Alonso et al. / International Journal of Pharmaceutics 495 (2015) 41–51 
 
Lipidic systems, namely Ambisome
1
, Abelcet
1
 and Amphotec
1
 do not 
display the high toxicity of Fungizone
1
. Nevertheless, high cost and 
biopharmaceutical instability are important limiting factors to their use (Das 
and Suresh, 2011; Chakraborty and Naik, 2003). Abelcet
1
 is formed by large 
size particles that are rapidly taken up by macrophages thus cumulating in 
liver and spleen, which on one side shortens the circulating and on the other 
increases its volume of distribution and clearance. Ambisome
1
 substantially 
escapes recognition and uptake by the mononuclear phagocyte system (MPS) 
but tends to accumulate in high amount in the liver and spleen. Finally, 
Amphotec
1
 exhibits dose-limiting infusion-related toxicities. Interestingly, 
clinical trials showed that despite the lipid-associated formulations were 
significantly less nephrotoxic than AmB/deoxycholate, they were not 
significantly better than the latter for treatment of several diseases, including 
AIDS-associated acute cryptococcal meningitis (Hamill, 2013). 
 
 
Polymeric micelles have some advantages over lipid-based systems such 
as easy preparation process, higher thermodynamic and kinetic stability, 
which confers higher stability towards dilution in vivo, and prolonged blood 
circulation due to a lower uptake from the MPS (Adams et al., 2003). A few 
PEG containing polymers have been used to produce AmB pharmaceutical 
products. PEG is a soluble non-toxic, low immunogenic and low antigenic 
polymer widely applied for preparation of hybrid macromolecules controlled 
drug delivery systems such as PEG-cyclodextrins (He et al., 2013; Salmaso et 
al., 2007). PEG prolongs the circulation of colloidal drug delivery systems as 
it prevents their massive accumulation in MPS rich organs, namely liver and 
spleen (Jung et al., 2009; Schreier et al., 2000), reduces the kidney 
elimination and the capillary penetration (Croy and Kwon, 2006; Yu et al., 
1998a,b; Lukyanov and Torchilin, 2004). Micelle formulations obtained using 
poly(ethylene glycol)-block-poly (-caprolactone-co-trimethylenecarbonate) 
and PEG–DSPE showed that the AmB solubility could increase of 2 order of 
magnitude (Vandermeulen et al., 2006). Interestingly, the physical combina-
tion of PEG–DSPE with sterol molecules was found to determine both the 
solubility and the aggregation state of AmB. 
 
 
 
Monomeric AmB is known to selectively interact with ergosterol in 
fungal cell membranes, forming channels by the classic barrel stave motif, 
while aggregated AmB preferentially associates with cholesterol, which 
causes toxicity in mammalian cells. Therefore, polymers containing sterol 
molecules have been hypothesized to be suitable materials for preparation of 
stable AmB colloidal formulations. Typically, PEG-cholesterol type polymers 
have been found to produce micelles with about 10 
6
 M CMC (Croy and 
Kwon, 2006; Lukyanov and Torchilin, 2004; Li et al., 2010), which are much 
more stable compared to sodium deoxycholate (CMC 2–6 10 
3
 M) (Li et al., 
2010). Recently, self-assembling polymers obtained by end-conjugation of 
cholanic acid to monomethoxypoly(ethylene glycol) chains have been 
investigated for the delivery of proteins and low mol. wt. drugs (Salmaso et 
al., 2012, 2014). These PEG-cholane polymers were found to associate with 
proteins by cholanic moiety docking into the hydrophobic clefts and 
interaction with hydrophobic surfaces of proteins yielding novel 
supramolecular systems for protein delivery. 
 
 
 
Due to the strong affinity of sterol moieties for AmB and the ability of 
PEG-cholane to dissolve hydrophobic drugs by forming micelles, these 
polymers seem to possess the requisites for obtaining new efficient colloidal 
systems for delivery of this antifungal drug. Accordingly, a dissolution study 
was carried out and spectrometric analyses were performed to evaluate the 
physical and biopharmaceutical properties of the new micelle formulation, 
namely drug aggregation and stability. Finally a biological study was carried 
out to evaluate the antifungal activity of the novel formulation. 
 
2. Materials and methods 
 
Amphotericin B (AmB) was purchased from Azelis (Barcelona, Spain) 
and Fungizone
1
 from Bristol-Myers Squibb (Madrid, Spain). Globulin free 
human serum albumin and 5b-cholanic acid were supplied by Sigma–Aldrich 
(Milan, Italy). 5 kDa amino-terminating monomethoxy-terminating 
poly(ethylene glycol) (PEG5kDa-NH2) and hydroxyl-terminating 
monomethoxy-terminating poly(ethyl-ene glycol) (PEG5kDa-OH) were 
supplied by Iris Biotech GmbH (Marktredwitz, Gemany). Certified Candida 
albicans strain (CECT1394) was a gift of Dr. Pérez Carrasco from Centro de 
Análisis Químico y Microbiológico (CAQYM), Universidad Alcalá de 
Henares (Madrid, Spain). Culture media were purchased from Pronadisa-
Conda Lab (Madrid, Spain). Technical grade and HPLC grade solvents and 
salts were purchased from Merck (Milan, Italy). 
 
 
2.1. Synthesis of monomethoxy-poly(ethylene glycol)-cholane 
(PEG5kDa-cholane) 
 
Monomethoxy-poly(ethylene glycol)-cholane (PEG5kDa-cholane) was 
synthesized according tothepreviously published protocol with modifications 
(Salmasoetal., 2012). Briefly, thionyl chloride (524 mL, 7.2 mmol) was added 
to 5b-cholanic acid (260 mg, 0.72 mmol) in 6 mL CH2Cl2. The mixture was 
refluxed under nitrogen atmosphere at 50 C for 3 h and then the unreacted 
thionyl chloride was removed by distillation. After solvent evaporation, an 
aliquot of activated cholane was reacted with CH3OH and analyzed by 
1
H 
NMR spectrometry using a Bruker Spectrospin 300 spectrometer (Bruker, 
Fallanden, Switzerland) to estimate the activation degree. Cholanyl chloride 
(218 mg, 0.576 mmol) in 1 mL CH2Cl2 was added of 53.5 mL TEA (0.384 
mmol) and 4 mL CH2Cl2 of 242.7 mg/mL PEG5kDa-NH2 (970.8 mg, 0.192 
mmol). The reaction solution was maintained overnight under stirring at room 
temperature and then dropwise added to 35 mL of diethyl ether. The 
precipitate was recovered by centrifugation at 4000 rpm for 15 min and re-
dissolved in 5 mL CH2Cl2. The precipitation was repeated three times. The 
precipitate was desiccated under vacuum and finally lyophilized in a Hetossic 
equipment (HETO Lab, Birkerod, Denmark). The degree of PEG-NH2 
derivatization with cholanyl chloride was evaluated by the TNBS colorimetric 
assay, which allows for determination of unreacted amino groups (Snyder and 
Sobocinski, 1975) and by 
1
H NMR spectrometry. 
 
 
1
H NMR (300 MHz, CDCl3): d 0.64 [s, 3H, CH3 cholane], d 0.911— 
0.911–0.928 [s + d, 6H, CH3 (C18) + CH3 (C21) cholane], d 3.381 [s, 3H, 
CH3O-MeO-PEG], d 3.645 [s, 4nH, ( CH2CH2-O)n MeO–PEG]. 
 
2.2. Amphotericin B dissolution 
 
Dissolution studies were carried out according to three methods: (1) direct 
dissolution; (2) co-solvent dissolution; (3) dissolution/pH change. 
 
2.2.1. Direct dissolution  
Samples of 4 mg AmB in 500 mL CH3OH where desiccated using a 
speed-vac system. The dried samples were added of 500 mL of 0.5, 1, 1.5, 2, 
3 and 6 mg/mL PEG5kDa-cholane or PEG5kDa-OH in water, pH 7.2, and 
maintained overnight under top–down mixing. The samples were centrifuged 
at 12,000 rpm for 10 min. The AmB concentration in the supernatant was 
determined by reverse-phase chromatography (RP-HPLC) using a Thermo 
Hypersil BDS
1
 C18 column (200 4.6 mm, 5 mm) operated on a Jasco HPLC 
system equipped with a Jasco PU-1580 pump and UV–vis detector set at 406 
nm (Jasco, Tokyo, Japan). The column was isocratically eluted at a flow rate 
of 1 mL/min with 52:4.3:43.7 v/v/v acetonitrile/acetic acid/water mobile 
phase (Espada et al., 2008a). The AmB concentration in the samples was 
determined 
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on the basis of the elution peak area, which was referred to a titration curve 
obtained by eluting AmB samples at concentrations in the range of 0.012–40 
mg/mL [(AmB concentration) = 115.1(peak area)–1.665; R
2
 = 1.00]. 
 
2.2.2. Co-solvent dissolution  
Samples of 4 mg of AmB in 500 mL CH3OH were added of 100 mL of 
2.5, 5, 7.5, 10, 15 and 30 mg/mL PEG5kDa-cholane or PEG5kDa-OH in water, 
pH 7.2. The mixtures were dried in speed-vac and the residues were re-
dispersed in 500 mL water at pH 7.2 and maintained overnight under top–
down mixing. The samples were centrifuged at 12,000 rpm for 10 min and the 
AmB in the supernatant was analyzed by RP-HPLC as reported above. 
 
 
2.2.3. Dissolution/pH change  
The AmB dissolution was performed according to the method described 
by Higuchi and Connors (1965). Briefly, 20 mg of AmB were dissolved in 1 
mL of 0.5, 1, 1.5, 2, 3 and 6 mg/mL PEG5kDa-cholane or PEG5kDa-OH in 
0.05 N NaOH. The pH was then shifted to 7.2 with 0.1 M ortophosphoric acid 
and the suspensions were centrifuged at 12,000 rpm for 10 min. The AmB in 
the supernatant was analyzed by RP-HPLC as reported above. 
 
 
2.3. Isothermal titration calorimetry 
 
Isothermal titration calorimetry (ITC) analyses were carried out using an 
MSC-ITC instrument (Microcal Inc., Northampton, MA). AmB solutions 
were prepared by dissolution/pH change and concentration was determined by 
RP-HPLC analysis as reported above. AmB (1.1 10 
5
 M) and PEG5kDa-
cholane (0.6 10 
3
 M) solutions in water at pH 3.5, 5.5, 7.2, 8.5 and 11.0, were 
degassed and thermostated at 25 C before the analysis. At 5 min intervals, 5 
mL volumes of PEG5kDa-cholane solutions were injected in 10 s into the 
calorimeter cell containing 1.5 mL AmB solutions at the same pH. Each assay 
was performed in triplicate and the data analysis was performed with 
Microcal Origin 3.5 software. 
 
 
2.4. Dynamic light scattering and zeta potential analyses 
 
AmB/PEG5kDa-cholane aqueous solutions (1 mg/mL AmB, 12:1 
AmB/PEG5kDa-cholane molar ratio) prepared by dissolution/ pH change were 
analyzed at different times (0, 7, 14, 21, 28, 35, 42, 49, 56 and 63 days) by 
dynamic light scattering (DLS) using a Malvern Zetasizer Nano-ZS (Malvern, 
Worcestershire, UK). The analyses were performed in triplicate at 25 C, 633 
nm wavelength and 173 detection angle to assess the mean particle size, size 
distribution and zeta potential. 
 
 
2.5. Freeze drying 
 
AmB/PEG5kDa-cholane samples (10 mL, 1 mg/mL AmB, 12:1 
AmB/PEG5kDa-cholane molar ratio) were prepared by dissolution/pH change, 
frozen with liquid N2 and lyophilized using a Lio-labor
1
 instrument (Telstar, 
Barcelona, Spain) for 48 h. The freezing and sublimation temperatures in the 
lyophilization chamber were 45 C and from 45 to 25 C, respectively. The 
sublimation pressure was 4.54 10 
4
 atm. The moisture content in the 
lyophilized product was determined as weight loss after heating at 105 C 
using a Mettler PM100 balance equipped with a Mettler LP16 infrared drying 
unit (Mettler Toledo, Greifensee, Switzerland). The end point was estimated 
after 120 s without weight variation. Reconstitution of the freeze dried 
samples was performed by the addition of 10 mL 10 mM phosphate buffer, 
0.15 M NaCl (PBS), pH 7.2. Particle size and AmB concentration analyses of 
reconstituted solutions were carried out at times 0, 7, 
 
14, 24 and 31 days by DLS and RP-HPLC, respectively, according to the 
analytical protocols reported above. 
 
2.6. Physicochemical analyses 
 
Samples of AmB, PEG5kDa-OH, PEG5kDa-cholane, lyophilized 
AmB/PEG5kDa-cholane (12:1 AmB/PEG5kDa-cholane molar ratio) prepared 
by dissolution/pH change and AmB/PEG5kDa-cholane physical mixtures 
(12:1 AmB/PEG5kDa-cholane molar ratio) obtained by mixing AmB and 
PEG5kDa-cholane dry powders were analysed by differential scanning 
calorimetry, hot stage microsco-py, X-ray diffractometry and Fourier-
transformed infrared spec-troscopy. 
 
2.6.1. Differential scanning calorimetry (DSC)  
DSC analyses were performed using a Mettler TA3000 differential 
scanning calorimeter DSC 20 (Mettler Toledo, Greifensee, Switzerland). 
Samples (10 mg) were placed on a pinhole aluminum lidded pan and heated 
in atmospheric air at a rate of 10 C/min from 30 to 250 C. 
 
 
2.6.2. Hot stage microscopy (HSM)  
HSM analyses were performed by placing the samples on a microscope 
covered slide and heated at a rate of 2 C/min from 25 to 250 C. Microscopy 
determinations were carried out using a Thermo Galen microscope fitted with 
the Kofler stage (Leica, Wien, Austria) (Ruiz-Caro and Veiga-Ochoa, 2009). 
 
 
2.6.3. X-ray diffractometry (XRD)  
XRD analyses were carried out with an X-ray diffractometer Philips
1
 
X’Pert-MPD (PANalytucal, Amelo, Netherlands). The samples were placed 
on a carrier, irradiated with monochromat-ized CuKa-radiation and analyzed 
between 2u angles of 5 and 50 with 0.04 steps of 1 s. The assay was 
performed at 30 mV voltage and 30 mA intensity. 
 
 
2.6.4. Fourier-transformed infrared spectroscopy (FT-IR)  
FT-IR spectra were recorded over the range 4000–400 cm 
1
 using a FT-IR 
Nicolet Magna 750 spectrometer (0.5 cm 
1
 resolu-tion) equipped with an 
attenuated total reflectance (ATR) Spectra Tech Performer with diamond 
crystal (Thermo Fisher Scientific, Waltham, MA, USA). The data were 
analysed with Thermo software. 
 
 
2.7. Transmission electron microscopy 
 
Samples for negative-stain transmission electron microscopy (TEM) 
analysis were prepared by depositing one drop of AmB/ PEG5kDa-cholane 
(12:1 molar ratio) micelles, prepared by dissolu-tion/pH change, stained with 
1% phosphotungstic acid for 20 s into Formvar/carbon-coated TEM copper 
grids (size 3.05 mm) for 30 s. The grids were left drying at room temperature 
for 15 min before the analysis. The samples were examined and photographed 
in a Jeol JEM 1010 transmission electron microscope (Jeol Ltd., Tokyo, 
Japan) equipped with a Megaview II imaging camera and operating at 100 kV 
(resolution 0.35 nm). 
 
 
2.8. Human serum albumin circular dichroism analyses 
 
Human serum albumin (HSA) solutions (1.5 10 
7
 M) in PBS, pH 7.2, in 
the absence or in the presence of 1.37 10 
7
 M AmB or equivalent AmB 
concentration of Fungizone
1
, heated Fungizone
1
 (obtained by 30 min heating 
Fungizone
1
 at 70 C) or AmB/PEG5kDa-cholane micelles (12:1 
AmB/PEG5kDa-cholane molar ratio) pre-pared by dissolution/pH change 
were analyzed by circular dichroism (CD) in the far UV (200–300 nm, 50 
nm/s with 8 s 
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response and 2 nm band width) using a J-810 Jasco spectrodichro-graph 
(Jasco, Tokyo, Japan). The spectra were processed by Dicroprot software and 
the protein secondary structure was calculated by KD2 analysis. CD analyses 
were also performed after sample incubation at 37 C for 15 min (Hartsel et 
al., 2001). 
 
2.9. Absorption and kinetics studies 
 
AmB (5 10 
5
 M) or AmB equivalent concentration of Fungizone
1
, heated 
Fungizone
1
 and AmB/PEG5kDa-cholane micelles (12:1 AmB/PEG5kDa-
cholane molar ratio) prepared by dissolution/pH change in PBS, pH 7.2, were 
1:10 diluted with a 2.3 10 
4
 M HSA in the same buffer and 
spectrophotometrically analyzed by UV absorption in the range of 300–450 
nm at 25 and 37 C using an Evolution 201 UV–vis spectrophotometer 
equipped with a single cell peltier system (Thermo Fisher Scientific). 
Absorption spectra were recorded at 0, 1, 2, 5, 10, 20 and 45 min. Kinetic 
analysis were performed recording the absorption at 413 nm, at 15 s intervals 
for the first 5 min and then at 1 min intervals for further 40 min (Vakil and 
Kwon, 2007). 
 
 
2.10. Dialysis studies 
 
One millilter of 30 mg/mL AmB equivalent of AmB/PEG5kDa-cholane 
micelles (12:1 AmB/PEG5kDa-cholane molar ratio) in PBS, pH 7.4, were 
dialyzed against 500 mL PBS, pH 7.4 using a Float-A-Lyzer
1
 G2 system, 
3.5–5 kDa cut-off. The AmB concentration inside the dialysis bag was 
determined at fixed time points by RP-HPLC according to the method 
reported above. 
 
2.11. Microbiological activity 
 
In vitro antifungal activity of AmB and AmB/PEG5kDa-cholane micelles 
(12:1 AmB/ PEG5kDa-cholane molar ratio) in PBS, pH 7.2, prepared 
according by dissolution/pH change, was assessed against C. albicans 
CECT1394. Yeast cells were cultured in Petri dishes containing agar 
Sabouraud medium for 72 h at 30 C and then 3 mL of a 0.5 McFarland 
standard suspension (1–5 10
6
 CFU/ mL) were seeded in plates of Agar 
Mueller Hinton supplemented with glucose (Roling et al., 2002). Methylene 
blue was used as contrast agent. Paper disks, impregnated with the AmB 
dissolved in DMSO were used as reference (S1 600 mg/mL; S2 200 mg/mL; 
S3 96 mg/mL; S4 38.4 mg/mL; S5 18.4 mg/mL). Twenty microliters of 96 
mg/mL AmB or equivalent AmB concentration of AmB/ PEG5kDacholane in 
0.2 M phosphate buffer, pH 10.5, were placed onto the paper disk that was 
then placed on the plates and incubated at 30 C. After 48 h of incubation, the 
inhibition zones were accurately measured using a caliper and referred to the 
reference (96 mg/mL AmB, S3). 
 
 
 
3. Results 
 
3.1. AmB/PEG5kDa-cholane solubility and association studies 
 
Solubility studies were carried out at pH 3.5, 5.5, 7.2, 8.5 and 11.0 by 
combining fixed amounts of AmB with increasing amounts of PEG5kDa-
cholane according to three different experimental protocols: (1) direct 
dissolution; (2) co-solvent dissolution; (3) dissolution/pH change. For 
comparison, the solubility of AmB in the presence of increasing amounts of 
PEG5kDa-OH was also examined. 
 
Preliminary studies showed that in the absence of PEG5kDa-cholane and 
PEG-OH, the direct AmB dissolution yielded lower drug concentrations than 
co-solvent dissolution and dissolution/ pH change. This behaviour was 
observed at all examined pHs (Supporting information, Fig. SI1) and was in 
fair agreement with 
 
studies reported in the literature (Mazerski et al., 1990). The UV spectra of 
dissolved AmB (Fig. SI2B) showed that the three dissolution methods yielded 
different physical forms of dissolved AmB, namely monomers and soluble 
aggregates such as dimers and tetramers. According to the literature, the 
absorption at 322 nm (Al322) and 413 nm (Al413) were elaborated to estimate 
the content of monomeric and nanoaggregated AmB in solution (Adams et al., 
2003; Vakil and Kwon, 2007). The lower Al322/Al413 ratio obtained by direct 
dissolution indicated that the monomeric form was the predominant AmB 
form in solution. On the contrary, the higher Al322/Al413 ratio obtained by 
co-solvent dissolution and dissolution/pH change indicated that in such a case 
the main form in solution was nanoaggregated AmB. Therefore, AmB 
dissolved by direct dissolution tends to be in the monomeric form while AmB 
dissolved by dissolution/pH change and co-solubilization was mainly in 
aggregated form. 
 
 
The solubility profiles reported in Fig. 1 show that PEG5kDa-OH has not 
relevant effect on the AmB solubility, which increased from 6 mg/mL to 17 
mg/mL as the polymer concentration increased from 0.5 to 6 mg/mL. 
Furthermore, similarly to AmB in the absence of polymers, the dissolution 
method did not affect remarkably the AmB solubility (data not shown). On 
the contrary, PEG5kDa-cholane dramatically increased the drug solubility and 
the dissolution method was found to significantly affect the AmB solubility. 
The direct dissolution yielded less than 0.5:1 AmB/PEG5kDa-cholane molar 
ratio while the co-solvent dissolution and the dissolution/ pH change 
protocols resulted in 12:1 AmB/PEG5kDa-cholane molar ratio, with identical 
dissolution profiles. 
 
The UV analysis of the AmB/PEG5kDa-cholane obtained by direct 
dissolution (Fig. SI2B) showed that the dissolved AmB was mainly in the 
monomeric form while the high absorption at 322 nm of samples obtained by 
co-solvent dissolution and dissolution/pH change demonstrated that in these 
samples the nanoaggregated AmB form predominated. 
 
The maximal solubility of AmB with PEG5kDa-cholane could not be 
determined because high polymer concentrations produced viscous 
dispersions that prevented the accurate analysis of dissolved AmB. 
 
Isothermal titration calorimetric (ITC) analyses were performed to 
investigate the AmB interaction with PEG5kDa-cholane at different pHs: 3.5, 
5.5, 7.2, 8.5 and 11.0. The ITC study was carried out by injecting volumes of 
polymer solutions into the cell containing the AmB solutions. The operative 
conditions were selected on the basis of the results obtained by the solubility 
studies. Blank runs were carried out by injecting polymer solutions 
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Fig. 1. Solubility profile of AmB with: PEG5kDa-cholane by direct dissolution (-^-); PEG5kDa-
cholane by dissolution/pH change and by co-solubilization (-&-); PEG-OH by dissolution/pH 
change (-*-). 
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Fig. 2. Isothermal calorimetry profiles of AmB titrated with PEG5kDa-cholane at pH 3.5 (A), 5.5 (B), 7.2 (C), 8.5 (D) and 11.0 (E). 
 
into the cell containing AmB free buffer or by injecting buffer into the cell 
containing AmB solutions.  
The buffer injection into AmB solutions did not elicit significant thermal 
effect. Instead, the injection of aliquots of polymer solutions into the cell 
containing buffer produced a pH indepen-dent bimodal exothermic ITC 
profile, which was due to the demicellisation and polymer dilution as reported 
elsewhere (Salmaso et al., 2014). The thermal profiles reported in Fig. 2 show 
that the polymer interaction with AmB occurs according to a multimodal pH-
dependent behaviour. The calorimetric raw data subtracted of the values 
obtained with the corresponding blanks were found to fit a three sequential 
binding site fitting model, with good correlation (Chi
2
). The association 
parameters derived from the analysis are summarized in Table 1. 
 
 
In all cases, the binding affinity constants (K) were found to decrease from 
the first to the third binding site and the drug/ polymer interactions occurred 
according to strong exothermic contributions (DH). The first binding was 
found to occur with high enthalpic and entropic contribution (DH1 and DS1, 
respectively). The second binding occurred with the lowest enthalpic 
contribu-tion (DH2) even though it was strongly favoured by a positive 
entropic change (DS2). The third binding was characterized by the lowest 
affinity constant (K3) and entropic contribution (DS3) but the highest 
enthalpic contribution (DH3). To note that at pH 11.0, the third binding 
occurred with negative DS. 
 
 
3.2. Dimensional, morphological and surface characterization of AmB/ 
PEG5kDa-cholane formulations 
 
Dynamic light scattering (DLS) and transmission electron microspcopy 
(TEM) analyses were performed to evaluate the 
 
Table 1 
 
dimensional, morphological and surface features of the AmB/ PEG5kDa-
cholane formulations obtained by dissolution/pH change. The DLS profile 
reported in Fig. 3A shows that the AmB association with PEG5kDa-cholane 
forms monodisperse size distribution micelles with mean diameter of 33.2 1.2 
nm (PDI 0.16), which was in good agreement with the dimensional values 
obtained with AmB free PEG5kDa-cholane formulations (Salmaso et al., 
2012). DLS analyses of AmB/PEG5kDa-cholane formulations performed in 
the pH range of 3.5–11.0 yielded similar dimensional profiles of AmB/ 
PEG5kDa-cholane formulations while AmB/PEG5kDa-OH mixtures did not 
show micelle formation at all pHs. The TEM image reported in Fig. 3B 
confirms the dimensional features obtained by DLS. The AmB/PEG5kDa-
cholane micelles have circular shape and gray shadow around the micelles 
due to the negative-staining of the PEG chains by phosphotungstic acid. 
 
Fig. 4 shows the zeta potential of the micelles at different pHs. At pH 5.5–
7.2 the overall micelle surface was nearly neutral. At pH below 5.5 the zeta 
potential shifted to slightly positive values and above pH 7.2 to negative 
values. Similar zeta potential values were obtained with AmB free PEG5kDa-
cholane micelles. 
 
3.3. AmB/MeO-PEG5kDa-cholane formulation lyophilization and 
stability 
 
The lyophilization of AmB/PEG5kDa-cholane formulations obtained by 
dissolution/pH change produced yellowish, fluffy and slightly electrostatic 
powders (Fig. 5, insert A). The moisture content in the lyophilized product 
was 7%. The lyophilized powder rapidly re-dissolved in buffer at pH 7.2 (Fig. 
5, insert B) to regenerate a clear yellow colloidal dispersion. 
 
Calorimetric parameters obtained by AmB titration with PEG5kDa-cholane at pH 3.5, 5.5, 7.2, 8.5 and 11.0: affinity constant (K), differential enthalpy (DH) differential entropy (DS), Chi squared 
(Chi
2
/DoF). 
 
 pH      
       
 3.5 5.5 7.2 8.5 11.0  
K110
5
 M 
1 
9.83  0.46 1.54  0.069 7.87  0.28 3.31  0.096 2.36  0.12  
DH1 2349  14.3 1071  9.36 1101  3.64 1414  7.99 3206  47.0  
DS1 19.5 20.1 23.3 20.5 13.8  
K2 10
5
 M 
1 
1.22  0.088 0.554  0.023 0.356  0.027 0.435  0.016 1.52  0.12  
DH2 485.4  24.5 769.1  21.4 964.5  29.3 104.9  19.3 125.5  56.4  
DS2 21.6 19.1 17.6 20.9 23.3  
K3 10
5
 M 
1 
0.149  0.009 0.531  0.022 0.234  0.012 0.246  0.008 0.062  0.004  
DH3 5251  134 1061  23.8 2053  50.8 3127  27.2 6924  277  
DS3 1.49 18.1 13.1 9.60 -5.87  
Chi
2
/DoF 114.7 17.87 18.29 19.19 142.5   
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Fig. 3. Dynamic light scattering profile (A) and transmission electron microscopy image (B) of AmB/PEG5kDa-cholane formulations. 
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Fig. 4. Zeta potential profiles of AmB/PEG5kDa-cholane micelles at different pHs. 
 
After re-dispersion, at 25 C, the micelle size of the colloidal system was 
32.2 3.4 nm and AmB was completely re-dissolved. Fig. 5 shows that both 
micelle size and AmB concentration remained stable over 1 month. After 2 
months storage neither the micelle size nor the size distribution changed while 
the AmB concentration decreased by 8 0.3%. Similar results were obtained 
with freshly prepared micelles. 
 
 
3.4. Structural characterizations 
 
Comparative structural characterizations of AmB, PEG5kDa-cholane, 
PEG5kDa-OH, lyophilized AmB/PEG5kDa-cholane micelles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Micelle size (-*-) and residual AmB content (-&-) time course profiles of lyophilized 
AmB/PEG5kDa-cholane formulation re-dispersed in buffer at pH 7.2. Insert A lyophilized 
formulation; insert B re-dispersed formulation. (For interpretation of the references to colour in 
the text, the reader is referred to the web version of this article.) 
 
and physical AmB/PEG5kDa-cholane mixture were performed by differential 
scanning calorimetry (DSC), X-ray diffractometry (XRD) and Fourier 
transformed infrared (FTIR).  
The DSC profiles (Fig. SI3) showed the typical water loss, melting and 
decomposition behaviors of the various samples. Unformulated AmB 
exhibited the characteristic endothermic peak of this drug at 104.6 C 
corresponding to the water loss process (Zu et al., 2014) and the characteristic 
decomposition peak above 160 C, namely at 188.6 C (Rajagopalan et al., 
1986). PEG5kDa-cholane showed a sharp endothermic peak at 58.9 C, 
correspond-ing to the polymer melting as observed by hot stage microscopy 
(60 C), followed by an exothermic event at 171.3 C, which corresponds to the 
polymer decomposition. Similarly to PEG5kDa-cholane, PEG5kDa-OH melted 
at 64.1 C and decomposed at 155.0 C. The thermal profile of the physical 
AmB/PEG5kDa-cholane mixture showed two endothermic peaks at 60.9 C 
and 92.9 C, and an exothermic peak at 178.5 C, which were in fair agreement 
with AmB melting and PEG5kDa-cholane melting and decomposition. The 
DSC profiles of AmB/PEG5kDa-cholane micelles showed only one 
endothermic peak at 172.5 C, corresponding to the PEG5kDa-cholane 
decomposition. 
 
 
The X-ray diffractometric (XRD) spectra (Fig. SI4) showed the 
characteristic peaks of the crystalline form of unformulated AmB at 
diffraction angles of 2u 14.82 , 17.22 , 18.38 , and 21.66 (Kim et al., 2010; 
Zu et al., 2014; Choi et al., 2008). PEG5kDa-cholane displayed broad peaks at 
19.02 and 23.38 while the AmB/PEG5kDa-cholane physical mixture showed 
the peaks corresponding to both crystalline AmB and PEG5kDa-cholane. The 
lyophilized AmB/ PEG5kDa-cholane micelle formulation did not show the 
character-istic peaks of AmB and PEG5kDa-cholane while exhibited two 
peaks at 22.11 and 26.14 . 
 
The Fourier transformed infrared (FTIR) spectra (Fig. SI5) provided 
additional information about the physical AmB/PEG5kDa-cholane interaction 
in the micelle lyophilized product. The unformulated AmB spectrum showed 
the typical signals reported in the literature (Gagos and Arczewska, 2010; Zu 
et al., 2014; Kim et al., 2010). The spectrum of the physical AmB/PEG5kDa-
cholane mixture showed the signals corresponding to both AmB, i.e. at 1039 
cm 
1
, [n(C O C)] pyranose, and PEG5kDa cholane, i.e. at 
 
Table 2  
Secondary structure (a-helix and b-helix content) of human serum albumin (HSA) and HSA 
incubated with AmB, Fungizone
1
, Heated Fungizone
1
 and AmB/MeO-PEG5kDa-cholane. 
 
  a-helix b-helix 
 HSA 0.67 0.04 
 AmB 0.63 0.06 
 Fungizone
1 
0.63 0.06 
 Heated Fungizone
1 
0.64 0.05 
 AmB/MeO-PEG5kDacholane 0.69 0.04  
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Fig. 6. Circular dichroism spectra. (A) Far UV spectra of HSA incubated with: AmB (
__
), Fungizone
1
 ( ); heated Fungizone
1
 (- -); AmB/PEG5kDa-cholane micelles ( - ) (B) Near UV spectra of 
AmB/PEG5kDa-cholane micelles in the absence of HSA (1); AmB/PEG5kDa-cholane micelles in the presence of HSA (3); Fungizone
1
 in the absence of HSA (2); Fungizone
1
 in the presence of HSA 
(4). 
 
1465 cm 
1
 [d(CH2)], 1359 cm 
1
 [d(CH)], 840.43 cm 
1
 [d(C H)] cyclic. The 
lyophilized AmB/PEG5kDa-cholane micelles displayed the same signals of 
the other samples. However, below 1700 cm 
1
 the main peaks characteristic 
of AmB [i.e. 1689.37 cm 
1
,n(C¼O); 1552.55 cm 
1
, d(N H); 1006.68 cm 
1
, 
d(¼C H)] (Nahar and Jain, 2009; Asher and Levin, 1977) and PEG5kDa-
cholane [i.e. at 1465 cm 
1
, d(CH2); 1342 cm 
1
, d(C O); 1097 cm 
1
, n(C N); 
960 cm 
1
, d(C H)] were missing. 
 
3.5. Human serum albumin spectroscopic analyses 
 
Circular dichroism studies were carried out to investigate the interaction 
of AmB with plasma proteins, which can either alter the protein structure or 
induce drug disaggregation (Vakil and Kwon, 2007; Hartsel et al., 2001). The 
study was comparatively performed using AmB, Fungizone
1
, heated 
Fungizone
1
 and AmB/PEG5kDa-cholane. 
 
Table 2 reports the secondary protein structure obtained by the KD2 
elaboration of the far UV CD spectra shown in Fig. 6A. The results reported 
in the table show that the secondary protein structure was not significantly 
altered by AmB regardless the formulation. 
 
Fig. 6B reports the near UV CD spectra of AmB/PEG5kDa-cholane 
micelles and fungizone showing the typical doublet (intense biphasic dichroic 
signals) of AmB in the absence or in the presence of HSA. The wavelengths 
of maximum (lmax) and minimum (lmin) ellipticity and the maximum–
minimum ellipticity amplitude intensity (Ai) represent the AmB aggregation: 
the lower lmax and lmin, the higher the AmB aggregation; the higher Ai, the 
higher AmB aggregation (Hartsel et al., 2001). 
 
In the comparative study, AmB in solution (Fig. 6B) presented the highest 
lmax and lmin and the lowest Ai either in the absence or in the presence of 
HSA (lmax 327 nm, lmin 353 nm and Ai 83.8 u in the absence of HSA; lmax 
326 nm, lmin 351 nm and Ai 44.4 u in the presence of HSA). In the absence 
of HSA the lmax, lmin and Ai of AmB/PEG5kDa-cholane were 316.5 nm, 
333.8 nm and 134.3 u, respectively, while in the presence of HSA lmax, lmin 
and Ai were 321.4 nm, 340.2 nm and 129.9 u, respectively. In the absence of 
HSA, Fungizone
1
 showed 319.5 nm lmax, 341.3 nm lmin and 139.71 u Ai 
while in the presence of HSA lmax, lmin and Ai were 324 nm 345.3 nm 138.66 u. 
Heated Fungizone
1
 (Fig. SI6) showed the lowest lmax and lmin and the highest Ai 
(lmax 313 nm, lmin 330 nm and Ai 175.7 u in the absence of HSA; lmax 314 nm, 
lmin 332 nm and Ai 184.59 u in the presence of HSA). Accordingly, the spectra 
obtained with Fungizone
1
 and AmB/PEG5kDa-cholane micelles showed a higher 
presence of aggregated AmB (Hartsel et al., 2001) 
 
either in the absence or in the presence of HSA compared to unformulated 
AmB. In both cases, the lmax and lmin of the doublet of Fungizone
1
 was 3–8 
nm higher compared to the ones obtained with AmB/PEG5kDa-cholane 
micelles indicating that AmB in Fungizone
1
 was less aggregated than in the 
PEG5kDa-cholane micelles. The addition of HSA was found to red-shift of 4–
7 nm the doublet of AmB formulated with PEG5kDa-cholane and Fungizone
1
 
indicating that in both cases HSA promotes the AmB disaggre-gation 
(Espuelas et al., 1997, 1998; Gaboriau et al., 1997). 
 
UV–vis absorption spectroscopic studies were performed in the range 
300–450 nm to determine the time course profile of AmB disaggregation in 
presence of HSA. The studies were comparatively performed with AmB, 
Fungizone
1
, heated Fungizone
1
 and AmB/ PEG5kDa-cholane micelles at 25 C 
and 37 C and the AmB disaggregation was determined by Gaussian fit of peak 
IV. The increase of the absorption area of peak IV (l 413 nm), which 
represents the monomeric state of AmB, indicates the drug disaggregation. 
 
 
The time course profiles reported in Fig. 7 show that at 37 C the 
unformulated AmB undergoes significant disaggregation. Fungizone
1
 
disaggregation was found to occur at less extent than free AmB while heated 
Fungizone
1
 was pretty stable as its disaggregation was very low. The extent 
of AmB disaggregation from the AmB/PEG5kDa-cholane micelles was found 
to be in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Disaggregation profiles at 37 C of AmB (-!-), Fungizone
1
 (-^-), heated Fungizone
1
 (-*-) 
and AmB/PEG5kDa-cholane micelles (-&-) incubated with HSA. Insert A and B: spectra profiles 
of Fungizone (A) and AmB/PEG5kDa-cholane micelles  
(B) registered at 0, 1, 2, 5, 10, 20, 45 min. 
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Fig. 8. AmB release profile from AmB/PEG5kDa-cholane micelles by dialysis in PBS. 
 
between Fungizone
1
 and heated Fungizone
1
. After 45 min, the peak IV area 
was 2.1 and 1.7 for Fungizone
1
 and AmB/PEG5kDa-cholane, respectively. 
 
The curves reported in Fig. 7 were found to fit a first order kinetic and 
were elaborated to get information on AmB dissocia-tion rate. At 37 C, the 
disaggregation half-life time (t1/2) was 194, 335, 463 and 618 s for 
unformulated AmB, Fungizone
1
, heated Fungizone
1
 and AmB/PEG5kDa-
cholane micelles, respectively. The t1/2 values calculated from disaggregation 
profiles obtained at 25 C (Fig. SI7) were 397, 507, 573 and 997 s for AmB in 
solution, Fungizone
1
, heated Fungizone
1
 and AmB/PEG5kDa-cholane 
micelles, respectively. 
 
3.6. AmB release and microbiological activity 
 
The AmB release from the micelles was evaluated by dialysis under sink 
conditions. Fig. 8 shows a burst release after which 50% of the drug is 
released in 6 h and 80% in 48 h. 
In vitro antifungal studies of AmB and AmB/PEG5kDa-cholane micelles 
were performed against C. albicans (Klepser et al., 1997). The diameters of 
the inhibition halos were, for both formulations, higher than 15 mm (18.47 
0.18 for AmB and 20.48 0.24 mm for AmB/PEG5kDa-cholane micelles), 
indicating that they are active against C. albicans (Espinel-Ingroff et al., 
2007a,b). The results reported in Fig. 9 show that AmB/PEG5kDa-cholane 
micelles were 15% less active than the standard solution of AmB and 15% 
more active than AmB in buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. C. albicans inhibition in the presence of AmB/PEG5kDa-cholane, AmB in buffer 
(suspension) and AmB in DMSO (p < 0.01). 
 
4. Discussion 
 
The results reported in this paper show that PEG5kDa-cholane can 
increase more than 10
3
 times the AmB solubility according to a linear 
[dissolved drug]/[polymer concentration] correlation. Sol-utions up to 12 
mg/mL AmB (6 mg/mL PEG5kDa-cholane) were obtained without significant 
change of buffer viscosity. Higher drug/polymer concentrations increased the 
viscosity, which prevented the accurate determination of the maximal AmB 
solubility. However, neither AmB separation nor inhomogeneity were 
observed up to 60 mg/mL AmB (30 mg/mL PEG5kDa-cholane). PEG5kDa-
OH was not found to significantly affect the AmB solubility indicating that 
the drug solubility was due to the supramolecular PEG5kDa-cholane self-
association into micelles as previously reported (Salmaso et al., 2012). 
 
 
The remarkable effect of PEG5kDa-cholane on AmB solubility is due to 
combined effects, which include the ability of PEG5kDa-cholane to form 
stable micelles with a low CMC (Salmaso et al., 2012) and the affinity of 
AmB for sterol molecules. AmB displays in fact its antifungal activity and 
cytotoxicity by interaction with ergosterol and cholesterol located in 
membranes of fungi and mammalian cells, respectively (Gray et al., 2012; 
Wilcock et al., 2013). It should be noted that sterols in DSPE–PEG micelles 
were found to favour the formation of soluble AmB aggregates (Diezi and 
Kwon, 2012). This study showed that both AmB solubility and aggregation 
depend on the chemical structure and content of sterols in the DSPE–PEG 
vesicles. 
 
High AmB solubility obtained using little amounts of excipients, namely 
solubilizing agents, is an important requisite for the development of safe 
products easily manageable in clinical practice. The use of high amounts of 
excipients may in fact be associated with toxic effect, in particular in 
parenteral admin-istrations, namely infusion. Little amounts of PEG5kDa-
cholane yielded very high AmB concentration solutions whilst commercial 
products, namely Fungizone
1
 and Ambisome
1
, and other formulations 
described in the literature contain high amounts of solubilizing excipients 
(Vandermeulen et al., 2006). In Fungizone
1
 and Ambisome
1
, for example, 50 
mg AmB are formulated with 41 mg sodium deoxycholate and 350 mg 
phospholipids/cholester-ol/tochopherol, respectively (Fukui et al., 2003), 
which are re-constituted in 15 mL saline solution resulting in 3.33 mg/mL 
AmB. The same amount of AmB could be dissolved with 25 mg of PEG5kDa-
cholane in about 4 mL buffer to yield 12.5 mg/mL AmB. It is worth to note 
that previous cell culture studies showed that PEG5kDa-cholane has negligible 
toxicity even at high doses. Furthermore, preliminary studies showed that, 
oppositely to sodium deoxycholate used in Fungizone
1
, PEG5kDa-cholane 
does not display significant hemolytic effect (Salmaso et al., 2012). 
 
 
 
The different capability of PEG5kDa-cholane to solubilize AmB observed 
with different dissolution methods can be explained by the effect of the 
dissolution conditions in the formation of monomeric and multimeric soluble 
species, typically dimers and tetramers (Mazerski et al., 1990). According to 
the UV and CD spectrometric data, the direct AmB dissolution process 
produces low drug concentrations where AmB is mainly associated in the 
monomeric form with PEG5kDa-cholane. On the contrary, the spectra 
obtained with AmB/PEG5kDa-cholane prepared by co-solvent dissolution or 
by dissolution/pH change showed the typical profile of aggregated AmB. 
Therefore, the high drug concentration obtained by these methods can be 
ascribed to the formation of AmB nanoaggregates, which are promptly 
stabilized by the polymer interaction. 
 
 
Dynamic light scattering (DLS) and transmission electron microscopy 
(TEM) confirmed that the AmB/PEG5kDa-cholane association forms micelles 
with homogeneous size. The particles size was similar to other 
nanoformulations such as nanosomal 
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AmB (34.6 nm) (Sheikh et al., 2010) or Ambisome
1
 (35–70 nm) (Lemke et 
al., 2005; Espada et al., 2008b; Fukui et al., 2003). The structure of the 
AmB/PEG5kDa-cholane micelles was confirmed by the TEM analyses, which 
showed the polymeric chains exposed on the vesicle surface, while the 
hydrophobic cholane moieties were localized inside the micelles. The similar 
zeta-potential of AmB-free and AmB-loaded micelles indicates that the AmB 
ionization does not affect the overall surface charge of the micelle, confirming 
that the drug was localized in the micelle core. 
 
The high affinity of AmB for PEG5kDa-cholane observed by isothermal 
calorimetry (ITC) is in agreement with the high affinity of this drug for 
steroidal polycycles described in the literature, which is responsible for its 
antifungal activity and cytotoxicity (Gray et al., 2012; Wilcock et al., 2013). 
However, the isothermal calorimetry (ITC) results highlighted the complexity 
of the PEG5kDa-cholane interaction with AmB, which takes place with 
different AmB soluble species, namely monomers, dimers, tetramers, and 
other multimeric nanoaggregates, which abun-dance depends on the pH. It 
has been reported that the presence of a net charge in the antibiotic molecule 
is the main factor that induces the solubility of AmB through the formation of 
the monomeric form. AmB pKa values are 5.7 for the carboxyl group and 
10.0 for the amino group. Therefore, at pH 11.0 AmB is mainly in the 
monomeric highly soluble anionic form (Mazerski et al., 1990). As the pH 
decreases to the isolectric point, the AmB anionic form and the drug solubility 
decrease with concurrent formation of less soluble nanoaggregates. At pH 3.5 
the AmB solubility slightly increases with the increase of the cationic form, 
which was found to be less soluble than the anionic form. The similar thermal 
profile obtained at pH 5.5 and 7.2 and the similar ones obtained at 3.5 and 8.5 
seem to indicate that the polymer interaction with the drug is strictly related to 
the solubility of AmB and hence to the relative abundance of the mono- or 
multi-meric species. 
 
 
 
The three different binding sites calculated by ITC analyses reasonably 
result from the PEG5kDa-cholane interaction with different AmB species 
through hydrophobic interactions between the cholane moiety and the 
heptaene side of the drug molecule to form different supramolecular 
structures. These results are in agreement with studies reported in the 
literature, which showed that the aggregation state of AmB depends on the 
sterol content physically incorporated in DSPE-PEG micelles. However, in all 
cases, the AmB/PEG5kDa-cholane interaction is enthalpically favored, 
regardless the binding site and the pH, indicating that the cholane interaction 
with AmB is thermodynamically favored as expected by the interaction of 
hydrophobic moieties in aqueous solution. 
 
 
The first and second bindings are also strongly entropically contributed 
suggesting that in these steps the polymer interaction with the drug provokes 
the disruption of ordered structures, namely AmB nanoaggregates, dimers and 
tetramers or by displacement of water molecules coordinated with the 
polymer and the drug. We hypothesize that these interactions occur by 
insertion of the cholanic moiety in between the heptaenic sides of coupled 
molecules in multimeric forms, dimers and tetramers. 
 
The affinity constant for the third binding site (K3) was remarkably lower 
than that calculated for the other sites. Despite the strongest enthalpic 
contribution, the entropic contribution to this interaction was lower than the 
first two interactions, especially at high and low pHs. At pH 11.0, the DS was 
negative indicating that this interaction can occur with the formation of 
ordered structures. This seems to be in agreement with the XRD spectra, 
which showed that the AmB incorporation into the polymer micelles occurs 
with the destruction of the typical crystalline form of AmB while novel 
ordered structures are formed. 
 
Importantly, the AmB/PEG5kDa-cholane formulation was found to be 
pharmaceutically stable. The lyophilization process produced 
 
a fluffy powder with low moisture content without cake formation. The 
lyophilized product was stable for prolonged time as AmB/ PEG5kDa-cholane 
solutions could be perfectly reconstituted by physiological buffer addition in 
few seconds, even without shaking, to yield a colloidal dispersion with the 
same physicochemical features of the freshly prepared formulation. It is worth 
to note that the reconstituted formulation was physically and chemically 
stable over 1 month at room temperature. 
 
The spectrometric and thermal analyses performed on lyophi-lized 
AmB/PEG5kDa-cholane provided information about the physical structure of 
the dried formulation. The Fourier transform infrared (FTIR) analysis showed 
new signals for the AmB/PEG5kDa-cholane micelle formulations, while the 
AmB/PEG5kDa-cholane physical mixture showed all the signals 
corresponding to the drug and the polymer. Similarly, the differential 
scanning calorimetry and X-ray diffraction (XRD) analyses evidenced the 
intimate AmB/ PEG5kDa-cholane interaction with disappearance of the 
typical thermal and diffraction signals of crystalline AmB and PEG5kDa-
cholane. On the contrary, the AmB/PEG5kDa-cholane physical mixture 
showed all signals of drug and polymer. However, it should be noted that as 
reported above the XRD spectrum of the lyophilized AmB/PEG5kDa-cholane 
micelles showed new signals suggesting that novel non-amorphous species 
are formed. 
 
The CD studies showed that, similarly to Fungizone
1
 and heated 
Fungizone
1
, AmB/PEG5kDa-cholane micelles did not induce structural 
alterations of human serum albumin (HSA). This indicates that the 
formulation should not have detrimental effect on native proteins after 
administration. In the presence of HSA, the AmB nanoaggregates in the 
PEG5kDa-cholane micelles are more stable and less rapidly disaggregated 
than in non-heated Fungizone
1
, which can result in lower toxicity. The AmB 
displacement from the PEG5kDa-cholane micelles is higher than from heated 
Fungizone
1
. Actually, heated Fungizone
1
 was reported to contain higher 
amount of aggregated AmB compared to normal Fungizone
1
, which results in 
a more stable and less toxic product (Gaboriau et al., 1997; Baas et al., 1999; 
Bartlett et al., 2004). Nevertheless, the therapeutic effect of heated 
Fungizone
1
 is less reproducible than non-heated Fungizone
1
 (Silva-Filho et 
al., 2012). Therefore, the aggregation results seem to indicate PEG5kDa-
cholane formulation can yield a product with higher AmB stability and lower 
toxicity compared to Fungizone
1
 and enhanced reproducibility compared to 
heated Fungizone
1
. 
 
Finally, drug release and biological investigations were carried out to 
evaluate the pharmaceutical effectiveness of the novel delivery system. The 
dialysis study showed that AmB release occurs with an initial burst which is 
consistent with free drug non incorporated in the micelles. The remaining 
drug is freely released under the experimental conditions, which guarantee the 
drug availability. 
 
The biological in vitro studies showed that the AmB formulated with 
PEG5kDa-cholane maintains high antimicrobial activity, which is very close 
to AmB in solution. This confirms that the drug is released from the micelles 
to interact with the cell membrane. The slightly lower activity of 
AmB/PEG5kDa-cholane compared to the standard may be ascribed to the drug 
release process from the micelles while the drug in solution is immediately 
available. Similarly, the higher activity of the micelle formulation compared 
to the AmB suspension may be attributed to the fastest drug release from the 
former than the dissolution from the solid dispersion. Moreover, considering 
that the mechanism for AmB activity seems to be related to the formation of 
multimeric drug associations, it could be possible that the drug released from 
the micelles is partially in the conformation for the interaction with the target. 
Furthermore, AmB in solution is obtained with DMSO, a solvent and 
absorption enhancer that also has irritant effects. The new formulation of 
AmB presented in this work shows a similar 
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antimicrobial activity without DMSO suggesting interesting practical 
application. 
 
5. Conclusions 
 
The results of this study show that, by virtue of its peculiar 
physicochemical features, PEG5kDa-cholane can be properly exploited to 
yield efficient AmB delivery. Indeed, the AmB/ PEG5kDa-cholane 
formulation possesses excellent biopharma-ceutical properties, namely high 
drug solubility and high physicochemical stability, which were in a few cases 
superior to the other formulations available in the market. Actually, 
PEG5kDa-cholane can be exploited for the delivery of a variety of small 
hydrophobic molecules forming stable micelles. However, this study open a 
new concept to the design of micelle forming biomaterials. Amphiphilic 
biomaterials can be in fact properly designed by selecting the 
hydrophobic/hydrophilic components according to the specific 
physicochemical features of the molecule that must be loaded in the 
hydrophobic core. In the case of PEG5kDa-cholane and AmB, the high 
loading efficiency is ascribable to the high affinity that the drug has for the 
polycyclic hydrophobic moiety of the polymer, which is structurally similar to 
the drug targets, namely ergosterol and cholesterol. This concept can be 
applied to other drug delivery systems resulting in efficient formulations. 
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5. CONCLUSIONS 
 
Note: 
This thesis includes the development of two different types of amphotericin B 
formulations: one topical formulation for the treatment of nail infections (AmB water-
impermeable nail lacquer), which is addressed in the Experimental part 1 (conclusions 
1-3) and another one for the treatment of sytemic fungal infections. The latest, tackled 
in Experimental part 2, consists of an AmB-pegylated nanoformulation (conclusions 4-
12). 
Conclusions: 
1.- A new water-impermeable stable nail lacquer formulation containing amphotericin B 
has been designed for the treatment of onychomycosis. The polymer (Eudragit L100®) 
and the amphotericin B solvent used (N-methyl-2-pyrrolidone) showed no 
incompatibility problems. Once applied over a surface, the nail lacquer formed a 
continuous, homogenous and smooth film resistant to water.   
2.- In vitro nail penetration studies showed that the lacquer was able to penetrate the nail 
(enhancement factor almost twice than the control). In vitro activity studies 
demonstrated the efficacy of the nail lacquer against dermatophyte and non-
dermatophyte molds as well as yeasts (gender Candida). 
3.- In vivo efficacy studies on keratinized structures of animal origin supported the 
efficacy of amphotericin B. After 30 days treatment on alternate days, the nail lacquer 
was able to clear up the infections caused by Trichophyton mentagrophytes, 
Trichophyton rubrum, Aspergillus niger, Fusarium. oxysporum and Fusarium solani. 
4.- A novel formulation for amphotericin B delivery has been developed by using a 
micelle forming 5 kDa monomethoxy-polyethylene glycol end functionalized with 
cholanic acid (PEG5kDa-cholane). This polymer was found to increase 10
5 times the 
amphotericin B solubility with a 12:1 AmB/PEG5kDa-cholane molar ratio (2:1 w/w 
ratio).  
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5.- The system AmB/PEG5kDa-cholane forms 30 nm micelles with the hydrophobic 
cholane moieties localized inside the micelles. Zeta potential analysis showed that at 
neutral pHs (5.5-7.2) the overall micelle surface is nearly neutral. The PEG5kDa-cholane 
interacts with amphotericin B according to three binding sites depending on the pH, 
suggesting that the polymer interaction depends on the amphotericin B ionization and 
aggregation.  
6.- Once lyophilized, the freeze-dried product could be promptly redispersed to form an 
homogeneous colloidal dispersion. The dispersion was physicochemically stable. 
Fourier Transform infrared spectrometry, differential scanning calorimetry and X-ray 
diffractometry showed that in the lyophilized product, amphotericin B and PEG5kDa-
cholane interacts intimately.  
7.- The amphotericin B release from the PEG5kDa-cholane micelles showed a biphasic 
profile. The best fittings were obtained with the Higuchi and Korsmeyer-Peppas 
models.  
8.- The toxicity of the new formulation was tested as hemolysis. The new 
AmB/PEG5kDa-cholane nanoformulation was always less hemolytic than the reference 
marketed formulation Fungizone®. 
9.- The amphotericin B antifungal activity assayed against Candida albicans showed 
that AmB/PEG5kDa-cholane was 15% more active than the free amphotericin B in 
buffer. 
10.- The IV pharmacokinetics profiles of the different formulations studied 
(Ambisome®, Fungizone® and AmB/PEG5kDa-cholane) were significantly different. 
The apparent elimination constant (Ke) of the new formulation is significantly (P<0.01) 
lower than both Ambisome® and Fungizone®. Accordingly, the half-life value of this 
new formulation was found to be higher. The IV administration of 1 mg/kg 
AmB/PEG5kDa-cholane caused less pain effect in the mice than the administration of the 
same dose of Fungizone® or Ambisome®.  
11.- Oral pharmacokinetic studies confirmed that this new formulation has a higher 
half-life than Ambisome® and Fungizone® marketed formulations. The AUC0-24 values 
were similar for all tested formulations. 
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12.- It can be concluded that the new AmB/PEG5kDa-cholane formulation is a promising 
soluble controlled delivery system for amphotericin B with lower toxicity than the 
reference marketed formulation Fungizone®. 
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